PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
17292948-0	2007	Dose-escalation study of rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--for the prevention of venous thromboembolism in patients undergoing total hip replacement.	Rivaroxaban	25-36	coagulation factor X	Homo sapiens	68-77
17292948-0	2007	Dose-escalation study of rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--for the prevention of venous thromboembolism in patients undergoing total hip replacement.	Rivaroxaban	38-49	coagulation factor X	Homo sapiens	68-77
17292948-1	2007	INTRODUCTION: Rivaroxaban (BAY 59-7939) is a novel, oral, direct Factor Xa inhibitor in clinical development for the prevention of thromboembolic disorders.	Rivaroxaban	14-25	coagulation factor X	Homo sapiens	65-74
17292948-1	2007	INTRODUCTION: Rivaroxaban (BAY 59-7939) is a novel, oral, direct Factor Xa inhibitor in clinical development for the prevention of thromboembolic disorders.	Rivaroxaban	27-38	coagulation factor X	Homo sapiens	65-74
15748242-1	2005	BAY 59-7939 is an oral, direct Factor Xa (FXa) inhibitor in development for the prevention and treatment of arterial and venous thrombosis.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	42-45
17116766-0	2006	A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement.	Rivaroxaban	48-59	coagulation factor X	Homo sapiens	27-36
17116766-0	2006	A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement.	Rivaroxaban	61-72	coagulation factor X	Homo sapiens	27-36
17116766-1	2006	BACKGROUND: Rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--could be an alternative to heparins and warfarin for the prevention and treatment of thromboembolic disorders.	Rivaroxaban	12-23	coagulation factor X	Homo sapiens	55-64
17116766-1	2006	BACKGROUND: Rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--could be an alternative to heparins and warfarin for the prevention and treatment of thromboembolic disorders.	Rivaroxaban	25-36	coagulation factor X	Homo sapiens	55-64
16920892-0	2006	Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban--an oral, direct factor Xa inhibitor--are not affected by aspirin.	Rivaroxaban	64-75	coagulation factor X	Homo sapiens	93-102
16920892-1	2006	Rivaroxaban (BAY 59-7939) is an oral, direct Factor Xa inhibitor in advanced clinical development for the prevention and treatment of thromboembolic disorders.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	45-54
16920892-1	2006	Rivaroxaban (BAY 59-7939) is an oral, direct Factor Xa inhibitor in advanced clinical development for the prevention and treatment of thromboembolic disorders.	Rivaroxaban	13-24	coagulation factor X	Homo sapiens	45-54
16859389-3	2006	There are two differing strategies of inhibiting factor Xa that are being pursued: indirect inhibition by compounds such as fondaparinux and idraparinux, requiring antithrombin as a cofactor; and direct inhibition by compounds such as rivaroxaban (BAY 597939), DX-9065a, otamixaban, LY517717 and YM150.	Rivaroxaban	235-246	coagulation factor X	Homo sapiens	49-58
16676051-6	2006	Several factor Xa inhibitors are currently subject to clinical trials, including Rivaroxaban; others may follow.	Rivaroxaban	81-92	coagulation factor X	Homo sapiens	8-17
16906775-4	2006	Of the new oral anticoagulants in development, the two agents in the most advanced stage are dabigatran etexilate (BIBR 1048) and rivaroxaban (BAY 59-7939), which inhibit factor IIa and factor Xa, respectively.	Rivaroxaban	130-141	coagulation factor X	Homo sapiens	186-195
16328318-0	2005	Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--after multiple dosing in healthy male subjects.	Rivaroxaban	50-62	coagulation factor X	Homo sapiens	79-88
16241946-0	2005	BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	29-38
16241946-2	2005	BACKGROUND: BAY 59-7939, a novel, oral, direct factor Xa inhibitor, is in clinical development for the prevention of venous thromboembolism (VTE), a frequent complication following orthopaedic surgery.	Rivaroxaban	12-23	coagulation factor X	Homo sapiens	47-56
16409461-0	2006	Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement.	Rivaroxaban	39-50	coagulation factor X	Homo sapiens	13-22
16409461-2	2006	OBJECTIVES: To assess the efficacy and safety of a novel, oral, direct factor Xa (FXa) inhibitor--BAY 59-7939--relative to enoxaparin in patients undergoing elective total hip replacement.	Rivaroxaban	97-109	coagulation factor X	Homo sapiens	71-80
16409461-2	2006	OBJECTIVES: To assess the efficacy and safety of a novel, oral, direct factor Xa (FXa) inhibitor--BAY 59-7939--relative to enoxaparin in patients undergoing elective total hip replacement.	Rivaroxaban	97-109	coagulation factor X	Homo sapiens	82-85
16409461-10	2006	CONCLUSIONS: When efficacy and safety were considered together, the oral, direct FXa inhibitor BAY 59-7939, at 2.5-10 mg b.i.d., compared favorably with enoxaparin for the prevention of venous thromboembolism in patients undergoing elective total hip replacement.	Rivaroxaban	95-106	coagulation factor X	Homo sapiens	81-84
16198660-0	2005	Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor.	Rivaroxaban	66-77	coagulation factor X	Homo sapiens	95-104
16198660-3	2005	The aim of this study was to investigate the safety, pharmacodynamics, and pharmacokinetics of BAY 59--7939, an oral, direct factor Xa inhibitor.	Rivaroxaban	95-107	coagulation factor X	Homo sapiens	125-134
16198660-9	2005	BAY 59--7939 selectively inhibited factor Xa activity; thrombin (factor IIa) and antithrombin were unaffected.	Rivaroxaban	0-12	coagulation factor X	Homo sapiens	35-44
16198660-12	2005	BAY 59--7939 was shown to be an effective and specific factor Xa inhibitor.	Rivaroxaban	0-12	coagulation factor X	Homo sapiens	55-64
16161994-4	2005	Lead optimization led to the discovery of BAY 59-7939 (5), a highly potent and selective, direct FXa inhibitor with excellent in vivo antithrombotic activity.	Rivaroxaban	42-53	coagulation factor X	Homo sapiens	97-100
15748242-2	2005	BAY 59-7939 competitively inhibits human FXa (K(i) 0.4 nm) with > 10 000-fold greater selectivity than for other serine proteases; it also inhibited prothrombinase activity (IC(50) 2.1 nm).	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	41-44
15748242-2	2005	BAY 59-7939 competitively inhibits human FXa (K(i) 0.4 nm) with > 10 000-fold greater selectivity than for other serine proteases; it also inhibited prothrombinase activity (IC(50) 2.1 nm).	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	152-166
15748242-3	2005	BAY 59-7939 inhibited endogenous FXa more potently in human and rabbit plasma (IC(50) 21 nm) than rat plasma (IC(50) 290 nm).	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	33-36
16305517-9	2005	Razaxaban, BAY59-7939, ZK-807834 and JTV-803 are orally active direct FXa inhibitors, which have been studied in phase II trials.	Rivaroxaban	11-21	coagulation factor X	Homo sapiens	70-73
33808367-10	2021	These data suggest that rivaroxaban should be considered to have significant potential for DDI, especially with CYP3A/P-gp modulators or with drugs that impair haemostasis.	Rivaroxaban	24-35	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	112-117
33814527-0	2021	Inhibitory Effect of Rivaroxaban on Atrial Arrhythmogenesis via Protease-Activated Receptor 2 Pathway.	Rivaroxaban	21-32	F2R like trypsin receptor 1	Homo sapiens	64-93
33808367-10	2021	These data suggest that rivaroxaban should be considered to have significant potential for DDI, especially with CYP3A/P-gp modulators or with drugs that impair haemostasis.	Rivaroxaban	24-35	phosphoglycolate phosphatase	Homo sapiens	118-122
33034105-7	2021	In addition, this study highlights the inequivalence of rivaroxaban binding to mammalian serum albumin.	Rivaroxaban	56-67	albumin	Homo sapiens	89-102
33800741-0	2021	The Development and Optimization of Hot-Melt Extruded Amorphous Solid Dispersions Containing Rivaroxaban in Combination with Polymers.	Rivaroxaban	93-104	alcohol dehydrogenase, iron containing, 1	Rattus norvegicus	36-39
29064044-3	2017	An antibody that reverses the effects of dabigatran is now available, and a factor Xa decoy is being developed as an antidote to apixaban, betrixaban, edoxaban, and rivaroxaban.	Rivaroxaban	165-176	coagulation factor X	Homo sapiens	76-85
34859601-0	2022	Non-synonymous alterations in AKR7A3 and ABCA6 correlate with bleeding in aged patients treated with rivaroxaban.	Rivaroxaban	101-112	aldo-keto reductase family 7 member A3	Homo sapiens	30-36
34538089-3	2022	METHODS: In the NAVIGATE ESUS trial (New Approach Rivaroxaban Inhibition of Factor Xa in a Global Trial Versus ASA to Prevent Embolism in Embolic Stroke of Undetermined Source), an MRI substudy was carried out at 87 sites in 15 countries.	Rivaroxaban	50-61	coagulation factor X	Homo sapiens	76-85
34913178-6	2022	RESULTS: Across 417 GP practices, the mean (range) in the relative prescribing of warfarin was 37% (6%-64%), apixaban was 32% (2%-65%), rivaroxaban 23% (0%-66%), dabigatran 3% (0%-23%) and edoxaban 6% (0%-59%).	Rivaroxaban	136-147	ring finger protein 130	Homo sapiens	20-22
34688719-1	2021	BACKGROUND: Rivaroxaban is a direct inhibitor of activated Factor X (FXa), an anti-inflammatory protein exerting a protective effect on the cardiac valve and vascular endothelium.	Rivaroxaban	12-23	coagulation factor X	Homo sapiens	69-72
34903821-8	2021	Both CrCL and CKD-EPI were associated with higher-than-expected ranges of dabigatran or rivaroxaban concentrations.	Rivaroxaban	88-99	CRCL	Homo sapiens	5-9
34903821-11	2021	In conclusion, CrCL and CKD-EPI both can be used to identify patients with high trough concentrations of dabigatran or rivaroxaban.	Rivaroxaban	119-130	CRCL	Homo sapiens	15-19
34894638-8	2021	In contrast to dual platelet inhibition using aspirin in combination with an ADP receptor antagonist and the direct thrombin inhibitor dabigatran, the oral factor Xa inhibitors apixaban and rivaroxaban show promising results according to current evidence.	Rivaroxaban	190-201	coagulation factor X	Homo sapiens	156-165
34585540-9	2022	Apixaban showed a lower correlation coefficient for all TG parameters compared with rivaroxaban, and thrombin generation was less influenced by apixaban than rivaroxaban at plasma levels >100 ng/ml.	Rivaroxaban	158-169	coagulation factor II, thrombin	Homo sapiens	101-109
34244010-0	2022	Indirect antiplatelet effects of rivaroxaban in a patient with intracranial hemorrhage: An underappreciated coagulopathy of factor Xa inhibitors?	Rivaroxaban	33-44	coagulation factor X	Homo sapiens	124-133
34244010-2	2022	The anticoagulation effects of rivaroxaban are produced by selectively binding and inhibiting factor Xa, causing delayed thrombin generation.	Rivaroxaban	31-42	coagulation factor X	Homo sapiens	94-103
34244010-2	2022	The anticoagulation effects of rivaroxaban are produced by selectively binding and inhibiting factor Xa, causing delayed thrombin generation.	Rivaroxaban	31-42	coagulation factor II, thrombin	Homo sapiens	121-129
34967380-13	2021	Patients with venous thrombosis caused by PROS1 mutations could receive rivaroxaban as the first choice of anticoagulation therapy.	Rivaroxaban	72-83	protein S	Homo sapiens	42-47
34967030-1	2022	Rivaroxaban is an oral anticoagulant directly inhibiting Factor Xa activity, which is widely used for prophylaxis of thromboembolic disorders and is required for therapeutic drug monitoring (TDM) during therapyfor individual dosage adjustment.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	57-66
34935100-6	2022	Then four drugs were selected to assess the half-maximal inhibitor concentration (IC50) values by measuring the intracellular accumulation of two P-gp-substrate drugs, apixaban and rivaroxaban.	Rivaroxaban	181-192	ATP binding cassette subfamily B member 1	Homo sapiens	146-150
34859601-0	2022	Non-synonymous alterations in AKR7A3 and ABCA6 correlate with bleeding in aged patients treated with rivaroxaban.	Rivaroxaban	101-112	ATP binding cassette subfamily A member 6	Homo sapiens	41-46
34859601-1	2022	Rivaroxaban is an oral anticoagulant that inhibits thrombin and blocks coagulation cascade through directly inactivating factors Xa.	Rivaroxaban	0-11	coagulation factor II, thrombin	Homo sapiens	51-59
34859601-3	2022	To explore potential drivers of individual differences in adverse reactions induced by rivaroxaban, we performed whole-exome sequencing and found that AKR7A3 rs1738023/rs1738025 and ABCA6 rs7212506 are susceptible sites for rivaroxaban-related bleeding in aged patients treated with rivaroxaban.	Rivaroxaban	87-98	aldo-keto reductase family 7 member A3	Homo sapiens	151-157
34859601-3	2022	To explore potential drivers of individual differences in adverse reactions induced by rivaroxaban, we performed whole-exome sequencing and found that AKR7A3 rs1738023/rs1738025 and ABCA6 rs7212506 are susceptible sites for rivaroxaban-related bleeding in aged patients treated with rivaroxaban.	Rivaroxaban	87-98	ATP binding cassette subfamily A member 6	Homo sapiens	182-187
34859601-3	2022	To explore potential drivers of individual differences in adverse reactions induced by rivaroxaban, we performed whole-exome sequencing and found that AKR7A3 rs1738023/rs1738025 and ABCA6 rs7212506 are susceptible sites for rivaroxaban-related bleeding in aged patients treated with rivaroxaban.	Rivaroxaban	224-235	aldo-keto reductase family 7 member A3	Homo sapiens	151-157
34859601-3	2022	To explore potential drivers of individual differences in adverse reactions induced by rivaroxaban, we performed whole-exome sequencing and found that AKR7A3 rs1738023/rs1738025 and ABCA6 rs7212506 are susceptible sites for rivaroxaban-related bleeding in aged patients treated with rivaroxaban.	Rivaroxaban	224-235	ATP binding cassette subfamily A member 6	Homo sapiens	182-187
34859601-3	2022	To explore potential drivers of individual differences in adverse reactions induced by rivaroxaban, we performed whole-exome sequencing and found that AKR7A3 rs1738023/rs1738025 and ABCA6 rs7212506 are susceptible sites for rivaroxaban-related bleeding in aged patients treated with rivaroxaban.	Rivaroxaban	283-294	aldo-keto reductase family 7 member A3	Homo sapiens	151-157
34859601-3	2022	To explore potential drivers of individual differences in adverse reactions induced by rivaroxaban, we performed whole-exome sequencing and found that AKR7A3 rs1738023/rs1738025 and ABCA6 rs7212506 are susceptible sites for rivaroxaban-related bleeding in aged patients treated with rivaroxaban.	Rivaroxaban	283-294	ATP binding cassette subfamily A member 6	Homo sapiens	182-187
34859601-4	2022	Gene functional annotation and signaling pathway enrichment indicated that homozygous mutations in AKR7A3 and ABCA6 might alter normal rivaroxaban transport and metabolism, and lead to continuous accumulation of activated drugs and toxic substances in vivo.	Rivaroxaban	135-146	aldo-keto reductase family 7 member A3	Homo sapiens	99-105
34859601-4	2022	Gene functional annotation and signaling pathway enrichment indicated that homozygous mutations in AKR7A3 and ABCA6 might alter normal rivaroxaban transport and metabolism, and lead to continuous accumulation of activated drugs and toxic substances in vivo.	Rivaroxaban	135-146	ATP binding cassette subfamily A member 6	Homo sapiens	110-115
34495376-2	2021	Recent studies with the direct factor Xa inhibitor rivaroxaban in combination with low-dose aspirin demonstrated a significant reduction of major cardiovascular events, especially in individuals with type 2 diabetes and proven cardiovascular disease.	Rivaroxaban	51-62	coagulation factor X	Homo sapiens	31-40
34495376-12	2021	CONCLUSIONS/INTERPRETATION: Our findings indicate that the direct factor Xa inhibitor rivaroxaban improved endothelial function in participants with type 2 diabetes and subclinical inflammation but also increased the risk of bleeding.	Rivaroxaban	86-97	coagulation factor X	Homo sapiens	66-75
34495376-6	2021	RESULTS: Rivaroxaban treatment for 20 weeks (n = 89) resulted in a significant improvement of post-ischaemic forearm blood flow (3.6 +- 4.7 vs 1.0 +- 5.2 ml/100 ml, p = 0.004), a numerically increased skin blood flow and reduced soluble P-Selectin plasma level vs aspirin.	Rivaroxaban	9-20	selectin P	Homo sapiens	237-247
34495376-9	2021	The number of PMPs increased significantly with both rivaroxaban (365.2 +- 372.1 vs 237.4 +- 157.1 mul-1, p = 0.005) and aspirin (266.0 +- 212.7 vs 201.7 +- 162.7 mul-1, p = 0.021).	Rivaroxaban	53-64	mitochondrial E3 ubiquitin protein ligase 1	Homo sapiens	99-104
34807769-1	2021	The use of direct factor Xa inhibitors rivaroxaban and apixaban (XABANs) has rapidly increased; however, there is no validated test available to monitor the effect on hemostasis.	Rivaroxaban	39-50	coagulation factor X	Homo sapiens	18-27
34694346-3	2021	Design, Setting, and Participants: Post hoc exploratory analysis of data from the New Approach Rivaroxaban Inhibition of Factor Xa in a Global Trial vs Aspirin to Prevent Embolism in ESUS (NAVIGATE ESUS) trial, a randomized, phase 3 clinical trial with enrollment from December 2014 to September 2017.	Rivaroxaban	95-106	coagulation factor X	Homo sapiens	121-130
34278930-2	2021	Rivaroxaban, a selective direct factor Xa inhibitor, is proposed as an additional pharmacologic option for managing this disease.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	32-41
34837144-0	2021	Comparison of 4-factor PCC reversal of apixaban and rivaroxaban versus warfarin for intracranial hemorrhage.	Rivaroxaban	52-63	crystallin gamma D	Homo sapiens	23-26
34837258-2	2022	A previously verified physiologically-based pharmacokinetic (PBPK) model of rivaroxaban established how its multiple pathways of elimination via both CYP3A4/2J2-mediated hepatic metabolism and organic anion transporter 3 (OAT3)/P-glycoprotein-mediated renal secretion predisposes rivaroxaban to drug-drug-disease interactions (DDDIs) with clinically relevant protein kinase inhibitors (PKIs).	Rivaroxaban	76-87	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	150-156
34837258-2	2022	A previously verified physiologically-based pharmacokinetic (PBPK) model of rivaroxaban established how its multiple pathways of elimination via both CYP3A4/2J2-mediated hepatic metabolism and organic anion transporter 3 (OAT3)/P-glycoprotein-mediated renal secretion predisposes rivaroxaban to drug-drug-disease interactions (DDDIs) with clinically relevant protein kinase inhibitors (PKIs).	Rivaroxaban	76-87	solute carrier family 22 member 8	Homo sapiens	193-220
34837258-2	2022	A previously verified physiologically-based pharmacokinetic (PBPK) model of rivaroxaban established how its multiple pathways of elimination via both CYP3A4/2J2-mediated hepatic metabolism and organic anion transporter 3 (OAT3)/P-glycoprotein-mediated renal secretion predisposes rivaroxaban to drug-drug-disease interactions (DDDIs) with clinically relevant protein kinase inhibitors (PKIs).	Rivaroxaban	76-87	solute carrier family 22 member 8	Homo sapiens	222-226
34837258-2	2022	A previously verified physiologically-based pharmacokinetic (PBPK) model of rivaroxaban established how its multiple pathways of elimination via both CYP3A4/2J2-mediated hepatic metabolism and organic anion transporter 3 (OAT3)/P-glycoprotein-mediated renal secretion predisposes rivaroxaban to drug-drug-disease interactions (DDDIs) with clinically relevant protein kinase inhibitors (PKIs).	Rivaroxaban	76-87	ATP binding cassette subfamily B member 1	Homo sapiens	228-242
34837258-2	2022	A previously verified physiologically-based pharmacokinetic (PBPK) model of rivaroxaban established how its multiple pathways of elimination via both CYP3A4/2J2-mediated hepatic metabolism and organic anion transporter 3 (OAT3)/P-glycoprotein-mediated renal secretion predisposes rivaroxaban to drug-drug-disease interactions (DDDIs) with clinically relevant protein kinase inhibitors (PKIs).	Rivaroxaban	280-291	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	150-156
34837258-2	2022	A previously verified physiologically-based pharmacokinetic (PBPK) model of rivaroxaban established how its multiple pathways of elimination via both CYP3A4/2J2-mediated hepatic metabolism and organic anion transporter 3 (OAT3)/P-glycoprotein-mediated renal secretion predisposes rivaroxaban to drug-drug-disease interactions (DDDIs) with clinically relevant protein kinase inhibitors (PKIs).	Rivaroxaban	280-291	solute carrier family 22 member 8	Homo sapiens	193-220
34837258-2	2022	A previously verified physiologically-based pharmacokinetic (PBPK) model of rivaroxaban established how its multiple pathways of elimination via both CYP3A4/2J2-mediated hepatic metabolism and organic anion transporter 3 (OAT3)/P-glycoprotein-mediated renal secretion predisposes rivaroxaban to drug-drug-disease interactions (DDDIs) with clinically relevant protein kinase inhibitors (PKIs).	Rivaroxaban	280-291	solute carrier family 22 member 8	Homo sapiens	222-226
34837258-2	2022	A previously verified physiologically-based pharmacokinetic (PBPK) model of rivaroxaban established how its multiple pathways of elimination via both CYP3A4/2J2-mediated hepatic metabolism and organic anion transporter 3 (OAT3)/P-glycoprotein-mediated renal secretion predisposes rivaroxaban to drug-drug-disease interactions (DDDIs) with clinically relevant protein kinase inhibitors (PKIs).	Rivaroxaban	280-291	ATP binding cassette subfamily B member 1	Homo sapiens	228-242
34837258-4	2022	EXPERIMENTAL APPROACH: The inhibitory potencies of the PKIs on CYP3A4/2J2-mediated metabolism of rivaroxaban were characterized.	Rivaroxaban	97-108	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	63-69
34837258-7	2022	KEY RESULTS: Mechanism-based inactivation (MBI) of CYP3A4-mediated rivaroxaban metabolism by both PKIs and MBI of CYP2J2 by erlotinib were established.	Rivaroxaban	67-78	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	51-57
34869643-13	2021	Rivaroxaban treatment inhibited PAR2/Akt/HIF1alpha signaling activation and Dll4 expression in FXa-exposed macrophages.	Rivaroxaban	0-11	coagulation factor II (thrombin) receptor-like 1	Mus musculus	32-36
34849448-15	2021	The RVV-X method seemed to better discriminate changes in TG curves due to increases in clotting potential as well as to FXa inhibition by rivaroxaban in goat plasma.	Rivaroxaban	139-150	coagulation factor X	Homo sapiens	121-124
34869643-13	2021	Rivaroxaban treatment inhibited PAR2/Akt/HIF1alpha signaling activation and Dll4 expression in FXa-exposed macrophages.	Rivaroxaban	0-11	thymoma viral proto-oncogene 1	Mus musculus	37-40
34779569-0	2021	Prothrombin complex concentrates for the urgent reversal of apixaban and rivaroxaban - an Australian retrospective cohort study.	Rivaroxaban	73-84	coagulation factor II, thrombin	Homo sapiens	0-11
34869643-13	2021	Rivaroxaban treatment inhibited PAR2/Akt/HIF1alpha signaling activation and Dll4 expression in FXa-exposed macrophages.	Rivaroxaban	0-11	hypoxia inducible factor 1, alpha subunit	Mus musculus	41-50
34869643-13	2021	Rivaroxaban treatment inhibited PAR2/Akt/HIF1alpha signaling activation and Dll4 expression in FXa-exposed macrophages.	Rivaroxaban	0-11	delta like canonical Notch ligand 4	Mus musculus	76-80
34869643-16	2021	Conclusion: Rivaroxaban suppresses AS by inhibiting FXa-induced PAR2/Akt/HIF1alpha signaling activation-mediated macrophage M1 polarization and high Dll4 expression.	Rivaroxaban	12-23	coagulation factor II (thrombin) receptor-like 1	Mus musculus	64-68
34869643-16	2021	Conclusion: Rivaroxaban suppresses AS by inhibiting FXa-induced PAR2/Akt/HIF1alpha signaling activation-mediated macrophage M1 polarization and high Dll4 expression.	Rivaroxaban	12-23	thymoma viral proto-oncogene 1	Mus musculus	69-72
34869643-16	2021	Conclusion: Rivaroxaban suppresses AS by inhibiting FXa-induced PAR2/Akt/HIF1alpha signaling activation-mediated macrophage M1 polarization and high Dll4 expression.	Rivaroxaban	12-23	hypoxia inducible factor 1, alpha subunit	Mus musculus	73-82
34869643-16	2021	Conclusion: Rivaroxaban suppresses AS by inhibiting FXa-induced PAR2/Akt/HIF1alpha signaling activation-mediated macrophage M1 polarization and high Dll4 expression.	Rivaroxaban	12-23	delta like canonical Notch ligand 4	Mus musculus	149-153
34538715-5	2021	The composite risk of stroke/SE was significantly lower in the rivaroxaban cohort compared with the warfarin cohort (HR 0.82; 95% CI 0.74-0.90).	Rivaroxaban	63-74	squalene epoxidase	Homo sapiens	29-31
34538715-8	2021	CONCLUSIONS: In NVAF patients with comorbidities of obesity and diabetes, rivaroxaban was associated with lower risks of stroke/SE and similar risk of major bleeding versus warfarin.	Rivaroxaban	74-85	squalene epoxidase	Homo sapiens	128-130
34314574-0	2021	Rivaroxaban for Extended Thromboprophylaxis in Acutely Ill Medical Patients 75 Years of Age or Older.	Rivaroxaban	0-11	renin binding protein	Homo sapiens	88-91
34314574-7	2021	The incidence of the primary efficacy outcomes in both age groups was numerically lower with rivaroxaban than with placebo (>=75: 1.2% and 1.6%, HR 0.73 95% CI 0.43, 1.22; <75 0.6% and 0.8%, HR 0.78 95% CI 0.46, 1.32; interaction p-value for age group=0.85).	Rivaroxaban	93-104	renin binding protein	Homo sapiens	55-58
34314574-7	2021	The incidence of the primary efficacy outcomes in both age groups was numerically lower with rivaroxaban than with placebo (>=75: 1.2% and 1.6%, HR 0.73 95% CI 0.43, 1.22; <75 0.6% and 0.8%, HR 0.78 95% CI 0.46, 1.32; interaction p-value for age group=0.85).	Rivaroxaban	93-104	renin binding protein	Homo sapiens	242-245
34285375-0	2021	Rivaroxaban attenuates cardiac hypertrophy by inhibiting protease-activated receptor-2 signaling in renin-overexpressing hypertensive mice.	Rivaroxaban	0-11	coagulation factor II (thrombin) receptor-like 1	Mus musculus	57-86
34824926-12	2021	These drugs, such as rivaroxaban, function by inhibiting factor Xa directly.	Rivaroxaban	21-32	coagulation factor X	Homo sapiens	57-66
34637608-1	2022	Rivaroxaban is a direct factor Xa inhibitor used for the management of thromboembolic disorders.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	24-33
34680252-4	2021	In particular, recent observations in murine systems demonstrated that myeloid-derived factor Xa (FXa) impedes anti-tumor immunity in the tumor microenvironment and that the oral FXa inhibitor (FXa-i) rivaroxaban synergizes with ICI.	Rivaroxaban	201-212	coagulation factor X	Homo sapiens	87-96
34730204-3	2021	In such cases, chemoprophylaxis with either direct oral anticoagulant therapy with factor-Xa inhibitors (i.e., rivaroxaban, apixaban, dabigatran) and aspirin are widely recommended.	Rivaroxaban	111-122	coagulation factor X	Homo sapiens	83-92
34705149-3	2021	Our subsequent in vitro studies discovered the pivotal involvement of human renal organic anion transporter 3 (hOAT3) in the renal secretion of rivaroxaban and the inhibitory potency of amiodarone.	Rivaroxaban	144-155	solute carrier family 22 member 8	Homo sapiens	111-116
34705149-7	2021	Further sensitivity analysis revealed that both hOAT3 dysfunction and age could affect the extent of DDDI, and age was shown to have a more pivotal role on rivaroxaban in vivo exposure.	Rivaroxaban	156-167	solute carrier family 22 member 8	Homo sapiens	48-53
34569249-3	2021	We used data from the ROCKET AF (Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) trial to determine the effect of primary efficacy-event tracking in the per-protocol cohort during the on-treatment period versus the intention-to-treat (ITT) cohort during the ITT period.	Rivaroxaban	33-44	coagulation factor X	Homo sapiens	68-77
34323663-12	2021	In HUVECs pre-stimulated with oxysterol, rivaroxaban decreased mRNA expression of IL-33, TNF-alpha, chemokines MCP-1, ICAM-1, VEGF and tissue factor (p < .01).	Rivaroxaban	41-52	interleukin 33	Homo sapiens	82-87
34323663-12	2021	In HUVECs pre-stimulated with oxysterol, rivaroxaban decreased mRNA expression of IL-33, TNF-alpha, chemokines MCP-1, ICAM-1, VEGF and tissue factor (p < .01).	Rivaroxaban	41-52	tumor necrosis factor	Homo sapiens	89-98
34323663-12	2021	In HUVECs pre-stimulated with oxysterol, rivaroxaban decreased mRNA expression of IL-33, TNF-alpha, chemokines MCP-1, ICAM-1, VEGF and tissue factor (p < .01).	Rivaroxaban	41-52	C-C motif chemokine ligand 2	Homo sapiens	111-116
34323663-12	2021	In HUVECs pre-stimulated with oxysterol, rivaroxaban decreased mRNA expression of IL-33, TNF-alpha, chemokines MCP-1, ICAM-1, VEGF and tissue factor (p < .01).	Rivaroxaban	41-52	intercellular adhesion molecule 1	Homo sapiens	118-124
34323663-12	2021	In HUVECs pre-stimulated with oxysterol, rivaroxaban decreased mRNA expression of IL-33, TNF-alpha, chemokines MCP-1, ICAM-1, VEGF and tissue factor (p < .01).	Rivaroxaban	41-52	vascular endothelial growth factor A	Homo sapiens	126-130
34323663-12	2021	In HUVECs pre-stimulated with oxysterol, rivaroxaban decreased mRNA expression of IL-33, TNF-alpha, chemokines MCP-1, ICAM-1, VEGF and tissue factor (p < .01).	Rivaroxaban	41-52	coagulation factor III, tissue factor	Homo sapiens	135-148
34323663-13	2021	Rivaroxaban 100 mg/ml+25-OHC increased the VE-cadherin expression in endothelium as compared to 25-OHC (p < .05).	Rivaroxaban	0-11	cadherin 5	Homo sapiens	43-54
34733438-7	2021	The anticoagulant prescribed at hospital discharge was rivaroxaban, a direct factor Xa inhibitor.	Rivaroxaban	55-66	coagulation factor X	Homo sapiens	77-86
34161660-8	2021	Crucially, a reduction in circulating levels of soluble P-selectin was observed in rivaroxaban-treated patients (compared with warfarin controls), which negatively correlated with the patient"s time on treatment.	Rivaroxaban	83-94	selectin P	Homo sapiens	56-66
34255420-1	2021	BACKGROUND: Studies suggest that the direct factor Xa inhibitor rivaroxaban compared to warfarin reduces the risk of post-thrombotic syndrome (PTS) after deep vein thrombosis (DVT), but this has not been evaluated for oral direct thrombin inhibitors.	Rivaroxaban	64-75	coagulation factor X	Homo sapiens	44-53
34630092-0	2021	Rivaroxaban Modulates TLR4/Myd88/NF-Kbeta Signaling Pathway in a Dose-Dependent Manner With Suppression of Oxidative Stress and Inflammation in an Experimental Model of Depression.	Rivaroxaban	0-11	toll-like receptor 4	Rattus norvegicus	22-26
34630092-0	2021	Rivaroxaban Modulates TLR4/Myd88/NF-Kbeta Signaling Pathway in a Dose-Dependent Manner With Suppression of Oxidative Stress and Inflammation in an Experimental Model of Depression.	Rivaroxaban	0-11	MYD88, innate immune signal transduction adaptor	Rattus norvegicus	27-32
34630092-14	2021	In conclusion, RVX in a dose-dependent manner possesses potent ameliorative effects against depression by reducing the oxidative stress and inflammatory process, through the regulation of the TLR4/Myd88/NF-kbeta signaling pathway.	Rivaroxaban	15-18	toll-like receptor 4	Rattus norvegicus	192-196
34630092-14	2021	In conclusion, RVX in a dose-dependent manner possesses potent ameliorative effects against depression by reducing the oxidative stress and inflammatory process, through the regulation of the TLR4/Myd88/NF-kbeta signaling pathway.	Rivaroxaban	15-18	MYD88, innate immune signal transduction adaptor	Rattus norvegicus	197-202
34630092-14	2021	In conclusion, RVX in a dose-dependent manner possesses potent ameliorative effects against depression by reducing the oxidative stress and inflammatory process, through the regulation of the TLR4/Myd88/NF-kbeta signaling pathway.	Rivaroxaban	15-18	neurofascin	Rattus norvegicus	203-205
34523673-2	2021	We investigated whether rivaroxaban, a direct oral anticoagulant factor Xa inhibitor would reduce COVID-19 progression.	Rivaroxaban	24-35	coagulation factor X	Homo sapiens	65-74
34524687-5	2022	The upregulation of pKr-2 expression was inhibited by both blood-brain barrier (BBB) reinforcement through caffeine supply and treatment with rivaroxaban, an inhibitor of factor Xa that is associated with thrombin production.	Rivaroxaban	142-153	coagulation factor II	Mus musculus	205-213
34521333-2	2022	Among them, the FIIa-direct thrombin inhibitor dabigatran and FXa inhibitors (rivaroxaban, apixaban, edoxaban) are the most broadly used.	Rivaroxaban	78-89	coagulation factor II, thrombin	Homo sapiens	28-36
34521333-2	2022	Among them, the FIIa-direct thrombin inhibitor dabigatran and FXa inhibitors (rivaroxaban, apixaban, edoxaban) are the most broadly used.	Rivaroxaban	78-89	coagulation factor X	Homo sapiens	62-65
34189909-5	2021	Here, we investigated and confirmed that ERD inactivated both CYP3A isoforms in a time-, concentration-, and NADPH-dependent manner with KI, kinact, and partition ratio of 4.01 and 10.04 muM, 0.120 and 0.045 min-1, and 32 and 55 for both CYP3A4 and CYP3A5, respectively, when rivaroxaban was employed as the probe substrate.	Rivaroxaban	276-287	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	62-67
34390638-1	2021	OBJECTIVES: The aim of this study is to assess micro-RNAs miR-142 and miR-39 as potential biomarkers for drug-monitoring of rivaroxaban among elderly patients with atrial fibrillation.	Rivaroxaban	124-135	microRNA 142	Homo sapiens	58-65
34390638-13	2021	CONCLUSIONS: This study has assessed new potential biomarkers for rivaroxaban therapeutic drug monitoring: miR-142 and miR-39.	Rivaroxaban	66-77	microRNA 142	Homo sapiens	107-114
34334529-5	2021	RESULTS: PS activity measured by the clotting assay reagents exhibited falsely high values depending on the plasma concentrations of FXa inhibitors in patients taking either rivaroxaban or edoxaban.	Rivaroxaban	174-185	coagulation factor X	Homo sapiens	133-136
34197012-1	2021	Rivaroxaban is a direct inhibitor of activated coagulation factor X and competitively targets factor Xa via reversible binding.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	47-67
34197012-1	2021	Rivaroxaban is a direct inhibitor of activated coagulation factor X and competitively targets factor Xa via reversible binding.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	94-103
34326139-5	2021	Our findings revealed that apart from being a potent noncompetitive reversible inhibitor of CYP3A4, INF inactivated CYP3A4 in a time-, concentration- and NADPH-dependent manner with K I, k inact and partition ratio of 2.45 microM, 0.053 min-1 and 41 respectively when rivaroxaban was employed as the probe substrate.	Rivaroxaban	268-279	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	92-98
34326139-5	2021	Our findings revealed that apart from being a potent noncompetitive reversible inhibitor of CYP3A4, INF inactivated CYP3A4 in a time-, concentration- and NADPH-dependent manner with K I, k inact and partition ratio of 2.45 microM, 0.053 min-1 and 41 respectively when rivaroxaban was employed as the probe substrate.	Rivaroxaban	268-279	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	116-122
34210765-6	2021	Serendipitously, we also discovered that BBR reversibly activated CYP3A5-mediated rivaroxaban hydroxylation where apparent V max increased and K m decreased with increasing BBR concentration.	Rivaroxaban	82-93	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	66-72
34210765-9	2021	Finally, non-covalent docking revealed that CYP3A5 can more favorably accommodate both BBR and rivaroxaban in concert as compared to CYP3A4 which further substantiated our experimental observations.	Rivaroxaban	95-106	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	44-50
34171754-3	2021	Herein, a multi-in-one strategy was established to modify biological valves with long-term antithrombogenicity and sequentially enhanced endothelialization triggered by glucose, in which the direct thrombin inhibitor rivaroxaban (RIVA)-loaded nanogels were embedded and the detachable polyethylene glycol (PEG) was grafted.	Rivaroxaban	217-228	coagulation factor II, thrombin	Homo sapiens	198-206
34189909-5	2021	Here, we investigated and confirmed that ERD inactivated both CYP3A isoforms in a time-, concentration-, and NADPH-dependent manner with KI, kinact, and partition ratio of 4.01 and 10.04 muM, 0.120 and 0.045 min-1, and 32 and 55 for both CYP3A4 and CYP3A5, respectively, when rivaroxaban was employed as the probe substrate.	Rivaroxaban	276-287	2,4-dienoyl-CoA reductase 1	Homo sapiens	109-114
34189909-5	2021	Here, we investigated and confirmed that ERD inactivated both CYP3A isoforms in a time-, concentration-, and NADPH-dependent manner with KI, kinact, and partition ratio of 4.01 and 10.04 muM, 0.120 and 0.045 min-1, and 32 and 55 for both CYP3A4 and CYP3A5, respectively, when rivaroxaban was employed as the probe substrate.	Rivaroxaban	276-287	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	238-244
34189909-5	2021	Here, we investigated and confirmed that ERD inactivated both CYP3A isoforms in a time-, concentration-, and NADPH-dependent manner with KI, kinact, and partition ratio of 4.01 and 10.04 muM, 0.120 and 0.045 min-1, and 32 and 55 for both CYP3A4 and CYP3A5, respectively, when rivaroxaban was employed as the probe substrate.	Rivaroxaban	276-287	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	249-255
34137279-6	2022	Only apixaban and rivaroxaban have CYP3A4 metabolism.	Rivaroxaban	18-29	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	35-41
34127969-7	2021	The anti-coagulant rivaroxaban directly inhibits FXa and facilitates viral entry, whereas the indirect inhibitor fondaparinux does not.	Rivaroxaban	19-30	coagulation factor X	Homo sapiens	49-52
34127969-8	2021	In a lethal humanized hACE2 mouse model of SARS-CoV-2, FXa prolonged survival while combination with rivaroxaban but not fondaparinux abrogated this protection.	Rivaroxaban	101-112	angiotensin converting enzyme 2	Homo sapiens	22-27
34825867-0	2021	Study on the relationship between rivaroxaban and factor Xa activity in blood based on HPLC-MS/MS.	Rivaroxaban	34-45	coagulation factor X	Homo sapiens	50-59
35366428-1	2022	The electrochemical behavior of rivaroxaban (RIV), a direct Factor Xa inhibitor, was investigated using a glassy carbon electrode (GCE) based on molecularly imprinted polymer (MIP).	Rivaroxaban	32-43	coagulation factor X	Homo sapiens	60-69
35599706-5	2022	Clinical Approach and Conclusions: Treatment with rivaroxaban alone was followed by platelet normalization despite persistence of anti-PF4 antibodies.	Rivaroxaban	50-61	platelet factor 4	Homo sapiens	135-138
35595781-3	2022	We performed a case-control study within the COMMANDER HF international, double-blind, randomized placebo-controlled trial investigating the effects of the factor-Xa inhibitor rivaroxaban.	Rivaroxaban	176-187	coagulation factor X	Homo sapiens	156-165
35600474-11	2022	In conclusion, the data of this pilot study indicate an inhibitory effect of rivaroxaban on the thrombin propagation phase of CD36-sensitive platelet thrombin formation in patients with PAD treated with ASA plus rivaroxaban combination therapy, which is associated with decreased PAR-1 but not thrombin-mediated platelet activation.	Rivaroxaban	77-88	coagulation factor II, thrombin	Homo sapiens	96-104
35577580-4	2022	The aim of the study was to assess the effect of rivaroxaban (Riv) and dabigatran (Dab) on the mRNA expression of anti-inflammatory cytokines TGF-beta, IL-37, IL-35 as well as of pro-inflammatory cytokines IL-18 and IL-23, in endothelial cells damaged by 25-OHC.	Rivaroxaban	49-60	transforming growth factor alpha	Homo sapiens	142-150
35577580-4	2022	The aim of the study was to assess the effect of rivaroxaban (Riv) and dabigatran (Dab) on the mRNA expression of anti-inflammatory cytokines TGF-beta, IL-37, IL-35 as well as of pro-inflammatory cytokines IL-18 and IL-23, in endothelial cells damaged by 25-OHC.	Rivaroxaban	49-60	interleukin 37	Homo sapiens	152-157
35577580-4	2022	The aim of the study was to assess the effect of rivaroxaban (Riv) and dabigatran (Dab) on the mRNA expression of anti-inflammatory cytokines TGF-beta, IL-37, IL-35 as well as of pro-inflammatory cytokines IL-18 and IL-23, in endothelial cells damaged by 25-OHC.	Rivaroxaban	49-60	interleukin 18	Homo sapiens	206-211
35577580-4	2022	The aim of the study was to assess the effect of rivaroxaban (Riv) and dabigatran (Dab) on the mRNA expression of anti-inflammatory cytokines TGF-beta, IL-37, IL-35 as well as of pro-inflammatory cytokines IL-18 and IL-23, in endothelial cells damaged by 25-OHC.	Rivaroxaban	49-60	interleukin 23 subunit alpha	Homo sapiens	216-221
35577580-4	2022	The aim of the study was to assess the effect of rivaroxaban (Riv) and dabigatran (Dab) on the mRNA expression of anti-inflammatory cytokines TGF-beta, IL-37, IL-35 as well as of pro-inflammatory cytokines IL-18 and IL-23, in endothelial cells damaged by 25-OHC.	Rivaroxaban	62-65	transforming growth factor alpha	Homo sapiens	142-150
35577580-4	2022	The aim of the study was to assess the effect of rivaroxaban (Riv) and dabigatran (Dab) on the mRNA expression of anti-inflammatory cytokines TGF-beta, IL-37, IL-35 as well as of pro-inflammatory cytokines IL-18 and IL-23, in endothelial cells damaged by 25-OHC.	Rivaroxaban	62-65	interleukin 37	Homo sapiens	152-157
35600474-11	2022	In conclusion, the data of this pilot study indicate an inhibitory effect of rivaroxaban on the thrombin propagation phase of CD36-sensitive platelet thrombin formation in patients with PAD treated with ASA plus rivaroxaban combination therapy, which is associated with decreased PAR-1 but not thrombin-mediated platelet activation.	Rivaroxaban	77-88	coagulation factor II, thrombin	Homo sapiens	150-158
35600474-11	2022	In conclusion, the data of this pilot study indicate an inhibitory effect of rivaroxaban on the thrombin propagation phase of CD36-sensitive platelet thrombin formation in patients with PAD treated with ASA plus rivaroxaban combination therapy, which is associated with decreased PAR-1 but not thrombin-mediated platelet activation.	Rivaroxaban	77-88	Prader Willi/Angelman region RNA 1	Homo sapiens	280-285
35600474-11	2022	In conclusion, the data of this pilot study indicate an inhibitory effect of rivaroxaban on the thrombin propagation phase of CD36-sensitive platelet thrombin formation in patients with PAD treated with ASA plus rivaroxaban combination therapy, which is associated with decreased PAR-1 but not thrombin-mediated platelet activation.	Rivaroxaban	77-88	coagulation factor II, thrombin	Homo sapiens	294-302
35600474-11	2022	In conclusion, the data of this pilot study indicate an inhibitory effect of rivaroxaban on the thrombin propagation phase of CD36-sensitive platelet thrombin formation in patients with PAD treated with ASA plus rivaroxaban combination therapy, which is associated with decreased PAR-1 but not thrombin-mediated platelet activation.	Rivaroxaban	212-223	coagulation factor II, thrombin	Homo sapiens	96-104
35600474-11	2022	In conclusion, the data of this pilot study indicate an inhibitory effect of rivaroxaban on the thrombin propagation phase of CD36-sensitive platelet thrombin formation in patients with PAD treated with ASA plus rivaroxaban combination therapy, which is associated with decreased PAR-1 but not thrombin-mediated platelet activation.	Rivaroxaban	212-223	coagulation factor II, thrombin	Homo sapiens	150-158
35601826-0	2022	Unexpected Dynamic Binding May Rescue the Binding Affinity of Rivaroxaban in a Mutant of Coagulation Factor X.	Rivaroxaban	62-73	coagulation factor X	Homo sapiens	89-109
35504629-3	2022	METHODS: A sequential nonlinear mixed effect pharmacokinetic/pharmacodynamic modeling method was used to establish the relation between rivaroxaban concentration and anti-factor Xa activity, prothrombin time, and activated partial thromboplastin time (aPTT) as pharmacodynamic biomarkers in a population of sixty-nine Iranian patients under treatment with oral rivaroxaban.	Rivaroxaban	136-147	coagulation factor X	Homo sapiens	171-180
35088420-5	2022	After accounting for probe substrate-dependency and protein binding effects, mechanistic static modelling with the direct factor Xa anticoagulant rivaroxaban estimated a 1.47-fold increase in its systemic exposure when co-administered with febuxostat based on OAT3 interaction which in turn exacerbates the bleeding risk from baseline for patients with atrial fibrillation by 1.51-fold.	Rivaroxaban	146-157	coagulation factor X	Homo sapiens	122-131
35600474-5	2022	ASA plus rivaroxaban treatment resulted in a significantly decreased thrombin peak in PRP for two triggers, namely, low concentration of tissue factor (TF) and thrombin, compared to ASA monotherapy.	Rivaroxaban	9-20	coagulation factor II, thrombin	Homo sapiens	69-77
35600474-5	2022	ASA plus rivaroxaban treatment resulted in a significantly decreased thrombin peak in PRP for two triggers, namely, low concentration of tissue factor (TF) and thrombin, compared to ASA monotherapy.	Rivaroxaban	9-20	coagulation factor III, tissue factor	Homo sapiens	137-150
35600474-5	2022	ASA plus rivaroxaban treatment resulted in a significantly decreased thrombin peak in PRP for two triggers, namely, low concentration of tissue factor (TF) and thrombin, compared to ASA monotherapy.	Rivaroxaban	9-20	coagulation factor II, thrombin	Homo sapiens	160-168
35600474-6	2022	TF-controlled thrombin generation was additionally characterized by a significantly prolonged lag time in PRP and platelet-free plasma during ASA plus rivaroxaban combination therapy.	Rivaroxaban	151-162	coagulation factor II, thrombin	Homo sapiens	14-22
35600474-7	2022	In comparison, ASA plus clopidogrel treatment presented a significant reduction of the thrombin peak in PRP, which was less pronounced than during subsequent ASA plus rivaroxaban therapy.	Rivaroxaban	167-178	coagulation factor II, thrombin	Homo sapiens	87-95
35577580-8	2022	mRNA expression of TGF-beta and IL-37 significantly increased following stimulation with rivaroxaban and dabigatran as compared to an untreated control (p<0.01).	Rivaroxaban	89-100	transforming growth factor alpha	Homo sapiens	19-27
35577580-8	2022	mRNA expression of TGF-beta and IL-37 significantly increased following stimulation with rivaroxaban and dabigatran as compared to an untreated control (p<0.01).	Rivaroxaban	89-100	interleukin 37	Homo sapiens	32-37
35577580-9	2022	In HUVECs pre-treated with oxysterol, rivaroxaban and dabigatran increased mRNA expression of TGF-beta, IL-37 and decreased mRNA expression of EBI3, p35, IL-23 and IL-18 as compared to 25-OHC(p<0.01).	Rivaroxaban	38-49	transforming growth factor alpha	Homo sapiens	94-102
35577580-9	2022	In HUVECs pre-treated with oxysterol, rivaroxaban and dabigatran increased mRNA expression of TGF-beta, IL-37 and decreased mRNA expression of EBI3, p35, IL-23 and IL-18 as compared to 25-OHC(p<0.01).	Rivaroxaban	38-49	interleukin 37	Homo sapiens	104-109
35577580-9	2022	In HUVECs pre-treated with oxysterol, rivaroxaban and dabigatran increased mRNA expression of TGF-beta, IL-37 and decreased mRNA expression of EBI3, p35, IL-23 and IL-18 as compared to 25-OHC(p<0.01).	Rivaroxaban	38-49	Epstein-Barr virus induced 3	Homo sapiens	143-147
35577580-9	2022	In HUVECs pre-treated with oxysterol, rivaroxaban and dabigatran increased mRNA expression of TGF-beta, IL-37 and decreased mRNA expression of EBI3, p35, IL-23 and IL-18 as compared to 25-OHC(p<0.01).	Rivaroxaban	38-49	interleukin 12A	Homo sapiens	149-152
35577580-9	2022	In HUVECs pre-treated with oxysterol, rivaroxaban and dabigatran increased mRNA expression of TGF-beta, IL-37 and decreased mRNA expression of EBI3, p35, IL-23 and IL-18 as compared to 25-OHC(p<0.01).	Rivaroxaban	38-49	interleukin 23 subunit alpha	Homo sapiens	154-159
35577580-9	2022	In HUVECs pre-treated with oxysterol, rivaroxaban and dabigatran increased mRNA expression of TGF-beta, IL-37 and decreased mRNA expression of EBI3, p35, IL-23 and IL-18 as compared to 25-OHC(p<0.01).	Rivaroxaban	38-49	interleukin 18	Homo sapiens	164-169
35460567-0	2022	Rivaroxaban in the treatment of TEK-related venous malformation.	Rivaroxaban	0-11	TEK receptor tyrosine kinase	Homo sapiens	32-35
35460567-3	2022	We present a case of venous malformation due to a variant in the TEK gene in a 38-year-old woman in whom treatment with low dose rivaroxaban was successful in controlling symptoms of chronic localized intravascular coagulation.	Rivaroxaban	129-140	TEK receptor tyrosine kinase	Homo sapiens	65-68
35456329-6	2022	Both agents allowed for accurate measurement of anti-factor Xa activity in the plasma containing rivaroxaban and heparins in the concentration range reached in patients" blood.	Rivaroxaban	97-108	coagulation factor X	Homo sapiens	53-62
35088420-5	2022	After accounting for probe substrate-dependency and protein binding effects, mechanistic static modelling with the direct factor Xa anticoagulant rivaroxaban estimated a 1.47-fold increase in its systemic exposure when co-administered with febuxostat based on OAT3 interaction which in turn exacerbates the bleeding risk from baseline for patients with atrial fibrillation by 1.51-fold.	Rivaroxaban	146-157	solute carrier family 22 member 8	Homo sapiens	260-264
35088420-6	2022	Taken together, our results suggested that the concomitant usage of febuxostat with rivaroxaban may potentially culminate in a clinically-significant drug-drug interaction and result in an increased risk of bleeding as a result of its OAT3 inhibition.	Rivaroxaban	84-95	solute carrier family 22 member 8	Homo sapiens	235-239
35354961-1	2022	Rivaroxaban, a direct factor Xa inhibitor, is widely used for stroke prevention in patients with non-valvular atrial fibrillation (NVAF).	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	22-31
35088420-0	2022	Febuxostat and its Major Acyl Glucuronide Metabolite are Potent Inhibitors of Organic Anion Transporter 3: Implications for Drug-Drug Interactions with Rivaroxaban.	Rivaroxaban	152-163	solute carrier family 22 member 8	Homo sapiens	78-105
35037739-8	2022	RESULTS: We provide evidence that the anti-FXa DOAC rivaroxaban and the anti-thrombin DOAC dabigatran are efficient in blocking their target proteases.	Rivaroxaban	52-63	coagulation factor X	Homo sapiens	43-46
35455642-0	2022	Impact of the Genotype and Phenotype of CYP3A and P-gp on the Apixaban and Rivaroxaban Exposure in a Real-World Setting.	Rivaroxaban	75-86	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	40-45
35455642-0	2022	Impact of the Genotype and Phenotype of CYP3A and P-gp on the Apixaban and Rivaroxaban Exposure in a Real-World Setting.	Rivaroxaban	75-86	phosphoglycolate phosphatase	Homo sapiens	50-54
35455642-1	2022	Apixaban and rivaroxaban are the two most prescribed direct factor Xa inhibitors.	Rivaroxaban	13-24	coagulation factor X	Homo sapiens	60-69
35455642-11	2022	P-gp activity (p < 0.001) also significantly impacted rivaroxaban AUC0-6h.	Rivaroxaban	54-65	phosphoglycolate phosphatase	Homo sapiens	0-4
35455642-12	2022	The phenotypic switch (from normal to poor metabolizer) of P-gp led to an increase of apixaban and rivaroxaban AUC0-6h by 16% and 25%, respectively, equivalent to a decrease of 38 mL/min in CrCl according to the apixaban model.	Rivaroxaban	99-110	phosphoglycolate phosphatase	Homo sapiens	59-63
35296141-9	2022	RESULTS: The anti-factor Xa level was increased after using the contrast agent in the rivaroxaban group (0.66 +- 0.32 U/mL vs. 0.67 +- 0.32 U/mL; P = 0.01) and the edoxaban group (0.74 +- 0.35 U/mL vs. 0.76 +- 0.36 U/mL; P = 0.006).	Rivaroxaban	86-97	coagulation factor X	Homo sapiens	18-27
35359859-2	2022	Recent preclinical studies find that factor Xa inhibitor (FXaI), rivaroxaban, promotes PN in animals receiving oxaliplatin.	Rivaroxaban	65-76	coagulation factor X	Homo sapiens	37-46
35001892-0	2022	Protective Effect of Rivaroxaban Against Amyloid Pathology and Neuroinflammation Through Inhibiting PAR-1 and PAR-2 in Alzheimer"s Disease Mice.	Rivaroxaban	21-32	pulmonary adenoma resistance 1	Mus musculus	100-105
35245113-3	2022	As an anticoagulant, rivaroxaban was encapsulated in nanogels cross-linked by thrombin-cleavable peptide and released upon the trigger of environmental thrombin, blocking the further coagulation cascade.	Rivaroxaban	21-32	coagulation factor II, thrombin	Homo sapiens	78-86
35245113-3	2022	As an anticoagulant, rivaroxaban was encapsulated in nanogels cross-linked by thrombin-cleavable peptide and released upon the trigger of environmental thrombin, blocking the further coagulation cascade.	Rivaroxaban	21-32	coagulation factor II, thrombin	Homo sapiens	152-160
35183904-2	2022	Similarly, the factor Xa inhibitor rivaroxaban reduces atherosclerosis in both apoE-/- and Ldlr-/- mice.	Rivaroxaban	35-46	apolipoprotein E	Mus musculus	79-83
35183904-2	2022	Similarly, the factor Xa inhibitor rivaroxaban reduces atherosclerosis in both apoE-/- and Ldlr-/- mice.	Rivaroxaban	35-46	low density lipoprotein receptor	Mus musculus	91-95
35200221-4	2022	Using a routine hybrid heparin anti-Factor Xa assay, 1 patient demonstrated a strong linear correlation up to a serum rivaroxaban concentration of 940 ng/mL.	Rivaroxaban	118-129	coagulation factor X	Homo sapiens	36-45
35227117-4	2022	Clinically relevant rivaroxaban activity was verified with an elevated low molecular weight heparin anti-factor Xa assay, and laboratory confirmed coagulopathy was demonstrated by a prolonged prothrombin time, thromboelastography (TEG) R-time, and activated clotting time (ACT).	Rivaroxaban	20-31	coagulation factor X	Homo sapiens	105-114
35174529-3	2022	OBJECTIVE: The aim of this study was to assess the potential P-gp-mediated drug-drug interactions between eleven TKIs with apixaban and rivaroxaban.	Rivaroxaban	136-147	ATP binding cassette subfamily B member 1	Homo sapiens	61-65
35174529-4	2022	METHODS: Bidirectional permeabilities of apixaban and rivaroxaban were investigated across MDCK-MDR1 models, to determine half maximal inhibitory concentration (IC50 ).	Rivaroxaban	54-65	ATP binding cassette subfamily B member 1	Homo sapiens	96-100
35114692-11	2022	Finally, we found that CM-352 reduced MMP-10 and rivaroxaban-related fibrinolytic effects in thromboelastometry and TAFI activation.	Rivaroxaban	49-60	carboxypeptidase B2 (plasma)	Mus musculus	116-120
35110348-11	2022	CONCLUSION: Prothrombin complex concentrate can effectively reverse the effects of warfarin and rivaroxaban in patients with major bleeding, but only partially reverses the effect of dabigatran.	Rivaroxaban	96-107	coagulation factor II, thrombin	Homo sapiens	12-23
35128064-3	2022	The effects of dabigatran and rivaroxaban on the activities of FII, FV, FVIII, FX, and activated protein C (APC) were analyzed.	Rivaroxaban	30-41	adenomatous polyposis coli protein	Oryctolagus cuniculus	87-106
35128064-3	2022	The effects of dabigatran and rivaroxaban on the activities of FII, FV, FVIII, FX, and activated protein C (APC) were analyzed.	Rivaroxaban	30-41	adenomatous polyposis coli protein	Oryctolagus cuniculus	108-111
35015795-3	2022	In this study we examined the binding of the Apixaban, Betrixaban and Rivaroxaban to the SARS-CoV-2 Mpro with the use of the MicroScale Thermophoresis technique.	Rivaroxaban	70-81	NEWENTRY	Severe acute respiratory syndrome-related coronavirus	100-104
34983074-1	2022	AIM: Inhibition of thrombin-mediated signaling processes using a vascular dose of rivaroxaban in adjunct to antiplatelet therapy, known as dual-pathway inhibition (DPI), reduces atherothrombotic events in patients with stable atherosclerotic disease.	Rivaroxaban	82-93	coagulation factor II, thrombin	Homo sapiens	19-27
34983074-7	2022	Rivaroxaban significantly reduced thrombin generation and was associated with a trend towards reduced TF-induced platelet aggregation.	Rivaroxaban	0-11	coagulation factor II, thrombin	Homo sapiens	34-42
35001892-0	2022	Protective Effect of Rivaroxaban Against Amyloid Pathology and Neuroinflammation Through Inhibiting PAR-1 and PAR-2 in Alzheimer"s Disease Mice.	Rivaroxaban	21-32	pulmonary adenoma resistance 2	Mus musculus	110-115
35001892-6	2022	RESULTS: Rivaroxaban treatment attenuated neuroinflammation, blood-brain barrier dysfunction, memory deficits, and amyloid-beta deposition through PAR-1/PAR-2 inhibition in the AD + CAA mice model compared with warfarin and no-treatment groups.	Rivaroxaban	9-20	pulmonary adenoma resistance 1	Mus musculus	147-152
35001892-6	2022	RESULTS: Rivaroxaban treatment attenuated neuroinflammation, blood-brain barrier dysfunction, memory deficits, and amyloid-beta deposition through PAR-1/PAR-2 inhibition in the AD + CAA mice model compared with warfarin and no-treatment groups.	Rivaroxaban	9-20	pulmonary adenoma resistance 2	Mus musculus	153-158
33836300-2	2021	Renal drug-drug interactions (DDIs) between amiodarone or dronedarone and rivaroxaban were previously ascribed to inhibition of rivaroxaban secretion by P-glycoprotein at the apical membrane of renal proximal tubular epithelial cells.	Rivaroxaban	74-85	ATP binding cassette subfamily B member 1	Homo sapiens	153-167
33836300-2	2021	Renal drug-drug interactions (DDIs) between amiodarone or dronedarone and rivaroxaban were previously ascribed to inhibition of rivaroxaban secretion by P-glycoprotein at the apical membrane of renal proximal tubular epithelial cells.	Rivaroxaban	128-139	ATP binding cassette subfamily B member 1	Homo sapiens	153-167
33836300-7	2021	Static modelling predicted 1.29-, 1.01-, 1.29- and 1.16-fold increase in rivaroxaban exposure, culminating in a predicted 1.29-, 1.01-, 1.28- and 1.15-fold increase in major bleeding risk respectively, suggesting potential OAT3-mediated DDI between amiodarone and rivaroxaban.	Rivaroxaban	73-84	solute carrier family 22 member 8	Homo sapiens	223-227
34030590-6	2021	To this end, a combination of sirolimus, an mTOR inhibitor, and rivaroxaban, a factor Xa inhibitor, were used to reduce the size of the lesion and minimize the risk of thromboembolic events.	Rivaroxaban	64-75	coagulation factor X	Homo sapiens	79-88
33667438-9	2021	Stroke/SE- and MB- related medical costs per-patient per-month were higher in warfarin, dabigatran, and rivaroxaban patients vs. apixaban.	Rivaroxaban	104-115	squalene epoxidase	Homo sapiens	7-17
33966491-10	2021	In the subanalysis by FXa inhibitor treatment group in the efficacy population, median of percent change in anti-FXa from baseline to nadir showed a decrease of 93.8% for apixaban-treated patients (n=99) and by 92.6% for rivaroxaban-treated patients (n=59).	Rivaroxaban	221-232	coagulation factor X	Homo sapiens	22-25
33966491-10	2021	In the subanalysis by FXa inhibitor treatment group in the efficacy population, median of percent change in anti-FXa from baseline to nadir showed a decrease of 93.8% for apixaban-treated patients (n=99) and by 92.6% for rivaroxaban-treated patients (n=59).	Rivaroxaban	221-232	coagulation factor X	Homo sapiens	113-116
34043814-8	2021	ABCB1 variants are potential factors affecting thromboembolic events in rivaroxaban users and bleeding events in apixaban users.	Rivaroxaban	72-83	ATP binding cassette subfamily B member 1	Homo sapiens	0-5
34036837-0	2021	Review of Prothrombin Complex Concentrates Use in Apixaban and Rivaroxaban Associated Intracranial Hemorrhages.	Rivaroxaban	63-74	coagulation factor II, thrombin	Homo sapiens	10-21
34036837-1	2021	STUDY OBJECTIVE: Summarize the studies evaluating the use of 4-factor prothrombin complex concentrates in the management of apixaban and rivaroxaban associated intracranial hemorrhages.	Rivaroxaban	137-148	coagulation factor II, thrombin	Homo sapiens	70-81
33788669-2	2021	It was recently shown that FXa induces platelet aggregation via protease activated receptor 1 (PAR-1) which is in turn attenuated by rivaroxaban.	Rivaroxaban	133-144	coagulation factor X	Homo sapiens	27-30
33612567-8	2021	Rivaroxaban attenuated RV remodeling in a rat model of PAH by reducing ERK, JNK and NF-kappaB activation.	Rivaroxaban	0-11	Eph receptor B1	Rattus norvegicus	71-74
33612567-8	2021	Rivaroxaban attenuated RV remodeling in a rat model of PAH by reducing ERK, JNK and NF-kappaB activation.	Rivaroxaban	0-11	mitogen-activated protein kinase 8	Rattus norvegicus	76-79
33884426-1	2021	This case report is about a 51-year-old active duty male with JAK2 mutation and medical history significant for prehepatic portal hypertension from portal vein thrombus on lifelong anticoagulation with rivaroxaban, an oral factor Xa inhibitor, presenting with closed-loop small bowel obstruction requiring emergent laparotomy.	Rivaroxaban	202-213	Janus kinase 2	Homo sapiens	62-66
33935730-0	2021	Influence of ABCB1 Gene Polymorphism on Rivaroxaban Blood Concentration and Hemorrhagic Events in Patients With Atrial Fibrillation.	Rivaroxaban	40-51	ATP binding cassette subfamily B member 1	Homo sapiens	13-18
33935730-2	2021	Here we tested the effects of ABCB1 (ATP-binding cassette subfamily B member 1) polymorphisms on the valley rivaroxaban blood concentration and on the frequency of hemorrhagic events in patients with AF and propose a personal anticoagulation therapy management protocol.	Rivaroxaban	108-119	ATP binding cassette subfamily B member 1	Homo sapiens	30-35
33935730-2	2021	Here we tested the effects of ABCB1 (ATP-binding cassette subfamily B member 1) polymorphisms on the valley rivaroxaban blood concentration and on the frequency of hemorrhagic events in patients with AF and propose a personal anticoagulation therapy management protocol.	Rivaroxaban	108-119	ATP binding cassette subfamily B member 1	Homo sapiens	37-78
33847849-1	2021	PURPOSE: The involvement of the intestinally expressed xenobiotic transporters P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP) have been implicated in rivaroxaban disposition based on in vitro studies, similar to what had previously been proposed for apixaban.	Rivaroxaban	169-180	ATP binding cassette subfamily B member 1	Homo sapiens	79-93
33847849-1	2021	PURPOSE: The involvement of the intestinally expressed xenobiotic transporters P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP) have been implicated in rivaroxaban disposition based on in vitro studies, similar to what had previously been proposed for apixaban.	Rivaroxaban	169-180	ATP binding cassette subfamily B member 1	Homo sapiens	95-99
33847849-1	2021	PURPOSE: The involvement of the intestinally expressed xenobiotic transporters P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP) have been implicated in rivaroxaban disposition based on in vitro studies, similar to what had previously been proposed for apixaban.	Rivaroxaban	169-180	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	105-137
33847849-1	2021	PURPOSE: The involvement of the intestinally expressed xenobiotic transporters P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP) have been implicated in rivaroxaban disposition based on in vitro studies, similar to what had previously been proposed for apixaban.	Rivaroxaban	169-180	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	139-143
33869783-3	2021	Rivaroxaban is a potent oral anticoagulant with the high selectivity of direct factor Xa inhibition.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	79-88
33725323-1	2021	BACKGROUND: Rivaroxaban is a selective inhibitor of coagulation factor Xa and its combination with aspirin showed better outcomes in the prevention of recurrent cardiovascular disease than aspirin alone.	Rivaroxaban	12-23	coagulation factor X	Homo sapiens	64-73
33788669-2	2021	It was recently shown that FXa induces platelet aggregation via protease activated receptor 1 (PAR-1) which is in turn attenuated by rivaroxaban.	Rivaroxaban	133-144	coagulation factor II thrombin receptor	Homo sapiens	64-93
33788669-2	2021	It was recently shown that FXa induces platelet aggregation via protease activated receptor 1 (PAR-1) which is in turn attenuated by rivaroxaban.	Rivaroxaban	133-144	coagulation factor II thrombin receptor	Homo sapiens	95-100
33788669-5	2021	This effect was abolished in the presence of 100pM rivaroxaban (Control 23.53 +- 14.15 ng/ml vs. FXa stimulated and rivaroxaban 22.15 +- 24.74 ng/ml; p = .5142).	Rivaroxaban	51-62	coagulation factor X	Homo sapiens	97-100
33788669-7	2021	Platelet aggregation quantified by maximum of aggregation (MoA%) was significantly lower in presence of rivaroxaban (U46619 40.18 +- 20.51% vs. U46619+ rivaroxaban 19.26 +- 15.46%; p = .0274).Conclusion: Our results indicate direct effects of rivaroxaban on the cyclooxygenase-1- TX axis during platelet aggregation.	Rivaroxaban	104-115	prostaglandin-endoperoxide synthase 1	Homo sapiens	262-278
33580664-8	2021	Rivaroxaban and betrixaban gained Food and Drug Administration (FDA) approval on the basis of results of the APEX and MARINER trials and a post hoc analysis of the MAGELLEN trial results.	Rivaroxaban	0-11	apurinic/apyrimidinic endodeoxyribonuclease 1	Homo sapiens	109-113
33276347-1	2021	Rivaroxaban (RXB), an oral direct factor Xa inhibitor, presents innovative therapeutic profile.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	34-43
33276347-1	2021	Rivaroxaban (RXB), an oral direct factor Xa inhibitor, presents innovative therapeutic profile.	Rivaroxaban	13-16	coagulation factor X	Homo sapiens	34-43
33733345-2	2022	Direct oral anticoagulants (DOACs), including the factor Xa inhibitor rivaroxaban, are used occasionally off-label for CVT based on individual treatment plans.	Rivaroxaban	70-81	coagulation factor X	Homo sapiens	50-59
33704609-4	2021	RECENT FINDINGS: The VOYAGER trial recently demonstrated that rivaroxaban 2.5 mg BID + ASA daily significantly reduces major adverse cardiac and limb events in patients following lower extremity revascularization.	Rivaroxaban	62-73	BH3 interacting domain death agonist	Homo sapiens	81-84
33870029-8	2021	The best correlation was observed with peak thrombin and rivaroxaban-specified anti-activated factor X (anti-Xa) activity (R2 = 0.60).	Rivaroxaban	57-68	coagulation factor II, thrombin	Homo sapiens	44-52
33685912-1	2021	We report the cases of two patients who developed worsening behavioural and psychological symptoms of dementia (BPSD), coinciding with starting the factor Xa inhibitor direct oral anticoagulant medications apixaban and rivaroxaban, respectively.	Rivaroxaban	219-230	coagulation factor X	Homo sapiens	148-157
33660875-2	2021	We evaluated the efficacy and safety of rivaroxaban, an oral direct factor Xa inhibitor, in subjects with sickle cell anemia.	Rivaroxaban	40-51	coagulation factor X	Homo sapiens	68-77
33660875-7	2021	Treatment with rivaroxaban resulted in a decrease from baseline of thrombin-antithrombin complex versus placebo (-34.4 ug/L [95% CI: -69.4, 0.53] vs. 0.35 ug/L [95% CI: -3.8, 4.5], p = .08), but the difference was not statistically significant.	Rivaroxaban	15-26	coagulation factor II, thrombin	Homo sapiens	67-75
33356742-1	2021	In the current study, chitosan (CS) caged classic liposomes (CLs) and flexible liposomes (FLs) were developed to enhance the oral bioavailability of rivaroxaban (RVX) in the fasted condition.	Rivaroxaban	149-160	citrate synthase	Homo sapiens	32-34
33356742-1	2021	In the current study, chitosan (CS) caged classic liposomes (CLs) and flexible liposomes (FLs) were developed to enhance the oral bioavailability of rivaroxaban (RVX) in the fasted condition.	Rivaroxaban	162-165	citrate synthase	Homo sapiens	32-34
33356742-6	2021	The result highlighted the efficacy of the prepared liquid formulation comprising CS coated liposomes in improving the oral bioavailability of RVX regardless of the fed state.	Rivaroxaban	143-146	citrate synthase	Homo sapiens	82-84
33856296-6	2021	Apixaban (52.1%) and rivaroxaban (45.8%) were the most commonly used fXa inhibitors.	Rivaroxaban	21-32	coagulation factor X	Homo sapiens	69-72
33609094-3	2021	RESULTS: 4F-PCC was ordered for 427 patients with warfarin-, apixaban-, or rivaroxaban-associated hemorrhage.	Rivaroxaban	75-86	crystallin gamma D	Homo sapiens	12-15
33599985-1	2021	Rivaroxaban is a factor-Xa inhibitor oral anticoagulant first approved for use in the United States in 2011.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	17-26
33234931-4	2021	Then, she has taken rivaroxaban (orally active direct factor Xa inhibitor) for 6 months and took follow-up V/Q scan.	Rivaroxaban	20-31	coagulation factor X	Homo sapiens	54-63
33227452-14	2021	In addition, FXa induced a significantly heightened expression of MMP2 in human aortic endothelial cells, which was ameliorated by rivaroxaban coadministration.	Rivaroxaban	131-142	coagulation factor X	Homo sapiens	13-16
32946681-6	2021	Overall, oral direct FXa (apixaban, betrixaban, edoxaban and rivaroxaban) and FIIa (dabigatran) antagonists may affect clot-based thrombophilia diagnostic tests resulting in false-positive or false-negative results.	Rivaroxaban	61-72	coagulation factor X	Homo sapiens	21-24
33227452-14	2021	In addition, FXa induced a significantly heightened expression of MMP2 in human aortic endothelial cells, which was ameliorated by rivaroxaban coadministration.	Rivaroxaban	131-142	matrix metallopeptidase 2	Homo sapiens	66-70
33227452-15	2021	CONCLUSIONS: Rivaroxaban attenuated both angiotensin II- and calcium chloride-induced abdominal aortic aneurysm (AAA) progressions, through inhibiting aortic remodeling and inflammation.	Rivaroxaban	13-24	angiotensinogen	Homo sapiens	41-55
33227452-16	2021	Rivaroxaban could be a promising therapeutic agent in attenuating AAA development by counteracting FXa-induced aortic wall inflammation.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	99-102
33505518-2	2021	In the last decade, DOACs were studied for various indications; this review is focused on rivaroxaban, a factor Xa inhibitor, which is used in an expanded evidence-based fashion for coronary artery disease, peripheral artery disease, heart failure, malignancy, and prophylaxis of deep venous thrombosis in acute medical illnesses.	Rivaroxaban	90-101	coagulation factor X	Homo sapiens	105-114
33440670-5	2021	Most of the results presented here have a lot to do with some SNPs of CES1 (rs2244613, rs8192935, and rs71647871) and ABCB1 (rs1128503, rs2032582, rs1045642, and rs4148738) genes, and dabigatran, rivaroxaban, and apixaban.	Rivaroxaban	196-207	carboxylesterase 1	Homo sapiens	70-74
33440670-5	2021	Most of the results presented here have a lot to do with some SNPs of CES1 (rs2244613, rs8192935, and rs71647871) and ABCB1 (rs1128503, rs2032582, rs1045642, and rs4148738) genes, and dabigatran, rivaroxaban, and apixaban.	Rivaroxaban	196-207	ATP binding cassette subfamily B member 1	Homo sapiens	118-123
33644649-2	2021	Rivaroxaban is a factor Xa and prothrombinase inhibitor indicated for stroke and venous thromboembolism prophylaxis in non-valvular atrial fibrillation as well as treatment of venous thromboembolism.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	17-26
33411110-0	2022	Identifying the Dominant Contribution of Human Cytochrome P450 2J2 to the Metabolism of Rivaroxaban, an Oral Anticoagulant.	Rivaroxaban	88-99	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	47-66
33411110-1	2022	PURPOSE: Rivaroxaban, an oral anticoagulant, undergoes the metabolism mediated by human cytochrome P450 (CYP).	Rivaroxaban	9-20	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	88-103
33411110-1	2022	PURPOSE: Rivaroxaban, an oral anticoagulant, undergoes the metabolism mediated by human cytochrome P450 (CYP).	Rivaroxaban	9-20	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	105-108
33411110-4	2022	Furthermore, the catalytic efficiency of CYP isoforms was compared via metabolic kinetic studies of rivaroxaban with recombinant CYP isoenzymes, as well as via CYP-specific inhibitory studies.	Rivaroxaban	100-111	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	41-44
33411110-6	2022	RESULTS: Multiple CYP isoforms were involved in the hydroxylation of rivaroxaban, with decreasing catalytic rates as follows: CYP2J2 > 3A4 > 2D6 > 4F3 > 1A1 > 3A5 > 3A7 > 2A6 > 2E1 > 2C9 > 2C19.	Rivaroxaban	69-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	18-21
33411110-6	2022	RESULTS: Multiple CYP isoforms were involved in the hydroxylation of rivaroxaban, with decreasing catalytic rates as follows: CYP2J2 > 3A4 > 2D6 > 4F3 > 1A1 > 3A5 > 3A7 > 2A6 > 2E1 > 2C9 > 2C19.	Rivaroxaban	69-80	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	126-132
33411110-8	2022	Notably, the intrinsic clearance of rivaroxaban catalyzed by CYP2J2 was nearly 39-, 64-, and 100-fold that catalyzed by CYP3A4, 2D6, and 4F3, respectively.	Rivaroxaban	36-47	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	61-67
33411110-8	2022	Notably, the intrinsic clearance of rivaroxaban catalyzed by CYP2J2 was nearly 39-, 64-, and 100-fold that catalyzed by CYP3A4, 2D6, and 4F3, respectively.	Rivaroxaban	36-47	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	120-126
33411110-9	2022	In addition, rivaroxaban hydroxylation was inhibited by 41.1% in the presence of the CYP2J2-specific inhibitor danazol, which was comparable to the inhibition rate of 43.3% by the CYP3A-specific inhibitor ketoconazole in mixed HLMs.	Rivaroxaban	13-24	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	85-91
33411110-9	2022	In addition, rivaroxaban hydroxylation was inhibited by 41.1% in the presence of the CYP2J2-specific inhibitor danazol, which was comparable to the inhibition rate of 43.3% by the CYP3A-specific inhibitor ketoconazole in mixed HLMs.	Rivaroxaban	13-24	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	180-185
33411110-10	2022	Furthermore, molecular simulations showed that rivaroxaban is principally bound to CYP2J2 by pi-alkyl bonds, carbon-hydrogen bonds, and alkyl interactions.	Rivaroxaban	47-58	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	83-89
33411110-11	2022	CONCLUSION: CYP2J2 dominated the hydroxylation of rivaroxaban, which may provide new insight into clinical drug interactions involving rivaroxaban.	Rivaroxaban	50-61	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	12-18
33411110-11	2022	CONCLUSION: CYP2J2 dominated the hydroxylation of rivaroxaban, which may provide new insight into clinical drug interactions involving rivaroxaban.	Rivaroxaban	135-146	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	12-18
33367661-13	2021	The DeltaAT in the FXa-based assay correlated with rivaroxaban and apixaban concentrations in the AT-deficient patients (r = 0.99, P < .001).	Rivaroxaban	51-62	coagulation factor X	Homo sapiens	19-22
32377955-0	2021	Thrombin Generation and other hemostatic parameters in patients with atrial fibrillation in use of warfarin or rivaroxaban.	Rivaroxaban	111-122	coagulation factor II, thrombin	Homo sapiens	0-8
33074284-3	2021	Design, Setting, and Participants: Subgroup analyses of the New Approach Rivaroxaban Inhibition of Factor Xa in a Global Trial vs Aspirin to Prevent Embolism in ESUS (NAVIGATE ESUS) international, double-blind, randomized, event-driven phase 3 clinical trial.	Rivaroxaban	73-84	coagulation factor X	Homo sapiens	99-108
33227452-0	2021	Factor Xa inhibitor rivaroxaban suppresses experimental abdominal aortic aneurysm progression via attenuating aortic inflammation.	Rivaroxaban	20-31	coagulation factor X	Homo sapiens	0-9
33227452-1	2021	OBJECTIVE: Rivaroxaban is a specific factor Xa (FXa) inhibitor for venous thromboembolism treatment.	Rivaroxaban	11-22	coagulation factor X	Homo sapiens	37-46
33227452-1	2021	OBJECTIVE: Rivaroxaban is a specific factor Xa (FXa) inhibitor for venous thromboembolism treatment.	Rivaroxaban	11-22	coagulation factor X	Homo sapiens	48-51
33227452-7	2021	In Ang II (angiotensin II)-infused ApoE-/- mice, the administration of high dose rivaroxaban (15 mg/kg/d) for 14 days significantly reduced the maximal aortic diameter, while low dose rivaroxaban (5 mg/kg/d) did not display such a protective role.	Rivaroxaban	81-92	angiotensinogen	Homo sapiens	11-25
33227452-7	2021	In Ang II (angiotensin II)-infused ApoE-/- mice, the administration of high dose rivaroxaban (15 mg/kg/d) for 14 days significantly reduced the maximal aortic diameter, while low dose rivaroxaban (5 mg/kg/d) did not display such a protective role.	Rivaroxaban	81-92	apolipoprotein E	Mus musculus	35-39
33227452-9	2021	Immunohistochemistry revealed a pronounced aortic remodeling including increased collagen content and enhanced elastin degradation in Ang II-induced AAAs, which was inhibited by high dose rivaroxaban treatment.	Rivaroxaban	188-199	elastin	Homo sapiens	111-118
33227452-10	2021	Further analysis demonstrated that rivaroxaban exerted its protective effects by decreasing leukocyte infiltration, inflammatory cytokines expression, and matrix metalloproteinases (MMPs) expression in the aortic wall.	Rivaroxaban	35-46	matrix metallopeptidase 2	Homo sapiens	182-186
33227452-12	2021	Mechanistically, in human aortic endothelial cells, FXa stimulation increased the expression of inflammatory cytokines (interleukin (IL)-1beta, IL-6, IL-8, monocyte chemoattractant protein-1) and adhesive molecules, which were all reversed by the cotreatment of rivaroxaban.	Rivaroxaban	262-273	coagulation factor X	Homo sapiens	52-55
33952817-7	2021	Since telmisartan is an inhibitor of P-glycoprotein (P-gp), the elimination of rivaroxaban and apixaban, which are substrates of P-gp, is hindered, resulting in increased blood levels of both drugs, thereby increasing the risk of hemorrhage.	Rivaroxaban	79-90	ATP binding cassette subfamily B member 1	Homo sapiens	37-51
33952817-7	2021	Since telmisartan is an inhibitor of P-glycoprotein (P-gp), the elimination of rivaroxaban and apixaban, which are substrates of P-gp, is hindered, resulting in increased blood levels of both drugs, thereby increasing the risk of hemorrhage.	Rivaroxaban	79-90	ATP binding cassette subfamily B member 1	Homo sapiens	53-57
33952817-7	2021	Since telmisartan is an inhibitor of P-glycoprotein (P-gp), the elimination of rivaroxaban and apixaban, which are substrates of P-gp, is hindered, resulting in increased blood levels of both drugs, thereby increasing the risk of hemorrhage.	Rivaroxaban	79-90	ATP binding cassette subfamily B member 1	Homo sapiens	129-133
34032122-3	2021	We evaluated in our study alterations in both platelet (PMP, CD42b) and endothelial-derived (EMP, CD144) microparticle levels on anticoagulant therapy with rivaroxaban in nonvalvular AF.	Rivaroxaban	156-167	cadherin 5	Homo sapiens	98-103
34032122-4	2021	After administration of rivaroxaban, PMP levels were increased (median, [IQR] 35.7 [28.8-47.3] vs. 48.4 [30.9-82.8] cells/microL; P = 0.012), along with an increase in EMP levels (14.6 [10.0-18.6] vs. 18.3 [12.9-37.1] cells/microL, P < 0.001).	Rivaroxaban	24-35	macrophage erythroblast attacher, E3 ubiquitin ligase	Homo sapiens	168-171
34032122-8	2021	Statins have promising potential in the prevention of rivaroxaban-related PMP and EMP release.	Rivaroxaban	54-65	macrophage erythroblast attacher, E3 ubiquitin ligase	Homo sapiens	82-85
33128729-1	2021	The article "Treatment of adults with intracranial hemorrhage on apixaban or rivaroxaban with prothrombin complex concentrate products", written by Renee Castillo, Alissa Chan, Steven Atallah, Katrina Derry, Mark Baje, Lara L. Zimmermann, Ryan Martin, Leonid Groysman, Sara Stern-Nezer, Anush Minokadeh, Alan Nova, WanTing Huang, William Cang, Kendra Schomer, was originally published electronically on the publisher"s internet portal on 4 June 2020 without open access.	Rivaroxaban	77-88	microtubule affinity regulating kinase 1	Homo sapiens	208-212
33644649-2	2021	Rivaroxaban is a factor Xa and prothrombinase inhibitor indicated for stroke and venous thromboembolism prophylaxis in non-valvular atrial fibrillation as well as treatment of venous thromboembolism.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	31-45
32279215-11	2020	Albumin levels were significantly associated with bleed risk in patients receiving rivaroxaban.	Rivaroxaban	83-94	albumin	Homo sapiens	0-7
33030266-2	2020	Since apixaban and rivaroxaban are predominantly eliminated by CYP3A and P-glycoprotein (P-gp), concomitant use of combined P-gp and strong CYP3A4 inhibitors and inducers should be avoided.	Rivaroxaban	19-30	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	63-68
33030266-2	2020	Since apixaban and rivaroxaban are predominantly eliminated by CYP3A and P-glycoprotein (P-gp), concomitant use of combined P-gp and strong CYP3A4 inhibitors and inducers should be avoided.	Rivaroxaban	19-30	ATP binding cassette subfamily B member 1	Homo sapiens	73-87
33030266-2	2020	Since apixaban and rivaroxaban are predominantly eliminated by CYP3A and P-glycoprotein (P-gp), concomitant use of combined P-gp and strong CYP3A4 inhibitors and inducers should be avoided.	Rivaroxaban	19-30	ATP binding cassette subfamily B member 1	Homo sapiens	89-93
33030266-2	2020	Since apixaban and rivaroxaban are predominantly eliminated by CYP3A and P-glycoprotein (P-gp), concomitant use of combined P-gp and strong CYP3A4 inhibitors and inducers should be avoided.	Rivaroxaban	19-30	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	140-146
33030266-5	2020	Furthermore, organic anion transporter-3 (OAT3), a renal uptake transporter, may also contribute the elimination of rivaroxaban from systemic circulation.	Rivaroxaban	116-127	solute carrier family 22 member 8	Homo sapiens	13-40
33030266-5	2020	Furthermore, organic anion transporter-3 (OAT3), a renal uptake transporter, may also contribute the elimination of rivaroxaban from systemic circulation.	Rivaroxaban	116-127	solute carrier family 22 member 8	Homo sapiens	42-46
33030266-10	2020	The developed apixaban and rivaroxaban models can be further applied to the investigation of interaction with other P-gp and/or CYP3A4 inhibitors and inducers.	Rivaroxaban	27-38	ATP binding cassette subfamily B member 1	Homo sapiens	116-120
33030266-10	2020	The developed apixaban and rivaroxaban models can be further applied to the investigation of interaction with other P-gp and/or CYP3A4 inhibitors and inducers.	Rivaroxaban	27-38	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	128-134
32700977-1	2020	BACKGROUND: Rivaroxaban is a highly selective factor Xa inhibitor approved for use in Europe for multiple indications.	Rivaroxaban	12-23	coagulation factor X	Homo sapiens	46-55
32279215-0	2020	Albumin and bleed risk in rivaroxaban treated patients.	Rivaroxaban	26-37	albumin	Homo sapiens	0-7
32279215-2	2020	Rivaroxaban is 92-95% protein bound, but the clinical effects of rivaroxaban in patients with low albumin are largely unknown.	Rivaroxaban	65-76	albumin	Homo sapiens	98-105
32279215-3	2020	The purpose of this study was to evaluate the relationship between albumin and bleeding in rivaroxaban treated patients.	Rivaroxaban	91-102	albumin	Homo sapiens	67-74
32279215-8	2020	The mean +- standard deviation albumin level nearest to the time of rivaroxaban initiation was significantly lower in patients who experienced a bleeding event (3.0 +- 0.75 g/dL vs 3.66 +- 0.54 g/dL, p < 0.0001).	Rivaroxaban	68-79	albumin	Homo sapiens	31-38
32900534-7	2020	For rivaroxaban, the trough anti-factor Xa concentration (AXA-C) (cutoff value of 400-500 ng/mL) had a sensitivity of 0.53 (95% CI, 0.16-0.87) and a specificity of 0.87 (95% CI, 0.71-0.94), with a diagnostic odds ratio of 7 (95% CI, 2-32).	Rivaroxaban	4-15	coagulation factor X	Homo sapiens	33-42
33301454-5	2020	RVX pre-treatment significantly reduced LPS mediated increase after 6h and 24h for IL-6 (4.4+-2.2 and 2.8+-1.7 fold), MCP-1 (1.4+-1.5 and 1.3+-1.4 fold) VCAM-1 (1.8+-2.0 and 1.7+-2.1 fold).	Rivaroxaban	0-3	interleukin 6	Rattus norvegicus	83-87
33301454-5	2020	RVX pre-treatment significantly reduced LPS mediated increase after 6h and 24h for IL-6 (4.4+-2.2 and 2.8+-1.7 fold), MCP-1 (1.4+-1.5 and 1.3+-1.4 fold) VCAM-1 (1.8+-2.0 and 1.7+-2.1 fold).	Rivaroxaban	0-3	mast cell protease 1-like 1	Rattus norvegicus	118-123
33301454-5	2020	RVX pre-treatment significantly reduced LPS mediated increase after 6h and 24h for IL-6 (4.4+-2.2 and 2.8+-1.7 fold), MCP-1 (1.4+-1.5 and 1.3+-1.4 fold) VCAM-1 (1.8+-2.0 and 1.7+-2.1 fold).	Rivaroxaban	0-3	vascular cell adhesion molecule 1	Rattus norvegicus	153-159
32356316-2	2020	We show that MA inhibited the enzymatic activity of FXa and platelet aggregation, induced by adenosine diphosphate (ADP) and a thromboxane A2 (TXA2 ) analog, U46619 with a similar antithrombotic efficacy to rivaroxaban, a direct FXa inhibitor used as a positive control.	Rivaroxaban	207-218	coagulation factor X	Homo sapiens	52-55
33444193-1	2020	OBJECTIVES: In the "Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism" (SELECT-D) trial, rivaroxaban showed relatively low venous thromboembolism (VTE) recurrence but higher bleeding compared with dalteparin in patients with cancer.	Rivaroxaban	167-178	coagulation factor X	Homo sapiens	42-51
33146024-1	2020	Rivaroxaban (RIV) is an oral anticoagulant that is the first available orally active direct inhibitor of factor Xa.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	105-114
33146024-1	2020	Rivaroxaban (RIV) is an oral anticoagulant that is the first available orally active direct inhibitor of factor Xa.	Rivaroxaban	13-16	coagulation factor X	Homo sapiens	105-114
32935597-3	2020	Rivaroxaban, a direct FXa inhibitor, offers the convenience of oral administration and predictable pharmacokinetics across a wide range of patients.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	22-25
33276942-4	2020	However, pharmacokinetic studies suggest that concomitant treatment with P-gp or CYP3A4 inhibitors will result in an increased exposure to rivaroxaban and apixaban, but the clinical relevance of these studies is unknown.	Rivaroxaban	139-150	phosphoglycolate phosphatase	Homo sapiens	73-77
33276942-4	2020	However, pharmacokinetic studies suggest that concomitant treatment with P-gp or CYP3A4 inhibitors will result in an increased exposure to rivaroxaban and apixaban, but the clinical relevance of these studies is unknown.	Rivaroxaban	139-150	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	81-87
33131001-3	2021	To investigate the age-related sensitivity to DOACs, we compared the pharmacological activity of the direct factor Xa inhibitor, rivaroxaban, between young and elderly subjects ex-vivo.	Rivaroxaban	129-140	coagulation factor X	Homo sapiens	108-117
33131001-7	2021	Rivaroxaban produced a greater prolongation of both Prothrombin Time (PT) and modified Prothrombin Time (mPT) (both p < 0.001) in the elderly compared to young subjects (with difference in mean PT increasing from 1.6 to 6.1s and for mPT from 23.5 to 71.1s at 100 ng/ml and 500 ng/ml plasma rivaroxaban concentration, respectively).	Rivaroxaban	0-11	coagulation factor II, thrombin	Homo sapiens	52-63
33131001-7	2021	Rivaroxaban produced a greater prolongation of both Prothrombin Time (PT) and modified Prothrombin Time (mPT) (both p < 0.001) in the elderly compared to young subjects (with difference in mean PT increasing from 1.6 to 6.1s and for mPT from 23.5 to 71.1s at 100 ng/ml and 500 ng/ml plasma rivaroxaban concentration, respectively).	Rivaroxaban	0-11	coagulation factor II, thrombin	Homo sapiens	87-98
33131001-9	2021	Rivaroxaban prolonged time-based parameters and suppressed the amount of thrombin generation to a significantly greater extent in the elderly compared to young subjects [%change from baseline for Endogenous Thrombin Potential (ETP): - 35.0 +- 4.4 vs - 29.8 +- 7.4 nM*min; p = 0.002].	Rivaroxaban	0-11	coagulation factor II, thrombin	Homo sapiens	73-81
33131001-9	2021	Rivaroxaban prolonged time-based parameters and suppressed the amount of thrombin generation to a significantly greater extent in the elderly compared to young subjects [%change from baseline for Endogenous Thrombin Potential (ETP): - 35.0 +- 4.4 vs - 29.8 +- 7.4 nM*min; p = 0.002].	Rivaroxaban	0-11	coagulation factor II, thrombin	Homo sapiens	207-215
32336024-7	2020	Amiodarone is predicted to increase rivaroxaban exposure, through inhibition of rivaroxaban elimination via CYP3A4 and P-gp.	Rivaroxaban	36-47	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	108-114
32336024-7	2020	Amiodarone is predicted to increase rivaroxaban exposure, through inhibition of rivaroxaban elimination via CYP3A4 and P-gp.	Rivaroxaban	36-47	phosphoglycolate phosphatase	Homo sapiens	119-123
32336024-7	2020	Amiodarone is predicted to increase rivaroxaban exposure, through inhibition of rivaroxaban elimination via CYP3A4 and P-gp.	Rivaroxaban	80-91	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	108-114
32336024-7	2020	Amiodarone is predicted to increase rivaroxaban exposure, through inhibition of rivaroxaban elimination via CYP3A4 and P-gp.	Rivaroxaban	80-91	phosphoglycolate phosphatase	Homo sapiens	119-123
32279215-12	2020	Albumin levels should be considered when evaluating candidates for rivaroxaban therapy.	Rivaroxaban	67-78	albumin	Homo sapiens	0-7
33408260-2	2020	Rivaroxaban, a factor Xa inhibitor, is a daily tablet approved for treatment of VTE and prophylaxis after orthopedic surgery.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	15-24
32537897-2	2020	METHODS: This cohort study was conducted using the British Clinical Practice Research Datalink (CPRD) to emulate the ROCKET AF (Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) trial.	Rivaroxaban	128-139	coagulation factor X	Homo sapiens	163-172
32975202-1	2020	Objectives For revealing the peculiarities of the drug-drug interaction of rivaroxaban (substrate CYP3A4 and P-gp) and calcium channel blockers (CCBs) (verapamil - inhibitor CYP3A4 and P-gp and amlodipine - substrate CYP3A4) in patients 80 years and older with nonvalvular atrial fibrillation (NAF) we studied 128 patients.	Rivaroxaban	75-86	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	98-104
32887180-1	2020	Objectives For revealing the peculiarities of the drug-drug interaction of rivaroxaban (substrate CYP3A4 and P-gp) and calcium channel blockers (CCBs) (verapamil - inhibitor CYP3A4 and P-gp and amlodipine - substrate CYP3A4) in patients 80 years and older with nonvalvular atrial fibrillation (NAF) we studied 128 patients.	Rivaroxaban	75-86	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	98-104
32887180-1	2020	Objectives For revealing the peculiarities of the drug-drug interaction of rivaroxaban (substrate CYP3A4 and P-gp) and calcium channel blockers (CCBs) (verapamil - inhibitor CYP3A4 and P-gp and amlodipine - substrate CYP3A4) in patients 80 years and older with nonvalvular atrial fibrillation (NAF) we studied 128 patients.	Rivaroxaban	75-86	phosphoglycolate phosphatase	Homo sapiens	109-113
32887180-1	2020	Objectives For revealing the peculiarities of the drug-drug interaction of rivaroxaban (substrate CYP3A4 and P-gp) and calcium channel blockers (CCBs) (verapamil - inhibitor CYP3A4 and P-gp and amlodipine - substrate CYP3A4) in patients 80 years and older with nonvalvular atrial fibrillation (NAF) we studied 128 patients.	Rivaroxaban	75-86	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	174-180
32887180-1	2020	Objectives For revealing the peculiarities of the drug-drug interaction of rivaroxaban (substrate CYP3A4 and P-gp) and calcium channel blockers (CCBs) (verapamil - inhibitor CYP3A4 and P-gp and amlodipine - substrate CYP3A4) in patients 80 years and older with nonvalvular atrial fibrillation (NAF) we studied 128 patients.	Rivaroxaban	75-86	phosphoglycolate phosphatase	Homo sapiens	185-189
32887180-1	2020	Objectives For revealing the peculiarities of the drug-drug interaction of rivaroxaban (substrate CYP3A4 and P-gp) and calcium channel blockers (CCBs) (verapamil - inhibitor CYP3A4 and P-gp and amlodipine - substrate CYP3A4) in patients 80 years and older with nonvalvular atrial fibrillation (NAF) we studied 128 patients.	Rivaroxaban	75-86	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	174-180
32975202-1	2020	Objectives For revealing the peculiarities of the drug-drug interaction of rivaroxaban (substrate CYP3A4 and P-gp) and calcium channel blockers (CCBs) (verapamil - inhibitor CYP3A4 and P-gp and amlodipine - substrate CYP3A4) in patients 80 years and older with nonvalvular atrial fibrillation (NAF) we studied 128 patients.	Rivaroxaban	75-86	phosphoglycolate phosphatase	Homo sapiens	185-189
32975202-1	2020	Objectives For revealing the peculiarities of the drug-drug interaction of rivaroxaban (substrate CYP3A4 and P-gp) and calcium channel blockers (CCBs) (verapamil - inhibitor CYP3A4 and P-gp and amlodipine - substrate CYP3A4) in patients 80 years and older with nonvalvular atrial fibrillation (NAF) we studied 128 patients.	Rivaroxaban	75-86	phosphoglycolate phosphatase	Homo sapiens	109-113
32975202-1	2020	Objectives For revealing the peculiarities of the drug-drug interaction of rivaroxaban (substrate CYP3A4 and P-gp) and calcium channel blockers (CCBs) (verapamil - inhibitor CYP3A4 and P-gp and amlodipine - substrate CYP3A4) in patients 80 years and older with nonvalvular atrial fibrillation (NAF) we studied 128 patients.	Rivaroxaban	75-86	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	174-180
32975202-1	2020	Objectives For revealing the peculiarities of the drug-drug interaction of rivaroxaban (substrate CYP3A4 and P-gp) and calcium channel blockers (CCBs) (verapamil - inhibitor CYP3A4 and P-gp and amlodipine - substrate CYP3A4) in patients 80 years and older with nonvalvular atrial fibrillation (NAF) we studied 128 patients.	Rivaroxaban	75-86	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	174-180
32804683-0	2020	Factor Xa Inhibitor, Rivaroxaban, Regulates the Burden of Atrial Fibrillation and Ventricular Premature Captures.	Rivaroxaban	21-32	coagulation factor X	Homo sapiens	0-9
32815916-5	2020	Here, we report two cases of recurrent VTE in two patients with hereditary protein S deficiency, owing to the same nonsense mutation in PROS1, which were successfully treated by rivaroxaban monotherapy.	Rivaroxaban	178-189	protein S	Homo sapiens	136-141
32855623-0	2020	Reversal of rivaroxaban anticoagulant effect by prothrombin complex concentrates: which dose is sufficient to restore normal thrombin generation?	Rivaroxaban	12-23	coagulation factor II, thrombin	Homo sapiens	48-59
32755422-4	2020	AREAS COVERED: The COMPASS trial demonstrated that in patients with stable atherosclerotic disease, very low-dose rivaroxaban, a direct factor Xa inhibitor, when combined with aspirin, reduced the rate of recurrent ischemic events, at the cost of increased bleeding.	Rivaroxaban	114-125	coagulation factor X	Homo sapiens	136-145
32113855-2	2020	This study assessed the relationships between rivaroxaban-specific anti-factor Xa activity (AXA) and unfractionated heparin (UFH)-specific AXA and determined the cutoff level for UFH-specific AXA in critical situations for patients undergoing rivaroxaban therapy.	Rivaroxaban	46-57	coagulation factor X	Homo sapiens	72-81
32521334-0	2020	Rivaroxaban ameliorates angiotensin II-induced cardiac remodeling by attenuating TXNIP/Trx2 interaction in KKAy mice.	Rivaroxaban	0-11	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	24-38
32521334-0	2020	Rivaroxaban ameliorates angiotensin II-induced cardiac remodeling by attenuating TXNIP/Trx2 interaction in KKAy mice.	Rivaroxaban	0-11	thioredoxin interacting protein	Mus musculus	81-86
32521334-0	2020	Rivaroxaban ameliorates angiotensin II-induced cardiac remodeling by attenuating TXNIP/Trx2 interaction in KKAy mice.	Rivaroxaban	0-11	thioredoxin 2	Mus musculus	87-91
32521334-2	2020	Based on those previous research results, we detected the roles of Rivaroxaban in Angiotensin II (AngII)-induced cardiac remodeling with KKAy mice and unraveled the underlying mechanisms.	Rivaroxaban	67-78	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	82-96
32521334-2	2020	Based on those previous research results, we detected the roles of Rivaroxaban in Angiotensin II (AngII)-induced cardiac remodeling with KKAy mice and unraveled the underlying mechanisms.	Rivaroxaban	67-78	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	98-103
32521334-3	2020	Rivaroxaban inhibited cardiac fibrosis and hypertrophy in AngII-infused KKAy mice.	Rivaroxaban	0-11	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	58-63
32521334-6	2020	Rivaroxaban inhibited the expression of thioredoxin binding protein (TXNIP) as well as the activation of apoptosis stimulating kinase 1 (ASK1).	Rivaroxaban	0-11	thioredoxin interacting protein	Mus musculus	40-67
32521334-6	2020	Rivaroxaban inhibited the expression of thioredoxin binding protein (TXNIP) as well as the activation of apoptosis stimulating kinase 1 (ASK1).	Rivaroxaban	0-11	thioredoxin interacting protein	Mus musculus	69-74
32521334-6	2020	Rivaroxaban inhibited the expression of thioredoxin binding protein (TXNIP) as well as the activation of apoptosis stimulating kinase 1 (ASK1).	Rivaroxaban	0-11	mitogen-activated protein kinase kinase kinase 5	Mus musculus	105-135
32521334-6	2020	Rivaroxaban inhibited the expression of thioredoxin binding protein (TXNIP) as well as the activation of apoptosis stimulating kinase 1 (ASK1).	Rivaroxaban	0-11	mitogen-activated protein kinase kinase kinase 5	Mus musculus	137-141
32521334-7	2020	In H9c2 cells treated with AngII and high glucose, Rivaroxaban inhibited TXNIP/thioredoxin2 (Trx2) interaction.	Rivaroxaban	51-62	angiotensinogen	Rattus norvegicus	27-32
32521334-7	2020	In H9c2 cells treated with AngII and high glucose, Rivaroxaban inhibited TXNIP/thioredoxin2 (Trx2) interaction.	Rivaroxaban	51-62	thioredoxin interacting protein	Rattus norvegicus	73-78
32521334-7	2020	In H9c2 cells treated with AngII and high glucose, Rivaroxaban inhibited TXNIP/thioredoxin2 (Trx2) interaction.	Rivaroxaban	51-62	thioredoxin 2	Rattus norvegicus	79-91
32521334-7	2020	In H9c2 cells treated with AngII and high glucose, Rivaroxaban inhibited TXNIP/thioredoxin2 (Trx2) interaction.	Rivaroxaban	51-62	thioredoxin 2	Mus musculus	93-97
32521334-9	2020	Thus, Rivaroxaban ameliorates AngII-induced cardiac remodeling via the suppression of TXNIP signaling in KKAy mice, providing novel mechanism underlying the protective roles of Rivaroxaban against cardiac damage.	Rivaroxaban	6-17	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	30-35
32521334-9	2020	Thus, Rivaroxaban ameliorates AngII-induced cardiac remodeling via the suppression of TXNIP signaling in KKAy mice, providing novel mechanism underlying the protective roles of Rivaroxaban against cardiac damage.	Rivaroxaban	6-17	thioredoxin interacting protein	Mus musculus	86-91
32521334-9	2020	Thus, Rivaroxaban ameliorates AngII-induced cardiac remodeling via the suppression of TXNIP signaling in KKAy mice, providing novel mechanism underlying the protective roles of Rivaroxaban against cardiac damage.	Rivaroxaban	177-188	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	30-35
32521334-9	2020	Thus, Rivaroxaban ameliorates AngII-induced cardiac remodeling via the suppression of TXNIP signaling in KKAy mice, providing novel mechanism underlying the protective roles of Rivaroxaban against cardiac damage.	Rivaroxaban	177-188	thioredoxin interacting protein	Mus musculus	86-91
33313467-1	2020	Background: Andexanet alfa (andexanet) is a modified human factor Xa (FXa) approved for anticoagulation reversal in patients with life-threatening bleeding treated with rivaroxaban or apixaban.	Rivaroxaban	169-180	coagulation factor X	Homo sapiens	70-73
32855623-0	2020	Reversal of rivaroxaban anticoagulant effect by prothrombin complex concentrates: which dose is sufficient to restore normal thrombin generation?	Rivaroxaban	12-23	coagulation factor II, thrombin	Homo sapiens	51-59
32855623-1	2020	Rivaroxaban has the most available data to support the use of prothrombin complex concentrates (PCC) as a reversal agent.	Rivaroxaban	0-11	coagulation factor II, thrombin	Homo sapiens	62-73
33305222-10	2020	Conclusions: This study provides a first look at how the introduction of rivaroxaban 2.5 mg might be integrated into the clinical management of ACS patients beyond the first year in Canada.	Rivaroxaban	73-84	1-aminocyclopropane-1-carboxylate synthase homolog (inactive)	Homo sapiens	144-147
33155949-6	2020	For prevention of complications in patients with AF and DM, current antithrombotic therapies can be used, specifically the oral factor Xa inhibitor, rivaroxaban, which is the best studied in patients with AF and DM and represents a possible alternative to warfarin in such patients.	Rivaroxaban	149-160	coagulation factor X	Homo sapiens	128-137
32762584-10	2021	Rivaroxaban and dabigatran inhibit OEC and HUVEC activation by FXa and thrombin, respectively.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	63-66
32762584-10	2021	Rivaroxaban and dabigatran inhibit OEC and HUVEC activation by FXa and thrombin, respectively.	Rivaroxaban	0-11	coagulation factor II	Mus musculus	71-79
32762584-11	2021	Rivaroxaban enhances thrombin-induced OEC and HUVEC activation, which is completely inhibited by vorapaxar.	Rivaroxaban	0-11	coagulation factor II	Mus musculus	21-29
32142808-0	2020	Rivaroxaban and dabigatran for suppression of mechanical heart valve-induced thrombin generation (Commentary).	Rivaroxaban	0-11	coagulation factor II, thrombin	Homo sapiens	77-85
32173474-0	2020	Factor Xa Inhibition by Rivaroxaban Modified Mitochondrial-Associated Proteins in Human Abdominal Aortic Aneurysms.	Rivaroxaban	24-35	coagulation factor X	Homo sapiens	0-9
32173474-5	2020	The effect of FXa was analyzed by in vitro incubation of AAA with 50 nmol/L rivaroxaban, an oral FXa inhibitor.	Rivaroxaban	76-87	coagulation factor X	Homo sapiens	14-17
32173474-5	2020	The effect of FXa was analyzed by in vitro incubation of AAA with 50 nmol/L rivaroxaban, an oral FXa inhibitor.	Rivaroxaban	76-87	coagulation factor X	Homo sapiens	97-100
32173474-7	2020	The addition of rivaroxaban to AAA reverted the activity of both citrate synthase and cytochrome C oxidase to similar values to control.	Rivaroxaban	16-27	citrate synthase	Homo sapiens	65-81
32173474-8	2020	Mitochondrial Drp-1 expression was higher in AAA sites than in either control aortas or rivaroxaban-incubated AAA sites.	Rivaroxaban	88-99	utrophin	Homo sapiens	14-19
30614371-1	2020	Andexanet alfa is the newly approved factor Xa inhibitor reversal agent for the treatment of life-threatening or uncontrolled bleeding from apixaban or rivaroxaban.	Rivaroxaban	152-163	coagulation factor X	Homo sapiens	37-46
32166540-0	2020	Monitoring the roles of prothrombin activation fragment 1 and 2 (F1 + 2) in patients with atrial fibrillation receiving rivaroxaban and apixaban.	Rivaroxaban	120-131	coagulation factor XII	Homo sapiens	65-71
32166540-10	2020	In the peri-ablation study, increased F1 + 2 levels were associated with decline of C-Xa levels after periprocedural discontinuation of FXa inhibitors, which was greater in the rivaroxaban group than in the apixaban group.	Rivaroxaban	177-188	coagulation factor XII	Homo sapiens	38-44
32166540-10	2020	In the peri-ablation study, increased F1 + 2 levels were associated with decline of C-Xa levels after periprocedural discontinuation of FXa inhibitors, which was greater in the rivaroxaban group than in the apixaban group.	Rivaroxaban	177-188	coagulation factor X	Homo sapiens	136-139
32358665-3	2020	Present hypothesis was aimed to examine the nephroprotective potential of RIVA in SUN-induced nephrotoxicity, mediated through the inhibition of oxidative stress-induced apoptosis and inflammation, via the TNF-alpha/NFk-B signaling pathways.	Rivaroxaban	74-78	tumor necrosis factor	Rattus norvegicus	206-215
32358665-3	2020	Present hypothesis was aimed to examine the nephroprotective potential of RIVA in SUN-induced nephrotoxicity, mediated through the inhibition of oxidative stress-induced apoptosis and inflammation, via the TNF-alpha/NFk-B signaling pathways.	Rivaroxaban	74-78	nuclear factor kappa B subunit 1	Rattus norvegicus	216-221
32517582-2	2020	METHODS: Exploratory analysis of major bleeds defined by International Society of Thrombosis and Hemostasis criteria occurring among 7213 participants in international NAVIGATE (New Approach Rivaroxaban Inhibition of Factor Xa in a Global trial) embolic stroke of undetermined source randomized trial comparing rivaroxaban 15 mg daily with aspirin 100 mg daily.	Rivaroxaban	191-202	coagulation factor X	Homo sapiens	217-226
32793635-4	2020	Therefore, this study was designed to define whether patients with AF treated either with an activated coagulation factor X (FXa) inhibitor (rivaroxaban) or with a vitamin K inhibitor (warfarin) present changes in peripheral levels of inflammatory mediators, mainly cytokines and chemokines.	Rivaroxaban	141-152	coagulation factor X	Homo sapiens	103-123
32793635-4	2020	Therefore, this study was designed to define whether patients with AF treated either with an activated coagulation factor X (FXa) inhibitor (rivaroxaban) or with a vitamin K inhibitor (warfarin) present changes in peripheral levels of inflammatory mediators, mainly cytokines and chemokines.	Rivaroxaban	141-152	coagulation factor X	Homo sapiens	125-128
32793635-9	2020	On the other hand, patients with AF using rivaroxaban presented increased levels of the chemokines (MCP-1 in comparison with warfarin users; MIG and IP-10 in comparison with controls).	Rivaroxaban	42-53	C-C motif chemokine ligand 2	Homo sapiens	100-105
32793635-9	2020	On the other hand, patients with AF using rivaroxaban presented increased levels of the chemokines (MCP-1 in comparison with warfarin users; MIG and IP-10 in comparison with controls).	Rivaroxaban	42-53	C-X-C motif chemokine ligand 9	Homo sapiens	141-144
32793635-9	2020	On the other hand, patients with AF using rivaroxaban presented increased levels of the chemokines (MCP-1 in comparison with warfarin users; MIG and IP-10 in comparison with controls).	Rivaroxaban	42-53	C-X-C motif chemokine ligand 10	Homo sapiens	149-154
32673510-4	2020	In patients without an indication for anticoagulation, the use of low doses of the factor Xa inhibitor, rivaroxaban, has shown benefit.	Rivaroxaban	104-115	coagulation factor X	Homo sapiens	83-92
32674675-10	2020	Thrombin-antithrombin complex and D-dimers were numerically lower with both rivaroxaban doses than with DAPT.	Rivaroxaban	76-87	coagulation factor II, thrombin	Homo sapiens	0-8
32674675-14	2020	CONCLUSIONS: Thrombin generation measured after LAAC was lower in patients treated by reduced rivaroxaban doses than DAPT, supporting an alternative to the antithrombotic regimens currently used after LAAC and deserves further evaluation in larger studies.	Rivaroxaban	94-105	coagulation factor II, thrombin	Homo sapiens	13-21
32323191-6	2020	Predicted rivaroxaban exposure and CrCl were significantly associated with both efficacy outcomes in the BID period.	Rivaroxaban	10-21	BH3 interacting domain death agonist	Homo sapiens	105-108
32605001-0	2020	Delayed Thrombin Generation Is Associated with Minor Bleedings in Venous Thromboembolism Patients on Rivaroxaban: Usefulness of Calibrated Automated Thrombography.	Rivaroxaban	101-112	coagulation factor II, thrombin	Homo sapiens	8-16
32605001-8	2020	By logistic regression, time to start thrombin generation (p = 0.007) and unprovoked VTE (p = 0.041) independently predicted MBs on rivaroxaban.	Rivaroxaban	132-143	coagulation factor II, thrombin	Homo sapiens	38-46
32605001-11	2020	Time to start thrombin generation measured about 24 h since the last rivaroxaban dose might help predict MBs.	Rivaroxaban	69-80	coagulation factor II, thrombin	Homo sapiens	14-22
32676276-2	2020	Target-specific anticoagulant rivaroxaban is a direct factor Xa inhibitor that can be safely used without laboratory monitoring.	Rivaroxaban	30-41	coagulation factor X	Homo sapiens	54-63
32461505-0	2020	Anti-Factor Xa Activity of Standard and Japan-Specific Doses of Rivaroxaban in Thai Patients With Non-Valvular Atrial Fibrillation.	Rivaroxaban	64-75	coagulation factor X	Homo sapiens	5-14
32461505-9	2020	CONCLUSIONS: A significantly higher proportion of Thai patients receiving the Japan-specific dose of rivaroxaban had anti-FXa activity at peak concentrations within the expected range.	Rivaroxaban	101-112	coagulation factor X	Homo sapiens	122-125
32466800-9	2020	The range of the steady state concentration in patients that took 15 mg rivaroxaban twice daily, 10 mg twice daily, 20 mg once daily, 15 mg once daily, and 10 mg once daily were 168.5 ~ 280.1 ng mL- 1, 74.2 ~ 271.4 ng mL- 1, 25.7 ~ 306.8 ng mL- 1, 24.5 ~ 306.4 ng mL- 1, and 15.4 ~ 229.2 ng mL- 1, respectively.	Rivaroxaban	72-83	L1 cell adhesion molecule	Mus musculus	195-200
32301471-7	2020	Based on these linear functions, we can analyse the rivaroxaban concentration with a detection time of 1 minute per test and the lowest detection limit of 2 mumol mL-1.	Rivaroxaban	52-63	L1 cell adhesion molecule	Mus musculus	163-167
32301471-8	2020	As compared to Raman spectroscopy method (its detection limit is about 80 mumol mL-1), our method has more potential and is practical for the clinical quantitative detection of rivaroxaban as well as other direct oral anticoagulants.	Rivaroxaban	177-188	L1 cell adhesion molecule	Mus musculus	80-84
32523458-6	2020	In the COMPASS study, the association of aspirin with the factor Xa inhibitor, rivaroxaban, in a dose of one-fourth of the dose used in atrial fibrillation, decreased by more than 20% the incidence of CV events in patients with multi-district ATS.	Rivaroxaban	79-90	coagulation factor X	Homo sapiens	58-67
32078255-9	2020	Roughly biphasic effects of rivaroxaban and dabigatran but not apixaban or edoxaban on fibrinolysis were observed through Maxn 1 and the fibrinolysis peak time, which was defined as a time length from the time when Maxp 1 (Maxp 1 time) to the time when Maxn 1 appears (Maxn 1 time).	Rivaroxaban	28-39	Ras association domain family member 5	Homo sapiens	215-221
32078255-9	2020	Roughly biphasic effects of rivaroxaban and dabigatran but not apixaban or edoxaban on fibrinolysis were observed through Maxn 1 and the fibrinolysis peak time, which was defined as a time length from the time when Maxp 1 (Maxp 1 time) to the time when Maxn 1 appears (Maxn 1 time).	Rivaroxaban	28-39	Ras association domain family member 5	Homo sapiens	223-229
32379576-0	2020	Letter by Violi et al Regarding Article, "Rivaroxaban Reduces Arterial Thrombosis by Inhibition of Fxa-Driven Platelet Activation via Protease Activated Receptor-1".	Rivaroxaban	42-53	coagulation factor X	Homo sapiens	99-102
32379576-0	2020	Letter by Violi et al Regarding Article, "Rivaroxaban Reduces Arterial Thrombosis by Inhibition of Fxa-Driven Platelet Activation via Protease Activated Receptor-1".	Rivaroxaban	42-53	coagulation factor II thrombin receptor	Homo sapiens	134-164
32379578-0	2020	Response by Petzold et al to Letter Regarding Article, "Rivaroxaban Reduces Arterial Thrombosis by Inhibition of Fxa-Driven Platelet Activation via Protease Activated Receptor-1".	Rivaroxaban	56-67	coagulation factor X	Homo sapiens	113-116
32379578-0	2020	Response by Petzold et al to Letter Regarding Article, "Rivaroxaban Reduces Arterial Thrombosis by Inhibition of Fxa-Driven Platelet Activation via Protease Activated Receptor-1".	Rivaroxaban	56-67	coagulation factor II thrombin receptor	Homo sapiens	148-178
32271680-0	2020	Response by Petzold et al to Letter Regarding Article, "Rivaroxaban Reduces Arterial Thrombosis by Inhibition of FXa-Driven Platelet Activation via Protease Activated Receptor-1".	Rivaroxaban	56-67	coagulation factor X	Homo sapiens	113-116
31991279-8	2020	Rivaroxaban and its most prominent transformation product acetoxamide were elucidated in multiple-stage mass spectrometry (MSn) experiments.	Rivaroxaban	0-11	moesin	Homo sapiens	123-126
32484618-3	2020	Specifically, rivaroxaban, a direct factor Xa inhibitor NOAC, has been shown to be successful in the treatment of livedoid vasculopathy.	Rivaroxaban	14-25	coagulation factor X	Homo sapiens	36-45
32271680-0	2020	Response by Petzold et al to Letter Regarding Article, "Rivaroxaban Reduces Arterial Thrombosis by Inhibition of FXa-Driven Platelet Activation via Protease Activated Receptor-1".	Rivaroxaban	56-67	coagulation factor II thrombin receptor	Homo sapiens	148-178
32271683-0	2020	Letter by Borst Regarding Article, "Rivaroxaban Reduces Arterial Thrombosis by Inhibition of FXa Driven Platelet Activation via Protease Activated Receptor-1".	Rivaroxaban	36-47	coagulation factor X	Homo sapiens	93-96
32271683-0	2020	Letter by Borst Regarding Article, "Rivaroxaban Reduces Arterial Thrombosis by Inhibition of FXa Driven Platelet Activation via Protease Activated Receptor-1".	Rivaroxaban	36-47	coagulation factor II thrombin receptor	Homo sapiens	128-158
32548552-2	2020	Anticoagulants are the cornerstone of therapy for the treatment and prevention of cancer-associated thrombosis (CAT); factor Xa-inhibiting direct oral anticoagulants (DOACs; apixaban, edoxaban, and rivaroxaban), which have long been recommended for the treatment of VTE in patients without cancer, have been investigated in this setting.	Rivaroxaban	198-209	coagulation factor X	Homo sapiens	118-127
31340380-1	2020	Rivaroxaban (Xarelto; Johnson & Johnson Services, Inc) is a direct oral anticoagulant (DOAC) that works by directly inhibiting the active site of factor Xa (FXa).	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	146-155
31195162-7	2020	Rivaroxaban, but not other NOACs, was associated with an increased risk for major GIB (RR from randomized controlled trials, 1.39; 95% CI, 1.17-1.65 and aHR from real-world studies, 1.14; 95% CI, 1.04-1.23; Pinteraction = .06).	Rivaroxaban	0-11	aryl hydrocarbon receptor	Homo sapiens	153-156
32039550-6	2020	RESULTS: Our data confirmed the overestimation of apixaban and rivaroxaban levels by the antithrombin-supplemented anti-Xa method (Berichrom).	Rivaroxaban	63-74	serpin family C member 1	Homo sapiens	89-101
31340380-1	2020	Rivaroxaban (Xarelto; Johnson & Johnson Services, Inc) is a direct oral anticoagulant (DOAC) that works by directly inhibiting the active site of factor Xa (FXa).	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	157-160
33693223-8	2020	Rivaroxaban also downregulated the mRNA expression levels of tumor necrosis factor-alpha, transforming growth factor-beta, PAR-1 and PAR-2 in the infarcted area, and both A-type and B-type natriuretic peptides in the non-infarcted area compared with the vehicle.	Rivaroxaban	0-11	tumor necrosis factor	Mus musculus	61-88
33693223-8	2020	Rivaroxaban also downregulated the mRNA expression levels of tumor necrosis factor-alpha, transforming growth factor-beta, PAR-1 and PAR-2 in the infarcted area, and both A-type and B-type natriuretic peptides in the non-infarcted area compared with the vehicle.	Rivaroxaban	0-11	coagulation factor II (thrombin) receptor	Mus musculus	123-128
33693223-8	2020	Rivaroxaban also downregulated the mRNA expression levels of tumor necrosis factor-alpha, transforming growth factor-beta, PAR-1 and PAR-2 in the infarcted area, and both A-type and B-type natriuretic peptides in the non-infarcted area compared with the vehicle.	Rivaroxaban	0-11	pulmonary adenoma resistance 2	Mus musculus	133-138
32180831-5	2020	Rivaroxaban 15 mg once daily plus a P2Y12 inhibitor compared with a VKA regimen was associated with a reduction of bleedings (HR 0.59; 95% CI [0.47-0.76]; p<0.001).	Rivaroxaban	0-11	purinergic receptor P2Y12	Homo sapiens	36-41
31945490-1	2020	ABC transporters, such as P-gp and BCRP, are involved in rivaroxaban pharmacokinetics and can lead to drug-drug interactions (DDIs).	Rivaroxaban	57-68	phosphoglycolate phosphatase	Homo sapiens	26-30
31945490-1	2020	ABC transporters, such as P-gp and BCRP, are involved in rivaroxaban pharmacokinetics and can lead to drug-drug interactions (DDIs).	Rivaroxaban	57-68	BCR pseudogene 1	Homo sapiens	35-39
31945490-3	2020	However, interpretation of rivaroxaban efflux transport and DDI studies in cell models may be influenced by P-gp and BCRP transporter abundance.	Rivaroxaban	27-38	phosphoglycolate phosphatase	Homo sapiens	108-112
31945490-3	2020	However, interpretation of rivaroxaban efflux transport and DDI studies in cell models may be influenced by P-gp and BCRP transporter abundance.	Rivaroxaban	27-38	BCR pseudogene 1	Homo sapiens	117-121
31893985-4	2020	Methods- We examined the association between atrial cardiopathy and atherosclerotic plaque in the NAVIGATE ESUS trial (New Approach Rivaroxaban Inhibition of Factor Xa in a Global Trial Versus ASA to Prevent Embolism in Embolic Stroke of Undetermined Source), which enrolled 7213 patients with recent ESUS during 2014 to 2017.	Rivaroxaban	132-143	coagulation factor X	Homo sapiens	158-167
31859592-0	2020	Rivaroxaban Reduces Arterial Thrombosis by Inhibition of FXa-Driven Platelet Activation via Protease Activated Receptor-1.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	57-60
31859592-0	2020	Rivaroxaban Reduces Arterial Thrombosis by Inhibition of FXa-Driven Platelet Activation via Protease Activated Receptor-1.	Rivaroxaban	0-11	coagulation factor II thrombin receptor	Homo sapiens	92-121
31859592-1	2020	RATIONALE: A reduced rate of myocardial infarction has been reported in patients with atrial fibrillation treated with FXa (factor Xa) inhibitors including rivaroxaban compared with vitamin K antagonists.	Rivaroxaban	156-167	coagulation factor X	Homo sapiens	119-122
31859592-1	2020	RATIONALE: A reduced rate of myocardial infarction has been reported in patients with atrial fibrillation treated with FXa (factor Xa) inhibitors including rivaroxaban compared with vitamin K antagonists.	Rivaroxaban	156-167	coagulation factor X	Homo sapiens	124-133
31859592-5	2020	METHODS AND RESULTS: In this study, we identified FXa as potent, direct agonist of the PAR-1 (protease-activated receptor 1), leading to platelet activation and thrombus formation, which can be inhibited by rivaroxaban.	Rivaroxaban	207-218	coagulation factor X	Homo sapiens	50-53
31859592-5	2020	METHODS AND RESULTS: In this study, we identified FXa as potent, direct agonist of the PAR-1 (protease-activated receptor 1), leading to platelet activation and thrombus formation, which can be inhibited by rivaroxaban.	Rivaroxaban	207-218	coagulation factor II thrombin receptor	Homo sapiens	87-92
31859592-5	2020	METHODS AND RESULTS: In this study, we identified FXa as potent, direct agonist of the PAR-1 (protease-activated receptor 1), leading to platelet activation and thrombus formation, which can be inhibited by rivaroxaban.	Rivaroxaban	207-218	coagulation factor II thrombin receptor	Homo sapiens	94-123
31733180-1	2020	BACKGROUND: Whether the direct factor Xa inhibitor rivaroxaban can prevent thromboembolic events after transcatheter aortic-valve replacement (TAVR) is unclear.	Rivaroxaban	51-62	coagulation factor X	Homo sapiens	31-40
32134407-1	2020	Although having different rationales and purposes, the PEGASUS-TIMI 54 and COMPASS trials present various points of contact and, especially after the first recommended year of dual antiplatelet therapy (DAPT) from an acute coronary syndrome, pose the clinical question of whether DAPT should be prolonged (PEGASUS strategy) or aspirin should be maintained by combining rivaroxaban 2.5 mg bid (COMPASS strategy).	Rivaroxaban	369-380	IKAROS family zinc finger 5	Homo sapiens	55-70
32134407-1	2020	Although having different rationales and purposes, the PEGASUS-TIMI 54 and COMPASS trials present various points of contact and, especially after the first recommended year of dual antiplatelet therapy (DAPT) from an acute coronary syndrome, pose the clinical question of whether DAPT should be prolonged (PEGASUS strategy) or aspirin should be maintained by combining rivaroxaban 2.5 mg bid (COMPASS strategy).	Rivaroxaban	369-380	IKAROS family zinc finger 5	Homo sapiens	55-62
31506888-0	2020	Determination of the cut-off prothrombin time to estimate plasma rivaroxaban overdose status.	Rivaroxaban	65-76	coagulation factor II, thrombin	Homo sapiens	29-40
32158254-0	2020	CYP2C19*17 May Increase the Risk of Death Among Patients with an Acute Coronary Syndrome and Non-Valvular Atrial Fibrillation Who Receive Clopidogrel and Rivaroxaban.	Rivaroxaban	154-165	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	0-7
32158254-6	2020	Conclusion: In situations of double or triple antithrombotic rivaroxaban and clopidogrel therapy among patients with atrial fibrillation and acute coronary syndrome, the genetic factors associated with bleeding complications risk (CYP2C19*17) may prove to be clinically relevant.	Rivaroxaban	61-72	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	231-238
31120118-0	2020	Early discharge and home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: an international multicentre single-arm clinical trial.	Rivaroxaban	114-125	coagulation factor X	Homo sapiens	94-103
31120118-1	2020	AIMS: To investigate the efficacy and safety of early transition from hospital to ambulatory treatment in low-risk acute PE, using the oral factor Xa inhibitor rivaroxaban.	Rivaroxaban	160-171	coagulation factor X	Homo sapiens	140-149
31532233-1	2020	Background: Rivaroxaban (Xarelto) is a reversible direct factor Xa inhibitor used for the treatment and prevention of coagulation in numerous syndromes.	Rivaroxaban	12-23	coagulation factor X	Homo sapiens	57-66
31912715-4	2019	Decreased ischemic events have been reported while comparing oral rivaroxaban and apixaban with aspirin to improve the therapeutic outcome in several clinical trials, including Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis in Myocardial Infarction 51, Apixaban for Prevention of Acute Ischemic and Safety Events, and GEMINI-ACS-1 phase II clinical trials.	Rivaroxaban	66-77	acyl-CoA synthetase long chain family member 1	Homo sapiens	411-416
31977912-12	2020	LESSONS: This case highlights that rivaroxaban, as a direct inhibitor of activated factor Xa, demonstrates a good therapeutic efficacy for treating AFE with DIC.	Rivaroxaban	35-46	coagulation factor X	Homo sapiens	83-92
30569801-1	2020	Factor Xa inhibitors are safe and effective alternatives to warfarin, but several studies indicate that rivaroxaban may cause a different risk profile for bleeding.	Rivaroxaban	104-115	coagulation factor X	Homo sapiens	0-9
30569801-10	2020	There was a trend toward a reduction of P-selectin during rivaroxaban treatment (peak concentration) compared to value without treatment (p = 0.06).	Rivaroxaban	58-69	selectin P	Homo sapiens	40-50
31397594-7	2020	Our case illustrates fondaparinux cross-reactivity in HIT manifesting as persisting thrombocytopenia, new thrombosis, and DIC, with successful rivaroxaban treatment, adding to emerging data that oral factor Xa inhibitors are efficacious for treating HIT.	Rivaroxaban	143-154	coagulation factor X	Homo sapiens	200-209
32862668-10	2020	Drug-drug interactions with apixaban and rivaroxaban was independently associated with the absence of CYP3A4 competition, P-glycoprotein inhibition, CYP3A4 induction, and drug class of tyrosine kinase inhibitors.	Rivaroxaban	41-52	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	102-108
32862668-10	2020	Drug-drug interactions with apixaban and rivaroxaban was independently associated with the absence of CYP3A4 competition, P-glycoprotein inhibition, CYP3A4 induction, and drug class of tyrosine kinase inhibitors.	Rivaroxaban	41-52	ATP binding cassette subfamily B member 1	Homo sapiens	122-136
32862668-10	2020	Drug-drug interactions with apixaban and rivaroxaban was independently associated with the absence of CYP3A4 competition, P-glycoprotein inhibition, CYP3A4 induction, and drug class of tyrosine kinase inhibitors.	Rivaroxaban	41-52	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	149-155
32128502-10	2020	Direct factor Xa inhibition by rivaroxaban provided an alternative mechanism for anticoagulation, which was found to be particularly useful in this patient with familial AT III deficiency, deep vein thrombosis, and PE.	Rivaroxaban	31-42	coagulation factor X	Homo sapiens	7-16
31393055-4	2019	OBJECTIVES: To test the hypothesis that the factor Xa inhibitor rivaroxaban reduces the growth of tissue factor (TF)-positive pancreatic tumors but not TF-negative pancreatic tumors in mice.	Rivaroxaban	64-75	coagulation factor X	Homo sapiens	44-53
31393055-10	2019	CONCLUSION: Our results indicate that inhibition of factor Xa with rivaroxaban does not affect the growth of two human pancreatic tumors in nude mice.	Rivaroxaban	67-78	coagulation factor X	Homo sapiens	52-61
31677449-0	2019	Concomitant assessment of rivaroxaban concentration and its impact on thrombin generation.	Rivaroxaban	26-37	coagulation factor II, thrombin	Homo sapiens	70-78
31677449-12	2019	CONCLUSIONS: Xross-CAT shows a good correlation with Biophen DiXaI that was previously confirmed to accurately assess rivaroxaban levels.	Rivaroxaban	118-129	catalase	Homo sapiens	19-22
31677591-5	2019	The decrease in the anti-factor Chia activity was also smaller in the patients with apixaban (-73.8 +- 12.7%) than with rivaroxaban (-87.9 +- 7.9%; P < 0.001) and edoxaban (N = 22, -81.9 +- 15.2%; P = 0.049), and its remaining activity 24 h after the last dose was the highest in the apixaban group.	Rivaroxaban	120-131	chitinase acidic	Homo sapiens	32-36
31706067-1	2019	This review provides the rationale for dual pathway inhibition with the combination of low-dose rivaroxaban (2.5 mg twice daily) to attenuate thrombin generation and aspirin (100 mg once daily) to reduce platelet activation.	Rivaroxaban	96-107	coagulation factor II, thrombin	Homo sapiens	142-150
31276324-0	2019	Enhancing the Quality of Rivaroxaban Exposure Estimates Using Prothrombin Time in the Absence of Pharmacokinetic Sampling.	Rivaroxaban	25-36	coagulation factor II, thrombin	Homo sapiens	62-73
31276324-1	2019	Prothrombin time (PT) is a measure of coagulation status and was assessed in the majority of patients in the rivaroxaban phase II and III clinical trials as a pharmacodynamic marker.	Rivaroxaban	109-120	coagulation factor II, thrombin	Homo sapiens	0-11
31506301-8	2019	Consideration of basolateral organic anion transporter (OAT) 3-mediated proximal tubular uptake in tandem with apical P-glycoprotein (P-gp)-mediated efflux facilitated mechanistic characterization of the renal elimination of rivaroxaban in both healthy and renal impaired patients.	Rivaroxaban	225-236	ATP binding cassette subfamily B member 1	Homo sapiens	118-132
31506301-9	2019	Retrospective drug-drug interaction (DDI) simulations, incorporating in vitro metabolic inhibitory parameters, accurately recapitulated clinically observed attenuation of rivaroxaban"s hepatic clearance due to enzyme-mediated DDIs with CYP3A4/2J2 inhibitors (verapamil and ketoconazole).	Rivaroxaban	171-182	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	236-242
31506301-10	2019	Notably, transporter-mediated DDI simulations between rivaroxaban and P-gp inhibitors (verapamil and ketoconazole) yielded minimal increases in rivaroxaban"s systemic exposure when P-gp-mediated efflux was solely inhibited.	Rivaroxaban	54-65	ATP binding cassette subfamily B member 1	Homo sapiens	181-185
31506301-10	2019	Notably, transporter-mediated DDI simulations between rivaroxaban and P-gp inhibitors (verapamil and ketoconazole) yielded minimal increases in rivaroxaban"s systemic exposure when P-gp-mediated efflux was solely inhibited.	Rivaroxaban	144-155	ATP binding cassette subfamily B member 1	Homo sapiens	70-74
31506301-13	2019	SIGNIFICANCE STATEMENT: Rivaroxaban is susceptible to drug-drug-disease interactions (DDDIs) comprising renal impairment, P-gp and CYP3A4/2J2 inhibition.	Rivaroxaban	24-35	ATP binding cassette subfamily B member 1	Homo sapiens	122-126
31506301-13	2019	SIGNIFICANCE STATEMENT: Rivaroxaban is susceptible to drug-drug-disease interactions (DDDIs) comprising renal impairment, P-gp and CYP3A4/2J2 inhibition.	Rivaroxaban	24-35	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	131-137
31506301-14	2019	Here, systematic construction and verification of a PBPK model of rivaroxaban, with the inclusion of a mechanistic kidney component, provided insight into the previously arcane role of OAT3-mediated basolateral uptake in influencing both clinically-observed renal elimination of rivaroxaban and differential extents of transporter-mediated DDIs.	Rivaroxaban	66-77	solute carrier family 22 member 8	Homo sapiens	185-189
31506301-14	2019	Here, systematic construction and verification of a PBPK model of rivaroxaban, with the inclusion of a mechanistic kidney component, provided insight into the previously arcane role of OAT3-mediated basolateral uptake in influencing both clinically-observed renal elimination of rivaroxaban and differential extents of transporter-mediated DDIs.	Rivaroxaban	279-290	solute carrier family 22 member 8	Homo sapiens	185-189
31511660-0	2019	Rivaroxaban monotherapy for AF and stable CAD.	Rivaroxaban	0-11	aconitate decarboxylase 1	Homo sapiens	42-45
31526123-3	2019	This exploratory analysis of NAVIGATE ESUS (New Approach Rivaroxaban Inhibition of Factor Xa in a Global Trial Versus ASA to Prevent Embolism in Embolic Stroke of Undetermined Source) focused on patients with AAA and assessed their characteristics, stroke recurrence rates, and response to treatment.	Rivaroxaban	57-68	coagulation factor X	Homo sapiens	83-92
31526123-12	2019	In patients with complex AAA, 4 strokes occurred among rivaroxaban-assigned patients and 4 strokes among aspirin-assigned patients.	Rivaroxaban	55-66	AAA1	Homo sapiens	25-28
31617197-0	2019	Effect of CYP3A4, CYP3A5, ABCB1 Gene Polymorphisms on Rivaroxaban Pharmacokinetics in Patients Undergoing Total Hip and Knee Replacement Surgery.	Rivaroxaban	54-65	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	10-16
32685588-1	2019	Background: Rivaroxaban, a fixed-dose oral direct factor Xa inhibitor, does not require continuous monitoring and thus reduces the hospital stay and economic burden in low-risk pulmonary embolism (LRPE) patients.	Rivaroxaban	12-23	coagulation factor X	Homo sapiens	50-59
31520256-13	2019	Polypharmacy was associated with adverse outcomes and attenuated the advantage in risk of major bleeding among rivaroxaban users, particularly in the presence of P-glycoprotein/CYP3A4-modulating drugs.	Rivaroxaban	111-122	ATP binding cassette subfamily B member 1	Homo sapiens	162-176
31520256-13	2019	Polypharmacy was associated with adverse outcomes and attenuated the advantage in risk of major bleeding among rivaroxaban users, particularly in the presence of P-glycoprotein/CYP3A4-modulating drugs.	Rivaroxaban	111-122	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	177-183
31617197-0	2019	Effect of CYP3A4, CYP3A5, ABCB1 Gene Polymorphisms on Rivaroxaban Pharmacokinetics in Patients Undergoing Total Hip and Knee Replacement Surgery.	Rivaroxaban	54-65	ATP binding cassette subfamily B member 1	Homo sapiens	26-31
31617197-0	2019	Effect of CYP3A4, CYP3A5, ABCB1 Gene Polymorphisms on Rivaroxaban Pharmacokinetics in Patients Undergoing Total Hip and Knee Replacement Surgery.	Rivaroxaban	54-65	hedgehog interacting protein	Homo sapiens	112-115
31617197-2	2019	Over the years, direct oral anticoagulants, such as rivaroxaban, have been widely used for thromboprophylaxis in patients undergoing knee and hip replacement surgery.	Rivaroxaban	52-63	hedgehog interacting protein	Homo sapiens	142-145
31617197-4	2019	AIM: Evaluation of CYP3A4, CYP3A5 and ABCB1 gene polymorphisms influence on rivaroxaban pharmacokinetics and prothrombin time dynamics in patients undergoing total hip and knee replacement surgery.	Rivaroxaban	76-87	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	19-25
31617197-4	2019	AIM: Evaluation of CYP3A4, CYP3A5 and ABCB1 gene polymorphisms influence on rivaroxaban pharmacokinetics and prothrombin time dynamics in patients undergoing total hip and knee replacement surgery.	Rivaroxaban	76-87	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	27-33
31617197-4	2019	AIM: Evaluation of CYP3A4, CYP3A5 and ABCB1 gene polymorphisms influence on rivaroxaban pharmacokinetics and prothrombin time dynamics in patients undergoing total hip and knee replacement surgery.	Rivaroxaban	76-87	ATP binding cassette subfamily B member 1	Homo sapiens	38-43
31617197-12	2019	However, there was a statistically significant average correlation between peak steady-state rivaroxaban concentration and prothrombin time (r = 0.421; r2 = 0.178; p < 0.001).	Rivaroxaban	93-104	coagulation factor II, thrombin	Homo sapiens	123-134
31617197-14	2019	The revealed statistically significant average correlation between the prothrombin time and peak steady-state rivaroxaban concentration is important in clinical practice for assessing the anticoagulant activity of rivaroxaban.	Rivaroxaban	110-121	coagulation factor II, thrombin	Homo sapiens	71-82
31617197-14	2019	The revealed statistically significant average correlation between the prothrombin time and peak steady-state rivaroxaban concentration is important in clinical practice for assessing the anticoagulant activity of rivaroxaban.	Rivaroxaban	214-225	coagulation factor II, thrombin	Homo sapiens	71-82
31356557-5	2019	Rivaroxaban, a new oral anticoagulant, is a selective direct factor Xa inhibitor that is used to reduce thrombin generation, which may bring hope to anticoagulation in patients with heart failure.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	61-70
30867376-7	2019	Echocardiography and the expression of BNP showed that rivaroxaban attenuated heart failure.	Rivaroxaban	55-66	natriuretic peptide type B	Mus musculus	39-42
30867376-9	2019	Rivaroxaban treatment decreased cardiac PAR2 levels and pro-inflammatory genes.	Rivaroxaban	0-11	pulmonary adenoma resistance 2	Mus musculus	40-44
30867376-12	2019	CONCLUSIONS: Rivaroxaban treatment just after MI in Hypo E mice prevented the progression of ICM by attenuating cardiac remodeling, partially through the suppression of the PAR2-mediated inflammatory pathway.	Rivaroxaban	13-24	pulmonary adenoma resistance 2	Mus musculus	173-177
31356557-5	2019	Rivaroxaban, a new oral anticoagulant, is a selective direct factor Xa inhibitor that is used to reduce thrombin generation, which may bring hope to anticoagulation in patients with heart failure.	Rivaroxaban	0-11	coagulation factor II, thrombin	Homo sapiens	104-112
31493618-8	2019	Anti-Factor Xa laboratory measurement was performed on &lt;1% of rivaroxaban cohort.	Rivaroxaban	65-76	coagulation factor X	Homo sapiens	5-14
31215111-0	2019	Rivaroxaban pharmacodynamics in healthy volunteers evaluated with thrombin generation and the active protein C system: Modeling and assessing interindividual variability.	Rivaroxaban	0-11	coagulation factor II, thrombin	Homo sapiens	66-74
31215111-6	2019	The PD models were built to characterize the relationships between plasma rivaroxaban concentrations and endogenous thrombin potential (ETP) or peak height induced by the lowest TF concentration.	Rivaroxaban	74-85	coagulation factor II, thrombin	Homo sapiens	116-124
31215111-6	2019	The PD models were built to characterize the relationships between plasma rivaroxaban concentrations and endogenous thrombin potential (ETP) or peak height induced by the lowest TF concentration.	Rivaroxaban	74-85	coagulation factor III, tissue factor	Homo sapiens	178-180
31215111-7	2019	RESULTS: Thrombin generation parameter time profiles with the lowest TF concentration showed a good sensitivity to rivaroxaban, especially +TM (active protein C negative feedback).	Rivaroxaban	115-126	coagulation factor II, thrombin	Homo sapiens	9-17
31215111-7	2019	RESULTS: Thrombin generation parameter time profiles with the lowest TF concentration showed a good sensitivity to rivaroxaban, especially +TM (active protein C negative feedback).	Rivaroxaban	115-126	coagulation factor III, tissue factor	Homo sapiens	69-71
31215111-9	2019	Mean rivaroxaban concentrations halving the baseline value of ETP and peak height (-TM) (C50 ) were of 284 and 33.2 ng/mL, respectively: +TM, C50 declined to 19.4 and 13.8 ng/mL, reflecting a powerful inhibitory effect.	Rivaroxaban	5-16	thrombomodulin	Homo sapiens	84-86
31215111-9	2019	Mean rivaroxaban concentrations halving the baseline value of ETP and peak height (-TM) (C50 ) were of 284 and 33.2 ng/mL, respectively: +TM, C50 declined to 19.4 and 13.8 ng/mL, reflecting a powerful inhibitory effect.	Rivaroxaban	5-16	thrombomodulin	Homo sapiens	138-140
31593135-6	2019	She received a treatment with low-molecular weight heparin and rivaroxaban.	Rivaroxaban	63-74	Src homology 2 domain containing E	Homo sapiens	0-3
30828771-1	2019	OBJECTIVES: The aim of this study was to prove the suitability of simultaneously administered microdoses of the factor Xa inhibitors (FXaIs) rivaroxaban, apixaban and edoxaban (100 microg in total).	Rivaroxaban	141-152	coagulation factor X	Homo sapiens	112-121
31541031-2	2019	Here, we show that rivaroxaban, a direct inhibitor of activated coagulation factor X (FX), promotes antitumor immunity by enhancing infiltration of dendritic cells and cytotoxic T cells at the tumor site.	Rivaroxaban	19-30	coagulation factor X	Mus musculus	64-84
31108011-0	2019	An unexpected dynamic binding mode between coagulation factor X and Rivaroxaban reveals importance of flexibility in drug binding.	Rivaroxaban	68-79	coagulation factor X	Homo sapiens	43-63
31108011-1	2019	Rivaroxaban (RIV) is a direct oral anticoagulant (DOAC) targeting activated coagulation factor X (FXa).	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	76-96
31108011-1	2019	Rivaroxaban (RIV) is a direct oral anticoagulant (DOAC) targeting activated coagulation factor X (FXa).	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	98-101
31108011-1	2019	Rivaroxaban (RIV) is a direct oral anticoagulant (DOAC) targeting activated coagulation factor X (FXa).	Rivaroxaban	13-16	coagulation factor X	Homo sapiens	76-96
31108011-1	2019	Rivaroxaban (RIV) is a direct oral anticoagulant (DOAC) targeting activated coagulation factor X (FXa).	Rivaroxaban	13-16	coagulation factor X	Homo sapiens	98-101
33843889-2	2019	Two of the most widely used direct oral anticoagulants (DOACs), rivaroxaban and apixaban, are factor Xa inhibitors.	Rivaroxaban	64-75	coagulation factor X	Homo sapiens	94-103
33843889-6	2019	The administration of a specific agent to reverse factor Xa inhibition may be clinically indicated in certain settings, such as when rivaroxaban and apixaban were given less than 12 hours earlier (assuming normal renal function), when the timing of the previous dose is unknown, or in the event of a catastrophic bleed.	Rivaroxaban	133-144	coagulation factor X	Homo sapiens	50-59
31450643-3	2019	Interestingly, rivaroxaban, another FXa inhibitor, suppresses oxidative stress induced by FXa.	Rivaroxaban	15-26	coagulation factor X	Homo sapiens	36-39
31410117-0	2019	Protective effect of rivaroxaban on arteriosclerosis obliterans in rats through modulation of the toll-like receptor 4/NF-kappaB signaling pathway.	Rivaroxaban	21-32	toll-like receptor 4	Rattus norvegicus	98-118
31410117-9	2019	Rivaroxaban treatment significantly reduced serum levels of interleukin-1, tumor necrosis factor-alpha and monocyte chemoattractant protein-1 (MCP-1), and increased the serum level of transforming growth factor-beta (TGF-beta).	Rivaroxaban	0-11	tumor necrosis factor	Rattus norvegicus	60-102
31410117-9	2019	Rivaroxaban treatment significantly reduced serum levels of interleukin-1, tumor necrosis factor-alpha and monocyte chemoattractant protein-1 (MCP-1), and increased the serum level of transforming growth factor-beta (TGF-beta).	Rivaroxaban	0-11	C-C motif chemokine ligand 2	Rattus norvegicus	107-141
31410117-9	2019	Rivaroxaban treatment significantly reduced serum levels of interleukin-1, tumor necrosis factor-alpha and monocyte chemoattractant protein-1 (MCP-1), and increased the serum level of transforming growth factor-beta (TGF-beta).	Rivaroxaban	0-11	C-C motif chemokine ligand 2	Rattus norvegicus	143-148
31410117-11	2019	Therefore rivaroxaban may have exerted its anti-atherosclerotic effects by regulating the expression of genes in the TLR4/NF-kappaB signaling pathway and the activation of the downstream molecules.	Rivaroxaban	10-21	toll-like receptor 4	Rattus norvegicus	117-121
31401971-2	2019	In this exploratory subgroup analysis of patients with carotid atherosclerosis in the NAVIGATE (New Approach Rivaroxaban Inhibition of Factor Xa in a Global Trial Versus ASA to Prevent Embolism)-ESUS trial, we assessed whether the treatment effect in this subgroup is consistent with the overall trial population and investigated the association of carotid atherosclerosis with recurrent ischemic stroke.	Rivaroxaban	109-120	coagulation factor X	Homo sapiens	135-144
31489274-3	2019	Rivaroxaban is a direct Factor Xa inhibitor and has been approved for use in several thromboembolic disorders, such as the prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation and the prevention of recurrent deep vein thrombosis and pulmonary embolism in adult patients.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	24-33
31450643-3	2019	Interestingly, rivaroxaban, another FXa inhibitor, suppresses oxidative stress induced by FXa.	Rivaroxaban	15-26	coagulation factor X	Homo sapiens	90-93
31248548-7	2019	Among patients with >=1 high-risk feature identified from the CART analysis, rivaroxaban and aspirin prevented 33 serious vascular events, whereas in lower-risk patients, rivaroxaban and aspirin treatment led to the avoidance of 10 events per 1,000 patients treated for 30 months.	Rivaroxaban	77-88	CART prepropeptide	Homo sapiens	62-66
30680652-1	2019	The COMPASS trial compared the impact of the selective direct factor Xa inhibitor, rivaroxaban, as monotherapy or in combination with aspirin on major adverse cardiovascular events (MACE) in patients with stable atherosclerotic disease.	Rivaroxaban	83-94	coagulation factor X	Homo sapiens	62-71
31269825-4	2019	Preclinical data strongly suggest that rivaroxaban exerts vascular protection through different mechanisms, including improvement of endothelial functionality and fibrinolytic activity at endothelium, anti-inflammatory properties, and platelet-dependent thrombin generation.	Rivaroxaban	39-50	coagulation factor II, thrombin	Homo sapiens	254-262
31251821-1	2019	The authors describe a case of unfractionated heparin (UFH) unresponsiveness in the operating room secondary to reversal of rivaroxaban with coagulation factor Xa (recombinant) inactivated-zhzo (andexanet alfa).	Rivaroxaban	124-135	coagulation factor X	Homo sapiens	153-162
31371788-0	2019	Rivaroxaban, a specific FXa inhibitor, improved endothelium-dependent relaxation of aortic segments in diabetic mice.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	24-27
31371788-2	2019	Here, we examined whether inhibition of FXa by rivaroxaban, a direct FXa inhibitor, attenuates endothelial dysfunction in streptozotocin (STZ)-induced diabetic mice.	Rivaroxaban	47-58	coagulation factor X	Homo sapiens	40-43
31371788-2	2019	Here, we examined whether inhibition of FXa by rivaroxaban, a direct FXa inhibitor, attenuates endothelial dysfunction in streptozotocin (STZ)-induced diabetic mice.	Rivaroxaban	47-58	coagulation factor X	Homo sapiens	69-72
30745002-1	2019	BACKGROUND: Although the efficacy and safety of the factor Xa inhibitor rivaroxaban for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF) were shown in global and Japanese phase III clinical trials, safety and effectiveness data from unselected patients in everyday clinical practice are limited.	Rivaroxaban	72-83	coagulation factor X	Homo sapiens	52-61
31132584-0	2019	Rivaroxaban, a direct Factor Xa inhibitor, versus acetylsalicylic acid as thromboprophylaxis in children post-Fontan procedure: Rationale and design of a prospective, randomized trial (the UNIVERSE study).	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	22-31
31132584-5	2019	Rivaroxaban, a direct Factor Xa inhibitor with a predictable pharmacokinetic profile, is a candidate to address this medical need.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	22-31
30912163-0	2019	Perpetrator effects of ciclosporin (P-glycoprotein inhibitor) and its combination with fluconazole (CYP3A inhibitor) on the pharmacokinetics of rivaroxaban in healthy volunteers.	Rivaroxaban	144-155	ATP binding cassette subfamily B member 1	Homo sapiens	36-50
30912163-0	2019	Perpetrator effects of ciclosporin (P-glycoprotein inhibitor) and its combination with fluconazole (CYP3A inhibitor) on the pharmacokinetics of rivaroxaban in healthy volunteers.	Rivaroxaban	144-155	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	100-105
30912163-1	2019	AIMS: Rivaroxaban exposure is considerably increased by drugs that are combined P-glycoprotein (P-gp) and strong cytochrome P450 (CYP) 3A inhibitors (e.g. ketoconazole).	Rivaroxaban	6-17	ATP binding cassette subfamily B member 1	Homo sapiens	80-94
30912163-1	2019	AIMS: Rivaroxaban exposure is considerably increased by drugs that are combined P-glycoprotein (P-gp) and strong cytochrome P450 (CYP) 3A inhibitors (e.g. ketoconazole).	Rivaroxaban	6-17	ATP binding cassette subfamily B member 1	Homo sapiens	96-100
30912163-1	2019	AIMS: Rivaroxaban exposure is considerably increased by drugs that are combined P-glycoprotein (P-gp) and strong cytochrome P450 (CYP) 3A inhibitors (e.g. ketoconazole).	Rivaroxaban	6-17	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	113-137
30912163-2	2019	The aim of the present study was to investigate the effects of the potent P-gp inhibitor ciclosporin and its combination with the moderate CYP3A inhibitor fluconazole on rivaroxaban pharmacokinetics and on CYP3A activity.	Rivaroxaban	170-181	ATP binding cassette subfamily B member 1	Homo sapiens	74-78
30912163-2	2019	The aim of the present study was to investigate the effects of the potent P-gp inhibitor ciclosporin and its combination with the moderate CYP3A inhibitor fluconazole on rivaroxaban pharmacokinetics and on CYP3A activity.	Rivaroxaban	170-181	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	139-144
30912163-8	2019	CONCLUSION: Patients treated with rivaroxaban in combination with single modulators of multiple elimination pathways or multiple modulators of single elimination pathways (CYP3A, P-gp) require particular care.	Rivaroxaban	34-45	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	172-177
30912163-8	2019	CONCLUSION: Patients treated with rivaroxaban in combination with single modulators of multiple elimination pathways or multiple modulators of single elimination pathways (CYP3A, P-gp) require particular care.	Rivaroxaban	34-45	ATP binding cassette subfamily B member 1	Homo sapiens	179-183
31195999-12	2019	Dabigatran and rivaroxaban were associated with similar risk of stroke/SE and major bleeding compared to warfarin.	Rivaroxaban	15-26	squalene epoxidase	Homo sapiens	71-73
31076635-6	2019	In the disproportionality analyses, a potential safety signal for spontaneous abortion emerged for rivaroxaban (Reporting Odds Ratio, ROR 2.70; 95% CI 1.79-4.07) and apixaban (ROR 6.76; 95% CI 2.99-15.25).	Rivaroxaban	99-110	receptor tyrosine kinase like orphan receptor 2	Homo sapiens	134-139
30725221-0	2019	Downregulation of ABCB1 gene in patients with total hip or knee arthroplasty influences pharmacokinetics of rivaroxaban: a population pharmacokinetic-pharmacodynamic study.	Rivaroxaban	108-119	ATP binding cassette subfamily B member 1	Homo sapiens	18-23
30725221-0	2019	Downregulation of ABCB1 gene in patients with total hip or knee arthroplasty influences pharmacokinetics of rivaroxaban: a population pharmacokinetic-pharmacodynamic study.	Rivaroxaban	108-119	hedgehog interacting protein	Homo sapiens	52-55
30725221-1	2019	PURPOSE: Rivaroxaban is a substrate for ABCB1 transporter and is commonly used in patients undergoing hip or knee replacement surgery for thromboprophylaxis.	Rivaroxaban	9-20	ATP binding cassette subfamily B member 1	Homo sapiens	40-45
30725221-1	2019	PURPOSE: Rivaroxaban is a substrate for ABCB1 transporter and is commonly used in patients undergoing hip or knee replacement surgery for thromboprophylaxis.	Rivaroxaban	9-20	hedgehog interacting protein	Homo sapiens	102-105
30725221-2	2019	The objective of this study was to develop a population pharmacokinetic-pharmacodynamic (PK-PD) model to investigate the influence of ABCB1 gene expression and polymorphism on rivaroxaban exposure and anticoagulation effects.	Rivaroxaban	176-187	ATP binding cassette subfamily B member 1	Homo sapiens	134-139
30725221-9	2019	CONCLUSIONS: We confirmed that variable rivaroxaban CL/F is associated with ABCB1 expression, which is in accordance with previous studies on P-glycoprotein involvement in rivaroxaban PK.	Rivaroxaban	40-51	ATP binding cassette subfamily B member 1	Homo sapiens	76-81
30725221-9	2019	CONCLUSIONS: We confirmed that variable rivaroxaban CL/F is associated with ABCB1 expression, which is in accordance with previous studies on P-glycoprotein involvement in rivaroxaban PK.	Rivaroxaban	40-51	ATP binding cassette subfamily B member 1	Homo sapiens	142-156
30725221-9	2019	CONCLUSIONS: We confirmed that variable rivaroxaban CL/F is associated with ABCB1 expression, which is in accordance with previous studies on P-glycoprotein involvement in rivaroxaban PK.	Rivaroxaban	172-183	ATP binding cassette subfamily B member 1	Homo sapiens	76-81
30725221-9	2019	CONCLUSIONS: We confirmed that variable rivaroxaban CL/F is associated with ABCB1 expression, which is in accordance with previous studies on P-glycoprotein involvement in rivaroxaban PK.	Rivaroxaban	172-183	ATP binding cassette subfamily B member 1	Homo sapiens	142-156
30698331-1	2019	INTRODUCTION: Co-administration of enoxaparin and a direct oral factor Xa inhibitor (xabans: apixaban, edoxaban, rivaroxaban) could give rise to the problem of overlapping the anti-Xa activity when measuring direct oral anticoagulant (DOAC) levels.	Rivaroxaban	113-124	coagulation factor X	Homo sapiens	64-73
31076635-6	2019	In the disproportionality analyses, a potential safety signal for spontaneous abortion emerged for rivaroxaban (Reporting Odds Ratio, ROR 2.70; 95% CI 1.79-4.07) and apixaban (ROR 6.76; 95% CI 2.99-15.25).	Rivaroxaban	99-110	long intergenic non-protein coding RNA, regulator of reprogramming	Homo sapiens	134-137
30771281-0	2019	Nox2-mediated platelet activation by glycoprotein (GP) VI: Effect of rivaroxaban alone and in combination with aspirin.	Rivaroxaban	69-80	cytochrome b-245 beta chain	Homo sapiens	0-4
30719803-2	2019	In this study, rivaroxaban, a direct factor X inhibitor, attenuates liver fibrosis induced by carbon tetrachloride (CCl4 ).	Rivaroxaban	15-26	C-C motif chemokine ligand 4	Rattus norvegicus	116-120
30846818-12	2019	Furthermore, expression of PARs and their activators, thrombin and FXa was diminished after rivaroxaban treatment.	Rivaroxaban	92-103	coagulation factor II	Mus musculus	54-62
30936131-2	2019	The direct oral anticoagulants dabigatran (direct thrombin inhibitor) and rivaroxaban, apixaban, and edoxaban (direct factor Xa inhibitors) are as efficacious as and in some instances superior to vitamin K antagonists in the prevention of stroke, systemic embolism, and major bleeding compared with warfarin for nonvalvular atrial fibrillation.	Rivaroxaban	74-85	coagulation factor X	Homo sapiens	118-127
31109423-1	2019	OBJECTIVE: To evaluate the effect and mechanism of rivaroxaban, an inhibitor of coagulation factor Xa (FXa), on endotoxin-induced injury to human umbilical vein endothelial cells (HUVEC).	Rivaroxaban	51-62	coagulation factor X	Homo sapiens	92-101
31109423-1	2019	OBJECTIVE: To evaluate the effect and mechanism of rivaroxaban, an inhibitor of coagulation factor Xa (FXa), on endotoxin-induced injury to human umbilical vein endothelial cells (HUVEC).	Rivaroxaban	51-62	coagulation factor X	Homo sapiens	103-106
31109423-9	2019	CONCLUSIONS: Rivaroxaban can effectively relieve the inflammatory response of HUVEC stimulated by LPS, which may be related to the inhibition of NF-KappaB signaling pathway activation rather than MAPK signaling pathway.	Rivaroxaban	13-24	nuclear factor kappa B subunit 1	Homo sapiens	145-154
30893910-1	2019	Concomitant use of rivaroxaban with non-dihydropyridine calcium channel blockers (non-DHPs) might lead to an increase of systemic rivaroxaban exposure and anticoagulant effects in relation to the inhibition of metabolic enzymes and/or transporters by non-DHPs.	Rivaroxaban	19-30	deoxyhypusine synthase	Rattus norvegicus	86-90
30893910-1	2019	Concomitant use of rivaroxaban with non-dihydropyridine calcium channel blockers (non-DHPs) might lead to an increase of systemic rivaroxaban exposure and anticoagulant effects in relation to the inhibition of metabolic enzymes and/or transporters by non-DHPs.	Rivaroxaban	19-30	deoxyhypusine synthase	Rattus norvegicus	255-259
30893910-1	2019	Concomitant use of rivaroxaban with non-dihydropyridine calcium channel blockers (non-DHPs) might lead to an increase of systemic rivaroxaban exposure and anticoagulant effects in relation to the inhibition of metabolic enzymes and/or transporters by non-DHPs.	Rivaroxaban	130-141	deoxyhypusine synthase	Rattus norvegicus	86-90
30771281-5	2019	Rivaroxaban alone significantly reduced PA, sGPVI, TxB2 and isoprostanes biosynthesis, concomitantly with Syk, sNox2-dp and PLA2 activation in a dose-dependent fashion; a significant effect was achieved with 30 ng/ml rivaroxaban.	Rivaroxaban	0-11	spleen associated tyrosine kinase	Homo sapiens	106-109
30771281-6	2019	Docking simulation analysis showed that rivaroxaban interacts with GPVI.	Rivaroxaban	40-51	glycoprotein VI platelet	Homo sapiens	67-71
30771281-7	2019	In platelets co-incubated with ASA, rivaroxaban amplified the ASA antiplatelet effect, which was achieved with 30 ng/ml and prevalently attributable to Nox2 inhibition and impaired isoprostane biosynthesis.	Rivaroxaban	36-47	cytochrome b-245 beta chain	Homo sapiens	152-156
30771281-8	2019	Here we show that rivaroxaban, at concentrations achievable in human circulation, inhibits PA via GPVI interaction and eventually Nox2-mediated isoprostanes biosynthesis and amplifies the ASA antiplatelet effect.	Rivaroxaban	18-29	glycoprotein VI platelet	Homo sapiens	98-102
30771281-8	2019	Here we show that rivaroxaban, at concentrations achievable in human circulation, inhibits PA via GPVI interaction and eventually Nox2-mediated isoprostanes biosynthesis and amplifies the ASA antiplatelet effect.	Rivaroxaban	18-29	cytochrome b-245 beta chain	Homo sapiens	130-134
31263649-4	2019	Rivaroxaban is a directly acting oral anticoagulant (DOAC) that inhibits factor Xa and is widely used for stroke prevention in patients with non-valvular atrial fibrillation (AFib).	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	73-82
30957622-8	2019	Moreover, rivaroxaban treatment attenuated histologic changes of glomerular hypertrophy, mesangial matrix expansion, effacement of the podocyte foot process, and thickened glomerular basement membrane in the Ren-TG.	Rivaroxaban	10-21	renin 1 structural	Mus musculus	208-211
30957622-9	2019	The renal expression of PAR -2 was increased in the Ren-TG, but was inhibited with rivaroxaban treatment.	Rivaroxaban	83-94	pulmonary adenoma resistance 2	Mus musculus	24-30
30957622-10	2019	In vitro study using the human podocytes showed that the expressions of PAR -2 and inflammatory genes and nuclear factor--kappaB activation were induced by angiotensin II stimulation, but were inhibited by rivaroxaban.	Rivaroxaban	206-217	F2R like trypsin receptor 1	Homo sapiens	72-78
30957622-12	2019	Conclusions These findings indicate that rivaroxaban exerts protective effects against angiotensin II-induced renal damage, partly through inhibition of the PAR -2 signaling-mediated inflammatory response.	Rivaroxaban	41-52	angiotensinogen	Homo sapiens	87-101
30957622-12	2019	Conclusions These findings indicate that rivaroxaban exerts protective effects against angiotensin II-induced renal damage, partly through inhibition of the PAR -2 signaling-mediated inflammatory response.	Rivaroxaban	41-52	pulmonary adenoma resistance 2	Mus musculus	157-163
30589161-8	2019	Ischaemic stroke risk was lowest for rivaroxaban, followed by apixaban, dabigatran and warfarin (HR 1.13, 95% CrI 1.07-1.20).	Rivaroxaban	37-48	EP300 interacting inhibitor of differentiation 1	Homo sapiens	110-115
30058959-5	2019	METHODS: COMPASS is a randomized superiority trial testing rivaroxaban 2.5 mg bid plus acetylsalicylic acid 100 mg and rivaroxaban 5 mg bid against acetylsalicylic acid 100 mg per day for the combined endpoint of MI, stroke, and cardiovascular death in individuals with stable coronary artery disease or peripheral artery disease.	Rivaroxaban	59-70	BH3 interacting domain death agonist	Homo sapiens	78-81
30846818-12	2019	Furthermore, expression of PARs and their activators, thrombin and FXa was diminished after rivaroxaban treatment.	Rivaroxaban	92-103	coagulation factor X	Homo sapiens	67-70
30839367-5	2019	Rivaroxaban 2.5 mg BID in triple therapy with DAPT, rivaroxaban 15 mg, or dabigatran 110/150 mg BID in dual therapy with P2Y12 inhibitor (mainly clopidogrel) is safer in terms of bleeding risk than triple therapy with VKA plus DAPT.	Rivaroxaban	0-11	BH3 interacting domain death agonist	Homo sapiens	19-22
30839367-5	2019	Rivaroxaban 2.5 mg BID in triple therapy with DAPT, rivaroxaban 15 mg, or dabigatran 110/150 mg BID in dual therapy with P2Y12 inhibitor (mainly clopidogrel) is safer in terms of bleeding risk than triple therapy with VKA plus DAPT.	Rivaroxaban	0-11	BH3 interacting domain death agonist	Homo sapiens	96-99
30839367-5	2019	Rivaroxaban 2.5 mg BID in triple therapy with DAPT, rivaroxaban 15 mg, or dabigatran 110/150 mg BID in dual therapy with P2Y12 inhibitor (mainly clopidogrel) is safer in terms of bleeding risk than triple therapy with VKA plus DAPT.	Rivaroxaban	0-11	purinergic receptor P2Y12	Homo sapiens	121-126
30839367-5	2019	Rivaroxaban 2.5 mg BID in triple therapy with DAPT, rivaroxaban 15 mg, or dabigatran 110/150 mg BID in dual therapy with P2Y12 inhibitor (mainly clopidogrel) is safer in terms of bleeding risk than triple therapy with VKA plus DAPT.	Rivaroxaban	52-63	BH3 interacting domain death agonist	Homo sapiens	19-22
29249166-2	2019	Inhibition of thrombin generation among high-risk ACS patients (biomarker-positive ACS) with the factor Xa inhibitor rivaroxaban may limit ongoing thrombus formation and myocardial necrosis and thereby improve clinical outcomes.	Rivaroxaban	117-128	coagulation factor II, thrombin	Homo sapiens	14-22
30515764-0	2019	Efficacy and safety of prothrombin complex concentrate in patients treated with rivaroxaban or apixaban compared to warfarin presenting with major bleeding.	Rivaroxaban	80-91	coagulation factor II, thrombin	Homo sapiens	23-34
29249166-2	2019	Inhibition of thrombin generation among high-risk ACS patients (biomarker-positive ACS) with the factor Xa inhibitor rivaroxaban may limit ongoing thrombus formation and myocardial necrosis and thereby improve clinical outcomes.	Rivaroxaban	117-128	coagulation factor X	Homo sapiens	97-106
30779598-3	2019	Rivaroxaban, an oral factor Xa inhibitor, was the first direct oral anticoagulant licensed for VTE prevention and treatment.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	21-30
30817570-2	2019	Rivaroxaban is a novel oral medication that directly inhibits factor Xa for the prevention and treatment of thromboembolic conditions.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	62-71
30538058-11	2019	Notably, Rivaroxaban use was also associated with a significant reduction in C reactive protein (CRP) (p < 0.001) during follow-up.	Rivaroxaban	9-20	C-reactive protein	Homo sapiens	77-95
30538058-11	2019	Notably, Rivaroxaban use was also associated with a significant reduction in C reactive protein (CRP) (p < 0.001) during follow-up.	Rivaroxaban	9-20	C-reactive protein	Homo sapiens	97-100
29337837-3	2019	One of the novel oral anticoagulants, rivaroxaban, is a direct Factor Xa inhibitor, used to reduce risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, deep vein thrombosis, and pulmonary embolism.	Rivaroxaban	38-49	coagulation factor X	Homo sapiens	63-72
30677622-9	2019	Additionally, inclusion of Rivaroxaban (0.6 mug/ml) significantly inhibited the response to fXa.	Rivaroxaban	27-38	coagulation factor X	Homo sapiens	92-95
30994603-6	2019	The most significant by the number of cases, duration of therapy, and methodology of analysis are the reports regarding rivaroxaban - an oral, direct factor Xa inhibitor.	Rivaroxaban	120-131	coagulation factor X	Homo sapiens	150-159
30658513-8	2019	ABCB1 SNPs are implicated in alteration of plasma drug levels of rivaroxaban and apixaban.	Rivaroxaban	65-76	ATP binding cassette subfamily B member 1	Homo sapiens	0-5
30658513-11	2019	Strong inhibitors and inducers of CYP3A4 and p-glycoprotein should be avoided in patients treated with rivaroxaban, apixaban, and edoxaban.	Rivaroxaban	103-114	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	34-40
30658513-11	2019	Strong inhibitors and inducers of CYP3A4 and p-glycoprotein should be avoided in patients treated with rivaroxaban, apixaban, and edoxaban.	Rivaroxaban	103-114	ATP binding cassette subfamily B member 1	Homo sapiens	45-59
31088146-0	2019	Factor Xa Inhibitory Profile of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban Does Not Fully Reflect Their Biologic Spectrum.	Rivaroxaban	68-79	coagulation factor X	Homo sapiens	0-9
31298056-8	2019	The FXa activity reversal profile varied with an observed decrease in apixaban (22%), betrixaban (56%), edoxaban (28%), and rivaroxaban (49%).	Rivaroxaban	124-135	coagulation factor X	Homo sapiens	4-7
30848768-1	2019	Direct oral anticoagulants (DOACs), including the direct thrombin inhibitor dabigatran and the direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban have at least comparable efficacy as vitamin K antagonists along with a better safety profile, reflected by a lower incidence of intracranial hemorrhage.	Rivaroxaban	123-134	coagulation factor X	Homo sapiens	102-111
30597497-1	2019	Non-vitamin K antagonist oral anticoagulants (NOACs) include dabigatran, which inhibits thrombin, and apixaban, betrixaban, edoxaban and rivaroxaban, which inhibit factor Xa.	Rivaroxaban	137-148	coagulation factor X	Homo sapiens	164-173
30566008-0	2018	Correction to: Efficacy and Safety of Rivaroxaban Compared With Warfarin Among Elderly Patients With Nonvalvular Atrial Fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).	Rivaroxaban	38-49	coagulation factor X	Homo sapiens	177-186
30581412-7	2018	Older AEDs, acting on cytochrome P450 isoenzymes, and especially on CYP3A4, such as phenobarbital, phenytoin, and carbamazepine are more likely to significantly reduce the anticoagulant effect of DOACs (especially rivaroxaban, apixaban, and edoxaban).	Rivaroxaban	214-225	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	68-74
30425877-1	2018	A 71-year-old man with known history of atrial fibrillation (treated with routine rivaroxaban therapy) was found to have incidental biochemical elevated calcium and parathyroid hormone (PTH) levels.	Rivaroxaban	82-93	parathyroid hormone	Homo sapiens	165-184
30534007-6	2018	In all age groups, PD parameters (prothrombin time, activated partial thromboplastin time and anti-Factor Xa activity) showed a linear relationship versus rivaroxaban plasma concentrations and were in line with previously acquired adult data, as well as in vitro spiking experiments.	Rivaroxaban	155-166	coagulation factor X	Homo sapiens	99-108
30227941-2	2018	We evaluated whether rivaroxaban (a direct oral factor Xa inhibitor with no interaction with vitamin K) will slow the progression in coronary plaque volumes compared with warfarin in patients with nonvalvular atrial fibrillation using coronary computed tomography angiography.	Rivaroxaban	21-32	coagulation factor X	Homo sapiens	48-57
30340765-5	2018	Among subjects with a history of CHF, both rivaroxaban doses reduced the primary composite end point of CV death, myocardial infarction, or stroke (2.5 mg BID vs placebo: hazard ratio [HR] 0.59, 95% confidence interval [CI] (0.42, 0.81), p = 0.001; 5 mg BID vs placebo: HR 0.61, 95% CI (0.44, 0.84), p = 0.002; p interaction = 0.006).	Rivaroxaban	43-54	BH3 interacting domain death agonist	Homo sapiens	155-158
30340765-5	2018	Among subjects with a history of CHF, both rivaroxaban doses reduced the primary composite end point of CV death, myocardial infarction, or stroke (2.5 mg BID vs placebo: hazard ratio [HR] 0.59, 95% confidence interval [CI] (0.42, 0.81), p = 0.001; 5 mg BID vs placebo: HR 0.61, 95% CI (0.44, 0.84), p = 0.002; p interaction = 0.006).	Rivaroxaban	43-54	BH3 interacting domain death agonist	Homo sapiens	254-257
30340765-6	2018	Both doses of rivaroxaban reduced CV mortality (rivaroxaban 2.5 mg BID vs placebo: 4.1% vs 9.0%, HR 0.45, 95% CI [0.27, 0.74], p = 0.002; rivaroxaban 5 mg BID vs placebo: 5.8% vs 9.0%, HR 0.62, 95% CI [0.40, 0.96], p = 0.031) as well as all-cause mortality.	Rivaroxaban	14-25	BH3 interacting domain death agonist	Homo sapiens	67-70
30340765-6	2018	Both doses of rivaroxaban reduced CV mortality (rivaroxaban 2.5 mg BID vs placebo: 4.1% vs 9.0%, HR 0.45, 95% CI [0.27, 0.74], p = 0.002; rivaroxaban 5 mg BID vs placebo: 5.8% vs 9.0%, HR 0.62, 95% CI [0.40, 0.96], p = 0.031) as well as all-cause mortality.	Rivaroxaban	14-25	BH3 interacting domain death agonist	Homo sapiens	155-158
30192025-1	2018	AIMS: We assessed the potential mutual interaction of oral macitentan (cytochrome P450 (CYP) 3A4 substrate) at steady-state with single-dose oral rivaroxaban (CYP3A4 and P-glycoprotein substrate) and evaluated the effect of the CYP3A and P-glycoprotein inducer St John"s wort (SJW) on the pharmacokinetics of these drugs in healthy volunteers.	Rivaroxaban	146-157	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	159-164
30244598-0	2018	Factors That Determine the Prothrombin Time in Patients With Atrial Fibrillation Receiving Rivaroxaban.	Rivaroxaban	91-102	coagulation factor II, thrombin	Homo sapiens	27-38
30270642-6	2018	Concerning TGA, endogenous thrombin potential (ETP) was significantly decreased in patients on rivaroxaban as compared to those treated with apixaban ( P &lt; .003).	Rivaroxaban	95-106	coagulation factor II, thrombin	Homo sapiens	27-35
30274772-3	2018	We hypothesised that anticoagulant treatment with rivaroxaban, an oral factor Xa inhibitor, would reduce the risk of recurrent ischaemic stroke compared with aspirin among patients with PFO enrolled in the NAVIGATE ESUS trial.	Rivaroxaban	50-61	coagulation factor X	Homo sapiens	71-80
30217378-2	2018	It was hypothesized that elevated baseline D-dimer would be associated with poor clinical outcomes in ACS, and that Factor Xa inhibition with Rivaroxaban would reduce D-dimer acutely and chronically.	Rivaroxaban	142-153	coagulation factor X	Homo sapiens	116-125
30217378-9	2018	In conclusion, elevated baseline D-dimer was associated with an increased risk of the composite outcome within 6 months of the ACS event and administration of the Factor Xa inhibitor rivaroxaban was associated with lower D-dimer levels compared with placebo after the first dose, at day 30 and day 180.	Rivaroxaban	183-194	coagulation factor X	Homo sapiens	163-172
29768734-11	2018	In contrast, rivaroxaban decreased thrombin generation by 55% in controls, but only by 11%-38% in patients.	Rivaroxaban	13-24	coagulation factor II, thrombin	Homo sapiens	35-43
30049684-0	2018	Association between prothrombin time and bleeding in hospitalized patients receiving rivaroxaban.	Rivaroxaban	85-96	coagulation factor II, thrombin	Homo sapiens	20-31
30049684-1	2018	PURPOSE: Results of an investigation of the pharmacodynamic effect of rivaroxaban anticoagulation, as measured by prothrombin time (PT), on bleeding risk and other outcomes in hospitalized patients are reported.	Rivaroxaban	70-81	coagulation factor II, thrombin	Homo sapiens	114-125
30455596-14	2018	All 3 patients with available genotyping data and higher-than-expected rivaroxaban levels were heterozygous or homozygous mutated for the ABCB1 1236C &gt; T, 2677G &gt; T, 3435 C &gt; T and rs4148738 single nucleotide polymorphisms (SNP).	Rivaroxaban	71-82	ATP binding cassette subfamily B member 1	Homo sapiens	138-143
30377413-1	2018	Five patients with paroxysmal nocturnal haemoglobinuria and thrombotic complications under oral antithrombotic treatment with vitamin K antagonist were switched to receive the direct oral anticoagulant rivaroxaban an factor Xa inhibitor.	Rivaroxaban	202-213	coagulation factor X	Homo sapiens	217-226
30364273-14	2018	Rivaroxaban significantly decreased elevation of fibrin and TF with significant reduction in serum creatinine, BUN and cystatin-c levels.	Rivaroxaban	0-11	coagulation factor III, tissue factor	Rattus norvegicus	60-62
30364273-14	2018	Rivaroxaban significantly decreased elevation of fibrin and TF with significant reduction in serum creatinine, BUN and cystatin-c levels.	Rivaroxaban	0-11	cystatin C	Rattus norvegicus	119-129
30146935-2	2018	We hypothesized that treatment with rivaroxaban, a factor Xa inhibitor, could reduce thrombin generation and improve outcomes for patients with worsening chronic heart failure and underlying coronary artery disease.	Rivaroxaban	36-47	coagulation factor II, thrombin	Homo sapiens	85-93
30039454-0	2018	First evidence: rivaroxaban and apixaban reduce thrombin-dependent platelet aggregation.	Rivaroxaban	16-27	coagulation factor II, thrombin	Homo sapiens	48-56
29672182-2	2018	The direct thrombin inhibitor dabigatran and the direct factor Xa inhibitors apixaban, edoxaban and rivaroxaban are now increasingly used in clinical practice.	Rivaroxaban	100-111	coagulation factor X	Homo sapiens	56-65
29749269-1	2018	OBJECTIVES: To assess association between 30 day readmission rate and treatment received after total hip and knee arthroplasty (THA/TKA) discharge (rivaroxaban vs. warfarin or non-anticoagulant).	Rivaroxaban	148-159	hedgehog interacting protein	Homo sapiens	101-104
30213724-0	2018	Factor Xa inhibition by rivaroxaban regulates fibrogenesis in human atrial fibroblasts with modulation of nitric oxide synthesis and calcium homeostasis.	Rivaroxaban	24-35	coagulation factor X	Homo sapiens	0-9
30213724-1	2018	BACKGROUND: Rivaroxaban, a widely used factor Xa inhibitor in reducing stroke in atrial fibrillation (AF) patients has multiple biological effects with activation of protease-activated receptor (PAR) signaling.	Rivaroxaban	12-23	coagulation factor X	Homo sapiens	39-48
30213724-10	2018	Additionally, rivaroxaban significantly attenuated the effects of thrombin, and TFLLR-NH2 on migratory, proliferative, and pro-collagen type I production capability in atrial fibroblasts.	Rivaroxaban	14-25	coagulation factor II, thrombin	Homo sapiens	66-74
30039454-1	2018	Rivaroxaban and apixaban are direct oral anticoagulants whose target specificity is to activate factor X (FXa).	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	106-109
30039454-7	2018	The thrombin-induced platelet aggregation is reduced in cardiovascular patients receiving rivaroxaban or apixaban.	Rivaroxaban	90-101	coagulation factor II, thrombin	Homo sapiens	4-12
30349888-9	2018	Conclusion: FVIII:C, FXI:C, FXII:C, and d-dimer measurements were influenced by rivaroxaban/apixaban intake, while fibrinogen and VWF:Ag were not.	Rivaroxaban	80-91	coagulation factor XI	Homo sapiens	21-24
29956554-0	2018	Left atrial thrombus resolution in non-valvular atrial fibrillation or flutter: biomarker substudy results from a prospective study with rivaroxaban (X-TRA).	Rivaroxaban	137-148	T cell receptor alpha locus	Homo sapiens	152-155
29956554-5	2018	RESULTS: There was a significant decrease in the mean levels of hsCRP, D-dimer, vWF, and TAT from baseline to end of treatment with rivaroxaban.	Rivaroxaban	132-143	von Willebrand factor	Homo sapiens	80-83
29050502-2	2018	Rivaroxaban and apixaban are 2 direct oral anticoagulants whose target specificity is activated factor X (FXa).	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	106-109
29050502-6	2018	The thrombin receptor activating peptide (TRAP)-induced platelet aggregation was significantly lower 2 hours after taking rivaroxaban or apixaban compared to baseline value (56.15% [8.53%] vs 29.51% [12.9%]; P = .000).	Rivaroxaban	122-133	TRAP	Homo sapiens	4-40
29050502-6	2018	The thrombin receptor activating peptide (TRAP)-induced platelet aggregation was significantly lower 2 hours after taking rivaroxaban or apixaban compared to baseline value (56.15% [8.53%] vs 29.51% [12.9%]; P = .000).	Rivaroxaban	122-133	TRAP	Homo sapiens	42-46
30210674-2	2018	As factor Xa-dependent protease-activated receptor 2 (PAR-2) is reported to be an important target in blood coagulation and other processes, an inhibitor of factor Xa, rivaroxaban, was tested in vivo in C57BL/6 mice with ALI induced by intratracheal injections of lipopolysaccharide (LPS) and in vitro in LPS-stimulated human umbilical vein endothelial cells.	Rivaroxaban	168-179	coagulation factor II (thrombin) receptor-like 1	Mus musculus	54-59
30210674-5	2018	The levels of tumor necrosis factor alpha, interleukin 1 beta, and interleukin 6, as well as total protein and Evans blue concentrations, were all significantly reduced in bronchoalveolar lavage fluid from mice treated with rivaroxaban.	Rivaroxaban	224-235	tumor necrosis factor	Mus musculus	14-41
30210674-5	2018	The levels of tumor necrosis factor alpha, interleukin 1 beta, and interleukin 6, as well as total protein and Evans blue concentrations, were all significantly reduced in bronchoalveolar lavage fluid from mice treated with rivaroxaban.	Rivaroxaban	224-235	interleukin 1 beta	Mus musculus	43-61
30210674-5	2018	The levels of tumor necrosis factor alpha, interleukin 1 beta, and interleukin 6, as well as total protein and Evans blue concentrations, were all significantly reduced in bronchoalveolar lavage fluid from mice treated with rivaroxaban.	Rivaroxaban	224-235	interleukin 6	Mus musculus	67-80
30210674-6	2018	Rivaroxaban treatment also ameliorated the LPS-induced PAR-2 increase and nuclear factor kappa B (NF-kappaB) activation.	Rivaroxaban	0-11	coagulation factor II (thrombin) receptor-like 1	Mus musculus	55-60
30210674-6	2018	Rivaroxaban treatment also ameliorated the LPS-induced PAR-2 increase and nuclear factor kappa B (NF-kappaB) activation.	Rivaroxaban	0-11	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	74-96
30210674-6	2018	Rivaroxaban treatment also ameliorated the LPS-induced PAR-2 increase and nuclear factor kappa B (NF-kappaB) activation.	Rivaroxaban	0-11	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	98-107
30210674-8	2018	Furthermore, rivaroxaban inhibited the phosphorylation of TAK1 and p65.	Rivaroxaban	13-24	mitogen-activated protein kinase kinase kinase 7	Mus musculus	58-62
30210674-8	2018	Furthermore, rivaroxaban inhibited the phosphorylation of TAK1 and p65.	Rivaroxaban	13-24	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	67-70
30210674-9	2018	These data show that rivaroxaban attenuates ALI and inflammation by inhibiting the PAR-2/NF-kappaB signaling pathway.	Rivaroxaban	21-32	coagulation factor II (thrombin) receptor-like 1	Mus musculus	83-88
30210674-9	2018	These data show that rivaroxaban attenuates ALI and inflammation by inhibiting the PAR-2/NF-kappaB signaling pathway.	Rivaroxaban	21-32	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	89-98
29614520-1	2018	INTRODUCTION: Rivaroxaban (RXA) is a direct oral factor Xa (Xa) antagonist with a short half-life and a fast onset and offset of effect.	Rivaroxaban	14-25	coagulation factor X	Homo sapiens	49-58
30071567-4	2018	Affinity of apixaban and rivaroxaban for GDFXa-alpha2M was only slightly decreased compared to FXa.	Rivaroxaban	25-36	PZP, alpha-2-macroglobulin like	Mus musculus	47-54
30071567-6	2018	Stoichiometric excess of GDFXa-alpha2M neutralized rivaroxaban and apixaban as attested by clot waveform assay and rotational thromboelastometry, whereas GDFXa-alpha2M alone had no effect on these assays.	Rivaroxaban	51-62	PZP, alpha-2-macroglobulin like	Mus musculus	31-38
30071567-9	2018	Single administration of GDFXa-alpha2M significantly decreased the rivaroxaban-induced bleeding time (p &lt; 0.001) and blood loss (p &lt; 0.01).	Rivaroxaban	67-78	PZP, alpha-2-macroglobulin like	Mus musculus	31-38
29709396-4	2018	Rivaroxaban, an oral factor Xa inhibitor and a new oral anticoagulants, shows effective anticoagulation within hours of administration.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	21-30
29526957-4	2018	The patient was administered the oral factor Xa inhibitor rivaroxaban (30 mg).	Rivaroxaban	58-69	coagulation factor X	Homo sapiens	38-47
29526957-6	2018	Rivaroxaban (15 mg) was continued for 6 months with no recurrence, indicating the efficacy of this factor Xa inhibitor for the treatment and prevention of VTE in patients with antithrombin deficiency.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	99-108
29526957-6	2018	Rivaroxaban (15 mg) was continued for 6 months with no recurrence, indicating the efficacy of this factor Xa inhibitor for the treatment and prevention of VTE in patients with antithrombin deficiency.	Rivaroxaban	0-11	serpin family C member 1	Homo sapiens	176-188
29996862-2	2018	The use of rivaroxaban, a highly selective and direct factor Xa inhibitor, has been used widely as a safe and efficacious way to prevent VTE after total joint replacements.	Rivaroxaban	11-22	coagulation factor X	Homo sapiens	54-63
29746227-3	2018	The purpose of this study was to assess if an oral factor Xa inhibitor, rivaroxaban, would offer an alternative treatment for VTE in patients with cancer.	Rivaroxaban	72-83	coagulation factor X	Homo sapiens	51-60
29862875-4	2018	Rivaroxaban, a factor Xa inhibitor, has been tested in different clinical scenarios and has proved to be effective and safe, even increasing the scope of the old VKA.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	15-24
30055890-0	2018	Factor Xa inhibition by rivaroxaban attenuates cardiac remodeling due to intermittent hypoxia.	Rivaroxaban	24-35	coagulation factor X	Homo sapiens	0-9
30055890-2	2018	Rivaroxaban, a coagulation factor Xa inhibitor, has recently been reported to show pleiotropic effects.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	27-36
30055890-8	2018	These findings demonstrate that rivaroxaban attenuates both atrial and ventricular remodeling induced by IH through the prevention of oxidative stress and fibrosis by suppressing the activation of ERK and NF-kappaB pathways via PAR-2.	Rivaroxaban	32-43	mitogen-activated protein kinase 1	Homo sapiens	197-200
30055890-8	2018	These findings demonstrate that rivaroxaban attenuates both atrial and ventricular remodeling induced by IH through the prevention of oxidative stress and fibrosis by suppressing the activation of ERK and NF-kappaB pathways via PAR-2.	Rivaroxaban	32-43	nuclear factor kappa B subunit 1	Homo sapiens	205-214
30055890-8	2018	These findings demonstrate that rivaroxaban attenuates both atrial and ventricular remodeling induced by IH through the prevention of oxidative stress and fibrosis by suppressing the activation of ERK and NF-kappaB pathways via PAR-2.	Rivaroxaban	32-43	F2R like trypsin receptor 1	Homo sapiens	228-233
29766772-2	2018	Anticoagulant treatment with rivaroxaban, an oral factor Xa inhibitor, may result in a lower risk of recurrent stroke than aspirin.	Rivaroxaban	29-40	coagulation factor X	Homo sapiens	50-59
29572341-9	2018	The IC50 values of the three PDE5is were 8, 28, and 5 microM for rivaroxaban and 23, 15, and 3 microM for apixaban, respectively.	Rivaroxaban	65-76	phosphodiesterase 5A	Homo sapiens	29-33
29525076-1	2018	BACKGROUND: The New Approach Rivaroxaban Inhibition of Factor Xa in a Global Trial vs. ASA to Prevent Embolism in Embolic Stroke of Undetermined Source (NAVIGATE-ESUS) trial is a randomized phase-III trial comparing rivaroxaban versus aspirin in patients with recent ESUS.	Rivaroxaban	29-40	coagulation factor X	Homo sapiens	55-64
29525076-1	2018	BACKGROUND: The New Approach Rivaroxaban Inhibition of Factor Xa in a Global Trial vs. ASA to Prevent Embolism in Embolic Stroke of Undetermined Source (NAVIGATE-ESUS) trial is a randomized phase-III trial comparing rivaroxaban versus aspirin in patients with recent ESUS.	Rivaroxaban	216-227	coagulation factor X	Homo sapiens	55-64
31249942-1	2018	Rivaroxaban and apixaban are both small molecules that reversibly inhibit factor Xa.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	74-83
30103248-3	2018	In the ATLAS-TIMI 52 trial, a low-dose direct factor Xa inhibition with rivaroxaban compared with placebo reduced the combined primary endpoint of cardiovascular mortality, myocardial infraction and stroke with an increase in major bleeding complications.	Rivaroxaban	72-83	coagulation factor X	Homo sapiens	46-55
30159173-4	2018	Both rivaroxaban and amiodarone are substrates for the CYP3A4 hepatic pathway, and concomitant use can result in increased plasma rivaroxaban levels causing an increased propensity to bleeding.	Rivaroxaban	5-16	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	55-61
30159173-4	2018	Both rivaroxaban and amiodarone are substrates for the CYP3A4 hepatic pathway, and concomitant use can result in increased plasma rivaroxaban levels causing an increased propensity to bleeding.	Rivaroxaban	130-141	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	55-61
29847020-8	2018	In vitro experiments performed using bovine interstitial valve cells (VIC) showed that treatment with rivaroxaban did not prevent the osteogenic conversion of the cells but reduce the over-expression of COX-2 induced by inflammatory mediators.	Rivaroxaban	102-113	cytochrome c oxidase subunit II	Bos taurus	203-208
29773500-0	2018	An analysis on distribution and inter-relationships of biomarkers under rivaroxaban in Japanese patients with non-valvular atrial fibrillation (CVI ARO 1).	Rivaroxaban	72-83	cytochrome P450 family 19 subfamily A member 1	Homo sapiens	148-153
29773500-6	2018	The pharmacokinetics of rivaroxaban were affected by creatinine clearance, alanine aminotransferase, and use of CYP3A4 or P-gp inhibitors.	Rivaroxaban	24-35	glutamic--pyruvic transaminase	Homo sapiens	75-99
29773500-6	2018	The pharmacokinetics of rivaroxaban were affected by creatinine clearance, alanine aminotransferase, and use of CYP3A4 or P-gp inhibitors.	Rivaroxaban	24-35	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	112-118
29773500-6	2018	The pharmacokinetics of rivaroxaban were affected by creatinine clearance, alanine aminotransferase, and use of CYP3A4 or P-gp inhibitors.	Rivaroxaban	24-35	phosphoglycolate phosphatase	Homo sapiens	122-126
30083644-0	2018	Anti-factor Xa Monitoring and Activated Charcoal for a Pediatric Patient With Rivaroxaban Overdose.	Rivaroxaban	78-89	coagulation factor X	Homo sapiens	5-14
30083644-1	2018	Rivaroxaban, an oral anticoagulant, directly inhibits factor Xa (FXa).	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	54-63
30083644-1	2018	Rivaroxaban, an oral anticoagulant, directly inhibits factor Xa (FXa).	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	65-68
30083644-6	2018	The present case is the first reported use of anti-FXa monitoring after rivaroxaban ingestion.	Rivaroxaban	72-83	coagulation factor X	Homo sapiens	51-54
30002384-0	2018	Effect of ABCB1 genetic polymorphisms on the transport of rivaroxaban in HEK293 recombinant cell lines.	Rivaroxaban	58-69	ATP binding cassette subfamily B member 1	Homo sapiens	10-15
30002384-6	2018	ABCB1 expression decreased the intracellular accumulation of rivaroxaban, when compared to control cells.	Rivaroxaban	61-72	ATP binding cassette subfamily B member 1	Homo sapiens	0-5
30002384-7	2018	This confirms the involvement of ABCB1 in the active transport of rivaroxaban.	Rivaroxaban	66-77	ATP binding cassette subfamily B member 1	Homo sapiens	33-38
29790645-2	2018	FIBPT-d method overestimates fibrinogen in rivaroxaban and low molecular weight heparin samples.	Rivaroxaban	43-54	fibrinogen beta chain	Homo sapiens	29-39
29720261-1	2018	BACKGROUND: Rivaroxaban, a direct factor Xa inhibitor, has seldom been used in patients with coronary artery disease.	Rivaroxaban	12-23	coagulation factor X	Homo sapiens	34-43
29844742-1	2018	Direct oral anticoagulants, which include the factor Xa inhibitor rivaroxaban, have some advantages over vitamin K antagonists in regard to stroke prevention in patients with atrial fibrillation.	Rivaroxaban	66-77	coagulation factor X	Homo sapiens	46-55
29844742-6	2018	The patient"s plasma anti-factor Xa level decreased from 0.4 IU/mL immediately before treatment to 0.21 IU/mL afterward, indicating that rivaroxaban had been actively removed from circulation.	Rivaroxaban	137-148	coagulation factor X	Homo sapiens	26-35
29576106-1	2018	Non-vitamin K antagonist oral anticoagulants (NOACs), which inhibit thrombin (dabigatran) and factor Xa (rivaroxaban, apixaban, edoxaban) have been introduced in several clinical indications.	Rivaroxaban	105-116	coagulation factor X	Homo sapiens	94-103
28895074-9	2018	CONCLUSION: This study allowed identification of three different profiles of ABC carrier-mediated transport: predominantly P-gp-dependent transport (dabigatran), preferential BCRP-dependent transport (apixaban) and approximately equivalent P-gp and BCRP-mediated transport (edoxaban and rivaroxaban).	Rivaroxaban	287-298	ATP binding cassette subfamily B member 6 (Langereis blood group)	Homo sapiens	77-80
29287144-1	2018	Rivaroxaban (RXB) is an orally active direct inhibitor of the activated serine protease Factor Xa, given as monotherapy in the treatment of venous thromboembolism (VTE).	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	88-97
29194698-1	2018	Pharmacokinetics and antithrombotic effects of the Factor Xa inhibitor rivaroxaban were studied in subjects with mild renal insufficiency concurrently taking the P-glycoprotein and moderate CYP3A inhibitor verapamil, a drug commonly administered to patients with hypertension, ischemic heart disease, or atrial fibrillation.	Rivaroxaban	71-82	coagulation factor X	Homo sapiens	51-60
29194698-8	2018	Prothrombin time (PT) prolongation and Factor Xa inhibition tracked plasma rivaroxaban, and were enhanced by verapamil.	Rivaroxaban	75-86	coagulation factor II, thrombin	Homo sapiens	0-11
29194698-8	2018	Prothrombin time (PT) prolongation and Factor Xa inhibition tracked plasma rivaroxaban, and were enhanced by verapamil.	Rivaroxaban	75-86	coagulation factor X	Homo sapiens	39-48
29239000-2	2018	However, rivaroxaban dosing in patients with mild renal impairment taking concomitant moderate inhibitors of CYP3A and P-glycoprotein is not addressed.	Rivaroxaban	9-20	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	109-114
29588304-4	2018	Coagulation- and platelet-dependent thrombin generation (TG), measured by means of the calibrated automated thrombogram, were significantly decreased after in vitro and in vivo addition of rivaroxaban.	Rivaroxaban	189-200	coagulation factor II, thrombin	Homo sapiens	36-44
29588304-5	2018	As shown by a total thrombus-formation analysis approach, rivaroxaban treatment led to a significantly decreased coagulation-dependent (AR-chip) thrombus formation in patients treated with ASA plus P2Y12 inhibitor (clopidogrel/ticagrelor), whereas the pure platelet-dependent (PL-chip) thrombus formation was not affected at all.	Rivaroxaban	58-69	purinergic receptor P2Y12	Homo sapiens	198-203
29588304-7	2018	Nevertheless, according to fluorescence-activated cell sorter analysis, VLD rivaroxaban treatment resulted in a significantly reduced expression of platelet HMGB-1, whereas P-selectin exposure was not affected.	Rivaroxaban	76-87	high mobility group box 1	Homo sapiens	157-163
28993090-11	2018	TAC-induced protein overexpression of monocyte chemoattractant protein-1, and mRNA overexpression of tumor necrosis factor-alpha, interleukin (IL)-1beta and IL-6 in the left atrium was suppressed by RVX treatment.	Rivaroxaban	199-202	chemokine (C-C motif) ligand 2	Mus musculus	38-72
28993090-11	2018	TAC-induced protein overexpression of monocyte chemoattractant protein-1, and mRNA overexpression of tumor necrosis factor-alpha, interleukin (IL)-1beta and IL-6 in the left atrium was suppressed by RVX treatment.	Rivaroxaban	199-202	tumor necrosis factor	Mus musculus	101-128
28993090-11	2018	TAC-induced protein overexpression of monocyte chemoattractant protein-1, and mRNA overexpression of tumor necrosis factor-alpha, interleukin (IL)-1beta and IL-6 in the left atrium was suppressed by RVX treatment.	Rivaroxaban	199-202	interleukin 1 beta	Mus musculus	130-152
28993090-12	2018	In cardiac fibroblasts, persistent intermittent stretch upregulated PAR-2, which was suppressed by RVX pre-incubation.	Rivaroxaban	99-102	pulmonary adenoma resistance 2	Mus musculus	68-73
31249942-4	2018	Although rivaroxaban and apixaban inhibited factor Xa with similar K i values at equilibrium, kinetic measurements revealed that rivaroxaban inhibited factor Xa up to 4-fold faster than apixaban ( p  &lt; 0.001).	Rivaroxaban	129-140	coagulation factor X	Homo sapiens	151-160
31249942-5	2018	Using a discontinuous chromogenic assay to monitor thrombin production by prothrombinase in a purified system, rivaroxaban was 4-fold more potent than apixaban (K i values of 0.7 +- 0.3 and 2.9 +- 0.5 nM, respectively; p  = 0.02).	Rivaroxaban	111-122	coagulation factor II, thrombin	Homo sapiens	51-59
31249942-5	2018	Using a discontinuous chromogenic assay to monitor thrombin production by prothrombinase in a purified system, rivaroxaban was 4-fold more potent than apixaban (K i values of 0.7 +- 0.3 and 2.9 +- 0.5 nM, respectively; p  = 0.02).	Rivaroxaban	111-122	coagulation factor X	Homo sapiens	74-88
31249942-6	2018	Likewise, in thrombin generation assays in plasma, rivaroxaban prolonged the lag time and suppressed endogenous thrombin potential to a greater extent than apixaban.	Rivaroxaban	51-62	coagulation factor II, thrombin	Homo sapiens	13-21
31249942-6	2018	Likewise, in thrombin generation assays in plasma, rivaroxaban prolonged the lag time and suppressed endogenous thrombin potential to a greater extent than apixaban.	Rivaroxaban	51-62	coagulation factor II, thrombin	Homo sapiens	112-120
31249942-9	2018	The association rates for the binding of rivaroxaban to either free factor Xa or factor Xa incorporated into the prothrombinase complex were 10- and 1,193-fold faster than those for apixaban, respectively, whereas dissociation rates were about 3-fold faster.	Rivaroxaban	41-52	coagulation factor X	Homo sapiens	68-77
31249942-9	2018	The association rates for the binding of rivaroxaban to either free factor Xa or factor Xa incorporated into the prothrombinase complex were 10- and 1,193-fold faster than those for apixaban, respectively, whereas dissociation rates were about 3-fold faster.	Rivaroxaban	41-52	coagulation factor X	Homo sapiens	81-90
31249942-9	2018	The association rates for the binding of rivaroxaban to either free factor Xa or factor Xa incorporated into the prothrombinase complex were 10- and 1,193-fold faster than those for apixaban, respectively, whereas dissociation rates were about 3-fold faster.	Rivaroxaban	41-52	coagulation factor X	Homo sapiens	113-127
31249942-10	2018	Collectively, these findings suggest that rivaroxaban and apixaban differ in their capacity to inhibit factor Xa and provide a plausible explanation for the observation that rivaroxaban has a greater effect on global tests of coagulation than apixaban.	Rivaroxaban	42-53	coagulation factor X	Homo sapiens	103-112
31249942-10	2018	Collectively, these findings suggest that rivaroxaban and apixaban differ in their capacity to inhibit factor Xa and provide a plausible explanation for the observation that rivaroxaban has a greater effect on global tests of coagulation than apixaban.	Rivaroxaban	174-185	coagulation factor X	Homo sapiens	103-112
29287144-1	2018	Rivaroxaban (RXB) is an orally active direct inhibitor of the activated serine protease Factor Xa, given as monotherapy in the treatment of venous thromboembolism (VTE).	Rivaroxaban	13-16	coagulation factor X	Homo sapiens	88-97
28940408-1	2018	AIMS: Rivaroxaban, a direct inhibitor of activated factor X (FXa), is the only new oral anticoagulant approved for secondary prevention after acute coronary syndrome.	Rivaroxaban	6-17	coagulation factor X	Homo sapiens	61-64
28940408-6	2018	RESULTS: Rivaroxaban (50 nM) only altered (&gt;2 fold change) the expression of matrix metallopeptidase 2 and urokinase plasminogen activator (u-PA), but counteracted the FXa (9 nM)-induced upregulation of several pro-inflammatory genes (P &lt; 0.05) and FXa-enhanced platelet adhesion over HUVEC.	Rivaroxaban	9-20	matrix metallopeptidase 2	Homo sapiens	80-105
28940408-6	2018	RESULTS: Rivaroxaban (50 nM) only altered (&gt;2 fold change) the expression of matrix metallopeptidase 2 and urokinase plasminogen activator (u-PA), but counteracted the FXa (9 nM)-induced upregulation of several pro-inflammatory genes (P &lt; 0.05) and FXa-enhanced platelet adhesion over HUVEC.	Rivaroxaban	9-20	plasminogen activator, urokinase	Homo sapiens	110-141
28940408-6	2018	RESULTS: Rivaroxaban (50 nM) only altered (&gt;2 fold change) the expression of matrix metallopeptidase 2 and urokinase plasminogen activator (u-PA), but counteracted the FXa (9 nM)-induced upregulation of several pro-inflammatory genes (P &lt; 0.05) and FXa-enhanced platelet adhesion over HUVEC.	Rivaroxaban	9-20	plasminogen activator, urokinase	Homo sapiens	143-147
28940408-6	2018	RESULTS: Rivaroxaban (50 nM) only altered (&gt;2 fold change) the expression of matrix metallopeptidase 2 and urokinase plasminogen activator (u-PA), but counteracted the FXa (9 nM)-induced upregulation of several pro-inflammatory genes (P &lt; 0.05) and FXa-enhanced platelet adhesion over HUVEC.	Rivaroxaban	9-20	coagulation factor X	Homo sapiens	171-174
28940408-6	2018	RESULTS: Rivaroxaban (50 nM) only altered (&gt;2 fold change) the expression of matrix metallopeptidase 2 and urokinase plasminogen activator (u-PA), but counteracted the FXa (9 nM)-induced upregulation of several pro-inflammatory genes (P &lt; 0.05) and FXa-enhanced platelet adhesion over HUVEC.	Rivaroxaban	9-20	coagulation factor X	Homo sapiens	255-258
28940408-7	2018	Rivaroxaban increased u-PA protein expression in HUVEC supernatants and enhanced u-PA activity (up to 4 IU ng-1 of u-PA).	Rivaroxaban	0-11	plasminogen activator, urokinase	Homo sapiens	22-26
28940408-7	2018	Rivaroxaban increased u-PA protein expression in HUVEC supernatants and enhanced u-PA activity (up to 4 IU ng-1 of u-PA).	Rivaroxaban	0-11	plasminogen activator, urokinase	Homo sapiens	81-85
28940408-7	2018	Rivaroxaban increased u-PA protein expression in HUVEC supernatants and enhanced u-PA activity (up to 4 IU ng-1 of u-PA).	Rivaroxaban	0-11	plasminogen activator, urokinase	Homo sapiens	81-85
28940408-8	2018	Rivaroxaban (1 nM-1 muM) showed a significant and dose-dependent positive effect on HUVEC growth that was inhibited by BC-11-hydroxibromide, an inhibitor of u-PA.	Rivaroxaban	0-11	latexin	Homo sapiens	20-23
28940408-8	2018	Rivaroxaban (1 nM-1 muM) showed a significant and dose-dependent positive effect on HUVEC growth that was inhibited by BC-11-hydroxibromide, an inhibitor of u-PA.	Rivaroxaban	0-11	plasminogen activator, urokinase	Homo sapiens	157-161
28940408-11	2018	CONCLUSIONS: Rivaroxaban enhanced viability, growth and migration of HUVEC, mainly by u-PA activation and upregulation, which also participate in the rivaroxaban-induced fibrinolytic activity at endothelial level.	Rivaroxaban	13-24	plasminogen activator, urokinase	Homo sapiens	86-90
28940408-11	2018	CONCLUSIONS: Rivaroxaban enhanced viability, growth and migration of HUVEC, mainly by u-PA activation and upregulation, which also participate in the rivaroxaban-induced fibrinolytic activity at endothelial level.	Rivaroxaban	150-161	plasminogen activator, urokinase	Homo sapiens	86-90
28940408-12	2018	Rivaroxaban also protected from the pro-inflammatory effects of FXa on HUVEC.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	64-67
29239121-0	2018	Effect of Rivaroxaban on thrombin generation in vivo.	Rivaroxaban	10-21	coagulation factor II, thrombin	Homo sapiens	25-33
29120909-2	2018	Rivaroxaban, an oral, direct factor Xa inhibitor, is one of the most used.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	29-38
29365322-0	2018	Rivaroxaban dose adjustment using thrombin generation in severe congenital protein C deficiency and warfarin-induced skin necrosis.	Rivaroxaban	0-11	coagulation factor II, thrombin	Homo sapiens	34-42
28735510-0	2017	FXa inhibition by rivaroxaban modifies mechanisms associated with the pathogenesis of human abdominal aortic aneurysms.	Rivaroxaban	18-29	coagulation factor X	Homo sapiens	0-3
29344007-0	2018	Four-factor prothrombin complex concentrate improves thrombin generation and prothrombin time in patients with bleeding complications related to rivaroxaban: a single-center pilot trial.	Rivaroxaban	145-156	coagulation factor II, thrombin	Homo sapiens	15-23
29391805-3	2018	Rivaroxaban, a direct factor Xa inhibitor and the most commonly used non-vitamin K oral anticoagulant, avoids many of these challenges and is being prescribed with increasing frequency for stroke prevention in non-valvular AF.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	22-31
29391805-4	2018	Randomized controlled trial (RCT) data from the ROCKET-AF(Rivaroxaban once daily oral direct Factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation) trial have shown rivaroxaban to be non-inferior to warfarin in preventing ischemic stroke and systemic embolism and to have comparable overall bleeding rates.	Rivaroxaban	58-69	coagulation factor X	Homo sapiens	93-102
28920711-5	2018	RESULTS: - The FVL-HET patients taking rivaroxaban had lower APCR ratios than wild-type patients ( P &lt; .001).	Rivaroxaban	39-50	coagulation factor V	Homo sapiens	15-18
28920711-6	2018	For FVL-HET patients taking rivaroxaban, mean APCR was 1.75 +- 0.12, versus 1.64 +- 0.3 in FVL-HET patients not taking rivaroxaban ( P = .005).	Rivaroxaban	28-39	coagulation factor V	Homo sapiens	4-7
29345985-1	2018	BACKGROUND: Rivaroxaban is metabolized in the liver via CYP3A4, the cytochrome involved in the metabolism of nearly 50% of all medications.	Rivaroxaban	12-23	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	56-62
29345985-3	2018	METHODS: The primary goal of our research was to study the correlation between the CYP3A family activity and the safety and efficacy of anticoagulant therapy with rivaroxaban in patients with deep vein thrombosis (DVT).	Rivaroxaban	163-174	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	83-88
29345985-6	2018	RESULTS: We found a direct statistically reliable correlation between CYP3A4 activity and both peak and trough rivaroxaban levels.	Rivaroxaban	111-122	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	70-76
29692238-3	2018	The importance of oral FXa inhibitors like rivaroxaban, apixaban and edoxaban in thromboembolic conditions is well supported by increasing number of patents and research publications during the recent years.	Rivaroxaban	43-54	coagulation factor X	Homo sapiens	23-26
29269019-7	2018	Quantitative RT-PCR analyses demonstrated that rivaroxaban reduced the expression of inflammatory molecules (e.g., IL-1beta and TNF-alpha) in injured arteries at seven days after surgery (P&lt;0.05, respectively).	Rivaroxaban	47-58	interleukin 1 beta	Mus musculus	115-123
29269019-7	2018	Quantitative RT-PCR analyses demonstrated that rivaroxaban reduced the expression of inflammatory molecules (e.g., IL-1beta and TNF-alpha) in injured arteries at seven days after surgery (P&lt;0.05, respectively).	Rivaroxaban	47-58	tumor necrosis factor	Mus musculus	128-137
29269019-8	2018	In vitro experiments using mouse peritoneal macrophages demonstrated that FXa increased the expression of inflammatory molecules (e.g., IL-1beta and TNF-alpha), which was blocked in the presence of rivaroxaban (P&lt;0.05).	Rivaroxaban	198-209	interleukin 1 beta	Mus musculus	136-144
29269019-8	2018	In vitro experiments using mouse peritoneal macrophages demonstrated that FXa increased the expression of inflammatory molecules (e.g., IL-1beta and TNF-alpha), which was blocked in the presence of rivaroxaban (P&lt;0.05).	Rivaroxaban	198-209	tumor necrosis factor	Mus musculus	149-158
28888219-0	2018	Factor Xa inhibition by rivaroxaban in the trough steady state can significantly reduce thrombin generation.	Rivaroxaban	24-35	coagulation factor X	Homo sapiens	0-9
28888219-0	2018	Factor Xa inhibition by rivaroxaban in the trough steady state can significantly reduce thrombin generation.	Rivaroxaban	24-35	coagulation factor II, thrombin	Homo sapiens	88-96
28888219-1	2018	AIMS: The aim of the present study was to demonstrate evidence of reduced thrombin generation at the trough plasma rivaroxaban concentration.	Rivaroxaban	115-126	coagulation factor II, thrombin	Homo sapiens	74-82
28888219-10	2018	CONCLUSIONS: Residual plasma rivaroxaban at the trough steady state may explain the antithrombin effect of rivaroxaban in patients with nonvalvular atrial fibrillation.	Rivaroxaban	29-40	serpin family C member 1	Homo sapiens	84-96
28888219-10	2018	CONCLUSIONS: Residual plasma rivaroxaban at the trough steady state may explain the antithrombin effect of rivaroxaban in patients with nonvalvular atrial fibrillation.	Rivaroxaban	107-118	serpin family C member 1	Homo sapiens	84-96
28735510-1	2017	AIMS: To evaluate if rivaroxaban, an oral factor Xa (FXa) inhibitor, could modify the expression in vitro of inflammatory and oxidative stress biomarkers in abdominal aortic aneurysmal (AAA) sites showing intraluminal thrombus.	Rivaroxaban	21-32	coagulation factor X	Homo sapiens	42-51
28735510-1	2017	AIMS: To evaluate if rivaroxaban, an oral factor Xa (FXa) inhibitor, could modify the expression in vitro of inflammatory and oxidative stress biomarkers in abdominal aortic aneurysmal (AAA) sites showing intraluminal thrombus.	Rivaroxaban	21-32	coagulation factor X	Homo sapiens	53-56
28735510-8	2017	Addition of rivaroxaban to AAA sites explants significantly reduced the release of interleukin-6 [median: 51.61 (interquartile range: 30.87-74.03) pg ml-1  mg tissue-1 , P &lt; 0.05 with respect to AAA alone] and the content of nitric oxide synthase 2, gp67 and gp91-phox NADPH subunits.	Rivaroxaban	12-23	interleukin 6	Homo sapiens	83-96
28735510-8	2017	Addition of rivaroxaban to AAA sites explants significantly reduced the release of interleukin-6 [median: 51.61 (interquartile range: 30.87-74.03) pg ml-1  mg tissue-1 , P &lt; 0.05 with respect to AAA alone] and the content of nitric oxide synthase 2, gp67 and gp91-phox NADPH subunits.	Rivaroxaban	12-23	nitric oxide synthase 2	Homo sapiens	228-251
28735510-8	2017	Addition of rivaroxaban to AAA sites explants significantly reduced the release of interleukin-6 [median: 51.61 (interquartile range: 30.87-74.03) pg ml-1  mg tissue-1 , P &lt; 0.05 with respect to AAA alone] and the content of nitric oxide synthase 2, gp67 and gp91-phox NADPH subunits.	Rivaroxaban	12-23	CD33 molecule	Homo sapiens	253-257
28735510-10	2017	Rivaroxaban also reduced matrix metallopeptidase 9 content in AAA sites to similar levels to control.	Rivaroxaban	0-11	matrix metallopeptidase 9	Homo sapiens	25-50
28735510-11	2017	CONCLUSIONS: FXa inhibition by rivaroxaban exerted anti-inflammatory and antioxidative stress properties in human AAA sites, suggesting a role of FXa in these mechanisms associated with the pathogenesis of AAA.	Rivaroxaban	31-42	coagulation factor X	Homo sapiens	13-16
28735510-11	2017	CONCLUSIONS: FXa inhibition by rivaroxaban exerted anti-inflammatory and antioxidative stress properties in human AAA sites, suggesting a role of FXa in these mechanisms associated with the pathogenesis of AAA.	Rivaroxaban	31-42	coagulation factor X	Homo sapiens	146-149
28952381-1	2017	INTRODUCTION: In the last decade, several direct oral anticoagulants (DOAC) targeting thrombin (dabigatran) or activated factor X (FXa) (rivaroxaban, apixaban and edoxaban) have been marketed for a number of indications related to prophylaxis and treatment of thrombotic diseases.	Rivaroxaban	137-148	coagulation factor X	Homo sapiens	131-134
29215061-9	2017	Inhibition of FXa signaling with rivaroxaban or knock down of IGFBP-5 significantly reduced FXa-induced VSMC senescence and inflammatory cytokine production.	Rivaroxaban	33-44	coagulation factor X	Homo sapiens	14-17
29215061-9	2017	Inhibition of FXa signaling with rivaroxaban or knock down of IGFBP-5 significantly reduced FXa-induced VSMC senescence and inflammatory cytokine production.	Rivaroxaban	33-44	coagulation factor X	Homo sapiens	92-95
29039441-10	2017	Our results showed that rivaroxaban markedly inhibited TAFI and PAI-1 expression levels, neutrophils, tissue factor, neutrophil extracellular traps (NETs), myeloperoxidase and macrophages in venous endothelial cells and in the rat model of deep venous thrombus.	Rivaroxaban	24-35	carboxypeptidase B2	Rattus norvegicus	55-59
29039441-10	2017	Our results showed that rivaroxaban markedly inhibited TAFI and PAI-1 expression levels, neutrophils, tissue factor, neutrophil extracellular traps (NETs), myeloperoxidase and macrophages in venous endothelial cells and in the rat model of deep venous thrombus.	Rivaroxaban	24-35	serpin family E member 1	Rattus norvegicus	64-69
29039441-10	2017	Our results showed that rivaroxaban markedly inhibited TAFI and PAI-1 expression levels, neutrophils, tissue factor, neutrophil extracellular traps (NETs), myeloperoxidase and macrophages in venous endothelial cells and in the rat model of deep venous thrombus.	Rivaroxaban	24-35	coagulation factor III, tissue factor	Rattus norvegicus	102-115
29039441-10	2017	Our results showed that rivaroxaban markedly inhibited TAFI and PAI-1 expression levels, neutrophils, tissue factor, neutrophil extracellular traps (NETs), myeloperoxidase and macrophages in venous endothelial cells and in the rat model of deep venous thrombus.	Rivaroxaban	24-35	myeloperoxidase	Rattus norvegicus	156-171
29039441-17	2017	On the whole, these results indicate that rivaroxaban attenuates deep venous thrombus through MMP-9-mediated NF-kappaB signaling pathway.	Rivaroxaban	42-53	matrix metallopeptidase 9	Rattus norvegicus	94-99
28708713-2	2017	The aim of this study was to test the effect of direct oral factor Xa inhibitors-rivaroxaban and apixaban-on platelet aggregation in patients with nonvalvular atrial fibrillation.	Rivaroxaban	81-92	coagulation factor X	Homo sapiens	60-69
28886856-0	2017	Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).	Rivaroxaban	60-71	coagulation factor X	Homo sapiens	149-158
28886856-2	2017	We retrospectively analyzed the outcomes of all patients who received thrombolytic therapy in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).	Rivaroxaban	98-109	coagulation factor X	Homo sapiens	133-142
28933799-4	2017	Rivaroxaban is a potent, oral, direct, factor Xa inhibitor approved for the prevention and treatment of thromboembolic events, including VTE.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	39-48
28210886-9	2017	Accordingly, rivaroxaban dose-dependently increased the CT 2- and 2.7-fold in WB, and 3.5- and 4-fold in plasma samples.	Rivaroxaban	13-24	solute carrier family 6 member 10, pseudogene	Homo sapiens	56-60
28835439-0	2017	Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study.	Rivaroxaban	14-25	coagulation factor II, thrombin	Homo sapiens	70-81
28835439-1	2017	There is uncertainty regarding the effectiveness and occurrence of thromboembolic events in patients treated with prothrombin complex concentrates (PCCs) for the management of major bleeding events (MBEs) on rivaroxaban or apixaban.	Rivaroxaban	208-219	coagulation factor II, thrombin	Homo sapiens	114-125
29017215-1	2017	Introduction Rivaroxaban, an oral factor Xa inhibitor, is approved for therapy of venous thromboembolism.	Rivaroxaban	13-24	coagulation factor X	Homo sapiens	34-43
28805299-3	2017	Rivaroxaban was associated with more prolonged inhibition of thrombin generation than apixaban.	Rivaroxaban	0-11	coagulation factor II, thrombin	Homo sapiens	61-69
28805299-11	2017	Rivaroxaban was associated with greater inhibition of endogenous thrombin potential (geometric mean area under the curve relative to baseline during the 0-24-h interval: 15.5 h versus 17.5 h) and a more pronounced maximal prolongation relative to baseline of prothrombin time (PT) (1.66-fold versus 1.14-fold) and activated partial thromboplastin time (APTT) (1.43-fold versus 1.16-fold) at steady state than apixaban.	Rivaroxaban	0-11	coagulation factor II, thrombin	Homo sapiens	65-73
28805299-12	2017	Conclusions Despite similar exposure to both drugs, rivaroxaban 20 mg once daily was associated with greater and more sustained inhibition of thrombin generation than apixaban 5 mg twice daily.	Rivaroxaban	52-63	coagulation factor II, thrombin	Homo sapiens	142-150
28674871-1	2017	BACKGROUND: The Xarelto for Prevention of Stroke in Patients with Atrial Fibrillation (XANTUS) registry investigated the safety and efficacy of the factor Xa inhibitor rivaroxaban.	Rivaroxaban	168-179	coagulation factor X	Homo sapiens	148-157
28625215-5	2017	If a kaolin-based hemostatic agent (QuikClot Combat Gauze), which works primarily by augmenting the clotting cascade upstream of factor Xa (FXa), is applied to rivaroxaban-anticoagulated blood, it will not be effective at improving coagulation.	Rivaroxaban	160-171	coagulation factor X	Homo sapiens	129-138
28625215-5	2017	If a kaolin-based hemostatic agent (QuikClot Combat Gauze), which works primarily by augmenting the clotting cascade upstream of factor Xa (FXa), is applied to rivaroxaban-anticoagulated blood, it will not be effective at improving coagulation.	Rivaroxaban	160-171	coagulation factor X	Homo sapiens	140-143
28735423-8	2017	In contrast, D-dimer and prothrombin fragment F1+2 plasma levels indicated a higher activation of the coagulation cascade in apixaban/heparin than in rivaroxaban/heparin patients.	Rivaroxaban	150-161	coagulation factor XII	Homo sapiens	46-50
28979172-4	2017	Andexanet alfa is a FXa decoy designed to reverse all anticoagulants that act through this part of the coagulation cascade including anti-FXa DOACs, such as apixaban, edoxaban and rivaroxaban, and indirect FXa inhibitors such as low-molecular-weight heparins.	Rivaroxaban	180-191	coagulation factor X	Homo sapiens	20-23
28794370-4	2017	We herein report the case of a 90-year-old woman with AT deficiency who was safely and successfully managed using rivaroxaban (a direct oral factor Xa inhibitor) during the perioperative period of surgery for right femur fracture.	Rivaroxaban	114-125	coagulation factor X	Homo sapiens	141-150
28794370-5	2017	The present case illustrates the effectiveness of rivaroxaban in preventing thromboembolisms due to surgery, even in very elderly patients with antithrombin deficiency.	Rivaroxaban	50-61	serpin family C member 1	Homo sapiens	144-156
28456731-2	2017	Apixaban inhibited hOAT3, hOATP1B1, and hOATP1B3, and rivaroxaban inhibited hOAT3 and hOATP1B3, with IC50 values of &gt;20 and &gt;5 muM, respectively.	Rivaroxaban	54-65	solute carrier family 22 member 8	Homo sapiens	76-81
28035779-0	2017	Reduction of intracerebral hemorrhage by rivaroxaban after tPA thrombolysis is associated with downregulation of PAR-1 and PAR-2.	Rivaroxaban	41-52	plasminogen activator, tissue type	Rattus norvegicus	59-62
28035779-0	2017	Reduction of intracerebral hemorrhage by rivaroxaban after tPA thrombolysis is associated with downregulation of PAR-1 and PAR-2.	Rivaroxaban	41-52	coagulation factor II (thrombin) receptor	Rattus norvegicus	113-118
28035779-0	2017	Reduction of intracerebral hemorrhage by rivaroxaban after tPA thrombolysis is associated with downregulation of PAR-1 and PAR-2.	Rivaroxaban	41-52	F2R like trypsin receptor 1	Rattus norvegicus	123-128
28035779-1	2017	This study aimed to assess the risk of intracerebral hemorrhage (ICH) after tissue-type plasminogen activator (tPA) treatment in rivaroxaban compared with warfarin-pretreated male Wistar rat brain after ischemia in relation to activation profiles of protease-activated receptor-1, -2, -3, and -4 (PAR-1, -2, -3, and -4).	Rivaroxaban	129-140	plasminogen activator, tissue type	Rattus norvegicus	76-109
28035779-1	2017	This study aimed to assess the risk of intracerebral hemorrhage (ICH) after tissue-type plasminogen activator (tPA) treatment in rivaroxaban compared with warfarin-pretreated male Wistar rat brain after ischemia in relation to activation profiles of protease-activated receptor-1, -2, -3, and -4 (PAR-1, -2, -3, and -4).	Rivaroxaban	129-140	plasminogen activator, tissue type	Rattus norvegicus	111-114
28035779-8	2017	The present study shows a lower risk of brain hemorrhage in rivaroxaban-pretreated compared with warfarin-pretreated rats following tPA administration to the ischemic brain.	Rivaroxaban	60-71	plasminogen activator, tissue type	Rattus norvegicus	132-135
28035779-9	2017	It is suggested that the relative downregulation of PAR-1 and PAR-2 by rivaroxaban compared with warfarin pretreatment might be partly involved in the mechanism of reduced hemorrhagic complications in patients receiving rivaroxaban in clinical trials.	Rivaroxaban	71-82	coagulation factor II thrombin receptor	Homo sapiens	52-57
28035779-9	2017	It is suggested that the relative downregulation of PAR-1 and PAR-2 by rivaroxaban compared with warfarin pretreatment might be partly involved in the mechanism of reduced hemorrhagic complications in patients receiving rivaroxaban in clinical trials.	Rivaroxaban	71-82	F2R like trypsin receptor 1	Homo sapiens	62-67
28035779-9	2017	It is suggested that the relative downregulation of PAR-1 and PAR-2 by rivaroxaban compared with warfarin pretreatment might be partly involved in the mechanism of reduced hemorrhagic complications in patients receiving rivaroxaban in clinical trials.	Rivaroxaban	220-231	coagulation factor II thrombin receptor	Homo sapiens	52-57
28035779-9	2017	It is suggested that the relative downregulation of PAR-1 and PAR-2 by rivaroxaban compared with warfarin pretreatment might be partly involved in the mechanism of reduced hemorrhagic complications in patients receiving rivaroxaban in clinical trials.	Rivaroxaban	220-231	F2R like trypsin receptor 1	Homo sapiens	62-67
28456731-2	2017	Apixaban inhibited hOAT3, hOATP1B1, and hOATP1B3, and rivaroxaban inhibited hOAT3 and hOATP1B3, with IC50 values of &gt;20 and &gt;5 muM, respectively.	Rivaroxaban	54-65	solute carrier organic anion transporter family member 1B3	Homo sapiens	86-94
28456731-4	2017	Specific uptake of rivaroxaban was observed only in human and mouse OAT3-expressing cells.	Rivaroxaban	19-30	solute carrier family 22 (organic anion transporter), member 8	Mus musculus	68-72
28456731-6	2017	A defect in mOat3 reduced the kidney-to-plasma concentration ratio of rivaroxaban by 38% in mice.	Rivaroxaban	70-81	solute carrier family 22 (organic anion transporter), member 8	Mus musculus	12-17
28456731-10	2017	Taken together, organic anion transporters, mainly OAT3, may mediate basolateral uptake of rivaroxaban in kidneys.	Rivaroxaban	91-102	solute carrier family 22 (organic anion transporter), member 8	Mus musculus	51-55
28771277-5	2017	The G20210A prothrombin mutation was the independent predictor for Ks and CLT before rivaroxaban intake.	Rivaroxaban	85-96	coagulation factor II, thrombin	Homo sapiens	12-23
28790786-4	2017	The direct acting oral anticoagulants include the direct thrombin inhibitor (dabigatran) and the factor Xa inhibitors (rivaroxaban, apixaban, and edoxaban).	Rivaroxaban	119-130	coagulation factor X	Homo sapiens	97-106
28574652-10	2017	Correlation was lower in rivaroxaban concentrations below 50 mug L-1 and above 200 mug L-1 .	Rivaroxaban	25-36	immunoglobulin kappa variable 1-16	Homo sapiens	65-90
28574652-13	2017	Conclusions Anti-Xa activity correlated well with rivaroxaban plasma concentrations, especially in a range between 50 and 200 mug L-1 .	Rivaroxaban	50-61	immunoglobulin kappa variable 1-16	Homo sapiens	130-133
30279820-8	2017	The present case suggests that rivaroxaban is a direct Factor Xa inhibitor and does not require cofactors such as antithrombin-III, thus it is suitable for anticoagulation therapy in patients with low antithrombin-III activity.&gt;.	Rivaroxaban	31-42	coagulation factor X	Homo sapiens	55-64
30279820-8	2017	The present case suggests that rivaroxaban is a direct Factor Xa inhibitor and does not require cofactors such as antithrombin-III, thus it is suitable for anticoagulation therapy in patients with low antithrombin-III activity.&gt;.	Rivaroxaban	31-42	serpin family C member 1	Homo sapiens	201-217
28196633-4	2017	Direct oral anticoagulants (DOACs) including Factor Xa inhibitors (rivaroxaban, apixaban and edoxaban) and thrombin inhibitor (dabigatran) are poised to replace warfarin.	Rivaroxaban	67-78	coagulation factor X	Homo sapiens	45-54
28498476-0	2017	Effects of unfractionated heparin and rivaroxaban on the expression of heparanase and fibroblast growth factor 2 in human osteoblasts.	Rivaroxaban	38-49	heparanase	Homo sapiens	71-81
28498476-0	2017	Effects of unfractionated heparin and rivaroxaban on the expression of heparanase and fibroblast growth factor 2 in human osteoblasts.	Rivaroxaban	38-49	fibroblast growth factor 2	Homo sapiens	86-112
28498476-4	2017	Therefore, the present study was designed to investigate the effects of unfractionated heparin and rivaroxaban on the expression of HPSE and FGF2 in human osteoblasts.	Rivaroxaban	99-110	heparanase	Homo sapiens	132-136
28498476-4	2017	Therefore, the present study was designed to investigate the effects of unfractionated heparin and rivaroxaban on the expression of HPSE and FGF2 in human osteoblasts.	Rivaroxaban	99-110	fibroblast growth factor 2	Homo sapiens	141-145
28498476-8	2017	Unfractionated heparin alone significantly inhibited the expression of HPSE and FGF2, whereas rivaroxaban inhibited the expression of FGF2 without affecting that of HPSE.	Rivaroxaban	94-105	fibroblast growth factor 2	Homo sapiens	134-138
28498476-9	2017	Furthermore, the overexpression of HPSE or FGF2 significantly reversed the inhibitory effects of unfractionated heparin and rivaroxaban on osteoblasts.	Rivaroxaban	124-135	heparanase	Homo sapiens	35-39
28498476-9	2017	Furthermore, the overexpression of HPSE or FGF2 significantly reversed the inhibitory effects of unfractionated heparin and rivaroxaban on osteoblasts.	Rivaroxaban	124-135	fibroblast growth factor 2	Homo sapiens	43-47
28498476-10	2017	These findings suggested that HPSE and FGF2 signals were involved in the detrimental role of unfractionated heparin and rivaroxaban in human osteoblasts, providing novel information on the side effects of anticoagulants.	Rivaroxaban	120-131	heparanase	Homo sapiens	30-34
28498476-10	2017	These findings suggested that HPSE and FGF2 signals were involved in the detrimental role of unfractionated heparin and rivaroxaban in human osteoblasts, providing novel information on the side effects of anticoagulants.	Rivaroxaban	120-131	fibroblast growth factor 2	Homo sapiens	39-43
27026636-3	2017	Rivaroxaban, an oral factor Xa inhibitor, is Food and Drug Administration (FDA) approved for the treatment and prevention of venous thromboembolism and offers the convenience of oral fixed-dose regimens, no routine laboratory monitoring, and has few drug and dietary interactions; however, its use in patients with cancer has not been largely studied.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	21-30
28185693-3	2017	Activated factor X (FXa) inhibition has emerged as a convenient pathway for management of VTE and currently three FXa inhibitors are available for anticoagulation management - rivaroxaban, apixaban, and edoxaban.	Rivaroxaban	176-187	coagulation factor X	Homo sapiens	114-117
28477860-0	2017	Relation of Risk of Stroke in Patients With Atrial Fibrillation to Body Mass Index (from Patients Treated With Rivaroxaban and Warfarin in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation Trial).	Rivaroxaban	111-122	coagulation factor X	Homo sapiens	178-187
28477860-0	2017	Relation of Risk of Stroke in Patients With Atrial Fibrillation to Body Mass Index (from Patients Treated With Rivaroxaban and Warfarin in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation Trial).	Rivaroxaban	143-154	coagulation factor X	Homo sapiens	178-187
28142199-8	2017	Rivaroxaban deactivated HSC, with decreased alpha-smooth muscle actin and mRNA expression of other HSC activation markers.	Rivaroxaban	0-11	actin gamma 2, smooth muscle	Rattus norvegicus	44-69
28230176-8	2017	Thrombin has an important role, suggesting the need for strategies directly targeting circulating thrombin or other factors of the coagulation cascade, such as oral anticoagulants (rivaroxaban), and the thrombin receptor on the platelet membrane (vorapaxar).	Rivaroxaban	181-192	coagulation factor II, thrombin	Homo sapiens	0-8
28169097-1	2017	BACKGROUND: Two forms of direct oral anticoagulant (DOAC) have recently been introduced: direct thrombin inhibitors (DTI; e.g., dabigatran) and factor Xa inhibitors (FXa; e.g., rivaroxaban and apixaban).	Rivaroxaban	177-188	coagulation factor X	Homo sapiens	166-169
28264892-0	2017	Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin: A ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) Analysis.	Rivaroxaban	68-79	coagulation factor X	Homo sapiens	143-152
28455317-0	2017	Letter by Machado-Alba et al Regarding Article, "Rivaroxaban Versus Dabigatran or Warfarin in Real-World Studies of Stroke Prevention in Atrial Fibrillation: Systematic Review and Meta-Analysis".	Rivaroxaban	49-60	afamin	Homo sapiens	18-22
28325638-2	2017	The factor Xa inhibitor rivaroxaban reduced mortality and ischaemic events when added to DAPT, but caused increased bleeding.	Rivaroxaban	24-35	coagulation factor X	Homo sapiens	4-13
28650000-4	2017	Rivaroxaban, apixaban and edoxaban are direct inhibitors of FXa approved for the management of venous thromboembolism and stroke prevention in atrial fibrillation.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	60-63
27796530-10	2017	Prothrombin time (r = 0.92, p &lt; 0.0001) and activated partial thromboplastin time (r = 0.54, p &lt; 0.0001) correlated with rivaroxaban concentration, but not D-dimer and F1 + 2 levels.	Rivaroxaban	127-138	coagulation factor II, thrombin	Homo sapiens	0-11
27796530-12	2017	Although trough level rivaroxaban suppresses F1 + 2 less than warfarin, the higher activities of protein C with rivaroxaban treatment compared to warfarin treatment may counterbalance this.	Rivaroxaban	22-33	coagulation factor XII	Homo sapiens	45-51
28316004-0	2017	Effect of the FXa inhibitors Rivaroxaban and Apixaban on platelet activation in patients with atrial fibrillation.	Rivaroxaban	29-40	coagulation factor X	Homo sapiens	14-17
28238163-1	2017	Rivaroxaban, an inhibitor of Factor Xa, is a direct oral anti-coagulant that has been found to be non-inferior to warfarin in preventing cerebral ischemia in patients with non-valvular atrial fibrillation and in the subgroup of patients with a history of the previous stroke or transient ischemic attack.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	29-38
28671072-1	2017	Rivaroxaban is an oral, direct factor Xa inhibitor used in human thrombotic disorders.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	31-40
28009346-6	2017	Rivaroxaban had the highest signal of association with both retinal and vitreous hemorrhage (ROR=7.41 (5.73-9.59) and ROR= 11.14 (7.37-16.86), respectively).	Rivaroxaban	0-11	long intergenic non-protein coding RNA, regulator of reprogramming	Homo sapiens	93-96
28009346-6	2017	Rivaroxaban had the highest signal of association with both retinal and vitreous hemorrhage (ROR=7.41 (5.73-9.59) and ROR= 11.14 (7.37-16.86), respectively).	Rivaroxaban	0-11	long intergenic non-protein coding RNA, regulator of reprogramming	Homo sapiens	118-121
29952167-7	2017	Since November 2015 the first specific antidote for dabigatran is available in Germany, a factor Xa antidote (apixaban, rivaroxaban, edoxaban) is being tested in a phase III study.	Rivaroxaban	120-131	coagulation factor X	Homo sapiens	90-99
27350265-2	2017	Rivaroxaban, apixaban and edoxaban directly inhibit factor Xa, whereas dabigatran inhibits factor IIa.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	52-61
28337024-0	2017	Angiotensin II promotes the anticoagulant effects of rivaroxaban via angiotensin type 2 receptor signaling in mice.	Rivaroxaban	53-64	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	0-14
28337024-4	2017	In this study, we investigate whether AngII influences anticoagulant effects of rivaroxaban by using an experimental mouse model with type 2 diabetes mellitus and advanced glycation end product (AGE)-exposed human umbilical vein endothelial cells (HUVECs).	Rivaroxaban	80-91	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	38-43
28337024-5	2017	We found that AngII promoted the anticoagulant effects of rivaroxaban in KKAy mice.	Rivaroxaban	58-69	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	14-19
28337024-6	2017	The combination of rivaroxaban and AngII enhanced in vivo tissue factor pathway inhibitor (TFPI) activity and induced TFPI expression and activity in AGE-exposed HUVECs.	Rivaroxaban	19-30	tissue factor pathway inhibitor	Mus musculus	58-89
28337024-6	2017	The combination of rivaroxaban and AngII enhanced in vivo tissue factor pathway inhibitor (TFPI) activity and induced TFPI expression and activity in AGE-exposed HUVECs.	Rivaroxaban	19-30	tissue factor pathway inhibitor	Mus musculus	91-95
28337024-6	2017	The combination of rivaroxaban and AngII enhanced in vivo tissue factor pathway inhibitor (TFPI) activity and induced TFPI expression and activity in AGE-exposed HUVECs.	Rivaroxaban	19-30	tissue factor pathway inhibitor	Mus musculus	118-122
28337024-7	2017	Angiotensin type 2 receptor (AT2R) and Mas antagonists attenuated the AngII-enhanced anticoagulant action of rivaroxaban in vivo, and abolished the increased endothelial TFPI expression and activity.	Rivaroxaban	109-120	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	70-75
28337024-10	2017	Our data suggest that the anticoagulant effects of rivaroxaban are promoted by AngII via AT2R and Mas signaling.	Rivaroxaban	51-62	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	79-84
28540312-4	2017	We present a case in which a patient successfully underwent a 3-month course of rivaroxaban in addition to his dual antiplatelet regimen of aspirin and ticagrelor for his STE-ACS and LV thrombus with resultant complete dissolution.	Rivaroxaban	80-91	1-aminocyclopropane-1-carboxylate synthase homolog (inactive)	Homo sapiens	175-178
28123155-1	2017	Rivaroxaban is an oral direct Factor Xa inhibitor approved in the European Union and the United Sates for the single-drug treatment of several thromboembolic diseases in adults.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	30-39
28373761-1	2017	Novel oral anticoagulants (NOACs), which include direct thrombin inhibitor (dabigatran) and direct factor Xa inhibitors (rivaroxaban, apixaban and edoxaban), are gaining popularity in the prevention of embolic stroke in non-valvular atrial fibrillation as well as in the prevention and treatment of venous thromboembolism.	Rivaroxaban	121-132	coagulation factor X	Homo sapiens	99-108
28264892-0	2017	Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin: A ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) Analysis.	Rivaroxaban	106-117	coagulation factor X	Homo sapiens	143-152
28053220-8	2017	In this study, in vitro inhibition assays using rivaroxaban as the probe substrate demonstrated that both dronedarone and NDBD produced reversible inhibition as well as irreversible mechanism-based inactivation of CYP3A4- and CYP2J2-mediated metabolism of rivaroxaban.	Rivaroxaban	48-59	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	214-220
28053220-1	2017	Rivaroxaban, a direct Factor Xa inhibitor, is indicated for stroke prevention in nonvalvular atrial fibrillation (AF).	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	22-31
28053220-8	2017	In this study, in vitro inhibition assays using rivaroxaban as the probe substrate demonstrated that both dronedarone and NDBD produced reversible inhibition as well as irreversible mechanism-based inactivation of CYP3A4- and CYP2J2-mediated metabolism of rivaroxaban.	Rivaroxaban	48-59	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	226-232
28053220-2	2017	Studies have revealed that the clearance of rivaroxaban is largely attributed to CYP3A4, CYP2J2 metabolism, and P-glycoprotein (P-gp) efflux pathways.	Rivaroxaban	44-55	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	81-87
28053220-2	2017	Studies have revealed that the clearance of rivaroxaban is largely attributed to CYP3A4, CYP2J2 metabolism, and P-glycoprotein (P-gp) efflux pathways.	Rivaroxaban	44-55	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	89-95
28053220-8	2017	In this study, in vitro inhibition assays using rivaroxaban as the probe substrate demonstrated that both dronedarone and NDBD produced reversible inhibition as well as irreversible mechanism-based inactivation of CYP3A4- and CYP2J2-mediated metabolism of rivaroxaban.	Rivaroxaban	256-267	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	214-220
28053220-2	2017	Studies have revealed that the clearance of rivaroxaban is largely attributed to CYP3A4, CYP2J2 metabolism, and P-glycoprotein (P-gp) efflux pathways.	Rivaroxaban	44-55	ATP binding cassette subfamily B member 1	Homo sapiens	112-126
28053220-8	2017	In this study, in vitro inhibition assays using rivaroxaban as the probe substrate demonstrated that both dronedarone and NDBD produced reversible inhibition as well as irreversible mechanism-based inactivation of CYP3A4- and CYP2J2-mediated metabolism of rivaroxaban.	Rivaroxaban	256-267	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	226-232
28053220-2	2017	Studies have revealed that the clearance of rivaroxaban is largely attributed to CYP3A4, CYP2J2 metabolism, and P-glycoprotein (P-gp) efflux pathways.	Rivaroxaban	44-55	ATP binding cassette subfamily B member 1	Homo sapiens	128-132
28053220-10	2017	In addition, amiodarone, NDEA, and dronedarone, but not NDBD, were determined to inhibit P-gp-mediated rivaroxaban transport.	Rivaroxaban	103-114	ATP binding cassette subfamily B member 1	Homo sapiens	89-93
28053220-12	2017	A separate model quantifying the inhibition of P-gp-mediated efflux by amiodarone or dronedarone projected a 9% increase in rivaroxaban exposure.	Rivaroxaban	124-135	ATP binding cassette subfamily B member 1	Homo sapiens	47-51
28198201-3	2017	Now, a specific antidote for the direct thrombin inhibitor, dabigatran has been approved for use, and antidotes for factor Xa inhibitors (rivaroxaban, apixaban and edoxaban) are being developed.	Rivaroxaban	138-149	coagulation factor X	Homo sapiens	116-125
28398382-1	2017	BACKGROUND: Rivaroxaban is a direct and selective inhibitor of factor Xa.	Rivaroxaban	12-23	coagulation factor X	Homo sapiens	63-72
28314697-0	2017	Demeanor of rivaroxaban in activated/inactivated FXa.	Rivaroxaban	12-23	coagulation factor X	Homo sapiens	49-52
28314697-3	2017	Although rivaroxaban is one of direct FXa inhibitors, its function in the inactivated coagulation cascade is unclear.	Rivaroxaban	9-20	coagulation factor X	Homo sapiens	38-41
28314697-5	2017	Upon FXa stimulation, the expressions of pro-inflammatory genes such as monocyte chemoattractant protein-1 (MCP-1), intracellular adhesion molecule-1, and interleukin-8 were maximally increased at 4 h after stimulation, and were suppressed by rivaroxaban.	Rivaroxaban	243-254	coagulation factor X	Homo sapiens	5-8
28314697-5	2017	Upon FXa stimulation, the expressions of pro-inflammatory genes such as monocyte chemoattractant protein-1 (MCP-1), intracellular adhesion molecule-1, and interleukin-8 were maximally increased at 4 h after stimulation, and were suppressed by rivaroxaban.	Rivaroxaban	243-254	C-C motif chemokine ligand 2	Homo sapiens	72-106
28314697-5	2017	Upon FXa stimulation, the expressions of pro-inflammatory genes such as monocyte chemoattractant protein-1 (MCP-1), intracellular adhesion molecule-1, and interleukin-8 were maximally increased at 4 h after stimulation, and were suppressed by rivaroxaban.	Rivaroxaban	243-254	C-C motif chemokine ligand 2	Homo sapiens	108-113
28314697-5	2017	Upon FXa stimulation, the expressions of pro-inflammatory genes such as monocyte chemoattractant protein-1 (MCP-1), intracellular adhesion molecule-1, and interleukin-8 were maximally increased at 4 h after stimulation, and were suppressed by rivaroxaban.	Rivaroxaban	243-254	C-X-C motif chemokine ligand 8	Homo sapiens	155-168
28314697-8	2017	Interestingly, rivaroxaban inhibited both time courses of MCP-1 expression.	Rivaroxaban	15-26	C-C motif chemokine ligand 2	Homo sapiens	58-63
28314697-9	2017	These results suggest that rivaroxaban may not influence gene modulation in the inactivated coagulation state, but can attenuate the endothelial damage evoked by FXa and pro-inflammatory cytokine genes.	Rivaroxaban	27-38	coagulation factor X	Homo sapiens	162-165
28219692-2	2017	Rivaroxaban, an oral factor Xa inhibitor, might simplify treatment compared with fondaparinux because it does not require daily subcutaneous injection and is cheaper.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	21-30
27555569-1	2017	BACKGROUND: The safety and efficacy of the oral anticoagulant rivaroxaban were studied in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF trial).	Rivaroxaban	62-73	coagulation factor X	Homo sapiens	129-138
27555569-1	2017	BACKGROUND: The safety and efficacy of the oral anticoagulant rivaroxaban were studied in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF trial).	Rivaroxaban	94-105	coagulation factor X	Homo sapiens	129-138
28262244-5	2017	Non-vitamin K-dependent oral anticoagulants, directly inhibiting factor Xa (rivaroxaban, apixaban, edoxaban) or thrombin (dabigatran), have simplified initial and long-term anticoagulation for PE while reducing major bleeding risk.	Rivaroxaban	76-87	coagulation factor X	Homo sapiens	65-74
28239301-9	2017	Compared to healthy controls, patients on rivaroxaban also had a prolonged lag time and decreased peak concentration, velocity index and endogenous thrombin potential (ETP) in platelet-poor plasma.	Rivaroxaban	42-53	coagulation factor II, thrombin	Homo sapiens	148-156
28123163-0	2017	Overview of Current Evidence on the Impact of the Initial High Dose of the Direct Factor Xa Inhibitor Rivaroxaban on Thrombus Resolution in the Treatment of Venous Thromboembolism.	Rivaroxaban	102-113	coagulation factor X	Homo sapiens	82-91
28170419-1	2017	Rivaroxaban is an oral direct factor Xa inhibitor, therapeutically indicated in the treatment of thromboembolic diseases.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	30-39
27892890-2	2017	The direct factor Xa inhibitor rivaroxaban may potentially reduce TAVR-related thrombotic complications and premature valve failure.	Rivaroxaban	31-42	coagulation factor X	Homo sapiens	11-20
28418370-2	2017	There were 42 patients in the study group which were treated with rivaroxaban (15 mg BID for 21 days, 20 mg od from day 22); 28 patients were in control group treated with conventional therapy (LMWH/VKA).	Rivaroxaban	66-77	BH3 interacting domain death agonist	Homo sapiens	85-88
28828188-5	2017	Rivaroxaban, a factor Xa inhibitor, is a well-known oral anticoagulant that is used for a variety of indications and has become a mainstay in the treatment of deep vein thrombosis.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	15-24
28201865-0	2017	Prolongation of prothrombin time in the presence of rivaroxaban: is this the only cause?	Rivaroxaban	52-63	coagulation factor II, thrombin	Homo sapiens	16-27
28201865-1	2017	Rivaroxaban is an oral direct Xa inhibitor that can lead to prolongation of prothrombin time and activated partial thromboplastin time.	Rivaroxaban	0-11	coagulation factor II, thrombin	Homo sapiens	76-87
28201865-3	2017	We report a case of a patient on rivaroxaban, where underlying factor VII deficiency led to confusion in the interpretation of prothrombin time results and delayed her surgery.	Rivaroxaban	33-44	coagulation factor II, thrombin	Homo sapiens	127-138
27893182-1	2017	Essentials Rivaroxaban and dabigatran are substrates of the P-glycoprotein (P-gp) encoded by the ABCB1 gene.	Rivaroxaban	11-22	ATP binding cassette subfamily B member 1	Homo sapiens	60-74
27893182-1	2017	Essentials Rivaroxaban and dabigatran are substrates of the P-glycoprotein (P-gp) encoded by the ABCB1 gene.	Rivaroxaban	11-22	ATP binding cassette subfamily B member 1	Homo sapiens	76-80
27893182-1	2017	Essentials Rivaroxaban and dabigatran are substrates of the P-glycoprotein (P-gp) encoded by the ABCB1 gene.	Rivaroxaban	11-22	ATP binding cassette subfamily B member 1	Homo sapiens	97-102
27893182-4	2017	Administration of P-gp inhibitors with dabigatran or rivaroxaban should be exercised with caution.	Rivaroxaban	53-64	ATP binding cassette subfamily B member 1	Homo sapiens	18-22
27893182-5	2017	SUMMARY: Background The direct oral anticoagulants (DOACs) dabigatran and rivaroxaban are both substrates of the P-glycoprotein (P-gp) transporter, encoded by the ABCB1 gene.	Rivaroxaban	74-85	ATP binding cassette subfamily B member 1	Homo sapiens	113-127
27893182-5	2017	SUMMARY: Background The direct oral anticoagulants (DOACs) dabigatran and rivaroxaban are both substrates of the P-glycoprotein (P-gp) transporter, encoded by the ABCB1 gene.	Rivaroxaban	74-85	ATP binding cassette subfamily B member 1	Homo sapiens	129-133
27893182-5	2017	SUMMARY: Background The direct oral anticoagulants (DOACs) dabigatran and rivaroxaban are both substrates of the P-glycoprotein (P-gp) transporter, encoded by the ABCB1 gene.	Rivaroxaban	74-85	ATP binding cassette subfamily B member 1	Homo sapiens	163-168
27893182-6	2017	Rivaroxaban is metabolized by cytochrome P450 A4 (CYP3A4).	Rivaroxaban	0-11	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	50-56
27893182-8	2017	Objective To assess the influence of ABCB1 polymorphisms on the pharmacokinetics of dabigatran and rivaroxaban, associated or not with clarithromycin, a P-gp and CYP3A4 inhibitor.	Rivaroxaban	99-110	ATP binding cassette subfamily B member 1	Homo sapiens	37-42
27893182-18	2017	Coadministration of a P-gp/CYP3A4 inhibitor with dabigatran or rivaroxaban may warrant caution in patients at risk of overexposure.	Rivaroxaban	63-74	ATP binding cassette subfamily B member 1	Homo sapiens	22-26
27893182-18	2017	Coadministration of a P-gp/CYP3A4 inhibitor with dabigatran or rivaroxaban may warrant caution in patients at risk of overexposure.	Rivaroxaban	63-74	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	27-33
28875044-15	2017	Phenytoin is a combined CYP3A4 and P-glycoprotein inducer, which might reduce rivaroxaban levels.	Rivaroxaban	78-89	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	24-30
28875044-15	2017	Phenytoin is a combined CYP3A4 and P-glycoprotein inducer, which might reduce rivaroxaban levels.	Rivaroxaban	78-89	ATP binding cassette subfamily B member 1	Homo sapiens	35-49
28412907-2	2017	Dabigatran - a direct thrombin inhibitor, apixaban and rivaroxaban - direct factor Xa inhibitors are now largely used for anticoagulation in patients with nonvalvular atrial fibrillation and in patients with venous thromboembolism.	Rivaroxaban	55-66	coagulation factor X	Homo sapiens	76-85
28524005-1	2017	BACKGROUND: Rivaroxaban represents a selective direct inhibitor of activated coagulation factor X (FXa) having peroral bioavailability and prompt onset of action.	Rivaroxaban	12-23	coagulation factor X	Homo sapiens	77-97
28524005-1	2017	BACKGROUND: Rivaroxaban represents a selective direct inhibitor of activated coagulation factor X (FXa) having peroral bioavailability and prompt onset of action.	Rivaroxaban	12-23	coagulation factor X	Homo sapiens	99-102
27993122-12	2017	Rivaroxaban, but not warfarin, significantly mitigated the thrombin-induced increase in membrane permeability.	Rivaroxaban	0-11	coagulation factor II, thrombin	Homo sapiens	59-67
27600911-5	2017	The novel oral anticoagulant agents (NOACs) assessed in the included studies were dabigatran (a direct thrombin inhibitor) and rivaroxaban (a Factor Xa inhibitor).	Rivaroxaban	127-138	coagulation factor X	Homo sapiens	142-151
28066243-0	2016	Rivaroxaban-Induced Hemorrhage Associated with ABCB1 Genetic Defect.	Rivaroxaban	0-11	ATP binding cassette subfamily B member 1	Homo sapiens	47-52
28215696-1	2017	BACKGROUND: The direct oral anticoagulant (DOAC) rivaroxaban, an oral Factor Xa inhibitor, is increasingly used as an alternative to vitamin-K-antagonists (VKAs).	Rivaroxaban	49-60	coagulation factor X	Homo sapiens	70-79
28066243-4	2016	The patient is a homozygous carrier of ABCB1 variant alleles, which could have participated to reduced elimination of rivaroxaban.	Rivaroxaban	118-129	ATP binding cassette subfamily B member 1	Homo sapiens	39-44
27919873-6	2016	unfractionated heparin (UFH) infusions could yield unquantifiable or inaccurate results, leading to unnecessary UFH dose reductions and potential treatment failures; the manufacturer labeling of oral factor Xa inhibitors (apixaban, edoxaban, and rivaroxaban) does not provide specific guidance on this issue.	Rivaroxaban	246-257	coagulation factor X	Homo sapiens	200-209
28066243-7	2016	Although in the present case moderate acute renal failure probably played a role, more clinical data are required to elucidate the impact of ABCB1 polymorphism on rivaroxaban pharmacokinetics and bleeding complications.	Rivaroxaban	163-174	ATP binding cassette subfamily B member 1	Homo sapiens	141-146
27913536-5	2016	Prothrombin time is potentially useful for rivaroxaban and edoxaban, but calibrated anti-Xa assays are optimal for determining clinically relevant levels of factor Xa inhibitors.	Rivaroxaban	43-54	coagulation factor II, thrombin	Homo sapiens	0-11
27812956-4	2016	RECENT FINDINGS: The recent RAPS trial demonstrated that APS patients treated with rivaroxaban had a significant twofold-increased thrombin potential, suggesting a higher thrombotic risk, in comparison with warfarin users.	Rivaroxaban	83-94	coagulation factor II, thrombin	Homo sapiens	131-139
26757012-2	2016	This study aimed to reveal the in-vitro effects of dabigatran and rivaroxaban on thrombin generation and platelet aggregation (PAg) derived via tissue factor (TF) pathway.	Rivaroxaban	66-77	coagulation factor II, thrombin	Homo sapiens	81-89
26757012-2	2016	This study aimed to reveal the in-vitro effects of dabigatran and rivaroxaban on thrombin generation and platelet aggregation (PAg) derived via tissue factor (TF) pathway.	Rivaroxaban	66-77	coagulation factor III, tissue factor	Homo sapiens	144-157
26757012-2	2016	This study aimed to reveal the in-vitro effects of dabigatran and rivaroxaban on thrombin generation and platelet aggregation (PAg) derived via tissue factor (TF) pathway.	Rivaroxaban	66-77	coagulation factor III, tissue factor	Homo sapiens	159-161
26757012-8	2016	Dabigatran and rivaroxaban significantly inhibit TF-induced hypercoagulation and platelet activation in vitro in a concentration-dependent manner.	Rivaroxaban	15-26	coagulation factor III, tissue factor	Homo sapiens	49-51
26757012-9	2016	Rivaroxaban displays stronger inhibition on thrombin generation and PAg than dabigatran.	Rivaroxaban	0-11	coagulation factor II, thrombin	Homo sapiens	44-52
27764730-0	2016	Effect of rivaroxaban on prothrombin fragment 1+2 compared with warfarin in patients with acute cardioembolic stroke: Insight from its serial measurement.	Rivaroxaban	10-21	coagulation factor II, thrombin	Homo sapiens	25-36
27829957-6	2016	The antithrombotic effects of rivaroxaban and apixaban (in terms of factor Xa inhibition) at the peak were strongly linked to those at the trough.	Rivaroxaban	30-41	coagulation factor X	Homo sapiens	68-77
27930571-5	2016	INTERVENTIONS: Direct factor Xa (FXa) inhibitor rivaroxaban (20 mg/d) was started for the patient.	Rivaroxaban	48-59	coagulation factor X	Homo sapiens	22-31
27930571-5	2016	INTERVENTIONS: Direct factor Xa (FXa) inhibitor rivaroxaban (20 mg/d) was started for the patient.	Rivaroxaban	48-59	coagulation factor X	Homo sapiens	33-36
27904005-1	2016	The use of rivaroxaban, a factor Xa inhibitor, has been increasing for prevention of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF) in Japan.	Rivaroxaban	11-22	coagulation factor X	Homo sapiens	26-35
27764730-11	2016	CONCLUSIONS: Rivaroxaban retains a normal thrombin generation even at its peak level with prolonged PT, whereas warfarin at therapeutic levels inhibits thrombin generation.	Rivaroxaban	13-24	coagulation factor II, thrombin	Homo sapiens	42-50
27752126-12	2016	However, rivaroxaban significantly restored FXa-induced impaired angiogenesis.	Rivaroxaban	9-20	coagulation factor X	Homo sapiens	44-47
27836786-3	2016	Non-vitamin K antagonist oral anticoagulants (NOACs) are direct antagonists of thrombin (dabigatran) and factor Xa (rivaroxaban, apixaban and edoxaban), and were designed to overcome the limitations of vitamin K antagonists.	Rivaroxaban	116-127	coagulation factor X	Homo sapiens	105-114
27623677-6	2016	RESULTS: When added in vitro, rivaroxaban was significantly (P&lt;0.05) correlated with ROTEM  thromboelastometry EXTEM (extrinsic coagulation pathway) clotting time (CT), time to maximal velocity (MaxV-t), and with all measured thrombin generation parameters.	Rivaroxaban	30-41	coagulation factor II, thrombin	Homo sapiens	229-237
27623677-7	2016	In vivo, CT, MaxV-t, lag time, and peak thrombin generation (Cmax) were significantly correlated with rivaroxaban concentrations.	Rivaroxaban	102-113	coagulation factor II, thrombin	Homo sapiens	40-48
27075709-0	2016	The Influence of Assay Selection on Prothrombin Time Measured in Patients Treated With Rivaroxaban for Nonvalvular Atrial Fibrillation.	Rivaroxaban	87-98	coagulation factor II, thrombin	Homo sapiens	36-47
27075709-1	2016	BACKGROUND: Prothrombin time (PT) can provide a qualitative assessment of the relative intensity of anticoagulation by rivaroxaban.	Rivaroxaban	119-130	coagulation factor II, thrombin	Homo sapiens	12-23
27541499-7	2016	Aims To establish whether rivaroxaban, a direct factor Xa inhibitor, limits complement activation compared with warfarin in APS patients with previous venous thromboembolism (VTE).	Rivaroxaban	26-37	coagulation factor X	Homo sapiens	48-57
27541499-14	2016	In 55 patients randomized to rivaroxaban, C3a, C5a and SC5b-9 were lower at day 42 (median (ng mL-1 ) [confidence interval] 64 [29-125] vs. 83 [35-147], 9 [2-15] vs. 12 [4-18] and 171 [56-245] vs. 201 [66-350], respectively) but levels of Bb fragment were unchanged.	Rivaroxaban	29-40	complement C3	Homo sapiens	42-45
27541499-14	2016	In 55 patients randomized to rivaroxaban, C3a, C5a and SC5b-9 were lower at day 42 (median (ng mL-1 ) [confidence interval] 64 [29-125] vs. 83 [35-147], 9 [2-15] vs. 12 [4-18] and 171 [56-245] vs. 201 [66-350], respectively) but levels of Bb fragment were unchanged.	Rivaroxaban	29-40	complement C5a receptor 1	Homo sapiens	47-50
27541499-14	2016	In 55 patients randomized to rivaroxaban, C3a, C5a and SC5b-9 were lower at day 42 (median (ng mL-1 ) [confidence interval] 64 [29-125] vs. 83 [35-147], 9 [2-15] vs. 12 [4-18] and 171 [56-245] vs. 201 [66-350], respectively) but levels of Bb fragment were unchanged.	Rivaroxaban	29-40	2'-5' oligoadenylate synthetase 1B	Mus musculus	95-99
27566988-11	2016	For rivaroxaban, the correlation between the anti-FXa assay and PT ranged from r = 0.91 to r = 0.73.	Rivaroxaban	4-15	coagulation factor X	Homo sapiens	50-53
27474775-1	2016	OBJECTIVE: To examine the effects of patients taking the direct blood coagulation factor Xa inhibitor rivaroxaban on lupus anticoagulant testing results in a clinical setting.	Rivaroxaban	102-113	coagulation factor X	Homo sapiens	82-91
27716428-7	2016	Rivaroxaban was administered after warfarin discontinuation (prothrombin time-international normalized ratio = 1.43) at a dosage of 15 mg every 12 hours for 3 weeks, followed by 20 mg once daily for 3 months.	Rivaroxaban	0-11	coagulation factor II, thrombin	Homo sapiens	61-72
27716428-11	2016	CONCLUSIONS: In this case report, a switch to rivaroxaban from warfarin was shown to be effective and safe for the treatment of postoperative deep vein thrombosis, whereas standard oral anticoagulation therapy, which required dose adjustments over a period of 3 months, was not able to stabilize the therapeutic range of prothrombin time-international normalized ratio nor improve our patient"s outcome.	Rivaroxaban	46-57	coagulation factor II, thrombin	Homo sapiens	321-332
27465882-4	2016	The direct thrombin inhibitor dabigatran and direct factor Xa inhibitors apixaban, edoxaban, and rivaroxaban are all noninferior to warfarin for the prevention of ischemic stroke and systemic embolism and are associated with reduced incidence of intracranial hemorrhage.	Rivaroxaban	97-108	coagulation factor X	Homo sapiens	52-61
27766804-3	2016	Dabigatran belongs to a class of anticoagulants called direct thrombin inhibitors, while rivaroxaban, apixaban, and edoxaban are direct Factor Xa inhibitors.	Rivaroxaban	89-100	coagulation factor X	Homo sapiens	136-145
27597298-7	2016	A new study is currently being conducted to test rivaroxaban in association with a P2Y12 inhibitor without aspirin.	Rivaroxaban	49-60	purinergic receptor P2Y12	Homo sapiens	83-88
27695181-0	2016	Hemopericardium with tamponade following rivaroxaban administration and its attenuation by CYP3A4 inhibitors.	Rivaroxaban	41-52	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	91-97
27695181-1	2016	Novel oral anticoagulants including the factor Xa inhibitor rivaroxaban are important alternatives to warfarin for the prevention of thromboembolic stroke in patients with nonvalvular atrial fibrillation.	Rivaroxaban	60-71	coagulation factor X	Homo sapiens	40-49
27695181-4	2016	A review of the patient"s medications revealed a total of seven agents known to be metabolized through cytochrome P450 3A4 (CYP3A4), the major pathway for rivaroxaban metabolism.	Rivaroxaban	155-166	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	103-122
27695181-4	2016	A review of the patient"s medications revealed a total of seven agents known to be metabolized through cytochrome P450 3A4 (CYP3A4), the major pathway for rivaroxaban metabolism.	Rivaroxaban	155-166	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	124-130
27900868-1	2016	Rivaroxaban is direct oral factor Xa inhibitor indicated for tromboembolic event rate reduction in patients with non-valvular atrial fibrillation.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	27-36
27623680-1	2016	The vast clinical research programme for the direct, oral factor Xa inhibitor rivaroxaban has generated a wealth of data since the first rivaroxaban approval in 2008 for the prevention of venous thromboembolism (VTE) in patients undergoing elective hip or knee replacement surgery.	Rivaroxaban	78-89	coagulation factor X	Homo sapiens	58-67
27623680-1	2016	The vast clinical research programme for the direct, oral factor Xa inhibitor rivaroxaban has generated a wealth of data since the first rivaroxaban approval in 2008 for the prevention of venous thromboembolism (VTE) in patients undergoing elective hip or knee replacement surgery.	Rivaroxaban	137-148	coagulation factor X	Homo sapiens	58-67
27623682-4	2016	Cancer Associated thrombosis - expLoring soLutions for patients through Treatment and Prevention with RivarOxaban (CALLISTO) is an international research programme exploring the potential of the direct, oral factor Xa inhibitor rivaroxaban for the prevention and treatment of CAT, supplementing existing data from EINSTEIN DVT and EINSTEIN PE.	Rivaroxaban	102-113	coagulation factor X	Homo sapiens	208-217
27623682-4	2016	Cancer Associated thrombosis - expLoring soLutions for patients through Treatment and Prevention with RivarOxaban (CALLISTO) is an international research programme exploring the potential of the direct, oral factor Xa inhibitor rivaroxaban for the prevention and treatment of CAT, supplementing existing data from EINSTEIN DVT and EINSTEIN PE.	Rivaroxaban	228-239	coagulation factor X	Homo sapiens	208-217
27623684-4	2016	The direct, oral factor Xa inhibitor rivaroxaban was the first to be approved for treatment of acute DVT and PE and secondary prevention of recurrent VTE events based on data from EINSTEIN DVT and EINSTEIN PE, respectively.	Rivaroxaban	37-48	coagulation factor X	Homo sapiens	17-26
27670439-1	2016	"Home treatment of patients with lowrisk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban.	Rivaroxaban	94-105	coagulation factor X	Homo sapiens	74-83
27573206-10	2016	After the bolus administration, the median anti-factor Xa activity decreased by 89% (95% confidence interval [CI], 58 to 94) from baseline among patients receiving rivaroxaban and by 93% (95% CI, 87 to 94) among patients receiving apixaban.	Rivaroxaban	164-175	coagulation factor X	Homo sapiens	48-57
27573206-12	2016	Four hours after the end of the infusion, there was a relative decrease from baseline of 39% in the measure of anti-factor Xa activity among patients receiving rivaroxaban and of 30% among those receiving apixaban.	Rivaroxaban	160-171	coagulation factor X	Homo sapiens	116-125
27155586-2	2016	Rivaroxaban is an oral anticoagulant, which directly inhibits Factor Xa.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	62-71
27725023-6	2016	Rivaroxaban, a DOAC targeting activated coagulation factor X (FXa), is registered for the prevention and treatment of VTED in South Africa.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	62-65
27725023-11	2016	RESULTS: The mean rivaroxaban anti-FXa level was 105.7 ng/mL.	Rivaroxaban	18-29	coagulation factor X	Homo sapiens	35-38
27177413-2	2016	This in vitro study investigated the effect of prothrombin complex concentrate (PCC), recombinant activated factor VII (rFVIIa) and activated prothrombin complex concentrate (aPCC) on supratherapeutic rivaroxaban concentrations using standard laboratory parameters (prothrombin time [PT], activated partial thromboplastin time [aPTT] and PT ratio) and thromboelastometry (clotting time [CT]).	Rivaroxaban	201-212	coagulation factor II, thrombin	Homo sapiens	47-58
31008276-3	2016	The New Approach riVaroxaban Inhibition of Factor Xa in a Global trial versus ASA to prevenT Embolism in Embolic Stroke of Undetermined Source international trial will compare the efficacy and safety of rivaroxaban, an oral factor Xa inhibitor, versus aspirin for secondary prevention in patients with recent embolic strokes of undetermined source.	Rivaroxaban	17-28	coagulation factor X	Homo sapiens	43-52
31008276-9	2016	Summary: The New Approach riVaroxaban Inhibition of Factor Xa in a Global trial versus ASA to prevenT Embolism in Embolic Stroke of Undetermined Source trial is evaluating the benefits and risks of rivaroxaban for secondary stroke prevention in embolic strokes of undetermined source patients.	Rivaroxaban	26-37	coagulation factor X	Homo sapiens	52-61
31008276-9	2016	Summary: The New Approach riVaroxaban Inhibition of Factor Xa in a Global trial versus ASA to prevenT Embolism in Embolic Stroke of Undetermined Source trial is evaluating the benefits and risks of rivaroxaban for secondary stroke prevention in embolic strokes of undetermined source patients.	Rivaroxaban	198-209	coagulation factor X	Homo sapiens	52-61
27570089-8	2016	Treatment effect was measured as the ratio of rivaroxaban to warfarin for thrombin generation.	Rivaroxaban	46-57	coagulation factor II, thrombin	Homo sapiens	74-82
27570089-12	2016	Peak thrombin generation was lower in the rivaroxaban group (56 nmol/L, 95% CI 47-66 vs 86 nmol/L, 72-102, treatment effect 0 6, 95% CI 0 5-0 8, p=0 0006).	Rivaroxaban	42-53	coagulation factor II, thrombin	Homo sapiens	5-13
28060970-2	2016	AIM: To evaluate the anticoagulant effect of rivaroxaban by anti-Xa factor activity and its correlation with thrombin-antithrombin complexes, thrombin generation and prothrombin time in patients newly diagnosed with non-valvular AF.	Rivaroxaban	45-56	coagulation factor II, thrombin	Homo sapiens	109-117
28060970-2	2016	AIM: To evaluate the anticoagulant effect of rivaroxaban by anti-Xa factor activity and its correlation with thrombin-antithrombin complexes, thrombin generation and prothrombin time in patients newly diagnosed with non-valvular AF.	Rivaroxaban	45-56	coagulation factor II, thrombin	Homo sapiens	122-130
27543264-4	2016	For the anti-factor Xa agents (rivaroxaban, apixaban, and edoxaban) a number of studies have shown that the administration of prothrombin complex concentrate resulted in a correction of the prolonged prothrombin time and restored depressed thrombin generation after rivaroxaban treatment in a controlled trial in healthy human subjects.	Rivaroxaban	31-42	coagulation factor II, thrombin	Homo sapiens	129-137
27543264-4	2016	For the anti-factor Xa agents (rivaroxaban, apixaban, and edoxaban) a number of studies have shown that the administration of prothrombin complex concentrate resulted in a correction of the prolonged prothrombin time and restored depressed thrombin generation after rivaroxaban treatment in a controlled trial in healthy human subjects.	Rivaroxaban	266-277	coagulation factor II, thrombin	Homo sapiens	129-137
27155586-3	2016	The objective of the current study was, in comparison to the standard-therapy method, to investigate the potential of rivaroxaban to improve the treatment of patients with PE, and to reduce hemorrhage in the standard-therapy group through adjusting the dose of warfarin by CYP2C9 and VKORC1 genotypes.	Rivaroxaban	118-129	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	273-279
27155586-3	2016	The objective of the current study was, in comparison to the standard-therapy method, to investigate the potential of rivaroxaban to improve the treatment of patients with PE, and to reduce hemorrhage in the standard-therapy group through adjusting the dose of warfarin by CYP2C9 and VKORC1 genotypes.	Rivaroxaban	118-129	vitamin K epoxide reductase complex subunit 1	Homo sapiens	284-290
27230587-3	2016	In this study, we assessed the risks and benefits of pre-treatment with warfarin or rivaroxaban after tissue-type plasminogen activator (tPA) thrombolysis in ischemic rat brain.	Rivaroxaban	84-95	plasminogen activator, tissue type	Rattus norvegicus	102-135
27230587-6	2016	RESULTS: Prothrombin time (PT) was significantly prolonged in the warfarin and rivaroxaban pretreated groups.	Rivaroxaban	79-90	coagulation factor II	Rattus norvegicus	9-20
27230587-7	2016	MMP-9 expression greatly increased in the warfarin group, and this was reduced in the rivaroxaban groups compared with the vehicle group.	Rivaroxaban	86-97	matrix metallopeptidase 9	Rattus norvegicus	0-5
26660521-9	2016	In contrast, the ATLAS ACS2 TIMI-51 trial interrogating the oral factor Xa inhibitor rivaroxaban in a low dose regimen showed significant reduction of cardiovascular events as well as total mortality.	Rivaroxaban	85-96	acyl-CoA synthetase long chain family member 5	Homo sapiens	23-27
27230587-8	2016	Tissue factor expression remarkably decreased in the warfarin and rivaroxaban groups.	Rivaroxaban	66-77	coagulation factor III, tissue factor	Rattus norvegicus	0-13
26660521-9	2016	In contrast, the ATLAS ACS2 TIMI-51 trial interrogating the oral factor Xa inhibitor rivaroxaban in a low dose regimen showed significant reduction of cardiovascular events as well as total mortality.	Rivaroxaban	85-96	coagulation factor X	Homo sapiens	65-74
27230587-11	2016	CONCLUSIONS: Our present study shows that pre-treatment with rivaroxaban was noninferior to warfarin in the anticoagulation, but a lower risk of NVU dysfunction and dissociation after tPA treatment in rivaroxaban.	Rivaroxaban	61-72	plasminogen activator, tissue type	Rattus norvegicus	184-187
27230587-11	2016	CONCLUSIONS: Our present study shows that pre-treatment with rivaroxaban was noninferior to warfarin in the anticoagulation, but a lower risk of NVU dysfunction and dissociation after tPA treatment in rivaroxaban.	Rivaroxaban	201-212	plasminogen activator, tissue type	Rattus norvegicus	184-187
26660521-10	2016	Thus, add-on treatment with low dose rivaroxaban emerged as a new option for patients with ACS.	Rivaroxaban	37-48	acyl-CoA synthetase long chain family member 5	Homo sapiens	91-94
27124307-2	2016	Dabigatran is a direct thrombin (factor II) inhibitor while rivaroxaban, apixaban and edoxaban are direct inhibitors of factor Xa.	Rivaroxaban	60-71	coagulation factor X	Homo sapiens	120-129
26961375-1	2016	Dabigatran and rivaroxaban are novel, vitamin K-independent oral anticoagulants (NOACs) and act via antagonism of the coagulation factor (F) IIa (dabigatran) or FXa (rivaroxaban), respectively.	Rivaroxaban	15-26	coagulation factor X	Homo sapiens	161-164
26961375-1	2016	Dabigatran and rivaroxaban are novel, vitamin K-independent oral anticoagulants (NOACs) and act via antagonism of the coagulation factor (F) IIa (dabigatran) or FXa (rivaroxaban), respectively.	Rivaroxaban	166-177	coagulation factor X	Homo sapiens	161-164
30609341-4	2016	The FXa inhibitors (Rivaroxaban, Apixaban, Edoxaban) bind directly to the catalytic site of FXa and inhibit both free and prothrombinase-bound FXa.	Rivaroxaban	20-31	coagulation factor X	Homo sapiens	4-7
27228488-1	2016	Rivaroxaban is an oral anticoagulant that acts as a direct, competitive factor Xa inhibitor.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	72-81
30609341-4	2016	The FXa inhibitors (Rivaroxaban, Apixaban, Edoxaban) bind directly to the catalytic site of FXa and inhibit both free and prothrombinase-bound FXa.	Rivaroxaban	20-31	coagulation factor X	Homo sapiens	92-95
30609341-4	2016	The FXa inhibitors (Rivaroxaban, Apixaban, Edoxaban) bind directly to the catalytic site of FXa and inhibit both free and prothrombinase-bound FXa.	Rivaroxaban	20-31	coagulation factor X	Homo sapiens	92-95
27318247-7	2016	Plasma MCP-1 levels were lower in RIVA-treated mice vs. vehicle-treated at 21days (389+-260 vs. 804+-292ng/mL, p=0.005).	Rivaroxaban	34-38	chemokine (C-C motif) ligand 2	Mus musculus	7-12
27318247-8	2016	Cell proliferation was less at day 7 in EJV from the RIVA-treated mice than vehicle-treated (5.0%+-3.0 vs. 11.5%+-3.6, p=0.0006), as were MMP-9 protein levels.	Rivaroxaban	53-57	matrix metallopeptidase 9	Mus musculus	138-143
26893445-1	2016	BACKGROUND: Rivaroxaban, a direct factor Xa inhibitor, has been developed to meet clinical needs in a broad range of indications in adults: prevention of venous thromboembolism after elective hip or knee replacement surgery, treatment and secondary prevention of venous thromboembolism, prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation having one or more risk factors, and in Europe, prevention of atherothrombotic events after an acute coronary syndrome in patients with elevated cardiac biomarkers.	Rivaroxaban	12-23	coagulation factor X	Homo sapiens	34-43
27010343-0	2016	Home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban.	Rivaroxaban	94-105	coagulation factor X	Homo sapiens	74-83
27010343-4	2016	The Home Treatment of Pulmonary Embolism (HoT-PE) study is a prospective international multicentre single-arm phase 4 management (cohort) trial aiming to determine whether home treatment of acute low-risk PE with the oral factor Xa inhibitor rivaroxaban is feasible, effective, and safe.	Rivaroxaban	242-253	coagulation factor X	Homo sapiens	222-231
27400196-6	2016	In vitro and in vivo, the rivaroxaban concentrations, measured by Biophen DiXaI, always showed good correlation with the inhibition of FXa activity, and PT values showed moderate correlation with the inhibition of FXa activity.	Rivaroxaban	26-37	coagulation factor X	Homo sapiens	135-138
25816811-2	2016	Large randomized trials have demonstrated that these agents, which act by directly targeting thrombin (dabigatran) and factor Xa (rivaroxaban, apixaban, and edoxaban), are at least as effective as warfarin, with lower rates of bleeding and fewer interactions with food and drugs.	Rivaroxaban	130-141	coagulation factor X	Homo sapiens	119-128
27396794-0	2016	The Direct Factor Xa Inhibitor Rivaroxaban Passes Into Human Breast Milk.	Rivaroxaban	31-42	coagulation factor X	Homo sapiens	11-20
28717737-3	2017	Recently, the oral anticoagulant rivaroxaban, which directly inhibits factor Xa, was approved for VTE treatment.	Rivaroxaban	33-44	coagulation factor X	Homo sapiens	70-79
26888572-2	2016	METHODS: Using Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) data, we analysed efficacy and safety outcomes, adjusting hazard ratios (HRs) for potential confounders using Cox regression analysis.	Rivaroxaban	15-26	coagulation factor X	Homo sapiens	52-61
27082776-2	2016	Direct thrombin inhibitor: dabigatran and factor Xa inhibitors: apixaban, rivaroxaban, and edoxaban directly inhibit the coagulation cascade.	Rivaroxaban	74-85	coagulation factor II, thrombin	Homo sapiens	7-15
27082776-2	2016	Direct thrombin inhibitor: dabigatran and factor Xa inhibitors: apixaban, rivaroxaban, and edoxaban directly inhibit the coagulation cascade.	Rivaroxaban	74-85	coagulation factor X	Homo sapiens	42-51
26908543-3	2016	A Food and Drug Administration advisory committee raised missing data as a serious concern in their review of results from the ATLAS ACS 2 TIMI 51 study, a large clinical trial that assessed rivaroxaban for its ability to reduce the risk of cardiovascular death, myocardial infarction or stroke in patients with acute coronary syndrome.	Rivaroxaban	191-202	acyl-CoA synthetase long chain family member 5	Homo sapiens	133-138
27384603-9	2016	It can be hypothesized that factor Xa inhibition by NOACs, such as rivaroxaban, could be insufficient in case of a thrombophilic state due to thrombin mutation.	Rivaroxaban	67-78	coagulation factor X	Homo sapiens	28-37
27066956-2	2016	This study aimed to evaluate the typical exposure range and effect of the direct factor Xa (FXa)-inhibitor rivaroxaban in a cohort of well-characterized patients with atrial fibrillation (AF).	Rivaroxaban	107-118	coagulation factor X	Homo sapiens	81-90
27066956-2	2016	This study aimed to evaluate the typical exposure range and effect of the direct factor Xa (FXa)-inhibitor rivaroxaban in a cohort of well-characterized patients with atrial fibrillation (AF).	Rivaroxaban	107-118	coagulation factor X	Homo sapiens	92-95
27066956-9	2016	The anti-FXa assay performed well upon rivaroxaban levels in a normal exposure range, although LC-MS/MS remains the only method that covers the whole concentration range with accuracy.	Rivaroxaban	39-50	coagulation factor X	Homo sapiens	9-12
26964028-2	2016	As of today, these direct oral anticoagulants (DOACs) include dabigatran etexilate (thrombin inhibitor) and apixaban, edoxaban and rivaroxaban (inhibitors of FXa).	Rivaroxaban	131-142	coagulation factor X	Homo sapiens	158-161
26995378-3	2016	The combination of rivaroxaban with P2Y12 inhibition in a "dual-pathway" approach may be an effective therapeutic regimen for the treatment of ACS, given the known importance of P2Y12 inhibition after stenting and intriguing data that the combination of an anticoagulant with clopidogrel after stenting in patients with atrial fibrillation appears an attractive option to this patient population.	Rivaroxaban	19-30	purinergic receptor P2Y12	Homo sapiens	178-183
26780749-4	2016	The novel oral anticoagulants (NOACs) dabigatran, rivaroxaban, apixaban, and edoxaban selectively target either thrombin or Factor Xa and have predictable pharmacologic profiles, removing the need for routine coagulation monitoring.	Rivaroxaban	50-61	coagulation factor II, thrombin	Homo sapiens	112-120
26780749-4	2016	The novel oral anticoagulants (NOACs) dabigatran, rivaroxaban, apixaban, and edoxaban selectively target either thrombin or Factor Xa and have predictable pharmacologic profiles, removing the need for routine coagulation monitoring.	Rivaroxaban	50-61	coagulation factor X	Homo sapiens	124-133
27734642-3	2016	Novel oral anticoagulants (NOACs, now referred as Non Vit K dependent oral anticoagulants), including the direct thrombin inhibitor dabigatran and direct Factor Xa inhibitors such as rivaroxaban and apixaban are now approved alternatives to warfarin for prophylaxis of stroke and systemic embolic events (SEE) in patients with NVAF and treatment and prophylaxis of VTE.	Rivaroxaban	183-194	coagulation factor X	Homo sapiens	154-163
27161683-5	2016	Rivaroxaban is a highly selective direct Factor Xa inhibitor with oral bioavailability.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	41-50
26966542-4	2016	Factor Xa inhibitors (rivaroxaban, apixaban, edoxaban) mainly inhibit factor Xa activity of the prothrombinase complex in the propagation phase.	Rivaroxaban	22-33	coagulation factor X	Homo sapiens	0-9
26966542-4	2016	Factor Xa inhibitors (rivaroxaban, apixaban, edoxaban) mainly inhibit factor Xa activity of the prothrombinase complex in the propagation phase.	Rivaroxaban	22-33	coagulation factor X	Homo sapiens	70-79
27131284-2	2016	Direct inhibition of thrombin activity (e.g. with dabigatran) or reducing its generation by inhibition of Factor Xa (e.g. with rivaroxaban) may therefore have anti-inflammatory effects.	Rivaroxaban	127-138	coagulation factor X	Homo sapiens	106-115
27131284-8	2016	Inflammatory gene expression after stimulation of thrombin generation was concentration-dependently suppressed by vorapaxar, dabigatran, and rivaroxaban.	Rivaroxaban	141-152	coagulation factor II, thrombin	Homo sapiens	50-58
26960279-3	2016	Direct oral anticoagulants represent an important advance in anticoagulation therapy, directly inhibiting thrombin (dabigatran) or factor Xa (rivaroxaban, apixaban) they represent an effective and safe alternatives to VKAs and heparins in the prevention and treatment of several thromboembolic disorders.	Rivaroxaban	142-153	coagulation factor X	Homo sapiens	131-140
27020515-4	2016	Results from the ATLAS ACS 2-TIMI 51 trial suggest that the addition of rivaroxaban 2.5mg twice daily to standard antiplatelet therapy may achieve this desired balance alongside careful patient selection.	Rivaroxaban	72-83	acyl-CoA synthetase long chain family member 5	Homo sapiens	23-28
27023335-3	2016	Non-vitamin K antagonist oral anticoagulants (NOACs) including direct thrombin inhibitor (dabigatran) and direct factor Xa inhibitors (rivaroxaban, apixaban and edoxaban) are now available and offer new options for stroke prevention.	Rivaroxaban	135-146	coagulation factor X	Homo sapiens	113-122
26228186-0	2016	Nontraumatic spinal subdural hematoma complicating direct factor Xa inhibitor treatment (rivaroxaban): a challenging management.	Rivaroxaban	89-100	coagulation factor X	Homo sapiens	58-67
26228186-1	2016	PURPOSE: We report on a 72-year-old male patient who developed a nontraumatic spinal subdural hematoma (SSDH) during rivaroxaban therapy, a relatively new orally administered direct factor Xa inhibitor.	Rivaroxaban	117-128	coagulation factor X	Homo sapiens	182-191
26330425-2	2016	XANTUS investigated the safety and efficacy of the Factor Xa inhibitor rivaroxaban in routine clinical use in the NVAF setting.	Rivaroxaban	71-82	coagulation factor X	Homo sapiens	51-60
26939028-5	2016	Andexanet alfa is a recombinant modified factor Xa that can bind and reverse oral and parenteral factor Xa inhibitors, including rivaroxaban, apixaban and edoxaban, and low molecular weight heparin.	Rivaroxaban	129-140	coagulation factor X	Homo sapiens	41-50
26467386-0	2016	Comment on the use of computational models to study the effect of apixaban and rivaroxaban on thrombin generation.	Rivaroxaban	79-90	coagulation factor II, thrombin	Homo sapiens	94-102
26489881-3	2016	This study examined whether prestroke anticoagulation with rivaroxaban, a novel direct factor Xa inhibitor, influences stroke severity, thrombin-mediated intracerebral thrombus formation and pro-inflammatory processes in a rat model of brain ischaemia/reperfusion injury.	Rivaroxaban	59-70	coagulation factor II	Rattus norvegicus	136-144
26489881-11	2016	Although rivaroxaban strongly reduced thrombin-mediated thrombus formation, this was not accompanied by an increased risk of ICH.	Rivaroxaban	9-20	coagulation factor II	Rattus norvegicus	38-46
26489881-12	2016	In addition, rivaroxaban dampened the inflammatory response in the ischaemic brain by downregulating ICAM-1 expression and the activation of CD68+-immune cells.	Rivaroxaban	13-24	intercellular adhesion molecule 1	Rattus norvegicus	101-107
26489881-12	2016	In addition, rivaroxaban dampened the inflammatory response in the ischaemic brain by downregulating ICAM-1 expression and the activation of CD68+-immune cells.	Rivaroxaban	13-24	Cd68 molecule	Rattus norvegicus	141-145
27161723-5	2016	AIM: To determine whether 14days of a preoperative oral Factor Xa inhibitor (Rivaroxaban) in oestrogen receptor negative early breast cancer patients results in inhibition of tumour proliferation as determined by a reduction in tumour Ki67 from baseline (pre-treatment) to 14days post treatment start (at time of surgical excision).	Rivaroxaban	77-88	coagulation factor X	Homo sapiens	56-65
27161723-9	2016	Rivaroxaban is an orally active direct Factor Xa inhibitor.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	39-48
26732970-1	2016	INTRODUCTION: New target-specific anticoagulants such as the direct thrombin inhibitor dabigatran and the factor Xa inhibitor rivaroxaban are used in an increasing number of patients.	Rivaroxaban	126-137	coagulation factor X	Homo sapiens	106-115
26403851-0	2016	Prothrombin complex concentrate administration through intraosseous access for reversal of rivaroxaban.	Rivaroxaban	91-102	coagulation factor II, thrombin	Homo sapiens	0-11
26214205-4	2016	Novel oral anticoagulants that directly inhibit thrombin (dabigatran) or factor Xa (rivaroxaban, apixaban) are shown as effective anticoagulants in preventing thromboembolism (venous thromboembolism) in various medical conditions.	Rivaroxaban	84-95	coagulation factor X	Homo sapiens	73-82
26569514-1	2016	Rivaroxaban, a highly selective direct factor Xa inhibitor, is a new oral anticoagulant approved by the US Food and Drug Administration in November 2011 for stroke prophylaxis in patients with nonvalvular atrial fibrillation.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	39-48
26875179-1	2016	The direct inhibitors of thrombin (dabigatran) or factor Xa (rivaroxaban, apixaban) are currently used in patients with venous thrombosis of the lower or upper limbs or with pulmonary embolism.	Rivaroxaban	61-72	coagulation factor X	Homo sapiens	50-59
26466613-2	2016	Rivaroxaban is a direct factor Xa inhibitor that has been extensively studied and is now approved for the prevention and therapy of a number of thromboembolic conditions.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	24-33
26867010-7	2016	Rivaroxaban as well as edoxaban significantly reduced the collagen-induced phosphorylation of both HSP27 and p44/p42 MAP kinase without affecting the platelet aggregation.	Rivaroxaban	0-11	heat shock protein family B (small) member 1	Homo sapiens	99-104
26867010-7	2016	Rivaroxaban as well as edoxaban significantly reduced the collagen-induced phosphorylation of both HSP27 and p44/p42 MAP kinase without affecting the platelet aggregation.	Rivaroxaban	0-11	interferon induced protein 44	Homo sapiens	109-112
26867010-7	2016	Rivaroxaban as well as edoxaban significantly reduced the collagen-induced phosphorylation of both HSP27 and p44/p42 MAP kinase without affecting the platelet aggregation.	Rivaroxaban	0-11	cyclin dependent kinase 20	Homo sapiens	113-116
26867010-8	2016	Rivaroxaban significantly inhibited the release of phosphorylated HSP27 from collagen-stimulated platelets but not the secretion of platelet derived growth factor-AB.	Rivaroxaban	0-11	heat shock protein family B (small) member 1	Homo sapiens	66-71
26867010-9	2016	In patients administrated with rivaroxaban, the collagen-induced levels of phosphorylated HSP27 were markedly diminished after 2 days of administration, which failed to affect the platelet aggregation.	Rivaroxaban	31-42	heat shock protein family B (small) member 1	Homo sapiens	90-95
26298448-0	2016	An Observational Study of the Factor Xa Inhibitors Rivaroxaban and Apixaban as Reported to Eight Poison Centers.	Rivaroxaban	51-62	coagulation factor X	Homo sapiens	30-39
26298448-1	2016	STUDY OBJECTIVE: Rivaroxaban and apixaban are part of a new group of oral anticoagulants targeting factor Xa and approved by the Food and Drug Administration in 2011 and 2012.	Rivaroxaban	17-28	coagulation factor X	Homo sapiens	99-108
26492202-1	2016	Direct oral anticoagulants (DOACs), including the direct thrombin inhibitor, dabigatran, and the direct factor Xa (FXa) inhibitors, rivaroxaban, apixaban and edoxaban, are approved for thromboembolism prevention and treatment.	Rivaroxaban	132-143	coagulation factor X	Homo sapiens	115-118
26492202-4	2016	Hemoclot  and ecarin-based assays can be used to quantify dabigatran level and calibrated chromogenic anti-FXa assays are suitable for measuring rivaroxaban, apixaban and edoxaban levels, but these tests are not yet widely available.	Rivaroxaban	145-156	coagulation factor X	Homo sapiens	107-110
26644369-12	2016	Rivaroxaban intake in the evening reduced morning F1+2 concentrations better at 8:00 AM than did administration on awakening (85 +- 25 nmol L(-1) vs. 106 +- 34 nmol L(-1) , CI: 9.4-32.1).	Rivaroxaban	0-11	coagulation factor XII	Homo sapiens	50-54
26586461-0	2016	Thrombin generation and other coagulation parameters in a patient with homozygous congenital protein S deficiency on treatment with rivaroxaban.	Rivaroxaban	132-143	coagulation factor II, thrombin	Homo sapiens	0-8
26853646-2	2016	Rivaroxaban is a direct factor Xa inhibitor that prevents thrombus formation.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	24-33
26258673-8	2015	Rivaroxaban had a greater influence on routine coagulation tests and reduced the maximum thrombin concentration more efficiently, as assessed by the thrombin generation test.	Rivaroxaban	0-11	coagulation factor II, thrombin	Homo sapiens	89-97
26846610-2	2016	Dabigatran, as well as the other new anticoagulants-rivaroxaban, apixaban, and edoxaban-are substrates for P-glycoprotein (P-gp).	Rivaroxaban	52-63	ATP binding cassette subfamily B member 1	Homo sapiens	107-121
26772828-0	2016	[Successful direct thrombin inhibitor treatment of a left atrial appendage thrombus developed under rivaroxaban therapy].	Rivaroxaban	100-111	coagulation factor II, thrombin	Homo sapiens	19-27
26081413-2	2016	Rivaroxaban is an oral anticoagulant that works by inhibiting factor Xa leading to a blockage of thrombin production, which inhibits platelet aggregation and thrombus formation.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	62-71
26081413-2	2016	Rivaroxaban is an oral anticoagulant that works by inhibiting factor Xa leading to a blockage of thrombin production, which inhibits platelet aggregation and thrombus formation.	Rivaroxaban	0-11	coagulation factor II, thrombin	Homo sapiens	97-105
26846610-2	2016	Dabigatran, as well as the other new anticoagulants-rivaroxaban, apixaban, and edoxaban-are substrates for P-glycoprotein (P-gp).	Rivaroxaban	52-63	ATP binding cassette subfamily B member 1	Homo sapiens	123-127
26163310-3	2016	OBJECTIVES: This study evaluates the authors" experience with rivaroxaban, an oral Factor Xa inhibitor, for VTE prophylaxis in abdominoplasty patients.	Rivaroxaban	62-73	coagulation factor X	Homo sapiens	83-92
26258673-8	2015	Rivaroxaban had a greater influence on routine coagulation tests and reduced the maximum thrombin concentration more efficiently, as assessed by the thrombin generation test.	Rivaroxaban	0-11	coagulation factor II, thrombin	Homo sapiens	149-157
26425918-0	2015	Chiral Inhibition of Rivaroxaban Derivatives Towards UDP-Glucuronosyltransferase (UGT) Isoforms.	Rivaroxaban	21-32	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	53-80
26425918-0	2015	Chiral Inhibition of Rivaroxaban Derivatives Towards UDP-Glucuronosyltransferase (UGT) Isoforms.	Rivaroxaban	21-32	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	82-85
26425918-1	2015	Rivaroxaban is an oral direct factor Xa (FXa) inhibitor clinically used to prevent and treat thromboembolic disorders.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	30-39
26425918-1	2015	Rivaroxaban is an oral direct factor Xa (FXa) inhibitor clinically used to prevent and treat thromboembolic disorders.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	41-44
26425918-6	2015	A significant influence of rivaroxaban derivatives towards UGT1A3 was observed.	Rivaroxaban	27-38	UDP glucuronosyltransferase family 1 member A3	Homo sapiens	59-65
26425918-7	2015	Chiral centers produce different effects towards the effect of four pairs of rivaroxaban derivatives towards UGT1A3 activity, with stronger inhibition potential of S1 than R1, but stronger inhibition capability of R2, R3, R4 than S2, S3, and S4.	Rivaroxaban	77-88	UDP glucuronosyltransferase family 1 member A3	Homo sapiens	109-115
26425918-9	2015	In conclusion, the significant influence of rivaroxaban derivatives towards UGT1A3"s activity was demonstrated in the present study.	Rivaroxaban	44-55	UDP glucuronosyltransferase family 1 member A3	Homo sapiens	76-82
26425918-10	2015	The chirality centers highly affected the inhibition behavior of rivaroxaban derivatives towards UGT1A3.	Rivaroxaban	65-76	UDP glucuronosyltransferase family 1 member A3	Homo sapiens	97-103
26416655-5	2015	For example, in the ATLAS ACS 2 TIMI 51 trial of rivaroxaban plus standard antiplatelet therapy following an acute coronary syndrome event, the current analysis demonstrates that 63 patients need to be treated (over 24 months) to prevent one all-cause mortality event compared with placebo (NNT = 63).	Rivaroxaban	49-60	acyl-CoA synthetase long chain family member 5	Homo sapiens	26-31
27747723-9	2015	Rivaroxaban, a substrate for cytochrome P450 (CYP) 3A4 and P-glycoprotein (P-gp), is contraindicated in patients concomitantly treated with strong inhibitors of both these systems, e.g. protease inhibitors (PIs) such as ritonavir (based on in vitro data and a pharmacokinetic study in healthy volunteers).	Rivaroxaban	0-11	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	29-54
27747723-9	2015	Rivaroxaban, a substrate for cytochrome P450 (CYP) 3A4 and P-glycoprotein (P-gp), is contraindicated in patients concomitantly treated with strong inhibitors of both these systems, e.g. protease inhibitors (PIs) such as ritonavir (based on in vitro data and a pharmacokinetic study in healthy volunteers).	Rivaroxaban	0-11	ATP binding cassette subfamily B member 1	Homo sapiens	59-73
27747723-9	2015	Rivaroxaban, a substrate for cytochrome P450 (CYP) 3A4 and P-glycoprotein (P-gp), is contraindicated in patients concomitantly treated with strong inhibitors of both these systems, e.g. protease inhibitors (PIs) such as ritonavir (based on in vitro data and a pharmacokinetic study in healthy volunteers).	Rivaroxaban	0-11	ATP binding cassette subfamily B member 1	Homo sapiens	75-79
26779514-6	2015	A more recent article published in the Lancet studied the use and outcomes of digoxin in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism in Atrial Fibrillation (ROCKET AF) trial.	Rivaroxaban	93-104	coagulation factor X	Homo sapiens	128-137
26607201-2	2015	The standard treatment for pulmonary embolism is anticoagulant therapy using low molecular weight heparin, fondaparinux and a vitamin K antagonist, but a recent clinical trial showed that rivaroxaban, an oral factor Xa inhibitor, was as effective as standard therapy for the initial and long-term treatment of pulmonary embolism and had less bleeding complications.	Rivaroxaban	188-199	coagulation factor X	Homo sapiens	209-218
26576274-3	2015	It was managed successfully with dual antiplatelet agents and factor Xa inhibitor rivaroxaban administered orally.	Rivaroxaban	82-93	coagulation factor X	Homo sapiens	62-71
26305919-0	2015	Comparison of the effects of heparin and the direct factor Xa inhibitor, rivaroxaban, on bone microstructure and metabolism in adult rats.	Rivaroxaban	73-84	coagulation factor X	Homo sapiens	52-61
26305919-2	2015	The direct factor Xa inhibitor, rivaroxaban, is used to prevent venous thromboembolism in patients suffering from trauma and joint arthroplasty.	Rivaroxaban	32-43	coagulation factor X	Homo sapiens	11-20
26727722-5	2015	Apixaban, edoxaban and rivaroxaban are direct factor Xa inhibitors, while dabigatran works as a direct thrombin inhibitor.	Rivaroxaban	23-34	coagulation factor X	Homo sapiens	46-55
26771971-9	2015	The mean anti-FXa values were significantly lower in patients before rivaroxaban dosing than after.	Rivaroxaban	69-80	coagulation factor X	Homo sapiens	14-17
25848131-2	2015	In these studies, we investigated the possible synergistic effects of rivaroxaban in combination with antiplatelet agents on thrombin generation and platelet aggregation in vitro and on arterial thrombosis and hemostasis in rat models.	Rivaroxaban	70-81	coagulation factor II	Rattus norvegicus	125-133
25848131-3	2015	MATERIALS AND METHODS: Thrombin generation was measured by the Calibrated Automated Thrombogram method (0.5 pmol/L tissue factor) using human platelet-rich plasma (PRP) spiked with rivaroxaban (15, 30, or 60 ng/mL), ticagrelor (1.0 microg/mL), and acetylsalicylic acid (ASA; 100 microg/mL).	Rivaroxaban	181-192	coagulation factor II, thrombin	Homo sapiens	23-31
25848131-6	2015	RESULTS: Rivaroxaban inhibited thrombin generation in a concentration-dependent manner and the effect was enhanced with ticagrelor and ticagrelor plus ASA.	Rivaroxaban	9-20	coagulation factor II	Rattus norvegicus	31-39
25817329-0	2015	Rivaroxaban, a novel oral anticoagulant, attenuates atherosclerotic plaque progression and destabilization in ApoE-deficient mice.	Rivaroxaban	0-11	apolipoprotein E	Mus musculus	110-114
25817329-4	2015	Administration of Riv (5 mg/kg/day) for 20 weeks to 8-week-old ApoE(-/-) mice reduced atherosclerotic lesion progression in the aortic arch as determined by en-face Sudan IV staining compared with the non-treated group (P &lt; 0.05) without alteration of plasma lipid levels and blood pressure.	Rivaroxaban	18-21	apolipoprotein E	Mus musculus	63-67
26270625-1	2015	BACKGROUND: Four-factor prothrombin complex concentrate (PCC) (Cofact; Sanquin Blood Supply) 50 IU kg(-1) increased thrombin generation beyond baseline values in healthy, rivaroxaban-treated subjects.	Rivaroxaban	171-182	coagulation factor II, thrombin	Homo sapiens	27-35
25318481-3	2015	METHODS: The Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis in Myocardial Infarction 51 (ATLAS ACS 2-TIMI 51) study randomized 15,526 patients with a recent ACS to rivaroxaban 2.5 mg BID, rivaroxaban 5 mg BID, or placebo.	Rivaroxaban	250-261	acyl-CoA synthetase long chain family member 5	Homo sapiens	181-186
25318481-3	2015	METHODS: The Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis in Myocardial Infarction 51 (ATLAS ACS 2-TIMI 51) study randomized 15,526 patients with a recent ACS to rivaroxaban 2.5 mg BID, rivaroxaban 5 mg BID, or placebo.	Rivaroxaban	274-285	acyl-CoA synthetase long chain family member 5	Homo sapiens	181-186
25804370-3	2015	We describe a case of HIT treated with rivaroxaban, a direct oral factor Xa inhibitor which could be used to inhibit the generation of thrombin, instead of DTIs.	Rivaroxaban	39-50	coagulation factor X	Homo sapiens	66-75
25804370-3	2015	We describe a case of HIT treated with rivaroxaban, a direct oral factor Xa inhibitor which could be used to inhibit the generation of thrombin, instead of DTIs.	Rivaroxaban	39-50	coagulation factor II, thrombin	Homo sapiens	135-143
26077117-0	2015	Rivaroxaban, a factor Xa inhibitor, improves neovascularization in the ischemic hindlimb of streptozotocin-induced diabetic mice.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	15-24
26731855-1	2015	The novel oral anticoagulants (NOAC) dabigatran, apixaban, edoxaban and rivaroxaban target either thrombin or factor Xa for the prevention and treatment of thrombosis.	Rivaroxaban	72-83	coagulation factor II, thrombin	Homo sapiens	98-106
26731855-1	2015	The novel oral anticoagulants (NOAC) dabigatran, apixaban, edoxaban and rivaroxaban target either thrombin or factor Xa for the prevention and treatment of thrombosis.	Rivaroxaban	72-83	coagulation factor X	Homo sapiens	110-119
26608490-1	2015	UNLABELLED: Rivaroxaban, a selective inhibitor of active factor X, is metabolized by cytochrom P450 3A4 (CYP3A4) and is a substrate for transporter protein--P-glycoprotein (P-gp).	Rivaroxaban	12-23	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	85-103
26608490-1	2015	UNLABELLED: Rivaroxaban, a selective inhibitor of active factor X, is metabolized by cytochrom P450 3A4 (CYP3A4) and is a substrate for transporter protein--P-glycoprotein (P-gp).	Rivaroxaban	12-23	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	105-111
26608490-1	2015	UNLABELLED: Rivaroxaban, a selective inhibitor of active factor X, is metabolized by cytochrom P450 3A4 (CYP3A4) and is a substrate for transporter protein--P-glycoprotein (P-gp).	Rivaroxaban	12-23	phosphoglycolate phosphatase	Homo sapiens	148-171
26608490-1	2015	UNLABELLED: Rivaroxaban, a selective inhibitor of active factor X, is metabolized by cytochrom P450 3A4 (CYP3A4) and is a substrate for transporter protein--P-glycoprotein (P-gp).	Rivaroxaban	12-23	phosphoglycolate phosphatase	Homo sapiens	173-177
26154612-4	2015	Rapid improvement in liver function tests despite use of an alternative factor Xa inhibitor suggests that rivaroxaban"s mechanism of hepatotoxicity may be unrelated to its pharmacologic action.	Rivaroxaban	106-117	coagulation factor X	Homo sapiens	72-81
25935131-0	2015	Initiation of rivaroxaban in patients with nonvalvular atrial fibrillation at the primary care level: the Swiss Therapy in Atrial Fibrillation for the Regulation of Coagulation (STAR) Study.	Rivaroxaban	14-25	steroidogenic acute regulatory protein	Homo sapiens	178-182
24974738-2	2015	SSEH with anticoagulants including warfarin and rivaroxaban (Factor Xa inhibitor) have been reported; however, SSEH with Factor X deficiency has not been described yet.	Rivaroxaban	48-59	coagulation factor X	Homo sapiens	61-70
26251639-1	2015	AIMS: Although quantitative anti-FXa assays can be used to measure rivaroxaban plasma levels, they are not widely performed or available.	Rivaroxaban	67-78	coagulation factor X	Homo sapiens	33-36
26251639-6	2015	The appropriate rivaroxaban plasma concentration to inhibit clotting mechanisms was based on the remaining FXa in plasma, which was expressed as the ratio of patients/normal, R-C.	Rivaroxaban	16-27	coagulation factor X	Homo sapiens	107-110
25940651-2	2015	These drugs include agents that inhibit activated factor X (FXa) (such as apixaban and rivaroxaban) or thrombin (such as dabigatran), and are collectively known today as non-VKA oral anticoagulants (NOACs).	Rivaroxaban	87-98	coagulation factor X	Homo sapiens	60-63
26059702-2	2015	Rivaroxaban, a direct oral Factor Xa inhibitor, is approved for use across several thromboembolic indications.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	27-36
26058941-0	2015	Is anti-factor Xa chromogenic assay for Rivaroxaban appropriate in clinical practice?	Rivaroxaban	40-51	coagulation factor X	Homo sapiens	8-17
26279635-1	2015	Rivaroxaban is an orally active direct factor Xa inhibitor used to treat venous thromboembolism with approved starting dose of 15 mg twice-daily.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	39-48
25855705-2	2015	Rivaroxaban concentration can be accurately and rapidly determined using a chromogenic anti-activated factor X (factor Xa) assay with specific drug calibrator material.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	112-121
25855705-7	2015	RESULTS: There was acceptable correlation between rivaroxaban levels and heparin anti-factor Xa activity using Berichrom and COAMATIC heparin kits.	Rivaroxaban	50-61	coagulation factor X	Homo sapiens	86-95
25855705-8	2015	The STA liquid heparin method was the most sensitive to presence of rivaroxaban.	Rivaroxaban	68-79	GCY	Homo sapiens	4-7
25855705-9	2015	CONCLUSION: This study demonstrates a strong correlation, but variability between kits, for assessing rivaroxaban concentrations using heparin anti-factor Xa assays.	Rivaroxaban	102-113	coagulation factor X	Homo sapiens	148-157
25855705-11	2015	The STA liquid heparin, being exquisitely sensitive to rivaroxaban, may be suitable for ruling out presence of the drug.	Rivaroxaban	55-66	GCY	Homo sapiens	4-7
25855705-12	2015	The routine use of heparin-calibrated anti-factor Xa assays to quantify rivaroxaban is not advocated, and when applied, it must be used with caution and limitations clearly understood.	Rivaroxaban	72-83	coagulation factor X	Homo sapiens	43-52
25869030-0	2015	Successful treatment with rivaroxaban of an extended superficial vein thrombosis in a patient with acquired antithrombin deficiency due to Peg-asparaginase treatment.	Rivaroxaban	26-37	serpin family C member 1	Homo sapiens	108-120
25869030-0	2015	Successful treatment with rivaroxaban of an extended superficial vein thrombosis in a patient with acquired antithrombin deficiency due to Peg-asparaginase treatment.	Rivaroxaban	26-37	progestagen associated endometrial protein	Homo sapiens	139-142
25854636-2	2015	Rivaroxaban, an oral factor Xa inhibitor, is approved for the prevention of stroke in patients with non-valvular AF.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	21-30
25724111-1	2015	The oral Factor Xa inhibitor rivaroxaban (Xarelto) has been the pharmacologic agent used for venous thromboembolism (VTE) prophylaxis after primary hip and knee arthroplasty (THA/TKA) at our institution since February 2012.	Rivaroxaban	29-40	coagulation factor X	Homo sapiens	9-18
25724111-1	2015	The oral Factor Xa inhibitor rivaroxaban (Xarelto) has been the pharmacologic agent used for venous thromboembolism (VTE) prophylaxis after primary hip and knee arthroplasty (THA/TKA) at our institution since February 2012.	Rivaroxaban	42-49	coagulation factor X	Homo sapiens	9-18
25761505-1	2015	Rivaroxaban and apixaban are selective direct inhibitors of free and prothrombinase-bound factor Xa (FXa).	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	101-104
25761505-6	2015	Simulation predicted that in TGA triggered with 20 pM tissue factor, 100 ng/ml apixaban or rivaroxaban increased 1.8- or 3.0-fold the lag time and 1.4- or 2.0-fold the time to peak, whilst decreasing 1.2- or 3.1-fold the maximum thrombin and 1.7- or 3.5-fold the endogenous thrombin potential.	Rivaroxaban	91-102	coagulation factor II, thrombin	Homo sapiens	229-237
25761505-6	2015	Simulation predicted that in TGA triggered with 20 pM tissue factor, 100 ng/ml apixaban or rivaroxaban increased 1.8- or 3.0-fold the lag time and 1.4- or 2.0-fold the time to peak, whilst decreasing 1.2- or 3.1-fold the maximum thrombin and 1.7- or 3.5-fold the endogenous thrombin potential.	Rivaroxaban	91-102	coagulation factor II, thrombin	Homo sapiens	274-282
26077117-6	2015	Rivaroxaban also increased endothelial nitric oxide synthase (eNOS) as well as vascular endothelial growth factor (VEGF) expressions in hyperglycemia-stimulated EPCs.	Rivaroxaban	0-11	nitric oxide synthase 3, endothelial cell	Mus musculus	27-60
26077117-6	2015	Rivaroxaban also increased endothelial nitric oxide synthase (eNOS) as well as vascular endothelial growth factor (VEGF) expressions in hyperglycemia-stimulated EPCs.	Rivaroxaban	0-11	vascular endothelial growth factor A	Mus musculus	79-113
26077117-6	2015	Rivaroxaban also increased endothelial nitric oxide synthase (eNOS) as well as vascular endothelial growth factor (VEGF) expressions in hyperglycemia-stimulated EPCs.	Rivaroxaban	0-11	vascular endothelial growth factor A	Mus musculus	115-119
26035221-0	2015	Favorable outcome of rivaroxaban-associated intracerebral hemorrhage reversed by 4-factor prothrombin complex concentrate: impact on thrombin generation.	Rivaroxaban	21-32	coagulation factor II, thrombin	Homo sapiens	93-101
26035221-5	2015	Thrombin generation tests may be suitable for assessing the clinical utility of reversal drugs on rivaroxaban-induced coagulopathy.	Rivaroxaban	98-109	coagulation factor II, thrombin	Homo sapiens	0-8
25769543-9	2015	A direct activated factor X inhibitor, rivaroxaban, added to human blood, suppressed both thrombin and fibrin formation.	Rivaroxaban	39-50	coagulation factor II, thrombin	Homo sapiens	90-98
26019695-7	2015	Direct thrombin inhibitor dabigatran and factor Xa inhibitors like rivaroxaban and apixaban have already been approved by the US Food and Drug Administration (FDA) for stroke prevention in patients with nonvalvular atrial fibrillation.	Rivaroxaban	67-78	coagulation factor II, thrombin	Homo sapiens	7-15
25948149-7	2015	The non-vitamin K antagonist oral anticoagulants (NOACs), including the factor Xa inhibitors apixaban, edoxaban and rivaroxaban as well as the direct-thrombin inhibitor dabigatran, are increasing the convenience of and options available for VTE treatment.	Rivaroxaban	116-127	coagulation factor X	Homo sapiens	72-81
26258969-2	2015	It concerns of orally direct inhibitors of thrombin (dabigatran etexilate), inhibitors of factor Xa (apixaban, rivaroxaban), respectively, with advantage of some properties not being seen in "classical" anticoagulants.	Rivaroxaban	111-122	coagulation factor X	Homo sapiens	90-99
25557176-5	2015	Recent clinical trials suggest that rivaroxaban, an oral direct inhibitor of factor Xa, provides an effective, safe, simplified approach to treatment.	Rivaroxaban	36-47	coagulation factor X	Homo sapiens	77-86
24057396-3	2015	Based on the results of the EINSTEIN clinical trial program, the oral, direct factor Xa inhibitor rivaroxaban is approved for the treatment of acute deep vein thrombosis (DVT) and pulmonary embolism (PE) and for the prevention of recurrent VTE.	Rivaroxaban	98-109	coagulation factor X	Homo sapiens	78-87
25973138-2	2015	Based on the results of the international phase III RECORD (Regulation of Coagulation in Orthopaedic Surgery to Prevent Deep Vein Thrombosis and Pulmonary Embolism) program, the oral, direct Factor Xa inhibitor rivaroxaban has been approved in many countries for the prevention of VTE after elective hip arthroplasty or knee arthroplasty.	Rivaroxaban	211-222	coagulation factor X	Homo sapiens	191-200
26060808-5	2015	Dabigatran, direct thrombin inhibitor, and rivaroxaban, apixaban, and edoxaban, inhibitors of factor Xa harbor great merits of rapid action time, short half-life, stable plasma concentration, and little drug interaction.	Rivaroxaban	43-54	coagulation factor X	Homo sapiens	94-103
25728496-0	2015	Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: A meta-analysis of 6 randomized clinical trials.	Rivaroxaban	29-40	coagulation factor X	Homo sapiens	7-16
25728496-1	2015	OBJECTIVE: A meta-analysis of randomized controlled trials (RCTs) was performed to compare the efficacy and safety of direct factor Xa inhibitors (rivaroxaban and apixaban) with enoxaparin for the prevention of venous thromboembolism (VTE) after total knee replacement.	Rivaroxaban	147-158	coagulation factor X	Homo sapiens	125-134
25743887-8	2015	RESULTS: For NOACs, correlations between calibrated STA -Staclot DRVV-Confirm and LC-MS/MS (rs=0.88 and 0.97 for rivaroxaban and dabigatran, respectively) were higher than the ones obtained with STA -Staclot DRVV-Screen (rs=0.87 and 0.91), PT (rs=0.83 to 0.86) or aPTT (rs=0.84 to 0.89).	Rivaroxaban	113-124	GCY	Homo sapiens	52-55
25743887-12	2015	CONCLUSIONS: STA -Staclot DRVV-Confirm provides a rapid estimation of the intensity of anticoagulation with rivaroxaban or dabigatran without specific calibrators.	Rivaroxaban	108-119	GCY	Homo sapiens	13-16
25736441-1	2015	BACKGROUND: In the ROCKET AF (Rivaroxaban-Once-daily, oral, direct Factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) trial, marked regional differences in control of warfarin anticoagulation, measured as the average individual patient time in the therapeutic range (iTTR) of the international normalized ratio (INR), were associated with longer inter-INR test intervals.	Rivaroxaban	30-41	coagulation factor X	Homo sapiens	67-76
25724781-9	2015	Compared with dabigatran, patients were more likely to fill rivaroxaban with high bleeding risk (aRR 1.16, 95% CI 1.09 to 1.24).	Rivaroxaban	60-71	arrestin beta 1	Homo sapiens	97-102
25819852-0	2015	Rationale and design of a study exploring the efficacy of once-daily oral rivaroxaban (X-TRA) on the outcome of left atrial/left atrial appendage thrombus in nonvalvular atrial fibrillation or atrial flutter and a retrospective observational registry providing baseline data (CLOT-AF).	Rivaroxaban	74-85	T cell receptor alpha locus	Homo sapiens	89-92
25819852-2	2015	Rivaroxaban (Xarelto ), a potent and highly selective oral, direct factor Xa inhibitor, is a new therapeutic option in this setting.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	67-76
25819852-2	2015	Rivaroxaban (Xarelto ), a potent and highly selective oral, direct factor Xa inhibitor, is a new therapeutic option in this setting.	Rivaroxaban	13-20	coagulation factor X	Homo sapiens	67-76
25819852-4	2015	The primary objective of the X-TRA study is to explore the efficacy of rivaroxaban in the treatment of LA/LAA thrombi in patients with nonvalvular AF or atrial flutter, scheduled to undergo cardioversion or AF ablation, in whom an LA/LAA thrombus has been found on transesophageal echocardiography (TEE) before the procedure.	Rivaroxaban	71-82	T cell receptor alpha locus	Homo sapiens	31-34
25819852-11	2015	Unique data on clot resolution with rivaroxaban in a prospective cohort would be obtained in X-TRA.	Rivaroxaban	36-47	T cell receptor alpha locus	Homo sapiens	95-98
25690076-2	2015	Rivaroxaban is an oral factor Xa inhibitor approved for stroke prevention in atrial fibrillation (AF) and for treatment and prevention of venous thromboembolism (VTE) in major orthopedic surgery.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	23-32
25616425-0	2015	Relevance of P-glycoprotein in stroke prevention with dabigatran, rivaroxaban, and apixaban.	Rivaroxaban	66-77	ATP binding cassette subfamily B member 1	Homo sapiens	13-27
25192595-6	2015	However, the prothrombin fragment 1+2 (F1+2) level, a marker of thrombin generation, was significantly higher in the rivaroxaban group than the warfarin group (202+-88pmol/l vs. 114+-79pmol/l, p&lt;0.001).	Rivaroxaban	117-128	coagulation factor II, thrombin	Homo sapiens	16-24
25396759-0	2015	Results of rotational thromboelastometry, coagulation activation markers and thrombin generation assays in orthopedic patients during thromboprophylaxis with rivaroxaban and enoxaparin: a prospective cohort study.	Rivaroxaban	158-169	coagulation factor II, thrombin	Homo sapiens	77-85
25396759-11	2015	Endogenous thrombin potential (ETP), unchanged with rivaroxaban, decreased significantly with enoxaparin; the maximal rising slope (mean velocity rate index) decreased more with rivaroxaban.	Rivaroxaban	178-189	coagulation factor II, thrombin	Homo sapiens	11-19
25396759-12	2015	CONCLUSION: Data show that prolonged CT in the extrinsic ROTEM and thrombin generation assays reflecting initiation and propagation of thrombin may be useful for detecting treatment with rivaroxaban.	Rivaroxaban	187-198	coagulation factor II, thrombin	Homo sapiens	67-75
25396759-12	2015	CONCLUSION: Data show that prolonged CT in the extrinsic ROTEM and thrombin generation assays reflecting initiation and propagation of thrombin may be useful for detecting treatment with rivaroxaban.	Rivaroxaban	187-198	coagulation factor II, thrombin	Homo sapiens	135-143
25561312-1	2015	BACKGROUND: Rivaroxaban is an oral direct factor Xa inhibitor increasingly used in stroke prevention in nonvascular atrial fibrillation, primary prevention and treatment of venous thromboembolism, and secondary prevention in acute coronary syndromes.	Rivaroxaban	12-23	coagulation factor X	Homo sapiens	42-51
25299352-8	2015	New oral anticoagulants, including the direct thrombin (dabigatran etexilate) and direct factor Xa inhibitors (rivaroxaban, apixaban, and edoxaban), have advantages over conventional agents such as oral administration at fixed doses, predictable pharmacokinetics and pharmacodynamics, minimal potential for food-drug and drug-drug interactions, and lack of required monitoring.	Rivaroxaban	111-122	coagulation factor X	Homo sapiens	89-98
25476589-0	2015	Comparison of methods to determine rivaroxaban anti-factor Xa activity.	Rivaroxaban	35-46	coagulation factor X	Homo sapiens	52-61
25476589-2	2015	The aims of the project were to correlate a Anti-Factor Xa assay using commercial calibrators and controls (Riva Activity) with serum drug levels analyzed by HPLC-MS/MS (Riva MS) in patients currently receiving rivaroxaban, and secondly, to correlate the PT/PTT, thrombin generation (CAT assay) and Thromboelastograph (TEG) with the Riva activity and Riva MS. METHODS: Recruited patients receiving rivaroxaban prospectively had a total of 3 blood samples taken at least 2 hours apart.	Rivaroxaban	211-222	coagulation factor X	Homo sapiens	49-58
25476589-11	2015	CONCLUSION: Riva anti-factor Xa activity assay measured with commercial calibrators and controls provides a reliable assessment of rivaroxaban serum levels for patients requiring measurement of anticoagulant activity.	Rivaroxaban	131-142	coagulation factor X	Homo sapiens	22-31
25555316-3	2015	The aim of this study was to compare the effects of warfarin and therapeutic dose rivaroxaban on ex-vivo thrombin generation (TG), and the in-vivo markers of coagulation activation, prothrombin fragment 1.2 (F1.2), thrombin-antithrombin complex (TAT), and D-dimer.	Rivaroxaban	82-93	coagulation factor II, thrombin	Homo sapiens	105-113
25483215-1	2015	INTRODUCTION: Rivaroxaban is an oral, direct Factor Xa inhibitor, approved for the treatment of pulmonary embolism (PE) and deep vein thrombosis (DVT) and the secondary prevention of recurrent PE and DVT as a fixed-dose, monotherapy regimen that does not require initial heparinisation, routine coagulation monitoring or dose adjustment.	Rivaroxaban	14-25	coagulation factor X	Homo sapiens	45-54
25555316-7	2015	Both rivaroxaban and warfarin reduced endogenous thrombin potential (ETP) and peak thrombin, and prolonged lag time and time to peak, compared to normal controls (p&lt;0.0001).	Rivaroxaban	5-16	coagulation factor II, thrombin	Homo sapiens	49-57
25555316-7	2015	Both rivaroxaban and warfarin reduced endogenous thrombin potential (ETP) and peak thrombin, and prolonged lag time and time to peak, compared to normal controls (p&lt;0.0001).	Rivaroxaban	5-16	coagulation factor II, thrombin	Homo sapiens	83-91
25555316-8	2015	The lag time and time to peak TG were longer, and peak thrombin was lower in patients receiving rivaroxaban (p&lt;0.0001) compared with warfarin, although warfarin-treated patients had lower ETP (p=0.0008).	Rivaroxaban	96-107	coagulation factor II, thrombin	Homo sapiens	55-63
26466700-3	2015	Finally, rivaroxaban (an oral direct Factor Xa inhibitor) was prescribed for chronic DIC, as well as non-valvular AF.	Rivaroxaban	9-20	coagulation factor X	Homo sapiens	37-46
25903537-3	2015	Recently, direct oral anticoagulants (DOACs), including the Factor Xa inhibitors rivaroxaban, apixaban and edoxaban, and the direct thrombin inhibitor dabigatran etexilate, have been developed to address limitations associated with traditional anticoagulant therapy.	Rivaroxaban	81-92	coagulation factor X	Homo sapiens	60-69
25954565-4	2015	Rivaroxaban is a new generation of anticoagulants that directly inhibits factor Xa and is used for DVT treatment in major orthopaedic surgery.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	73-82
25431993-1	2015	Thrombin inhibitor dabigatran and factor Xa inhibitors rivaroxaban, apixaban and edoxaban form a new class of non-vitamin K antagonist oral anticoagulants and have been extensively studied in patients with venous thromboembolism and atrial fibrillation.	Rivaroxaban	55-66	coagulation factor II, thrombin	Homo sapiens	0-8
26370374-0	2015	Rivaroxaban Inhibits Angiotensin II-Induced Activation in Cultured Mouse Cardiac Fibroblasts Through the Modulation of NF-kappaB Pathway.	Rivaroxaban	0-11	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	119-128
26370374-6	2015	In mouse cytokine array measuring 40 cytokines, the productions of interleukin-16, TIMP-1, and tumor necrosis factor-alpha (TNF-alpha) were significantly reduced with 0.1 mug/mL of rivaroxaban pretreatment (all P &lt; 0.05).	Rivaroxaban	181-192	interleukin 16	Mus musculus	67-81
26370374-6	2015	In mouse cytokine array measuring 40 cytokines, the productions of interleukin-16, TIMP-1, and tumor necrosis factor-alpha (TNF-alpha) were significantly reduced with 0.1 mug/mL of rivaroxaban pretreatment (all P &lt; 0.05).	Rivaroxaban	181-192	tissue inhibitor of metalloproteinase 1	Mus musculus	83-89
26370374-6	2015	In mouse cytokine array measuring 40 cytokines, the productions of interleukin-16, TIMP-1, and tumor necrosis factor-alpha (TNF-alpha) were significantly reduced with 0.1 mug/mL of rivaroxaban pretreatment (all P &lt; 0.05).	Rivaroxaban	181-192	tumor necrosis factor	Mus musculus	95-122
26370374-6	2015	In mouse cytokine array measuring 40 cytokines, the productions of interleukin-16, TIMP-1, and tumor necrosis factor-alpha (TNF-alpha) were significantly reduced with 0.1 mug/mL of rivaroxaban pretreatment (all P &lt; 0.05).	Rivaroxaban	181-192	tumor necrosis factor	Mus musculus	124-133
26370374-7	2015	TIMP-1 levels in the culture supernatant measured by ELISA were also decreased by rivaroxaban pretreatment in Ang II-induced CFs (35% decrease at 0.01 mug/mL, 47% at 0.1 mug/mL, 47% at 1 mug/mL, and 57% at 5 mug/mL).	Rivaroxaban	82-93	tissue inhibitor of metalloproteinase 1	Mus musculus	0-6
25786449-2	2015	Restoring the warfarin dose with ordinary control for two months did not result in any changes in the size of the thrombus; however, the subsequent substitution of rivaroxaban (oral treatment with a direct Factor Xa inhibitor) for warfarin ultimately resolved the thrombosis.	Rivaroxaban	164-175	coagulation factor X	Homo sapiens	206-215
26601525-3	2015	The data of increase in sensitivity to thrombomodulin indicated about work enchancement of protein C system against the background of rivaroxaban therapy.	Rivaroxaban	134-145	thrombomodulin	Homo sapiens	39-53
25106734-1	2015	Rivaroxaban is a novel, selective and potent oral direct factor Xa inhibitor, therapeutically indicated in the treatment of thromboembolic diseases.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	57-66
26111863-9	2015	Rivaroxaban attenuated the accumulation of malonyldialdehyde (MDA) and transforming growth-factor beta1 (TGF-beta1) and the activities of myeloperoxidase (MPO), matrix metalloproteinase-3 and tissue inhibitor of metalloproteinases-1.	Rivaroxaban	0-11	transforming growth factor, beta 1	Rattus norvegicus	71-103
26111863-9	2015	Rivaroxaban attenuated the accumulation of malonyldialdehyde (MDA) and transforming growth-factor beta1 (TGF-beta1) and the activities of myeloperoxidase (MPO), matrix metalloproteinase-3 and tissue inhibitor of metalloproteinases-1.	Rivaroxaban	0-11	transforming growth factor, beta 1	Rattus norvegicus	105-114
26111863-9	2015	Rivaroxaban attenuated the accumulation of malonyldialdehyde (MDA) and transforming growth-factor beta1 (TGF-beta1) and the activities of myeloperoxidase (MPO), matrix metalloproteinase-3 and tissue inhibitor of metalloproteinases-1.	Rivaroxaban	0-11	myeloperoxidase	Rattus norvegicus	138-153
26111863-9	2015	Rivaroxaban attenuated the accumulation of malonyldialdehyde (MDA) and transforming growth-factor beta1 (TGF-beta1) and the activities of myeloperoxidase (MPO), matrix metalloproteinase-3 and tissue inhibitor of metalloproteinases-1.	Rivaroxaban	0-11	myeloperoxidase	Rattus norvegicus	155-158
26111863-9	2015	Rivaroxaban attenuated the accumulation of malonyldialdehyde (MDA) and transforming growth-factor beta1 (TGF-beta1) and the activities of myeloperoxidase (MPO), matrix metalloproteinase-3 and tissue inhibitor of metalloproteinases-1.	Rivaroxaban	0-11	matrix metallopeptidase 3	Rattus norvegicus	161-232
25148838-1	2014	AIMS: We investigated clinical characteristics and outcomes of patients with significant valvular disease (SVD) in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) trial.	Rivaroxaban	119-130	coagulation factor X	Homo sapiens	154-163
25500152-14	2014	Rivaroxaban affects the coagulation cascade and inhibits the factor Xa-dependent conversion of prothrombin to thrombin, thereby considerably reducing the risk of thrombosis.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	61-70
25500152-14	2014	Rivaroxaban affects the coagulation cascade and inhibits the factor Xa-dependent conversion of prothrombin to thrombin, thereby considerably reducing the risk of thrombosis.	Rivaroxaban	0-11	coagulation factor II, thrombin	Homo sapiens	98-106
25319314-6	2014	The ICER of rivaroxaban versus warfarin was SG$29,697 (US$26,727) per QALY.	Rivaroxaban	12-23	cAMP responsive element modulator	Homo sapiens	4-8
25041869-9	2014	The FXa inhibitor, rivaroxaban, failed to prevent the reduced expression of pyruvate dehydrogenase induced by FXa but reduced acetyl-CoA content and reverted the decreased aconitase activity observed with FXa alone.	Rivaroxaban	19-30	coagulation factor X	Homo sapiens	4-7
25041869-10	2014	Rivaroxaban + FXa but not FXa alone increased the expression level of carnitine palmitoyltransferase I and II, two mitochondrial long chain fatty acid transporters.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	14-17
25041869-10	2014	Rivaroxaban + FXa but not FXa alone increased the expression level of carnitine palmitoyltransferase I and II, two mitochondrial long chain fatty acid transporters.	Rivaroxaban	0-11	carnitine palmitoyltransferase 2	Homo sapiens	70-109
25041869-11	2014	Rivaroxaban also prevented the increased expression of oxidative stress-related proteins induced by FXa alone.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	100-103
25319314-9	2014	Deterministic sensitivity analyses showed that the ICER of rivaroxaban versus warfarin was sensitive to cost of rivaroxaban and utilities for rivaroxaban and warfarin.	Rivaroxaban	59-70	cAMP responsive element modulator	Homo sapiens	51-55
25319314-9	2014	Deterministic sensitivity analyses showed that the ICER of rivaroxaban versus warfarin was sensitive to cost of rivaroxaban and utilities for rivaroxaban and warfarin.	Rivaroxaban	112-123	cAMP responsive element modulator	Homo sapiens	51-55
25319314-9	2014	Deterministic sensitivity analyses showed that the ICER of rivaroxaban versus warfarin was sensitive to cost of rivaroxaban and utilities for rivaroxaban and warfarin.	Rivaroxaban	112-123	cAMP responsive element modulator	Homo sapiens	51-55
24926732-11	2014	Patients on rivaroxaban had a significantly better rate of persistence (aHR: 0.63, 95% CI 0.59-0.68) and lower rate of discontinuation (aHR: 0.54, 95% CI 0.49-0.58) compared to warfarin recipients.	Rivaroxaban	12-23	aryl hydrocarbon receptor	Homo sapiens	72-75
25485923-1	2014	The direct thrombin inhibitor dabigatran and factor Xa inhibitors rivaroxaban and apixaban are US Food and Drug Administration (FDA)-approved target-specific oral anticoagulants (TSOACs) that have emerged onto the market for use in some indications similar to those for warfarin; in addition, edoxaban is seeking FDA approval.	Rivaroxaban	66-77	coagulation factor II, thrombin	Homo sapiens	11-19
24964176-1	2014	Two previously conducted rivaroxaban studies showed that, separately, renal impairment (RI) and concomitant administration of erythromycin (P-glycoprotein and moderate cytochrome P450 3A4 [CYP3A4] inhibitor) can result in increases in rivaroxaban exposure.	Rivaroxaban	25-36	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	168-187
24964176-1	2014	Two previously conducted rivaroxaban studies showed that, separately, renal impairment (RI) and concomitant administration of erythromycin (P-glycoprotein and moderate cytochrome P450 3A4 [CYP3A4] inhibitor) can result in increases in rivaroxaban exposure.	Rivaroxaban	25-36	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	189-195
25419161-11	2014	CONCLUSION: Apixaban 2.5 mg BID demonstrated less intersubject variability in exposure, lower AXA AUC, and higher trough and smaller peak-to-trough fluctuations in plasma concentration and AXA, suggesting more constant anticoagulation compared with rivaroxaban 10 mg QD.	Rivaroxaban	249-260	BH3 interacting domain death agonist	Homo sapiens	28-31
25692828-3	2014	Only one of them (ATLAS ACS 2-TIMI 51) indicated that treatment with small dose of rivaroxaban (2 x 2.5 mg) may be added to dual strategy of acetylsalicylic acid and clopidogrel.	Rivaroxaban	83-94	acyl-CoA synthetase long chain family member 5	Homo sapiens	24-29
25426077-0	2014	Computational investigation of potential dosing schedules for a switch of medication from warfarin to rivaroxaban-an oral, direct Factor Xa inhibitor.	Rivaroxaban	102-113	coagulation factor X	Homo sapiens	130-139
25426077-2	2014	The objective of this study was to examine in silico the anticoagulant effect of rivaroxaban, an oral, direct Factor Xa inhibitor, combined with the residual effect of discontinued warfarin.	Rivaroxaban	81-92	coagulation factor X	Homo sapiens	110-119
25440788-7	2014	Finally, the combination of aspirin, clopidogrel, and low-dose rivaroxaban has recently been approved by the European Medicines Agency (but not the Food and Drug Administration) for secondary prevention after ACS.	Rivaroxaban	63-74	1-aminocyclopropane-1-carboxylate synthase homolog (inactive)	Homo sapiens	209-212
25179762-6	2014	A multicentre prospective phase 4 trial will determine whether early discharge and out-of-hospital treatment of low-risk PE with the oral factor Xa inhibitor rivaroxaban is feasible, effective, and safe.	Rivaroxaban	158-169	coagulation factor X	Homo sapiens	138-147
24615682-5	2014	We demonstrate that FX and FXa use different mechanisms: the use of Rivaroxaban (RX) a specific inhibitor of FXa attenuated its anti-angiogenic properties but did not modify the anti-angiogenic effect of FX.	Rivaroxaban	68-79	coagulation factor X	Homo sapiens	27-30
24615682-5	2014	We demonstrate that FX and FXa use different mechanisms: the use of Rivaroxaban (RX) a specific inhibitor of FXa attenuated its anti-angiogenic properties but did not modify the anti-angiogenic effect of FX.	Rivaroxaban	68-79	coagulation factor X	Homo sapiens	109-112
24659084-1	2014	Rivaroxaban, a direct factor Xa inhibitor, is a novel oral anticoagulant approved for stroke prevention in patients with nonvalvular atrial fibrillation and also approved in Europe (but not in the United States) to prevent recurrent ischemic events in patients with recent acute coronary syndromes.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	22-31
24659084-4	2014	In patients at risk of stroke due to atrial fibrillation, rivaroxaban was noninferior compared to warfarin in preventing stroke/systemic embolism in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET-AF) trial and was associated with a similar risk of major bleeding; the incidence of intracranial hemorrhage was 33% lower with rivaroxaban.	Rivaroxaban	58-69	coagulation factor X	Homo sapiens	188-197
24659084-7	2014	In patients with recent acute coronary syndrome, low-dose rivaroxaban reduced mortality and the composite end point of death from cardiovascular causes, myocardial infarction and stroke, but this was accompanied by an increased risk of intracranial hemorrhage and major bleeding in the Rivaroxaban in Combination With Aspirin Alone or With Aspirin and a Thienopyridine in Patients With Acute Coronary Syndromes-Thrombolysis in Myocardial Infarction (ATLAS ACS 2-TIMI) 51 trial.	Rivaroxaban	58-69	acyl-CoA synthetase long chain family member 5	Homo sapiens	456-461
25280819-0	2014	Intravenous thrombolysis with recombinant tissue plasminogen activator in a stroke patient treated with rivaroxaban.	Rivaroxaban	104-115	chromosome 20 open reading frame 181	Homo sapiens	42-70
25280819-2	2014	Here, we report an acute stroke patient taking rivaroxaban who received intravenous thrombolysis with recombinant tissue plasminogen activator (rt-PA).	Rivaroxaban	47-58	chromosome 20 open reading frame 181	Homo sapiens	114-142
25196577-0	2014	Comparison of the effects of apixaban and rivaroxaban on prothrombin and activated partial thromboplastin times using various reagents.	Rivaroxaban	42-53	coagulation factor II, thrombin	Homo sapiens	57-68
25196577-2	2014	Although quantitative anti-FXa (FXa) assays can be used to measure plasma levels of apixaban or rivaroxaban, turnaround is often slow and many laboratories do not perform these assays.	Rivaroxaban	96-107	coagulation factor X	Homo sapiens	27-30
25196577-2	2014	Although quantitative anti-FXa (FXa) assays can be used to measure plasma levels of apixaban or rivaroxaban, turnaround is often slow and many laboratories do not perform these assays.	Rivaroxaban	96-107	coagulation factor X	Homo sapiens	32-35
25211369-5	2014	Single doses of ticagrelor, dabigatran or rivaroxaban caused comparable decreases in shed blood beta-TG and were more pronounced than phenprocoumon at an INR of 2.0-3.0.	Rivaroxaban	42-53	pro-platelet basic protein	Homo sapiens	96-103
25211369-6	2014	In contrast, thrombin generation was more affected by rivaroxaban and phenprocoumon than by dabigatran.	Rivaroxaban	54-65	coagulation factor II, thrombin	Homo sapiens	13-21
25030773-7	2014	Rivaroxaban, an oral factor Xa inhibitor, attenuates thrombin generation.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	21-30
25030773-7	2014	Rivaroxaban, an oral factor Xa inhibitor, attenuates thrombin generation.	Rivaroxaban	0-11	coagulation factor II, thrombin	Homo sapiens	53-61
25698904-3	2014	Rivaroxaban, a direct Factor Xa inhibitor, is approved in the European Union and the United States for the single-drug treatment of deep vein thrombosis and pulmonary embolism and the secondary prevention of recurrent VTE in adults.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	22-31
24926732-11	2014	Patients on rivaroxaban had a significantly better rate of persistence (aHR: 0.63, 95% CI 0.59-0.68) and lower rate of discontinuation (aHR: 0.54, 95% CI 0.49-0.58) compared to warfarin recipients.	Rivaroxaban	12-23	aryl hydrocarbon receptor	Homo sapiens	136-139
25658892-5	2014	NOACs work to prevent and treat thrombosis by targeting either thrombin (as with dabigatran) or factor Xa (as with rivaroxaban and apixaban).	Rivaroxaban	115-126	coagulation factor X	Homo sapiens	96-105
25964962-4	2014	Rivaroxaban, an oral factor Xa inhibitor anticoagulant, has been authorised for use following an acute coronary syndrome, but at a new dose strength of 2.5 mg, in combination with aspirin alone or aspirin plus clopidogrel.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	21-30
27526542-1	2014	The aim of this study was to examine the effects of NOACs (dabigatran, rivaroxaban, and apixaban) on the thrombin generation assay (TGA) in vivo.	Rivaroxaban	71-82	coagulation factor II, thrombin	Homo sapiens	105-113
27526542-3	2014	As a result, rivaroxaban and apixaban, which are direct Xa inhibitors, significantly decreased thrombin generation after administration within four to six hours.	Rivaroxaban	13-24	coagulation factor II, thrombin	Homo sapiens	95-103
27526542-5	2014	Also, with rivaroxaban, although there were milder effects as compared with apixaban, thrombin production was significantly decreased after administration within 24 hours.	Rivaroxaban	11-22	coagulation factor II, thrombin	Homo sapiens	86-94
25179681-2	2014	On the basis of the X-ray crystal structure of FXa and its inhibitor rivaroxaban, we designed and synthesized a series of conformationally restricted mimics containing a novel [6,6,5] tricyclic fused oxazolidinone scaffold.	Rivaroxaban	69-80	coagulation factor X	Homo sapiens	47-50
22487774-5	2014	Current data suggest that the oral direct factor Xa inhibitor rivaroxaban is a safe and effective alternative to warfarin.	Rivaroxaban	62-73	coagulation factor X	Homo sapiens	42-51
24880102-1	2014	Target-specific oral anticoagulants (TSOACs) provide safe and effective anticoagulation for the prevention and treatment of thrombosis in a variety of clinical settings by interfering with the activity of thrombin (dabigatran) or factor Xa (rivaroxaban, apixaban, edoxaban, betrixaban).	Rivaroxaban	241-252	coagulation factor X	Homo sapiens	230-239
25017622-3	2014	The ATLAS ACS 2-TIMI 51 trial demonstrated that rivaroxaban (2.5 mg twice daily) significantly reduced recurrent vascular events, increased the risk of major bleeding but not the risk of fatal bleeding, and resulted in reduced rates of death from cardiovascular causes.	Rivaroxaban	48-59	acyl-CoA synthetase long chain family member 5	Homo sapiens	10-15
24931429-1	2014	BACKGROUND: The determination of rivaroxaban and apixaban from serum samples of patients may be beneficial in specific clinical situations when additional blood sampling for plasma and thus the determination of factor Xa activity is not feasible or results are not plausible.	Rivaroxaban	33-44	coagulation factor X	Homo sapiens	211-220
25178252-2	2014	To date, the direct Factor Xa inhibitor rivaroxaban is the most widely approved of the new agents.	Rivaroxaban	40-51	coagulation factor X	Homo sapiens	20-29
24811969-6	2014	In contrast, three-factor PCC reversed rivaroxaban-induced changes in thrombin generation more than four-factor PCC.	Rivaroxaban	39-50	crystallin gamma D	Homo sapiens	26-29
24811969-6	2014	In contrast, three-factor PCC reversed rivaroxaban-induced changes in thrombin generation more than four-factor PCC.	Rivaroxaban	39-50	coagulation factor II, thrombin	Homo sapiens	70-78
25040104-1	2014	Rivaroxaban is a direct factor Xa inhibitor approved for prevention of stroke, prevention and treatment of venous thromboembolism and secondary prevention of acute coronary syndrome in many countries.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	24-33
25298850-4	2014	The newer agents include direct thrombin inhibitors, like dabigatran, and factor Xa inhibitors, like rivaroxaban and apixaban.	Rivaroxaban	101-112	coagulation factor X	Homo sapiens	32-83
25074401-11	2014	Herbal products and various drugs may increase rivaroxaban levels by inhibiting P-glycoprotein and cytochrome P450 3A4 activity.	Rivaroxaban	47-58	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	99-118
24984746-1	2014	BACKGROUND AND PURPOSE: This study aimed to assess the risk and benefit of tissue-type plasminogen activator treatment after oral anticoagulation with rivaroxaban or apixaban compared with warfarin or placebo.	Rivaroxaban	151-162	plasminogen activator, tissue type	Rattus norvegicus	75-108
24668660-5	2014	Prothrombin time and prothrombinase-induced clotting time exhibited a near-linear relationship with rivaroxaban plasma concentration; inhibitory effects were observed through to 24 hours post-dose.	Rivaroxaban	100-111	coagulation factor II, thrombin	Homo sapiens	0-11
24681117-1	2014	BACKGROUND &amp; AIMS: Rivaroxaban is an oral direct factor Xa inhibitor that has been marketed worldwide since 2008 for the primary and secondary prevention and treatment of thromboembolic disorders.	Rivaroxaban	23-34	coagulation factor X	Homo sapiens	53-62
24984746-9	2014	Furthermore, activation of matrix metalloproteinase-9 in the ipsilateral warfarin-pretreated brain was greatly reduced in rivaroxaban- and apixaban-pretreated rats.	Rivaroxaban	122-133	matrix metallopeptidase 9	Rattus norvegicus	27-53
24984746-10	2014	CONCLUSIONS: This study shows a lower risk of intracerebral hemorrhage after tissue-type plasminogen activator treatment in rats with ischemic stroke that are pretreated with rivaroxaban and apixaban compared with pretreatment with warfarin.	Rivaroxaban	175-186	plasminogen activator, tissue type	Rattus norvegicus	77-110
24418940-10	2014	Rivaroxaban caused a significant increase in the clotting time for PT and aPTT as well as an increase in lag time (as measured by thrombin generation) in neonates when compared with adults.	Rivaroxaban	0-11	coagulation factor II, thrombin	Homo sapiens	130-138
25083135-2	2014	The Phase III ROCKET AF (Rivaroxaban Once-Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) trial showed that rivaroxaban, an oral, direct Factor Xa inhibitor, was noninferior to warfarin for the reduction of stroke or systemic embolism in patients with AF.	Rivaroxaban	25-36	coagulation factor X	Homo sapiens	60-69
25083135-2	2014	The Phase III ROCKET AF (Rivaroxaban Once-Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) trial showed that rivaroxaban, an oral, direct Factor Xa inhibitor, was noninferior to warfarin for the reduction of stroke or systemic embolism in patients with AF.	Rivaroxaban	202-213	coagulation factor X	Homo sapiens	60-69
25083135-2	2014	The Phase III ROCKET AF (Rivaroxaban Once-Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) trial showed that rivaroxaban, an oral, direct Factor Xa inhibitor, was noninferior to warfarin for the reduction of stroke or systemic embolism in patients with AF.	Rivaroxaban	202-213	coagulation factor X	Homo sapiens	231-240
24895454-0	2014	Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).	Rivaroxaban	23-34	coagulation factor X	Homo sapiens	162-171
24895454-2	2014	The oral factor Xa inhibitor rivaroxaban was noninferior to warfarin in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).	Rivaroxaban	29-40	coagulation factor X	Homo sapiens	9-18
24813326-0	2014	Intravenous thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke in a patient treated with rivaroxaban.	Rivaroxaban	123-134	chromosome 20 open reading frame 181	Homo sapiens	42-70
24768192-0	2014	Patient-reported compliance with thromboprophylaxis using an oral factor Xa inhibitor (rivaroxaban) following total hip and total knee arthroplasty.	Rivaroxaban	87-98	coagulation factor X	Homo sapiens	66-75
24768192-1	2014	This prospective study examines patient non-compliance (NC) for an oral factor Xa inhibitor (Rivaroxaban) when used as venous thromboembolic (VTE) prophylaxis following lower limb arthroplasty.	Rivaroxaban	93-104	coagulation factor X	Homo sapiens	72-81
24725815-1	2014	We report a case of a nonvalvular atrial fibrillation (NVAF) patient with acute cardioembolic stroke in whom rivaroxaban, an oral direct factor Xa inhibitor, reduced a smoke-like echo in the left atrium and resolved a thrombus in the left atrial appendage.	Rivaroxaban	109-120	coagulation factor X	Homo sapiens	137-146
24202701-3	2014	Here, we present a case of a consumptive coagulopathy due to a large venous malformation with a sustained correction of the fibrinogen depletion and associated bleeding tendency both with subcutaneous enoxaparin and with the oral factor Xa inhibitor rivaroxaban.	Rivaroxaban	250-261	fibrinogen beta chain	Homo sapiens	124-134
24202701-3	2014	Here, we present a case of a consumptive coagulopathy due to a large venous malformation with a sustained correction of the fibrinogen depletion and associated bleeding tendency both with subcutaneous enoxaparin and with the oral factor Xa inhibitor rivaroxaban.	Rivaroxaban	250-261	coagulation factor X	Homo sapiens	230-239
24766850-2	2014	OBJECTIVES: To compare the effects of rivaroxaban with those of melagatran and dabigatran on thrombin generation (TG) and tissue factor-induced hypercoagulability and to explore the possible involvement of the thrombin-thrombomodulin/activated protein C system.	Rivaroxaban	38-49	coagulation factor II, thrombin	Homo sapiens	93-101
24352511-0	2014	Thrombin generation using the calibrated automated thrombinoscope to assess reversibility of dabigatran and rivaroxaban.	Rivaroxaban	108-119	coagulation factor II, thrombin	Homo sapiens	0-8
24794785-1	2014	OBJECTIVES AND BACKGROUND: Rivaroxaban, an oral direct factor Xa-inhibitor was non-inferior to adjusted dose warfarin in the prevention of stroke and embolism among patients with atrial fibrillation (AF) in the ROCKET-AF trial and has been approved for stroke prevention in AF.	Rivaroxaban	27-38	coagulation factor X	Homo sapiens	55-64
24794785-5	2014	Coagulation tests 28 h after rivaroxaban-intake showed INR 2.26, PT 35%, aPTT 38.3 s and anti-Factor Xa-activity 2.00 U/ml.	Rivaroxaban	29-40	coagulation factor X	Homo sapiens	94-103
24987185-1	2014	Rivaroxaban is an oral anticoagulant agent that directly inhibits Factor Xa and interrupts both the intrinsic and extrinsic pathway of the coagulation cascade and is currently indicated for use in patients for atrial fibrillation and prophylaxis of deep venous thrombosis.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	66-75
24650612-0	2014	[Pharmacologic and clinical characteristics of direct inhibitors of factor Xa: rivaroxaban, apixaban, edoxaban and betrixaban].	Rivaroxaban	79-90	coagulation factor X	Homo sapiens	68-77
24650612-3	2014	Nowadays, four new inhibitors of factor Xa are used orally (rivaroxaban, apixaban, edoxaban, betrixaban), and they are at least as efficient as heparins and vitamin K antagonists.	Rivaroxaban	60-71	coagulation factor X	Homo sapiens	33-42
24650612-8	2014	Apixaban is another direct inhibitor of factor Xa used orally which is developed in the same indications as rivaroxaban.	Rivaroxaban	108-119	coagulation factor X	Homo sapiens	40-49
24582461-7	2014	RESULTS: Extended duration rivaroxaban resulted in higher treatment costs ($22,645 vs. $22,083) but yielded greater QALYs (16.167 vs. 16.134) as compared to placebo; corresponding to an ICER of $17,030/QALY gained.	Rivaroxaban	27-38	cAMP responsive element modulator	Homo sapiens	186-190
25096568-1	2014	The approval of the oral direct thrombin inhibitor dabigatranetexilat and the oral factor Xa inhibitors rivaroxaban and apixaban as thromboprophylaxis challenges the position of the vitamin K antagonists (VKA).	Rivaroxaban	104-115	coagulation factor X	Homo sapiens	83-92
24418940-4	2014	Rivaroxaban is the first oral, direct Factor Xa inhibitor available for the prevention of VTE in adults.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	38-47
24507871-0	2014	PROS1 mutations associated with protein S deficiency in Polish patients with residual vein obstruction on rivaroxaban therapy.	Rivaroxaban	106-117	protein S	Homo sapiens	0-5
24966680-7	2014	New orally active anticoagulant (NOAC) agents are specific inhibitors of activated factor Xa (FXa) (rivaroxaban and apixaban) or thrombin (dabigatran).	Rivaroxaban	100-111	coagulation factor X	Homo sapiens	83-92
24966680-7	2014	New orally active anticoagulant (NOAC) agents are specific inhibitors of activated factor Xa (FXa) (rivaroxaban and apixaban) or thrombin (dabigatran).	Rivaroxaban	100-111	coagulation factor X	Homo sapiens	94-97
24746010-4	2014	Rivaroxaban, a new oral factor Xa inhibitor, has been tried for this indication in the "Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects With Acute Coronary Syndrome ACS 2-Thrombolysis In Myocardial Infarction 51" (ATLAS ACS 2-TIMI 51) trial using a low dose regimen in an attempt to balance the adverse effects of bleeding related to chronic anticoagulation on background of dual antiplatelet therapy for ACS, and the beneficial effects on recurrent coronary ischemia.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	24-33
24746010-4	2014	Rivaroxaban, a new oral factor Xa inhibitor, has been tried for this indication in the "Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects With Acute Coronary Syndrome ACS 2-Thrombolysis In Myocardial Infarction 51" (ATLAS ACS 2-TIMI 51) trial using a low dose regimen in an attempt to balance the adverse effects of bleeding related to chronic anticoagulation on background of dual antiplatelet therapy for ACS, and the beneficial effects on recurrent coronary ischemia.	Rivaroxaban	0-11	acyl-CoA synthetase long chain family member 5	Homo sapiens	208-213
24338703-5	2014	Rivaroxaban, a FXa inhibitor, reduced the rates of ischemic events but increased major bleeding rates.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	15-18
24763930-1	2014	BACKGROUND AND PURPOSE: In Rivaroxaban Once Daily Oral Direct Factor Xa Inhibitor Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) trial, rivaroxaban was noninferior to dose-adjusted warfarin in preventing stroke or systemic embolism among patients with nonvalvular atrial fibrillation at moderate to high stroke risk.	Rivaroxaban	27-38	coagulation factor X	Homo sapiens	62-71
24861792-1	2014	The direct thrombin inhibitor, dabigatran, as well as the direct factor Xa inhibtors rivaroxaban, apixaban, and edoxaban, display pharmacodynamic features quite similar to low-molecular-weight heparins, with a time to peak level of 1-4 hours after oral administration, and a half-life between 5 and 14 hours.	Rivaroxaban	85-96	coagulation factor X	Homo sapiens	65-74
24306948-3	2014	Rivaroxaban is a direct competitive factor Xa inhibitor that is taken orally.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	36-45
24599439-10	2014	Novel oral anticoagulants that directly inhibit thrombin such as dabigatran or factor Xa, including rivaroxaban and apixaban have several potential advantages; however, due to limited data in the cancer population, the use of these newer oral anticoagulants is not currently recommended for patients with malignancy and VTE.	Rivaroxaban	100-111	coagulation factor II, thrombin	Homo sapiens	48-56
24529498-7	2014	In contrast, inhibition of endogenous thrombin potential (ETP) was strongly reversed by aPCC, with significant increases over baseline at low rivaroxaban concentrations.	Rivaroxaban	142-153	coagulation factor II, thrombin	Homo sapiens	38-46
24624928-10	2014	Blockade of the crosstalk between AGE-RAGE axis and coagulation system by rivaroxaban might be a novel therapeutic target for thromboembolic disorders in diabetes.	Rivaroxaban	74-85	long intergenic non-protein coding RNA 914	Homo sapiens	38-42
24711920-1	2014	Rivaroxaban is an oral factor Xa inhibitor used for stroke prevention in atrial fibrillation.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	23-32
24315894-0	2014	Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation).	Rivaroxaban	82-93	coagulation factor X	Homo sapiens	117-126
24315894-1	2014	OBJECTIVES: This study sought to report additional safety results from the ROCKET AF (Rivaroxaban Once-daily oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).	Rivaroxaban	86-97	coagulation factor X	Homo sapiens	121-130
24648742-1	2014	Rivaroxaban is a direct factor Xa inhibitor that is widely available to reduce the risk of stroke or systemic embolism in patients with nonvalvular atrial fibrillation and one or more risk factors for stroke.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	24-33
24711240-8	2014	Due to the high protein binding the direkt FXa-inhibitors rivaroxaban (Xarelto ) and apixaban (Eliquis ) can not be hemodialysed.	Rivaroxaban	58-69	coagulation factor X	Homo sapiens	43-46
24711240-8	2014	Due to the high protein binding the direkt FXa-inhibitors rivaroxaban (Xarelto ) and apixaban (Eliquis ) can not be hemodialysed.	Rivaroxaban	71-78	coagulation factor X	Homo sapiens	43-46
24893548-4	2014	The newest agents available to clinicians are the broad group of novel anticoagulants, such as direct thrombin and direct factor Xa inhibitors, including molecules such as dabigatran, rivaroxaban, apixaban and edoxaban.	Rivaroxaban	184-195	coagulation factor X	Homo sapiens	122-131
24452610-8	2014	However, in Rivaroxaban in Combination With Aspirin Alone or With Aspirin and a Thienopyridine in Patients With Acute Coronary Syndromes (ATLAS ACS 2 TIMI 51), fatal bleeding or fatal ICH did not increase with low-dose rivaroxaban added to low-dose acetylsalicylic acid-based standard care compared with standard care alone.	Rivaroxaban	12-23	acyl-CoA synthetase long chain family member 5	Homo sapiens	144-149
24734100-3	2014	Rivaroxaban is an oral factor Xa inhibitor, however its anticoagulation effects before or after administration of fibrinolytics in massive PE are still unknown.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	23-32
24624626-1	2014	The new direct oral anticoagulants directly targeting thrombin (factor IIa) or factor-Xa, are currently used for the treatment of deep venous thrombosis and pulmonary embolism (rivaroxaban, Xarelto) or for the prevention of systemic embolism in non-valvular atrial fibrillation (rivaroxaban; dabigatran, Pradaxa; Apixaban, Eliquis).	Rivaroxaban	177-188	coagulation factor II, thrombin	Homo sapiens	54-88
24624626-1	2014	The new direct oral anticoagulants directly targeting thrombin (factor IIa) or factor-Xa, are currently used for the treatment of deep venous thrombosis and pulmonary embolism (rivaroxaban, Xarelto) or for the prevention of systemic embolism in non-valvular atrial fibrillation (rivaroxaban; dabigatran, Pradaxa; Apixaban, Eliquis).	Rivaroxaban	190-197	coagulation factor II, thrombin	Homo sapiens	54-88
24624626-1	2014	The new direct oral anticoagulants directly targeting thrombin (factor IIa) or factor-Xa, are currently used for the treatment of deep venous thrombosis and pulmonary embolism (rivaroxaban, Xarelto) or for the prevention of systemic embolism in non-valvular atrial fibrillation (rivaroxaban; dabigatran, Pradaxa; Apixaban, Eliquis).	Rivaroxaban	279-290	coagulation factor II, thrombin	Homo sapiens	54-88
24218999-4	2014	This review discusses the mechanism of action, pharmacokinetics, and pharmacodynamics of one of these newer agents - the direct Factor Xa inhibitor rivaroxaban - and provides an overview of the results of phase III clinical studies.	Rivaroxaban	148-159	coagulation factor X	Homo sapiens	128-137
24218999-6	2014	Rivaroxaban, which has a rapid onset of action, targets free and clot-bound Factor Xa and Factor Xa in the prothrombinase complex.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	76-85
24218999-6	2014	Rivaroxaban, which has a rapid onset of action, targets free and clot-bound Factor Xa and Factor Xa in the prothrombinase complex.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	90-99
24430916-1	2014	Rivaroxaban (Xarelto( )), an oral direct factor Xa inhibitor, is approved for the initial treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as the prevention of recurrent DVT and PE.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	41-50
24430916-1	2014	Rivaroxaban (Xarelto( )), an oral direct factor Xa inhibitor, is approved for the initial treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as the prevention of recurrent DVT and PE.	Rivaroxaban	13-20	coagulation factor X	Homo sapiens	41-50
24381151-1	2014	Dabigatran, rivaroxaban, and apixaban are direct oral anticoagulants (DOAC) inhibiting thrombin or factor Xa and effectively preventing thromboembolic complications using fixed doses without need for laboratory-guided dose adjustment.	Rivaroxaban	12-23	coagulation factor II, thrombin	Homo sapiens	87-95
24381151-1	2014	Dabigatran, rivaroxaban, and apixaban are direct oral anticoagulants (DOAC) inhibiting thrombin or factor Xa and effectively preventing thromboembolic complications using fixed doses without need for laboratory-guided dose adjustment.	Rivaroxaban	12-23	coagulation factor X	Homo sapiens	99-108
24861799-4	2014	Recently, the addition of rivaroxaban, a low dose oral direct factor Xa inhibitor (2.5 mg twice daily), to DAPT (aspirin plus second-generation P2Y12 inhibitor) showed a significant reduction of cardiovascular and overall mortality in the major phase III clinical trial ATLAS ACS 2 TIMI 51.	Rivaroxaban	26-37	purinergic receptor P2Y12	Homo sapiens	144-149
24535922-2	2014	More recently, rivaroxaban at a low dosage of 2.5 mg twice daily, co-administered with aspirin alone or aspirin plus either clopidogrel or ticlopidine, was approved for use in the EU for patients with a recent acute coronary syndrome (ACS).	Rivaroxaban	15-26	acyl-CoA synthetase long chain family member 5	Homo sapiens	235-238
24535922-3	2014	The approval of rivaroxaban in ACS was primarily based on findings of the phase III ATLAS ACS 2-TIMI 51 trial, which showed that after a median of 13.1 months of treatment with rivaroxaban 2.5 mg twice daily (combined with aspirin or aspirin plus either clopidogrel or ticlopidine) there was a statistically significant reduction in the rate of the primary composite endpoint, which was death from cardiovascular causes, myocardial infarction or stroke, compared with placebo.	Rivaroxaban	16-27	acyl-CoA synthetase long chain family member 5	Homo sapiens	31-34
24535922-3	2014	The approval of rivaroxaban in ACS was primarily based on findings of the phase III ATLAS ACS 2-TIMI 51 trial, which showed that after a median of 13.1 months of treatment with rivaroxaban 2.5 mg twice daily (combined with aspirin or aspirin plus either clopidogrel or ticlopidine) there was a statistically significant reduction in the rate of the primary composite endpoint, which was death from cardiovascular causes, myocardial infarction or stroke, compared with placebo.	Rivaroxaban	16-27	acyl-CoA synthetase long chain family member 5	Homo sapiens	90-95
24535922-7	2014	In conclusion, results of the ATLAS ACS 2-TIMI 51 trial suggest a potentially important role for rivaroxaban 2.5 mg twice daily co-administered with aspirin alone or aspirin plus either clopidogrel or ticlopidine in patients with a recent ACS.	Rivaroxaban	97-108	acyl-CoA synthetase long chain family member 5	Homo sapiens	36-41
24535922-7	2014	In conclusion, results of the ATLAS ACS 2-TIMI 51 trial suggest a potentially important role for rivaroxaban 2.5 mg twice daily co-administered with aspirin alone or aspirin plus either clopidogrel or ticlopidine in patients with a recent ACS.	Rivaroxaban	97-108	acyl-CoA synthetase long chain family member 5	Homo sapiens	36-39
24591854-1	2014	The direct factor Xa inhibitor rivaroxaban was the first within the group of orally available direct factor Xa inhibitors to gain clinical approval for oral anticoagulation in patients with nonvalvular atrial fibrillation in 2011.	Rivaroxaban	31-42	coagulation factor X	Homo sapiens	11-20
24591854-1	2014	The direct factor Xa inhibitor rivaroxaban was the first within the group of orally available direct factor Xa inhibitors to gain clinical approval for oral anticoagulation in patients with nonvalvular atrial fibrillation in 2011.	Rivaroxaban	31-42	coagulation factor X	Homo sapiens	101-110
24591854-2	2014	The -xabans, as drugs from the group of oral direct factor Xa inhibitors are often referred to, comprise currently three drugs (apixaban, edoxaban, and rivaroxaban) with clinical approval for a variety of clinical indications that require oral anticoagulation therapy.	Rivaroxaban	152-163	coagulation factor X	Homo sapiens	52-61
24385535-1	2014	Target-specific oral anticoagulants (TSOACs) that directly inhibit thrombin (dabigatran) or factor Xa (rivaroxaban, apixaban) are effective and safe alternatives to vitamin K antagonists (VKAs) and low-molecular-weight heparin (LMWH).	Rivaroxaban	103-114	coagulation factor X	Homo sapiens	92-101
24154682-1	2014	BACKGROUND: The direct factor Xa inhibitor rivaroxaban is approved for venous thromboembolism (VTE) treatment in adults.	Rivaroxaban	43-54	coagulation factor X	Homo sapiens	23-32
24218999-0	2014	Pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor.	Rivaroxaban	41-54	coagulation factor X	Homo sapiens	70-79
25088126-2	2014	Recently, two new groups of novel oral anticoagulants- direct thrombin inhibitors (dabigatran) and factor Xa inhibitors (rivaroxaban, apixaban, edoxaban) have shown promising results in well conducted clinical trials in terms of efficacy, safety and convenience of usage.	Rivaroxaban	121-132	coagulation factor X	Homo sapiens	62-108
23912563-3	2014	The oral, direct Factor Xa inhibitor rivaroxaban has been approved in adult patients for several thromboembolic disorders, and its well-defined pharmacokinetic and pharmacodynamic characteristics and efficacy and safety profiles in adults warrant further investigation of this agent in the paediatric population.	Rivaroxaban	37-48	coagulation factor X	Homo sapiens	17-26
23999929-1	2014	Rivaroxaban is an oral, direct Factor Xa inhibitor that targets free and clot-bound Factor Xa and Factor Xa in the prothrombinase complex.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	31-40
23999929-1	2014	Rivaroxaban is an oral, direct Factor Xa inhibitor that targets free and clot-bound Factor Xa and Factor Xa in the prothrombinase complex.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	84-93
23999929-1	2014	Rivaroxaban is an oral, direct Factor Xa inhibitor that targets free and clot-bound Factor Xa and Factor Xa in the prothrombinase complex.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	84-93
24696784-1	2014	Rivaroxaban is an oral, direct Factor Xa inhibitor, approved for the prevention and treatment of several thromboembolic disorders.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	31-40
24696784-5	2014	Rivaroxaban plasma concentrations can be assessed quantitatively using anti-Factor Xa chromogenic assays, or qualitatively using prothrombin time assays (using rivaroxaban-sensitive reagents).	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	76-85
24497951-1	2014	Dabigatran and rivaroxaban are novel oral anticoagulants that specifically inhibit thrombin and factor Xa, respectively.	Rivaroxaban	15-26	coagulation factor II, thrombin	Homo sapiens	83-91
24497951-1	2014	Dabigatran and rivaroxaban are novel oral anticoagulants that specifically inhibit thrombin and factor Xa, respectively.	Rivaroxaban	15-26	coagulation factor X	Homo sapiens	96-105
25136597-10	2014	Based on human clinical trial evidence, the 4-factor PCC (Kcentra) is suggested for patients with refractory rivaroxaban- or apixaban-associated hemorrhage.	Rivaroxaban	109-120	crystallin gamma D	Homo sapiens	53-56
25477972-5	2014	Seven days after the direct factor Xa inhibitor, rivaroxaban, was initiated, transthoracic echocardiography was repeated, revealing disappearance of the LV thrombus without any clinical signs of cardiogenic embolism.	Rivaroxaban	49-60	coagulation factor X	Homo sapiens	28-37
24451650-0	2014	Rivaroxaban in clinical practice for atrial fibrillation with special reference to prothrombin time.	Rivaroxaban	0-11	coagulation factor II, thrombin	Homo sapiens	83-94
24451650-1	2014	BACKGROUND:  Prothrombin time (PT) distribution in Japanese nonvalvular atrial fibrillation (NVAF) patients under rivaroxaban therapy remains to be clarified.	Rivaroxaban	114-125	coagulation factor II, thrombin	Homo sapiens	13-24
24241912-8	2014	Several studies show that administration of direct oral anticoagulants, like dabigatran and rivaroxaban, attenuate atherosclerosis development in ApoE(-/-) mice.	Rivaroxaban	92-103	apolipoprotein E	Mus musculus	146-150
23860880-2	2014	Novel anticoagulants including oral factor Xa inhibitors rivaroxaban and apixaban and the direct thrombin inhibitor dabigatran have emerged as important therapeutic treatment options for prevention of stroke in non-valvular atrial fibrillation.	Rivaroxaban	57-68	coagulation factor X	Homo sapiens	36-45
24293106-2	2014	Based on a half-life of 5-13 h, it is expected that the Factor Xa inhibitor rivaroxaban would be best suited to a twice-daily rather than a once-daily dose regimen.	Rivaroxaban	76-87	coagulation factor X	Homo sapiens	56-65
24338453-8	2013	These drugs focus directly on inhibiting either Factor Xa (rivaroxaban, apixaban, edoxaban) or thrombin (dabigatran).	Rivaroxaban	59-70	coagulation factor X	Homo sapiens	48-57
25494843-6	2014	Andexanet alfa (r-Antidote, PRT064445; Portola Pharmaceuticals) is a truncated form of enzymatically inactive factor Xa, which binds and reverses the anticoagulant action of the factor Xa inhibitors (e.g.: rivaroxaban, apixaban and edoxaban).	Rivaroxaban	206-217	coagulation factor X	Homo sapiens	110-119
25494843-6	2014	Andexanet alfa (r-Antidote, PRT064445; Portola Pharmaceuticals) is a truncated form of enzymatically inactive factor Xa, which binds and reverses the anticoagulant action of the factor Xa inhibitors (e.g.: rivaroxaban, apixaban and edoxaban).	Rivaroxaban	206-217	coagulation factor X	Homo sapiens	178-187
25215263-6	2014	Vitamin K antagonists (e.g., warfarin), direct thrombin inhibitors (dabigatran), and factor Xa inhibitors (rivaroxaban and apixaban) are all oral anticoagulants that have been FDA approved for the prevention of stroke in atrial fibrillation.	Rivaroxaban	107-118	coagulation factor X	Homo sapiens	85-94
24324436-2	2013	Rivaroxaban is an oral, direct factor Xa inhibitor that inhibits free and clot-bound factor Xa and factor Xa in the prothrombinase complex.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	31-40
24136072-6	2013	Both APPRAISE-2 and ATLAS ACS 2-TIMI 51 trials confirm a dose-dependent increase in major bleeding events, including intracranial, with apixaban and rivaroxaban when combined with DAPT.	Rivaroxaban	149-160	acyl-CoA synthetase long chain family member 5	Homo sapiens	26-31
24324436-2	2013	Rivaroxaban is an oral, direct factor Xa inhibitor that inhibits free and clot-bound factor Xa and factor Xa in the prothrombinase complex.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	74-108
24324436-6	2013	The pharmacodynamic effects of rivaroxaban (for example, inhibition of factor Xa and prolongation of prothrombin time) were closely correlated with rivaroxaban concentrations in plasma.	Rivaroxaban	31-42	coagulation factor X	Homo sapiens	71-80
24259602-6	2013	Phase I DDI studies have reported pharmacokinetic DDIs mediated by P-gp alone (dabigatran etexilate) or in combination with CYP3A4 enzymes (rivaroxaban and apixaban).	Rivaroxaban	140-151	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	124-130
24259602-9	2013	DDI studies involving rifampicin suggest that rivaroxaban and apixaban should be avoided when strong inducers of P-gp and CYP3A4 are used concurrently.	Rivaroxaban	46-57	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	122-128
23650254-1	2013	Novel oral anticoagulants (NOAs) which directly inhibit thrombin (dabigatran) or factor Xa (rivaroxaban and apixaban) have recently been developed.	Rivaroxaban	92-103	coagulation factor X	Homo sapiens	81-90
23463187-0	2013	Tissue factor-mediated activation of the prothrombin complex concentrate (PCC) is differently inhibited by dabigatran, rivaroxaban, and apixaban: potential clinical implication.	Rivaroxaban	119-130	coagulation factor III, tissue factor	Homo sapiens	0-13
24100724-9	2013	The administration of coagulation factors (fresh frozen plasma, prothrombin complex concentrates or recombinant activated FVII) is more successful in reversing the activity of the upstream inhibitors of coagulation (rivaroxaban and apixaban) than dabigatran which is a direct thrombin inhibitor.	Rivaroxaban	216-227	coagulation factor II, thrombin	Homo sapiens	67-75
23417780-1	2013	Rivaroxaban is a direct factor Xa inhibitor, which is rapidly absorbed in the upper gastrointestinal (GI) tract.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	24-33
22987320-10	2013	Positive results of the Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis in Myocardial Infarction 51 (ATLAS ACS 2-TIMI 51) trial of rivaroxaban in ACS are also encouraging.	Rivaroxaban	216-227	acyl-CoA synthetase long chain family member 5	Homo sapiens	192-197
22987320-10	2013	Positive results of the Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis in Myocardial Infarction 51 (ATLAS ACS 2-TIMI 51) trial of rivaroxaban in ACS are also encouraging.	Rivaroxaban	216-227	acyl-CoA synthetase long chain family member 5	Homo sapiens	192-195
23712587-5	2013	Rivaroxaban has a short half-life, undergoes a dual mode of elimination (hepatic and renal), and is a substrate for P-glycoprotein.	Rivaroxaban	0-11	ATP binding cassette subfamily B member 1	Homo sapiens	116-130
24171796-2	2013	These include the direct thrombin inhibitor dabigatran and the factor Xa inhibitors rivaroxaban, apixaban, and edoxaban.	Rivaroxaban	84-95	coagulation factor X	Homo sapiens	63-72
24150953-1	2013	Rivaroxaban is an oral highly selective direct factor Xa inhibitor.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	47-56
23663291-5	2013	These results were compared with those obtained with rivaroxaban, a new oral anticoagulant known to be a P-gp substrate.	Rivaroxaban	53-64	phosphoglycolate phosphatase	Homo sapiens	105-109
24041930-10	2013	Rivaroxaban and GB83 prevented upregulation of PARs, ICAM-1, LOX-1, IL-8, and activation of MAP kinases.	Rivaroxaban	0-11	intercellular adhesion molecule 1	Homo sapiens	53-59
24041930-10	2013	Rivaroxaban and GB83 prevented upregulation of PARs, ICAM-1, LOX-1, IL-8, and activation of MAP kinases.	Rivaroxaban	0-11	oxidized low density lipoprotein receptor 1	Homo sapiens	61-66
24041930-10	2013	Rivaroxaban and GB83 prevented upregulation of PARs, ICAM-1, LOX-1, IL-8, and activation of MAP kinases.	Rivaroxaban	0-11	C-X-C motif chemokine ligand 8	Homo sapiens	68-72
24041930-11	2013	The elevation in the expression of PAI-1 was hindered in the presence of SCH79797, or Rivaroxaban.	Rivaroxaban	86-97	serpin family E member 1	Homo sapiens	35-40
24041930-14	2013	Rivaroxaban prevented effectively FXa-induced molecular effects in human atrial tissue particularly during rapid pacing.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	34-37
23663291-11	2013	The efflux of rivaroxaban was strongly inhibited by the two P-gp inhibitors.	Rivaroxaban	14-25	phosphoglycolate phosphatase	Homo sapiens	60-64
24030117-0	2013	Management of disseminated intravascular coagulopathy with direct factor Xa inhibitor rivaroxaban in Klippel-Trenaunay syndrome.	Rivaroxaban	86-97	coagulation factor X	Homo sapiens	66-75
24022544-5	2013	Dual pathway regimens that combine antiplatelets (aspirin and a thienopyridine), along with an anticoagulant such as rivaroxaban may prove to be a therapeutic option in patients with ACS.	Rivaroxaban	117-128	1-aminocyclopropane-1-carboxylate synthase homolog (inactive)	Homo sapiens	183-186
23540535-1	2013	Apixaban and rivaroxaban are oral direct factor Xa (FXa) inhibitors used for VTE prevention after total hip (THA) and total knee arthroplasty (TKA).	Rivaroxaban	13-24	coagulation factor X	Homo sapiens	41-50
23540535-1	2013	Apixaban and rivaroxaban are oral direct factor Xa (FXa) inhibitors used for VTE prevention after total hip (THA) and total knee arthroplasty (TKA).	Rivaroxaban	13-24	coagulation factor X	Homo sapiens	52-55
23711804-0	2013	Comparison of the efficacy and safety of two rivaroxaban doses in acute coronary syndrome (from ATLAS ACS 2-TIMI 51).	Rivaroxaban	45-56	acyl-CoA synthetase long chain family member 5	Homo sapiens	102-107
23663291-0	2013	Role of P-glycoprotein in the uptake/efflux transport of oral vitamin K antagonists and rivaroxaban through the Caco-2 cell model.	Rivaroxaban	88-99	ATP binding cassette subfamily B member 1	Homo sapiens	8-22
23846019-1	2013	Rivaroxaban, an oral, direct factor Xa inhibitor, has been approved for the treatment of deep-vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE as a fixed-dose, single-drug regimen that does not require initial heparinisation, routine coagulation monitoring or dose adjustment.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	29-38
23846172-2	2013	Prothrombin time (PT) or chromogenic anti-Xa assays such as the Biophen Direct Factor Xa Inhibitor  (DiXaI) have been proposed to estimate rivaroxaban concentrations but are mainly based on in vitro studies.	Rivaroxaban	139-150	coagulation factor II, thrombin	Homo sapiens	0-11
23746003-3	2013	Among these agents, rivaroxaban, a direct Factor Xa inhibitor, has been approved for clinical use in many countries for the management of several thromboembolic disorders.	Rivaroxaban	20-31	coagulation factor X	Homo sapiens	42-51
23305158-1	2013	AIMS: The anticoagulant rivaroxaban is an oral, direct Factor Xa inhibitor for the management of thromboembolic disorders.	Rivaroxaban	24-35	coagulation factor X	Homo sapiens	55-64
23305158-3	2013	METHODS: The pharmacokinetic effects of substrates or inhibitors of CYP3A4, P-gp and Bcrp (ABCG2) on rivaroxaban were studied in healthy volunteers.	Rivaroxaban	101-112	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	68-74
23305158-3	2013	METHODS: The pharmacokinetic effects of substrates or inhibitors of CYP3A4, P-gp and Bcrp (ABCG2) on rivaroxaban were studied in healthy volunteers.	Rivaroxaban	101-112	ATP binding cassette subfamily B member 1	Homo sapiens	76-80
23305158-3	2013	METHODS: The pharmacokinetic effects of substrates or inhibitors of CYP3A4, P-gp and Bcrp (ABCG2) on rivaroxaban were studied in healthy volunteers.	Rivaroxaban	101-112	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	85-89
23305158-3	2013	METHODS: The pharmacokinetic effects of substrates or inhibitors of CYP3A4, P-gp and Bcrp (ABCG2) on rivaroxaban were studied in healthy volunteers.	Rivaroxaban	101-112	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	91-96
23305158-7	2013	A significant increase in rivaroxaban exposure was demonstrated with the strong CYP3A4, P-gp/Bcrp (ABCG2) inhibitors (and potential CYP2J2 inhibitors) ketoconazole (158% increase [95% CI 136%, 182%] for a 400 mg once daily dose) and ritonavir (153% increase [95% CI 134%, 174%]).	Rivaroxaban	26-37	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	80-86
23305158-7	2013	A significant increase in rivaroxaban exposure was demonstrated with the strong CYP3A4, P-gp/Bcrp (ABCG2) inhibitors (and potential CYP2J2 inhibitors) ketoconazole (158% increase [95% CI 136%, 182%] for a 400 mg once daily dose) and ritonavir (153% increase [95% CI 134%, 174%]).	Rivaroxaban	26-37	ATP binding cassette subfamily B member 1	Homo sapiens	88-92
23305158-7	2013	A significant increase in rivaroxaban exposure was demonstrated with the strong CYP3A4, P-gp/Bcrp (ABCG2) inhibitors (and potential CYP2J2 inhibitors) ketoconazole (158% increase [95% CI 136%, 182%] for a 400 mg once daily dose) and ritonavir (153% increase [95% CI 134%, 174%]).	Rivaroxaban	26-37	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	93-97
23305158-7	2013	A significant increase in rivaroxaban exposure was demonstrated with the strong CYP3A4, P-gp/Bcrp (ABCG2) inhibitors (and potential CYP2J2 inhibitors) ketoconazole (158% increase [95% CI 136%, 182%] for a 400 mg once daily dose) and ritonavir (153% increase [95% CI 134%, 174%]).	Rivaroxaban	26-37	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	99-104
23305158-7	2013	A significant increase in rivaroxaban exposure was demonstrated with the strong CYP3A4, P-gp/Bcrp (ABCG2) inhibitors (and potential CYP2J2 inhibitors) ketoconazole (158% increase [95% CI 136%, 182%] for a 400 mg once daily dose) and ritonavir (153% increase [95% CI 134%, 174%]).	Rivaroxaban	26-37	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	132-138
23305158-8	2013	CONCLUSIONS: Results suggest that rivaroxaban may be co-administered with CYP3A4 and/or P-gp substrates/moderate inhibitors, but not with strong combined CYP3A4, P-gp and Bcrp (ABCG2) inhibitors (mainly comprising azole-antimycotics, apart from fluconazole, and HIV protease inhibitors), which are multi-pathway inhibitors of rivaroxaban clearance and elimination.	Rivaroxaban	34-45	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	74-80
23305158-8	2013	CONCLUSIONS: Results suggest that rivaroxaban may be co-administered with CYP3A4 and/or P-gp substrates/moderate inhibitors, but not with strong combined CYP3A4, P-gp and Bcrp (ABCG2) inhibitors (mainly comprising azole-antimycotics, apart from fluconazole, and HIV protease inhibitors), which are multi-pathway inhibitors of rivaroxaban clearance and elimination.	Rivaroxaban	34-45	ATP binding cassette subfamily B member 1	Homo sapiens	88-92
23305158-8	2013	CONCLUSIONS: Results suggest that rivaroxaban may be co-administered with CYP3A4 and/or P-gp substrates/moderate inhibitors, but not with strong combined CYP3A4, P-gp and Bcrp (ABCG2) inhibitors (mainly comprising azole-antimycotics, apart from fluconazole, and HIV protease inhibitors), which are multi-pathway inhibitors of rivaroxaban clearance and elimination.	Rivaroxaban	34-45	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	177-182
23681109-9	2013	Rivaroxaban, apixaban and edoxaban are direct FXa inhibitors, whereas dabigtran etexilate is a direct thrombin inhibitor.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	46-49
23822763-2	2013	Based on the results of phase III clinical trials, rivaroxaban, a direct Factor Xa inhibitor, has been approved in many countries for the management of several thromboembolic disorders.	Rivaroxaban	51-62	coagulation factor X	Homo sapiens	73-82
23602776-0	2013	Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51.	Rivaroxaban	85-96	acyl-CoA synthetase long chain family member 5	Homo sapiens	106-111
23602776-1	2013	OBJECTIVES: The aim of this study was to determine if rivaroxaban is associated with a reduction in stent thrombosis among patients with acute coronary syndromes (ACS) in the ATLAS-ACS 2 TIMI 51 (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects With Acute Coronary Syndrome-Thrombolysis in Myocardial Infarction 51) trial.	Rivaroxaban	54-65	acyl-CoA synthetase long chain family member 5	Homo sapiens	163-166
23602776-1	2013	OBJECTIVES: The aim of this study was to determine if rivaroxaban is associated with a reduction in stent thrombosis among patients with acute coronary syndromes (ACS) in the ATLAS-ACS 2 TIMI 51 (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects With Acute Coronary Syndrome-Thrombolysis in Myocardial Infarction 51) trial.	Rivaroxaban	54-65	acyl-CoA synthetase long chain family member 5	Homo sapiens	181-186
23602776-8	2013	CONCLUSIONS: Among stented patients with ACS treated with DAPT, the administration of twice-daily rivaroxaban 2.5 mg was associated with a reduction in stent thrombosis and mortality.	Rivaroxaban	98-109	acyl-CoA synthetase long chain family member 5	Homo sapiens	41-44
23532364-4	2013	Other major advantages of oral direct thrombin inhibitors (dabigatran) and Xa inhibitors (rivaroxaban and apixaban) include rapid onset and offset of action and predictable pharmacodynamics with relatively wide therapeutic window allowing for unmonitored drug use.	Rivaroxaban	90-101	coagulation factor II, thrombin	Homo sapiens	38-46
27121789-1	2013	Rivaroxaban, an oral, direct factor Xa inhibitor, is currently used in clinical practice for the prevention and treatment of thromboembolic disorders.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	29-38
23294275-0	2013	Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor.	Rivaroxaban	94-105	coagulation factor X	Homo sapiens	123-132
27121789-6	2013	The results showed that rivaroxaban (10 mg) and enoxaparin (40 mg) had a similar and rapid onset of action, as indicated by the similar anti-factor Xa activity-time curves, suggesting that both drugs have a similar duration of pharmacological activity at the factor X site.	Rivaroxaban	24-35	coagulation factor X	Homo sapiens	141-150
23809871-2	2013	Rivaroxaban and apixaban directly inhibit Factor Xa, whereas dabigatran directly inhibits thrombin.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	42-51
23809871-9	2013	The anti-Factor Xa chromogenic assays now available are likely to provide the most appropriate means of determining plasma concentrations of rivaroxaban and apixaban, and specific assays for dabigatran are in development.	Rivaroxaban	141-152	coagulation factor X	Homo sapiens	9-18
23818798-5	2013	Three new oral anticoagulants, the direct thrombin inhibitor, dabigatran etexilate, and the factor Xa inhibitors, rivaroxaban and apixaban, have been approved in the US for reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation; rivaroxaban is also approved for prophylaxis and treatment of deep vein thrombosis, which may lead to pulmonary embolism in patients undergoing knee or hip replacement surgery.	Rivaroxaban	114-125	coagulation factor X	Homo sapiens	92-101
23818798-5	2013	Three new oral anticoagulants, the direct thrombin inhibitor, dabigatran etexilate, and the factor Xa inhibitors, rivaroxaban and apixaban, have been approved in the US for reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation; rivaroxaban is also approved for prophylaxis and treatment of deep vein thrombosis, which may lead to pulmonary embolism in patients undergoing knee or hip replacement surgery.	Rivaroxaban	273-284	coagulation factor X	Homo sapiens	92-101
23778903-1	2013	BACKGROUND: In ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation), a large randomized, clinical trial, rivaroxaban was noninferior to warfarin in preventing stroke or systemic embolism in patients with atrial fibrillation.	Rivaroxaban	26-37	coagulation factor X	Homo sapiens	63-72
23778903-1	2013	BACKGROUND: In ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation), a large randomized, clinical trial, rivaroxaban was noninferior to warfarin in preventing stroke or systemic embolism in patients with atrial fibrillation.	Rivaroxaban	224-235	coagulation factor X	Homo sapiens	63-72
23953905-1	2013	The direct thrombin inhibitor, dabigatran, and the selective factor Xa inhibitors, rivaroxaban and apixaban, are new oral anticoagulants that are approved in many countries for prevention of venous thromboembolism in patients undergoing elective hip or knee arthroplasty.	Rivaroxaban	83-94	coagulation factor X	Homo sapiens	61-70
22952215-2	2013	Novel anticoagulants, such as dabigatran etexilate, a direct thrombin inhibitor, and rivaroxaban, a direct factor Xa inhibitor, have been approved by the US Food and Drug Administration for the prevention of stroke and systemic embolism in patients with nonvalvular AF.	Rivaroxaban	85-96	coagulation factor X	Homo sapiens	107-116
23644213-3	2013	These compounds resulted from our efforts to merge the pharmacophores of selective factor Xa inhibitor rivaroxaban with a mimic of the Arg-Gly-Asp (RGD) sequence of fibrinogen to obtain designed multiple ligands with potential antithrombotic activity.	Rivaroxaban	103-114	coagulation factor X	Homo sapiens	83-92
23500262-2	2013	BACKGROUND: In ATLAS ACS-2-TIMI-51 (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction-51), rivaroxaban reduced cardiovascular events across the spectrum of acute coronary syndrome (ACS).	Rivaroxaban	199-210	acyl-CoA synthetase long chain family member 5	Homo sapiens	21-26
23578206-0	2013	In vitro assessment, using thrombin generation, of the applicability of prothrombin complex concentrate as an antidote for Rivaroxaban.	Rivaroxaban	123-134	coagulation factor II, thrombin	Homo sapiens	72-83
23578206-3	2013	OBJECTIVES: In the present study, we have evaluated the influence of prothrombin complex concentrate (PCC) on the anticoagulant effects of Rivaroxaban as measured by prothrombin time (PT) and thrombin generation tests (TGTs).	Rivaroxaban	139-150	coagulation factor II, thrombin	Homo sapiens	69-80
23578206-3	2013	OBJECTIVES: In the present study, we have evaluated the influence of prothrombin complex concentrate (PCC) on the anticoagulant effects of Rivaroxaban as measured by prothrombin time (PT) and thrombin generation tests (TGTs).	Rivaroxaban	139-150	coagulation factor II, thrombin	Homo sapiens	72-80
23640529-6	2013	The activity of oral factor Xa inhibitors (i.e., rivaroxaban and apixaban) is higher up the common pathway of the coagulation cascade and thus may be easier to reverse than that of direct thrombin inhibitors.	Rivaroxaban	49-60	coagulation factor II, thrombin	Homo sapiens	188-196
23068568-7	2013	Moreover, the incomplete CV follow-up in the ATLAS ACS 2 trial was later revealed to be around 12%, which lead to the rejection of rivaroxaban for the treatment of ACS.	Rivaroxaban	131-142	acyl-CoA synthetase long chain family member 5	Homo sapiens	51-56
23677801-1	2013	Rivaroxaban (Xarelto( )), a direct factor Xa inhibitor, is approved for the prevention of stroke and systemic embolism in patients with atrial fibrillation (AF) in Canada or those with nonvalvular AF (NVAF) in the EU, US and Japan.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	35-44
23677801-1	2013	Rivaroxaban (Xarelto( )), a direct factor Xa inhibitor, is approved for the prevention of stroke and systemic embolism in patients with atrial fibrillation (AF) in Canada or those with nonvalvular AF (NVAF) in the EU, US and Japan.	Rivaroxaban	13-20	coagulation factor X	Homo sapiens	35-44
23412293-1	2013	INTRODUCTION: Rivaroxaban is the first licensed oral direct inhibitor of factor Xa.	Rivaroxaban	14-25	coagulation factor X	Homo sapiens	73-82
23544968-11	2013	Rivaroxaban, a new oral factor Xa inhibitor, in a low-dose regimen-reduced ischemic events including mortality across a broad ACS population in the ATLAS-ACS trial with increased bleeding but without increasing fatal bleeding.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	24-33
23414291-3	2013	Rivaroxaban (Xarelto ) is an oral Factor Xa inhibitor approved in many countries for long-term treatment of patients with atrial fibrillation or venous thromboembolism.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	34-43
23389892-0	2013	Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment.	Rivaroxaban	64-75	coagulation factor X	Homo sapiens	43-52
23389892-4	2013	In subjects with moderately impaired liver function (i.e. Child-Pugh classification B), the area under the plasma concentration-time curve (AUC) of rivaroxaban (10 mg single dose) is increased by 2.27-fold, which is paralleled by an increase in FXa inhibition.	Rivaroxaban	148-159	coagulation factor X	Homo sapiens	245-248
23414291-3	2013	Rivaroxaban (Xarelto ) is an oral Factor Xa inhibitor approved in many countries for long-term treatment of patients with atrial fibrillation or venous thromboembolism.	Rivaroxaban	13-20	coagulation factor X	Homo sapiens	34-43
23518332-4	2013	New oral anticoagulants, such as the direct thrombin inhibitor dabigatran and the factor Xa inhibitor rivaroxaban, have been approved recently; however, intracerebral haemorrhage during dabigatran or rivaroxaban anticoagulation has not been characterised, and whether anticoagulation reversal can be beneficial in this scenario is unknown.	Rivaroxaban	102-113	coagulation factor X	Homo sapiens	82-91
23389753-1	2013	Novel oral anticoagulants (NOACs) that directly inhibit thrombin (dabigatran) or factor Xa (rivaroxaban, apixaban, edoxaban) are effective therapies for the prevention and treatment of thromboembolism with reduced bleeding complications compared with warfarin for some indications.	Rivaroxaban	92-103	coagulation factor X	Homo sapiens	81-90
23455714-5	2013	In rabbits treated with the direct fXa inhibitor rivaroxaban, r-Antidote restored hemostasis in a liver laceration model.	Rivaroxaban	49-60	coagulation factor X	Homo sapiens	35-38
23514988-10	2013	New oral anticoagulants targeting thrombin (dabigatran) or factor Xa (rivaroxaban, apixaban and edoxaban) may replace warfarin in many patients with atrial fibrillation due to convincing data both on efficacy and safety as well as convenience.	Rivaroxaban	70-81	coagulation factor X	Homo sapiens	59-68
23514989-3	2013	These agents, which include the direct thrombin inhibitor dabigatran etexilate and the Factor Xa inhibitors rivaroxaban and idrabiotaparinux are free from many of the limitations of VKAs.	Rivaroxaban	108-119	coagulation factor X	Homo sapiens	87-96
22958812-8	2013	Interestingly, rivaroxaban brain-to-plasma ratio did not differ in mice lacking only Mdr1a or Bcrp, but more than two times higher in the Mdr1a/Mdr1b(-/-)/Bcrp(-/-) mice.	Rivaroxaban	15-26	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	144-149
22958812-8	2013	Interestingly, rivaroxaban brain-to-plasma ratio did not differ in mice lacking only Mdr1a or Bcrp, but more than two times higher in the Mdr1a/Mdr1b(-/-)/Bcrp(-/-) mice.	Rivaroxaban	15-26	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	155-159
22958812-9	2013	Rivaroxaban is a shared substrate of MDR1 and BCRP.	Rivaroxaban	0-11	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	37-41
22958812-9	2013	Rivaroxaban is a shared substrate of MDR1 and BCRP.	Rivaroxaban	0-11	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	46-50
22958812-10	2013	In vivo, MDR and BCRP function synergistically to modulate rivaroxaban disposition and appear to be particularly relevant to limiting its central nervous system entry.	Rivaroxaban	59-70	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	17-21
22958812-11	2013	These data have important implications for safety and efficacy of anticoagulation therapy with rivaroxaban as many drugs in clinical use are known MDR1 inhibitors and loss-of-function polymorphisms in BCRP are common.	Rivaroxaban	95-106	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	147-151
22958812-11	2013	These data have important implications for safety and efficacy of anticoagulation therapy with rivaroxaban as many drugs in clinical use are known MDR1 inhibitors and loss-of-function polymorphisms in BCRP are common.	Rivaroxaban	95-106	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	201-205
23381840-0	2013	The influence of age and gender on the pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct Factor Xa inhibitor.	Rivaroxaban	80-91	coagulation factor X	Homo sapiens	109-118
23381840-1	2013	A randomized, single-blind, placebo-controlled, parallel-group study was conducted to assess the effect of age and gender on the pharmacokinetics and pharmacodynamics of rivaroxaban - an oral, direct Factor Xa inhibitor.	Rivaroxaban	170-181	coagulation factor X	Homo sapiens	200-209
23397554-6	2013	Dabigatran, an oral thrombin inhibitor, and the factor Xa inhibitors, rivaroxaban and apixaban, have demonstrated efficacy for stroke prevention and a reduced risk of intracranial hemorrhage relative to warfarin.	Rivaroxaban	70-81	coagulation factor X	Homo sapiens	48-57
23313382-9	2013	Rivaroxaban added to plasma or WB before clotting, in reducing thrombin generation, led to the formation of a looser clot that is more degradable by fibrinolytic enzymes.	Rivaroxaban	0-11	coagulation factor II, thrombin	Homo sapiens	63-71
24382036-7	2013	Use of carbamazepine, a CYP3A4 inducer, probably led to an increased clearance of rivaroxaban resulting in pulmonary embolisms.	Rivaroxaban	82-93	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	24-30
22958812-0	2013	Absence of both MDR1 (ABCB1) and breast cancer resistance protein (ABCG2) transporters significantly alters rivaroxaban disposition and central nervous system entry.	Rivaroxaban	108-119	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	16-20
22958812-0	2013	Absence of both MDR1 (ABCB1) and breast cancer resistance protein (ABCG2) transporters significantly alters rivaroxaban disposition and central nervous system entry.	Rivaroxaban	108-119	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	22-27
22958812-0	2013	Absence of both MDR1 (ABCB1) and breast cancer resistance protein (ABCG2) transporters significantly alters rivaroxaban disposition and central nervous system entry.	Rivaroxaban	108-119	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	33-65
22958812-0	2013	Absence of both MDR1 (ABCB1) and breast cancer resistance protein (ABCG2) transporters significantly alters rivaroxaban disposition and central nervous system entry.	Rivaroxaban	108-119	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	67-72
22958812-3	2013	As renal rivaroxaban clearance exceeds glomerular filtration rate, we suggested that active secretion by efflux transporters P-glycoprotein (MDR1) and breast cancer resistance protein (BCRP) contributes to rivaroxaban clearance.	Rivaroxaban	9-20	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	141-145
22958812-3	2013	As renal rivaroxaban clearance exceeds glomerular filtration rate, we suggested that active secretion by efflux transporters P-glycoprotein (MDR1) and breast cancer resistance protein (BCRP) contributes to rivaroxaban clearance.	Rivaroxaban	9-20	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	151-183
22958812-3	2013	As renal rivaroxaban clearance exceeds glomerular filtration rate, we suggested that active secretion by efflux transporters P-glycoprotein (MDR1) and breast cancer resistance protein (BCRP) contributes to rivaroxaban clearance.	Rivaroxaban	9-20	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	185-189
22958812-3	2013	As renal rivaroxaban clearance exceeds glomerular filtration rate, we suggested that active secretion by efflux transporters P-glycoprotein (MDR1) and breast cancer resistance protein (BCRP) contributes to rivaroxaban clearance.	Rivaroxaban	206-217	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	141-145
22958812-3	2013	As renal rivaroxaban clearance exceeds glomerular filtration rate, we suggested that active secretion by efflux transporters P-glycoprotein (MDR1) and breast cancer resistance protein (BCRP) contributes to rivaroxaban clearance.	Rivaroxaban	206-217	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	151-183
22958812-3	2013	As renal rivaroxaban clearance exceeds glomerular filtration rate, we suggested that active secretion by efflux transporters P-glycoprotein (MDR1) and breast cancer resistance protein (BCRP) contributes to rivaroxaban clearance.	Rivaroxaban	206-217	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	185-189
22958812-4	2013	The ability of MDR1 and BCRP efflux transporters to mediate rivaroxaban transport in vitro was assessed in polarized cell monolayers.	Rivaroxaban	60-71	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	15-19
22958812-4	2013	The ability of MDR1 and BCRP efflux transporters to mediate rivaroxaban transport in vitro was assessed in polarized cell monolayers.	Rivaroxaban	60-71	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	24-28
22958812-7	2013	However, rivaroxaban clearance was significantly reduced in Mdr1a/Mdr1b(-/-)/Bcrp(-/-) mice.	Rivaroxaban	9-20	ATP-binding cassette, sub-family B (MDR/TAP), member 1A	Mus musculus	60-65
22958812-7	2013	However, rivaroxaban clearance was significantly reduced in Mdr1a/Mdr1b(-/-)/Bcrp(-/-) mice.	Rivaroxaban	9-20	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	66-71
22958812-7	2013	However, rivaroxaban clearance was significantly reduced in Mdr1a/Mdr1b(-/-)/Bcrp(-/-) mice.	Rivaroxaban	9-20	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	77-81
22958812-8	2013	Interestingly, rivaroxaban brain-to-plasma ratio did not differ in mice lacking only Mdr1a or Bcrp, but more than two times higher in the Mdr1a/Mdr1b(-/-)/Bcrp(-/-) mice.	Rivaroxaban	15-26	ATP-binding cassette, sub-family B (MDR/TAP), member 1A	Mus musculus	138-143
23513780-6	2013	The direct thrombin inhibitor dabigatran and factor Xa inhibitors rivaroxaban and apixaban are new oral anticoagulants that are at least as efficacious and safe as VKA in non valvular AF.	Rivaroxaban	66-77	coagulation factor II, thrombin	Homo sapiens	11-19
23271455-1	2013	Rivaroxaban and dabigatran are new oral anticoagulants (NOACs) that inhibit directly factor Xa and thrombin, respectively.	Rivaroxaban	0-11	coagulation factor II, thrombin	Homo sapiens	99-107
23212720-2	2013	METHODS AND RESULTS: In ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation), 14 264 patients with nonvalvular AF and creatinine clearance &gt;=30 mL/min were randomized to rivaroxaban or dose-adjusted warfarin.	Rivaroxaban	35-46	coagulation factor X	Homo sapiens	72-81
23229461-1	2013	BACKGROUND: In the Japanese Rivaroxaban Once-daily oral direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation (J-ROCKET AF) study, rivaroxaban 15 mg once daily was given to patients with creatinine clearance (CrCl) &gt;= 50 ml/min (preserved renal function), and was reduced to 10mg once daily in patients with CrCl 30-49 ml/min (moderate renal impairment).	Rivaroxaban	28-39	coagulation factor X	Homo sapiens	63-72
23328267-0	2013	Rivaroxaban: an oral factor Xa inhibitor.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	21-30
23381840-5	2013	The area under the concentration-time curve (AUC) of rivaroxaban was 41% higher in elderly compared with young subjects; corresponding AUC values for the inhibition of Factor Xa activity and prolongation of prothrombin time were also higher.	Rivaroxaban	53-64	coagulation factor X	Homo sapiens	168-177
23292752-7	2013	FXa inhibitors, e.g. rivaroxaban and apixaban, are potent, oral direct inhibitors of prothrombinase-bound, clot-associated or free FXa.	Rivaroxaban	21-32	coagulation factor X	Homo sapiens	0-3
23292752-7	2013	FXa inhibitors, e.g. rivaroxaban and apixaban, are potent, oral direct inhibitors of prothrombinase-bound, clot-associated or free FXa.	Rivaroxaban	21-32	coagulation factor X	Homo sapiens	131-134
23292752-9	2013	Since both are substrates, co-administration of rivaroxaban and apixaban with strong cytochrome P450 (CYP) 3A4 and permeability glycoprotein (P-gp) inhibitors and inducers can result in substantial changes in plasma concentrations due to altered clearance rates; consequently, their concomitant use is contraindicated and caution is required when used concomitantly with strong CYP3A4 and P-gp inducers.	Rivaroxaban	48-59	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	378-384
23220847-1	2013	Novel oral anticoagulants that directly inhibit thrombin (dabigatran) or factor Xa (rivaroxaban, apixaban) are currently available for prevention of venous thromboembolism (VTE) after orthopaedic surgery, treatment of acute VTE, and prevention of arterial thromboembolism in non-valvular atrial fibrillation.	Rivaroxaban	84-95	coagulation factor X	Homo sapiens	73-82
23466964-7	2013	The CAT parameters that are related to the rate of thrombin generation during the propagation phase (ie, peak thrombin and Vmax) are more sensitive to activities of apixaban and rivaroxaban than dabigatran.	Rivaroxaban	178-189	coagulation factor II, thrombin	Homo sapiens	51-59
23466964-7	2013	The CAT parameters that are related to the rate of thrombin generation during the propagation phase (ie, peak thrombin and Vmax) are more sensitive to activities of apixaban and rivaroxaban than dabigatran.	Rivaroxaban	178-189	coagulation factor II, thrombin	Homo sapiens	110-118
23466965-10	2013	The activated factor X (factor Xa) inhibitor rivaroxaban was recently approved by the FDA both for prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism in patients undergoing knee or hip arthroplasty, and for reducing the risk of stroke and systemic embolism in patients with nonvalvular AF.	Rivaroxaban	45-56	coagulation factor X	Homo sapiens	14-33
23466968-2	2013	Recently, new oral anticoagulants (the direct thrombin inhibitor dabigatran and the direct activated factor X (factor Xa) inhibitors rivaroxaban and apixaban) have completed phase 3 clinical trials for the same indications.	Rivaroxaban	133-144	coagulation factor X	Homo sapiens	84-120
23335022-9	2013	Anti-Xa measurement and Hemoclot, a thrombin diluted clotting assay, are specific assays which have been proposed for rivaroxaban and dabigatran respectively.	Rivaroxaban	118-129	coagulation factor II, thrombin	Homo sapiens	36-44
24319220-1	2013	The availability of new oral anticoagulants (NOACs) targeting either thrombin (dabigatran etexilate) or factor Xa (rivaroxaban and apixaban) for the prevention and treatment of thrombosis has been highly anticipated.	Rivaroxaban	115-126	coagulation factor X	Homo sapiens	104-113
23391669-5	2013	The US Food and Drug Administration has approved a direct thrombin inhibitor (dabigatran) and 2 factor Xa inhibitors (rivaroxaban and apixaban) for stroke prevention in patients with nonvalvular AF.	Rivaroxaban	118-129	coagulation factor X	Homo sapiens	96-105
23631182-0	2013	[Factor Xa inhibitor (rivaroxaban and drugs under investigation)].	Rivaroxaban	22-33	coagulation factor X	Homo sapiens	1-10
23631182-1	2013	The first factor Xa inhibitor, rivaroxaban had been released on market, and apixaban and edoxaban are preparing for clinical use in patients with atrial fibrillation.	Rivaroxaban	31-42	coagulation factor X	Homo sapiens	10-19
24139508-1	2013	INTRODUCTION: Rivaroxaban is an oral direct factor Xa inhibitor that is noninferior to warfarin in the prevention of recurrent venous thromboembolism (VTE).	Rivaroxaban	14-25	coagulation factor X	Homo sapiens	44-53
24291856-1	2013	Novel oral anticoagulants (NOAC) such as the direct thrombin inhibitor, dabigatran, and oral factor Xa inhibitors, rivaroxaban and apixaban, have recently approved for prevention of stroke in nonvalvular atrial fibrillation (NVAF).	Rivaroxaban	115-126	coagulation factor X	Homo sapiens	93-102
23533746-4	2013	Rivaroxaban is one of the new oral anticoagulants and is a direct factor Xa inhibitor that has demonstrated superior efficacy to that of enoxaparin.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	66-75
23023369-1	2012	OBJECTIVE: Rivaroxaban is an oral anticoagulant that directly targets both free factor Xa and factor Xa in complex with its protein cofactor, factor Va, in the prothrombinase complex.	Rivaroxaban	11-22	coagulation factor X	Homo sapiens	70-103
23023369-1	2012	OBJECTIVE: Rivaroxaban is an oral anticoagulant that directly targets both free factor Xa and factor Xa in complex with its protein cofactor, factor Va, in the prothrombinase complex.	Rivaroxaban	11-22	coagulation factor X	Homo sapiens	160-174
23023369-3	2012	The purpose of this study was to determine the degree to which rivaroxaban, over a range of physiologically relevant free plasma concentrations, inhibits preassembled prothrombinase at a typical venous shear rate (100 s(-1)) and to determine the dynamics of rivaroxaban washout.	Rivaroxaban	63-74	coagulation factor X	Homo sapiens	167-181
23023369-6	2012	The degree of inactivation of preassembled prothrombinase is sensitive to the solution-phase rivaroxaban concentration; however, prothrombinase unmasking upon removal of rivaroxaban is concentration independent.	Rivaroxaban	93-104	coagulation factor X	Homo sapiens	43-57
23023369-6	2012	The degree of inactivation of preassembled prothrombinase is sensitive to the solution-phase rivaroxaban concentration; however, prothrombinase unmasking upon removal of rivaroxaban is concentration independent.	Rivaroxaban	170-181	coagulation factor X	Homo sapiens	129-143
23023369-7	2012	CONCLUSIONS: The model system presented suggests that when rivaroxaban plasma concentrations decrease after cessation of therapy, there will be an unmasking of thrombus-associated prothrombinase that may be related to the reported rebound phenomena.	Rivaroxaban	59-70	coagulation factor X	Homo sapiens	180-194
23122646-1	2012	Rivaroxaban is a direct oral anticoagulant targeting factor Xa.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	53-62
23083002-3	2012	OBJECTIVE: To study the antithrombotic effects of the FXa inhibitor rivaroxaban alone or in combination with DAT.	Rivaroxaban	68-79	coagulation factor X	Homo sapiens	54-57
23153406-4	2012	The direct thrombin inhibitor dabigatran etexilate and factor Xa inhibitors rivaroxaban and apixaban are new oral anticoagulants that are at least as efficacious and safe as warfarin.	Rivaroxaban	76-87	coagulation factor X	Homo sapiens	55-64
23109641-2	2012	In this analysis of pooled data from four large, randomised, phase III clinical trials that compared the oral, direct Factor Xa inhibitor rivaroxaban with subcutaneous enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement (n = 12,729), the incidence of complications, including bleeding and adverse events related to surgery (such as wound infection, wound dehiscence and haemarthrosis) are reported.	Rivaroxaban	138-149	coagulation factor X	Homo sapiens	118-127
23127435-0	2012	Rivaroxaban, an oral, direct factor Xa inhibitor: a new option for thromboprophylaxis.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	29-38
23272472-4	2012	The new oral anticoagulants (direct thrombin inhibitor [dabigatran], and direct factor Xa inhibitors [rivaroxaban and apixaban]) have all shown non inferiority or superiority, with better safety, considering the risk of intracranial haemorrhage.	Rivaroxaban	102-113	coagulation factor X	Homo sapiens	80-89
22884545-3	2012	Rivaroxaban is the first oral, direct Factor Xa inhibitor available for the prevention of venous thromboembolism in adults.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	38-47
23089710-0	2012	Measuring Rivaroxaban in a clinical laboratory setting, using common coagulation assays, Xa inhibition and thrombin generation.	Rivaroxaban	10-21	coagulation factor II, thrombin	Homo sapiens	107-115
23052711-2	2012	We hypothesised that anti-coagulation with rivaroxaban, a direct factor Xa inhibitor, would differentially modulate biologically-relevant plasma proteins, compared with warfarin, a multi-coagulation protein antagonist.	Rivaroxaban	43-54	coagulation factor X	Homo sapiens	65-74
23052711-5	2012	Compared with warfarin, rivaroxaban treatment was associated with a greater increase in thrombomodulin (Delta 0.1 vs. 0.3 pg/ml, p=0.0026) and a trend towards a reduction in matrix metalloproteinase-9 (Delta 2.2 vs. -4.9 pg/ml, p=0.0757) over 24 weeks.	Rivaroxaban	24-35	thrombomodulin	Homo sapiens	88-102
23052711-5	2012	Compared with warfarin, rivaroxaban treatment was associated with a greater increase in thrombomodulin (Delta 0.1 vs. 0.3 pg/ml, p=0.0026) and a trend towards a reduction in matrix metalloproteinase-9 (Delta 2.2 vs. -4.9 pg/ml, p=0.0757) over 24 weeks.	Rivaroxaban	24-35	matrix metallopeptidase 9	Homo sapiens	174-200
23052711-8	2012	The greater upregulation of thrombomodulin among patients randomised to rivaroxaban represents a proof-of-principle that pharmacoproteomics can be employed to discern novel effects of factor Xa inhibition beyond standard pharmacodynamic measures.	Rivaroxaban	72-83	thrombomodulin	Homo sapiens	28-42
23052711-8	2012	The greater upregulation of thrombomodulin among patients randomised to rivaroxaban represents a proof-of-principle that pharmacoproteomics can be employed to discern novel effects of factor Xa inhibition beyond standard pharmacodynamic measures.	Rivaroxaban	72-83	coagulation factor X	Homo sapiens	184-193
23014816-0	2012	Management consensus guidance for the use of rivaroxaban--an oral, direct factor Xa inhibitor.	Rivaroxaban	45-56	coagulation factor X	Homo sapiens	74-83
22821003-1	2012	Dabigatran and rivaroxaban are new oral inhibitors of the thrombin (F2a) and F10a, respectively.	Rivaroxaban	15-26	coagulation factor II, thrombin	Homo sapiens	58-66
22528328-6	2012	Rivaroxaban inhibited the activation of platelets induced by tissue factor and to a lesser extent activation induced by thrombin, effects that were accentuated when combined with cangrelor.	Rivaroxaban	0-11	coagulation factor II, thrombin	Homo sapiens	120-128
22528328-9	2012	In conclusion, rivaroxaban attenuated in vitro the activation of platelets mediated by thrombin.	Rivaroxaban	15-26	coagulation factor II, thrombin	Homo sapiens	87-95
23498067-7	2012	At present, a thrombin inhibitor (dabigatran) and two FXa inhibitors (rivaroxaban and apixaban) are available for prophylaxis in patients after total knee or total hip arthroplasty.	Rivaroxaban	70-81	coagulation factor X	Homo sapiens	54-57
22528328-10	2012	In light of the pivotal role of thrombin in platelet activation after rupture of an atherosclerotic plaque, rivaroxaban should attenuate platelet activation in vivo, an effect that is accentuated by combination with a P2Y12 antagonist.	Rivaroxaban	108-119	coagulation factor II, thrombin	Homo sapiens	32-40
22528328-10	2012	In light of the pivotal role of thrombin in platelet activation after rupture of an atherosclerotic plaque, rivaroxaban should attenuate platelet activation in vivo, an effect that is accentuated by combination with a P2Y12 antagonist.	Rivaroxaban	108-119	purinergic receptor P2Y12	Homo sapiens	218-223
23026659-2	2012	The factor Xa inhibitor, rivaroxaban, has shown promising results in the treatment of acute coronary syndrome but is not yet approved for that indication.	Rivaroxaban	25-36	coagulation factor X	Homo sapiens	4-13
23365716-2	2012	In addition to traditional agents such as vitamin K antagonists and heparins, newer oral agents - such as the factor Xa inhibitors rivaroxaban, apixaban, and edoxaban, and the direct thrombin inhibitor dabigatran - have been shown to be effective across several indications.	Rivaroxaban	131-142	coagulation factor X	Homo sapiens	110-119
23023509-7	2012	This article focuses on rivaroxaban, apixaban, and edoxaban, the oral factor Xa inhibitors in the most advanced stages of development.	Rivaroxaban	24-35	coagulation factor X	Homo sapiens	70-79
22651881-8	2012	The ICER for rivaroxaban was $27,498 per QALY.	Rivaroxaban	13-24	cAMP responsive element modulator	Homo sapiens	4-8
22575324-2	2012	BACKGROUND: Data for warfarin compared against the new oral anticoagulants (OACs) in large phase III clinical trials of stroke prevention in atrial fibrillation (AF) are now available for the oral direct thrombin inhibitor, dabigatran etexilate, in 2 doses (150 mg twice daily [BID], 110 mg BID), and the oral Factor Xa inhibitors, rivaroxaban and apixaban.	Rivaroxaban	332-343	coagulation factor II, thrombin	Homo sapiens	204-212
22370770-8	2012	Novel anticoagulants targeting inhibition of factor Xa and thrombin (factor IIa) have now been incorporated into clinical practice based on the results of large randomized clinical trials, with the recent U.S. Food and Drug Administration approval of dabigatran for stroke prevention in atrial fibrillation and rivaroxaban for deep vein thrombosis and stroke prevention in atrial fibrillation, with multiple other agents in various stages of development for these and other indications.	Rivaroxaban	311-322	coagulation factor X	Homo sapiens	45-54
22682643-6	2012	RESULTS: Rivaroxaban, an oral factor Xa inhibitor, is approved for once-daily use in treatment of nonvalvular atrial fibrillation and deep vein thrombosis prophylaxis after replacement of a hip or knee.	Rivaroxaban	9-20	coagulation factor X	Homo sapiens	30-39
22564122-5	2012	Direct thrombin inhibitor dabigatran and factor Xa inhibitors rivaroxaban and apixaban have proven, in large, multicenter, randomized, phase III, clinical studies, to be at least as efficient as warfarin in stroke prevention in patients with AF.	Rivaroxaban	62-73	coagulation factor X	Homo sapiens	41-50
22935021-6	2012	This review focuses on the mechanism, efficacy, safety profile and clinical trial evidence of P2 Y12 receptor antagonist antiplatelet agents, glycoprotein IIb/IIIa receptor inhibitors (GPI), protease-activated receptor-1 (PAR-1) inhibitors, thrombin inhibitor bivalirudin and Factor Xa inhibitors fondaparinaux and rivaroxaban.	Rivaroxaban	315-326	purinergic receptor P2Y12	Homo sapiens	94-100
23086101-5	2012	Apixaban, rivaroxaban, endoxaban, and betrixaban are specific direct inhibitors of factor Xa, while dabigatran inhibits factor IIa.	Rivaroxaban	10-21	coagulation factor X	Homo sapiens	83-92
22858920-2	2012	In recent randomized clinical trials (RCTs) oral direct thrombin inhibitor (Dabigatran) and factor Xa inhibitors (Rivaroxaban and Apixaban) challenged the efficacy and safety benchmarks set by warfarin.	Rivaroxaban	114-125	coagulation factor X	Homo sapiens	92-101
22627883-8	2012	Rivaroxaban affects quantitative and kinetic parameters, including the endogenous thrombin potential (ETP-AUC and more pronouncedly the thrombin peak), the lag-time and time to peak.	Rivaroxaban	0-11	coagulation factor II, thrombin	Homo sapiens	82-90
22627883-8	2012	Rivaroxaban affects quantitative and kinetic parameters, including the endogenous thrombin potential (ETP-AUC and more pronouncedly the thrombin peak), the lag-time and time to peak.	Rivaroxaban	0-11	coagulation factor II, thrombin	Homo sapiens	136-144
22828994-2	2012	New oral anticoagulants for the prevention of stroke in patients with nonvalvular atrial fibrillation have been available for a few months, among them the reversible direct thrombin inhibitor dabigatran and the factor Xa antagonist rivaroxaban.	Rivaroxaban	232-243	coagulation factor X	Homo sapiens	211-220
22541034-6	2012	The results from the only phase III study concluded with good results, the ATLAS-ACS 2 TIMI 51 study, conducted with rivaroxaban, are presented.	Rivaroxaban	117-128	acyl-CoA synthetase long chain family member 5	Homo sapiens	81-86
22871192-3	2012	Rivaroxaban, a direct orally available factor Xa inhibitor, is the first of a new class of drugs that target a central factor of the coagulation cascade upstream of thrombin.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	39-48
22871192-3	2012	Rivaroxaban, a direct orally available factor Xa inhibitor, is the first of a new class of drugs that target a central factor of the coagulation cascade upstream of thrombin.	Rivaroxaban	0-11	coagulation factor II, thrombin	Homo sapiens	165-173
22871192-6	2012	Very recently, rivaroxaban in addition to dual antiplatelet therapy, was shown to reduce mortality in patients with a recent acute coronary syndrome in the ATLAS ACS 2-TIMI 51 clinical trial.	Rivaroxaban	15-26	acyl-CoA synthetase long chain family member 5	Homo sapiens	162-167
28496748-7	2012	In addition, factor Xa inhibitors, such as rivaroxaban (recently approved by the Federal Drug Administration [FDA]) and apixaban, may exhibit the same cost savings as dabigatran in terms of reduction of bleeding and elimination of therapeutic level monitoring costs.	Rivaroxaban	43-54	coagulation factor X	Homo sapiens	13-22
21874549-0	2012	Spontaneous spinal epidural haematoma during Factor Xa inhibitor treatment (Rivaroxaban).	Rivaroxaban	76-87	coagulation factor X	Homo sapiens	45-54
23251773-6	2012	The oral direct thrombin inhibitor, dabigatran, and the oral factor Xa inhibitors, rivaroxaban and apixaban, have been evaluated in a large phase III trial.	Rivaroxaban	83-94	coagulation factor X	Homo sapiens	61-70
22577900-5	2012	Rivaroxaban , the first oral FXa inhibitor, acts by direct inhibition of FXa and does not require an antithrombin cofactor for its activity.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	29-32
22577900-5	2012	Rivaroxaban , the first oral FXa inhibitor, acts by direct inhibition of FXa and does not require an antithrombin cofactor for its activity.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	73-76
22577900-10	2012	EXPERT OPINION: The mortality benefit with low-dose rivaroxaban in ACS patients was first demonstrated in ATLAS ACS2 TIMI-51 trial.	Rivaroxaban	52-63	acyl-CoA synthetase long chain family member 5	Homo sapiens	112-116
22577900-11	2012	With its rapid oral bioavailability, predictable PK, low drug-drug interaction and no need for monitoring, the use of low-dose rivaroxaban in addition to dual antiplatelet therapy offers an appealing new option in improving outcomes following ACS in the modern era of novel oral FXa inhibitors.	Rivaroxaban	127-138	coagulation factor X	Homo sapiens	279-282
22534775-7	2012	However, the assay with the addition of exogenous antithrombin detected falsely high concentrations of rivaroxaban even in plasma samples from controls who had not taken rivaroxaban (intercept values using the high calibrator set and the low calibrator set: +26.49 ng/ml and +13.71 ng/ml, respectively).	Rivaroxaban	103-114	serpin family C member 1	Homo sapiens	50-62
22684583-2	2012	The oral direct thrombin inhibitors (e.g., dabigatran) and oral direct inhibitors of factor Xa (e.g., rivaroxaban, apixaban) have emerged recently as an alternative to VKAs for stroke prevention in AF.	Rivaroxaban	102-113	coagulation factor X	Homo sapiens	85-94
22595814-5	2012	Dabigatran etexilate, a direct thrombin inhibitor, was approved in 2010 for the reduction of stroke and systemic embolism in patients with nonvalvular AF, and the factor Xa inhibitor rivaroxaban was approved for a similar indication in 2011.	Rivaroxaban	183-194	coagulation factor X	Homo sapiens	163-172
22595815-3	2012	Specifically, agents targeting thrombin (dabigatran) and factor Xa (apixaban and rivaroxaban) have either reached late stages of clinical development (apixaban) or have received approval (dabigatran, rivaroxaban) by the US Food and Drug Administration for use in patients with nonvalvular AF.	Rivaroxaban	81-92	coagulation factor X	Homo sapiens	57-66
22595815-3	2012	Specifically, agents targeting thrombin (dabigatran) and factor Xa (apixaban and rivaroxaban) have either reached late stages of clinical development (apixaban) or have received approval (dabigatran, rivaroxaban) by the US Food and Drug Administration for use in patients with nonvalvular AF.	Rivaroxaban	200-211	coagulation factor II, thrombin	Homo sapiens	31-39
22655676-13	2012	EXPERT OPINION: A large body of Phase II and Phase III data is now available for FXa inhibitors such as rivaroxaban, apixaban, edoxaban and betrixaban.	Rivaroxaban	104-115	coagulation factor X	Homo sapiens	81-84
22539097-2	2012	Two novel oral anticoagulants, namely the direct thrombin inhibitor dabigatran and the direct factor Xa inhibitor rivaroxaban, have recently been approved for treatment of atrial fibrillation.	Rivaroxaban	114-125	coagulation factor X	Homo sapiens	94-103
22592953-4	2012	A number of new drugs for oral anticoagulation including direct factor Xa inhibitors, such as rivaroxaban and direct thrombin inhibitors, such as dabigatran have shown promising results, including higher efficacy and significantly lower incidences of intracranial bleeding compared with warfarin.	Rivaroxaban	94-105	coagulation factor X	Homo sapiens	64-73
22691670-0	2012	Rivaroxaban, an oral, direct factor Xa inhibitor: a new option for thromboprophylaxis.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	29-38
22371186-3	2012	Rivaroxaban is an oral, direct factor Xa inhibitor that has advantages over traditional VTE therapies, including minimal drug and food interactions and no requirement for routine coagulation monitoring.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	31-40
22495943-2	2012	Apixaban and rivaroxaban are direct inhibitors of Factor Xa, while dabigatran inhibits Factor IIa.	Rivaroxaban	13-24	coagulation factor X	Homo sapiens	50-59
22820359-4	2012	A new generation of anticoagulants are available, the direct thrombin inhibitors (dabigatran) and factor Xa inhibitors (rivaroxaban and apixaban), with obvious advantages over conventional anticoagulants.	Rivaroxaban	120-131	coagulation factor X	Homo sapiens	61-107
22398011-7	2012	Moreover, inhibition of factor Xa or thrombin with novel selective agents, including rivaroxaban and dabigatran, inhibits inflammation associated with atherosclerosis in apoE(-/-) mice.	Rivaroxaban	85-96	coagulation factor II	Mus musculus	37-45
22398011-7	2012	Moreover, inhibition of factor Xa or thrombin with novel selective agents, including rivaroxaban and dabigatran, inhibits inflammation associated with atherosclerosis in apoE(-/-) mice.	Rivaroxaban	85-96	apolipoprotein E	Mus musculus	170-174
22449293-1	2012	BACKGROUND: A fixed-dose regimen of rivaroxaban, an oral factor Xa inhibitor, has been shown to be as effective as standard anticoagulant therapy for the treatment of deep-vein thrombosis, without the need for laboratory monitoring.	Rivaroxaban	36-47	coagulation factor X	Homo sapiens	57-66
22270945-1	2012	BACKGROUND: Rivaroxaban is an oral Factor Xa inhibitor.	Rivaroxaban	12-23	coagulation factor X	Homo sapiens	35-44
22270945-2	2012	The primary objective of this communication was to quantitatively predict changes in rivaroxaban exposure when individuals with varying degrees of renal impairment are co-administered with another drug that is both a P-gp and a moderate CYP3A4 inhibitor.	Rivaroxaban	85-96	phosphoglycolate phosphatase	Homo sapiens	217-221
22270945-2	2012	The primary objective of this communication was to quantitatively predict changes in rivaroxaban exposure when individuals with varying degrees of renal impairment are co-administered with another drug that is both a P-gp and a moderate CYP3A4 inhibitor.	Rivaroxaban	85-96	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	237-243
22387577-0	2012	Evaluation of the prothrombin time for measuring rivaroxaban plasma concentrations using calibrators and controls: results of a multicenter field trial.	Rivaroxaban	49-60	coagulation factor II, thrombin	Homo sapiens	18-29
22387577-1	2012	This study evaluated the prothrombin time (PT) assay for the measurement of plasma concentrations of rivaroxaban using calibrators and controls.	Rivaroxaban	101-112	coagulation factor II, thrombin	Homo sapiens	25-36
22355190-6	2012	Novel oral anticoagulants, including the direct thrombin inhibitor dabigatran and direct Factor Xa inhibitors such as rivaroxaban, apixaban, and edoxaban, have now been approved or are currently in late-stage clinical development in AF.	Rivaroxaban	118-129	coagulation factor X	Homo sapiens	89-98
22371104-4	2012	Apixaban, betrixaban, edoxaban, and rivaroxaban are small-molecule, selective inhibitors that directly and reversibly bind to the active site of factor Xa.	Rivaroxaban	36-47	coagulation factor X	Homo sapiens	145-154
21840043-0	2012	Rivaroxaban: Quantification by anti-FXa assay and influence on coagulation tests: a study in 9 Swiss laboratories.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	36-39
24281379-4	2012	Rivaroxaban is an oral, direct Factor Xa inhibitor; in clinical practice, it is likely that rivaroxaban will be given to patients who also receive antiplatelet therapy, such as clopidogrel.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	31-40
24281379-12	2012	As expected, owing to the mode of action of each study drug, the results of this study demonstrated that co-administration of the Factor Xa inhibitor rivaroxaban and the antiplatelet clopidogrel increased the bleeding time in healthy subjects without affecting other pharmacokinetic or pharmacodynamic parameters of each drug.	Rivaroxaban	150-161	coagulation factor X	Homo sapiens	130-139
22049520-0	2012	Heparin-induced thrombocytopenia: in vitro studies on the interaction of dabigatran, rivaroxaban, and low-sulfated heparin, with platelet factor 4 and anti-PF4/heparin antibodies.	Rivaroxaban	85-96	platelet factor 4	Homo sapiens	156-159
22348973-4	2012	Several oral, direct factor Xa inhibitors are undergoing investigation and large, phase III clinical trials of two agents, apixaban and rivaroxaban, in patients with an ACS have been completed.	Rivaroxaban	136-147	coagulation factor X	Homo sapiens	21-30
22308278-1	2012	In this issue of Blood, Krauel and colleagues identify two potential off-label treatments(rivaroxaban, dabigatran) for heparin-induced thrombocytopenia (HIT),and also outline aHIT prevention strategy through disrupting PF4/heparin complexes with low-sulfated heparin; the former approach will be easy to implement, the latter much harder:but potentially more worthwhile	Rivaroxaban	90-101	platelet factor 4	Homo sapiens	219-222
22422332-1	2012	Rivaroxaban is one of the novel oral direct factor Xa inhibitors, which is effective in preventing thromboembolic complications at fixed doses (i.e., once daily), without the need for dose adjustment according to laboratory monitoring.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	44-53
22422332-9	2012	Chromogenic substrate assays specific for factor Xa are also sensitive to rivaroxaban.	Rivaroxaban	74-85	coagulation factor X	Homo sapiens	42-51
22261539-7	2012	Of these alternatives, the direct oral thrombin inhibitor dabigatran and the oral factor Xa inhibitor rivaroxaban, which have minimal interactions and require no INR monitoring, have already been approved by the FDA.	Rivaroxaban	102-113	coagulation factor X	Homo sapiens	82-91
21883447-4	2012	The direct thrombin inhibitor dabigatran and the direct factor Xa inhibitors rivaroxaban and apixaban have recently been investigated to prove whether they fulfill the high expectancy of an ideal anticoagulant with respect to a more favorable efficacy/safety profile and without the need for coagulation controls, thereby improving quality of life.	Rivaroxaban	77-88	coagulation factor X	Homo sapiens	56-65
22187932-2	2012	OBJECTIVE: Clinical trials have demonstrated the efficacy of rivaroxaban, a once-daily, orally administered Factor Xa inhibitor, for the prevention of VTE in patients undergoing THR or TKR.	Rivaroxaban	61-72	coagulation factor X	Homo sapiens	108-117
22187012-0	2012	Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls.	Rivaroxaban	74-85	coagulation factor X	Homo sapiens	23-32
22187012-1	2012	Rivaroxaban is an oral, direct factor Xa inhibitor.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	31-40
22187012-9	2012	The results suggest that, by using rivaroxaban calibrators and controls, the anti-factor Xa chromogenic method is suitable for measuring a wide range of rivaroxaban plasma concentrations (20-660 ng/ml), which covers the expected rivaroxaban plasma levels after therapeutic doses.	Rivaroxaban	35-46	coagulation factor X	Homo sapiens	82-91
22187012-9	2012	The results suggest that, by using rivaroxaban calibrators and controls, the anti-factor Xa chromogenic method is suitable for measuring a wide range of rivaroxaban plasma concentrations (20-660 ng/ml), which covers the expected rivaroxaban plasma levels after therapeutic doses.	Rivaroxaban	153-164	coagulation factor X	Homo sapiens	82-91
22187012-9	2012	The results suggest that, by using rivaroxaban calibrators and controls, the anti-factor Xa chromogenic method is suitable for measuring a wide range of rivaroxaban plasma concentrations (20-660 ng/ml), which covers the expected rivaroxaban plasma levels after therapeutic doses.	Rivaroxaban	153-164	coagulation factor X	Homo sapiens	82-91
22077192-2	2012	Since factor Xa plays a central role in thrombosis, the inhibition of factor Xa with low-dose rivaroxaban might improve cardiovascular outcomes in patients with a recent acute coronary syndrome.	Rivaroxaban	94-105	coagulation factor X	Homo sapiens	6-15
22077192-2	2012	Since factor Xa plays a central role in thrombosis, the inhibition of factor Xa with low-dose rivaroxaban might improve cardiovascular outcomes in patients with a recent acute coronary syndrome.	Rivaroxaban	94-105	coagulation factor X	Homo sapiens	70-79
22042412-3	2012	Objectives were to study efficacy and safety of recombinant activated factor VII (rFVIIa) and prothrombin complex concentrate (PCC) to reverse the anticoagulant effect of an overdose of rivaroxaban in a rabbit model of bleeding and thrombosis.	Rivaroxaban	186-197	prothrombin	Oryctolagus cuniculus	94-105
22042412-9	2012	RESULTS: Rivaroxaban increased blood loss (17 g [8-32] vs. 7 g [5-18] for control (median [range]), P = 0.0004), ear bleeding time, clotting times, thrombelastographic clotting time, and decreased thrombin generation.	Rivaroxaban	9-20	prothrombin	Oryctolagus cuniculus	197-205
21831129-4	2012	Rivaroxaban, apixaban (both oral direct Factor Xa inhibitors) and dabigatran (a direct thrombin inhibitor) all exhibit predictable anticoagulant responses and few drug-drug interactions and do not require routine coagulation monitoring.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	40-49
21831129-4	2012	Rivaroxaban, apixaban (both oral direct Factor Xa inhibitors) and dabigatran (a direct thrombin inhibitor) all exhibit predictable anticoagulant responses and few drug-drug interactions and do not require routine coagulation monitoring.	Rivaroxaban	0-11	coagulation factor II, thrombin	Homo sapiens	87-95
21848931-1	2012	Rivaroxaban, an oral, direct factor Xa inhibitor, is a small molecule drug capable of inhibiting not only free factor Xa with high selectivity but also prothrombinase-bound and clot-associated factor Xa in a concentration-dependent manner.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	29-38
21848931-1	2012	Rivaroxaban, an oral, direct factor Xa inhibitor, is a small molecule drug capable of inhibiting not only free factor Xa with high selectivity but also prothrombinase-bound and clot-associated factor Xa in a concentration-dependent manner.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	111-120
21848931-1	2012	Rivaroxaban, an oral, direct factor Xa inhibitor, is a small molecule drug capable of inhibiting not only free factor Xa with high selectivity but also prothrombinase-bound and clot-associated factor Xa in a concentration-dependent manner.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	111-120
21848931-6	2012	Rivaroxaban is a substrate of CYP3A4 and P-glycoprotein and therefore not recommended for concomitant use with strong inhibitors of both pathways, e.g. most azole antimycotics and protease inhibitors.	Rivaroxaban	0-11	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	30-36
21848931-6	2012	Rivaroxaban is a substrate of CYP3A4 and P-glycoprotein and therefore not recommended for concomitant use with strong inhibitors of both pathways, e.g. most azole antimycotics and protease inhibitors.	Rivaroxaban	0-11	ATP binding cassette subfamily B member 1	Homo sapiens	41-55
22298161-3	2012	Recently, three major trials comparing the efficacy and safety of new drugs: a thrombin inhibitor dabigatran and two inhibitors of factor Xa - rivaroxaban and apixaban, with that of warfarin, have been published.	Rivaroxaban	143-154	coagulation factor X	Homo sapiens	131-140
22800431-0	2012	The effects of direct factor Xa inhibitor (Rivaroxaban) on the human osteoblastic cell line SaOS2.	Rivaroxaban	43-54	coagulation factor X	Homo sapiens	22-31
22800431-2	2012	Rivaroxaban (XARELTO( )) is a novel anticoagulant with specific ability to inhibit factor Xa, a serine endopeptidase, which plays a key role in coagulation.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	83-92
22259168-3	2012	Recent advances included the development of orally active FXa inhibitors rivaroxaban and apixaban.	Rivaroxaban	73-84	coagulation factor X	Homo sapiens	58-61
22826692-6	2012	Newer anticoagulant agents such as dabigatran (a direct thrombin inhibitor) and rivaroxaban (a direct factor Xa inhibitor) have already been approved by US Food and Drug Administration for stroke prevention in patients with nonvalvular atrial fibrillation.	Rivaroxaban	80-91	coagulation factor X	Homo sapiens	102-111
23206451-1	2012	OBJECTIVE: To investigate potential interactions between rivaroxaban, an oral direct Factor Xa inhibitor approved for the management of thromboembolic disorders, and digoxin or atorvastatin.	Rivaroxaban	57-68	coagulation factor X	Homo sapiens	85-94
22955200-4	2012	The direct thrombin inhibitor dabigatran, as well as the direct FXa inhibitors rivaroxaban and apixaban provide more consistent anticoagulation and have proven their efficacy and safety against VKAs in several large scale randomized clinical trials for stroke prevention in atrial fibrillation as well as for the treatment and prevention of venous thromboembolism.	Rivaroxaban	79-90	coagulation factor X	Homo sapiens	64-67
23114797-1	2012	UNLABELLED: Rivaroxaban, the first direct factor-Xa inhibitor anticoagulant, has been approved for the prevention of venous thromboembolism in adult patients undergoing elective hip or knee replacement surgery, for stroke prophylaxis in patients with non-valvular atrial fibrillation and for the treatment of deep vein thrombosis.	Rivaroxaban	12-23	coagulation factor X	Homo sapiens	42-51
21900088-0	2011	Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects.	Rivaroxaban	12-23	coagulation factor II, thrombin	Homo sapiens	42-53
22494267-1	2012	OBJECTIVES: A cost-effectiveness model for rivaroxaban evaluated the cost-effectiveness of prophylaxis with rivaroxaban (a once-daily, orally administered Factor Xa inhibitor) vs enoxaparin in the prevention of venous thromboembolism (VTE) after total hip replacement (THR) and total knee replacement (TKR).	Rivaroxaban	108-119	coagulation factor X	Homo sapiens	155-164
22565540-1	2012	New oral anticoagulants for atrial fibrillation: the factor Xa inhibitors rivaroxaban and apixaban.	Rivaroxaban	74-85	coagulation factor X	Homo sapiens	53-62
23029611-4	2012	Factor Xa inhibitor rivaroxaban has a new recommendation by ACCP and is gradually being adopted by the joint arthroplasty community as an effective oral agent.	Rivaroxaban	20-31	coagulation factor X	Homo sapiens	0-9
22701330-2	2012	Rivaroxaban is an oral direct factor Xa inhibitor, which was shown to be effective for the prevention of venous thromboembolism after elective hip and knee arthroplasty in the RECORD study program.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	30-39
22973107-6	2012	The indication for rivaroxaban in nonvalvular atrial fibrillation was evaluated in ROCKET-AF (Rivaroxaban-once daily, Oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation).	Rivaroxaban	19-30	coagulation factor X	Homo sapiens	131-140
21920015-2	2011	The most advanced substances in this field are the oral direct factor Xa-inhibitors rivaroxaban, apixaban and edoxaban and the oral direct thrombin inhibitor dabigatran.	Rivaroxaban	84-95	coagulation factor X	Homo sapiens	63-72
22008738-4	2011	Dabigatran etexilate is a specific oral thrombin inhibitor and rivaroxaban and apixaban are oral inhibitors of factor Xa.	Rivaroxaban	63-74	coagulation factor X	Homo sapiens	111-120
21900088-1	2011	BACKGROUND: Rivaroxaban and dabigatran are new oral anticoagulants that specifically inhibit factor Xa and thrombin, respectively.	Rivaroxaban	12-23	coagulation factor II, thrombin	Homo sapiens	107-115
21900088-7	2011	Rivaroxaban induced a significant prolongation of the prothrombin time (15.8+-1.3 versus 12.3+-0.7 seconds at baseline; P&lt;0.001) that was immediately and completely reversed by PCC (12.8+-1.0; P&lt;0.001).	Rivaroxaban	0-11	coagulation factor II, thrombin	Homo sapiens	54-65
21900088-8	2011	The endogenous thrombin potential was inhibited by rivaroxaban (51+-22%; baseline, 92+-22%; P=0.002) and normalized with PCC (114+-26%; P&lt;0.001), whereas saline had no effect.	Rivaroxaban	51-62	coagulation factor II, thrombin	Homo sapiens	15-23
21900088-11	2011	CONCLUSION: Prothrombin complex concentrate immediately and completely reverses the anticoagulant effect of rivaroxaban in healthy subjects but has no influence on the anticoagulant action of dabigatran at the PCC dose used in this study.	Rivaroxaban	108-119	coagulation factor II, thrombin	Homo sapiens	12-23
21752066-4	2011	From fondaparinux to its long acting derivative idraparinux, and the factor Xa inhibitor rivaroxaban to the direct thrombin inhibitor dabigatran, the advent of new anticoagulants is radically changing anticoagulation.	Rivaroxaban	89-100	coagulation factor X	Homo sapiens	69-78
21799400-7	2011	The impact of rivaroxaban on thrombin generation parameters showed better comparability between neonatal cord and adult samples.	Rivaroxaban	14-25	coagulation factor II, thrombin	Homo sapiens	29-37
21799400-9	2011	Rivaroxaban shows a very similar pattern in neonatal cord and adult plasma in suppressing thrombin generation and prolonging activated partial thromboplastin time values, suggesting that dose finding may be easier with rivaroxaban in neonates.	Rivaroxaban	0-11	coagulation factor II, thrombin	Homo sapiens	90-98
21774881-9	2011	Furthermore, the direct Factor Xa inhibitor rivaroxaban has been shown to be more effective than enoxaparin in preventing VTE.	Rivaroxaban	44-55	coagulation factor X	Homo sapiens	24-33
21830957-2	2011	Rivaroxaban, an oral factor Xa inhibitor, may provide more consistent and predictable anticoagulation than warfarin.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	21-30
21873708-2	2011	Rivaroxaban, an oral, direct factor Xa inhibitor metabolized predominantly by the liver, preserves the benefit of warfarin for stroke prevention while causing fewer intracranial and fatal haemorrhages.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	29-38
22099406-3	2011	The main direct activated factor X (FXa) inhibitors are rivaroxaban, apixaban and edoxaban.	Rivaroxaban	56-67	coagulation factor X	Homo sapiens	36-39
21895039-1	2011	BACKGROUND AND OBJECTIVE: Rivaroxaban is an oral, direct Factor Xa inhibitor, which is at an advanced stage of clinical development for prevention and treatment of thromboembolic disorders.	Rivaroxaban	26-37	coagulation factor X	Homo sapiens	57-66
21668558-4	2011	Recently developed anticoagulants include the direct thrombin inhibitor, dabigatran, and the factor Xa inhibitors rivaroxaban, apixaban, edoxaban, to name those in the most advanced stages of clinical development.	Rivaroxaban	114-125	coagulation factor X	Homo sapiens	93-102
22041827-0	2011	Rivaroxaban: direct factor Xa inhibition to treat acute deep vein thrombosis.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	20-29
21833915-2	2011	Dabigatran is a direct thrombin (FIIa) inhibitor, whereas Rivaroxaban and Apixaban are direct factor Xa (FXa) inhibitors.	Rivaroxaban	58-69	coagulation factor X	Homo sapiens	94-103
21833915-2	2011	Dabigatran is a direct thrombin (FIIa) inhibitor, whereas Rivaroxaban and Apixaban are direct factor Xa (FXa) inhibitors.	Rivaroxaban	58-69	coagulation factor X	Homo sapiens	105-108
21421599-4	2011	The efficacy and safety of the direct thrombin inhibitor dabigatran etexilate, as well as of the selective factor Xa inhibitors rivaroxaban and apixaban, have been demonstrated in Phase III trials for stroke prevention in AF and the treatment and secondary prophylaxis of venous thrombo-embolism.	Rivaroxaban	128-139	coagulation factor X	Homo sapiens	107-116
21570509-9	2011	SUMMARY: The ATLAS-ACS 2 TIMI 51 is testing the hypothesis that anticoagulation with the oral factor Xa inhibitor rivaroxaban reduces cardiovascular death, MI, and stroke among patients with ACS treated with guideline-based therapies for ACS.	Rivaroxaban	114-125	coagulation factor X	Homo sapiens	94-103
21537165-3	2011	In separate clinical trials, the oral direct thrombin inhibitor dabigatran etexilate and the short-acting oral factor Xa inhibitor rivaroxaban were noninferior or superior to dose-adjusted warfarin for prevention of thromboembolic stroke and systemic embolism, without increasing the risk of bleeding, and were well tolerated.	Rivaroxaban	131-142	coagulation factor X	Homo sapiens	111-120
21892362-6	2011	These agents have been designed to target either thrombin (dabigatran etexilate) or factor Xa (rivaroxaban and apixaban), which are key coagulation cascade enzymes.	Rivaroxaban	95-106	coagulation factor X	Homo sapiens	84-93
21781237-4	2011	New oral anticoagulants that selectively inhibit either thrombin (dabigatran etexilate) or factor Xa (rivaroxaban, apixaban) have now gained approval in many countries for some clinical indications.	Rivaroxaban	102-113	coagulation factor X	Homo sapiens	91-100
21655672-8	2011	The AT assay dependent on thrombin activity was not influenced by rivaroxaban, whereas the AT levels dependent on factor Xa activity were significantly increased by rivaroxaban.	Rivaroxaban	165-176	serpin family C member 1	Homo sapiens	91-93
21554163-1	2011	INTRODUCTION: Rivaroxaban is the first orally bioavailable direct factor Xa inhibitor and its role in acute coronary syndrome is not fully understood.	Rivaroxaban	14-25	coagulation factor X	Homo sapiens	66-75
20888031-0	2011	The mechanism of action of rivaroxaban--an oral, direct Factor Xa inhibitor--compared with other anticoagulants.	Rivaroxaban	27-38	coagulation factor X	Homo sapiens	56-65
20888031-3	2011	Rivaroxaban--the first oral, direct Factor Xa inhibitor--is a small-molecule oxazolidinone derivative that binds directly and reversibly to Factor Xa via the S1 and S4 pockets.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	36-45
20888031-3	2011	Rivaroxaban--the first oral, direct Factor Xa inhibitor--is a small-molecule oxazolidinone derivative that binds directly and reversibly to Factor Xa via the S1 and S4 pockets.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	140-149
20888031-4	2011	Rivaroxaban competitively inhibits Factor Xa and is more than 10,000-fold more selective for Factor Xa than other related serine proteases, and it does not require cofactors (such as antithrombin) to exert its anticoagulant effect.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	35-44
20888031-4	2011	Rivaroxaban competitively inhibits Factor Xa and is more than 10,000-fold more selective for Factor Xa than other related serine proteases, and it does not require cofactors (such as antithrombin) to exert its anticoagulant effect.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	93-102
20888031-5	2011	Unlike indirect Factor Xa inhibitors, rivaroxaban inhibits both free and clot-bound Factor Xa, as well as prothrombinase activity, thereby prolonging clotting times.	Rivaroxaban	38-49	coagulation factor X	Homo sapiens	84-93
21809964-2	2011	Rivaroxaban is the first of a new class of anticoagulant drugs, the direct, selective inhibitors of Factor Xa.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	100-109
21666147-0	2011	Response to "Role of orally available antagonists of factor Xa in the treatment and prevention of thromboembolic disease: focus on rivaroxaban".	Rivaroxaban	131-142	coagulation factor X	Homo sapiens	53-62
21515813-0	2011	In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban.	Rivaroxaban	65-76	phosphoglycolate phosphatase	Mus musculus	21-35
21515813-1	2011	Rivaroxaban, an oral, direct factor Xa inhibitor, has a dual mode of elimination in humans, with two-thirds metabolized by the liver and one-third renally excreted unchanged.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	29-38
21515813-3	2011	To investigate whether rivaroxaban is a substrate of P-gp, the bidirectional flux of rivaroxaban across Caco-2, wild-type, and P-gp-overexpressing LLC-PK1 cells was investigated.	Rivaroxaban	23-34	phosphoglycolate phosphatase	Mus musculus	53-57
21515813-4	2011	Furthermore, the inhibitory effect of rivaroxaban toward P-gp was determined.	Rivaroxaban	38-49	phosphoglycolate phosphatase	Mus musculus	57-61
21515813-7	2011	Of a set of potential P-gp inhibitors, ketoconazole and ritonavir, but not clarithromycin or erythromycin, inhibited P-gp-mediated transport of rivaroxaban, with half-maximal inhibitory concentration values in the range of therapeutic plasma concentrations.	Rivaroxaban	144-155	phosphoglycolate phosphatase	Mus musculus	22-26
21515813-7	2011	Of a set of potential P-gp inhibitors, ketoconazole and ritonavir, but not clarithromycin or erythromycin, inhibited P-gp-mediated transport of rivaroxaban, with half-maximal inhibitory concentration values in the range of therapeutic plasma concentrations.	Rivaroxaban	144-155	phosphoglycolate phosphatase	Mus musculus	117-121
21515813-8	2011	These findings are in line with observed area under the plasma concentration-time curve increases in clinical drug-drug interaction studies indicating a possible involvement of P-gp in the distribution and excretion of rivaroxaban.	Rivaroxaban	219-230	phosphoglycolate phosphatase	Mus musculus	177-181
21515813-9	2011	In vivo studies in wild-type and P-gp double-knockout mice demonstrated that the impact of P-gp alone on the pharmacokinetics of rivaroxaban is minor.	Rivaroxaban	129-140	phosphoglycolate phosphatase	Mus musculus	33-37
21515813-9	2011	In vivo studies in wild-type and P-gp double-knockout mice demonstrated that the impact of P-gp alone on the pharmacokinetics of rivaroxaban is minor.	Rivaroxaban	129-140	phosphoglycolate phosphatase	Mus musculus	91-95
21515813-12	2011	In addition to P-gp, a further transport protein might be involved in the secretion of rivaroxaban.	Rivaroxaban	87-98	phosphoglycolate phosphatase	Mus musculus	15-19
21352091-12	2011	Rivaroxaban, an oral direct factor Xa inhibitor, has also shown promising results.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	28-37
21241235-4	2011	ZK-807834, otamixaban, apixaban, and rivaroxaban are all direct FXa inhibitors that have undergone preclinical and some clinical testing for use in CAD.	Rivaroxaban	37-48	coagulation factor X	Homo sapiens	64-67
21277622-11	2011	Rivaroxaban increased aPTTr and PTr around 1.5 fold and modified the initiation and amplification phases of thrombin generation, with a lowered and prolonged thrombin burst.	Rivaroxaban	0-11	coagulation factor II, thrombin	Homo sapiens	108-116
21277622-11	2011	Rivaroxaban increased aPTTr and PTr around 1.5 fold and modified the initiation and amplification phases of thrombin generation, with a lowered and prolonged thrombin burst.	Rivaroxaban	0-11	coagulation factor II, thrombin	Homo sapiens	158-166
21526168-1	2011	Rivaroxaban is an oral, direct Factor Xa inhibitor approved in the European Union and several other countries for the prevention of venous thromboembolism in adult patients undergoing elective hip or knee replacement surgery and is in advanced clinical development for the treatment of thromboembolic disorders.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	31-40
21434944-5	2011	This paper describes the development and future potential of rivaroxaban (Xarelto; Bayer Schering Pharma AG, Berlin, Germany)-the first oral, direct Factor Xa inhibitor to be approved for clinical use in the prevention of venous thromboembolism in adult patients undergoing elective hip or knee replacement surgery.	Rivaroxaban	61-72	coagulation factor X	Homo sapiens	149-158
21436363-7	2011	ROCKET-AF suggests that the factor-Xa inhibitor rivaroxaban may be as effective as warfarin in patients with atrial fibrillation.	Rivaroxaban	48-59	coagulation factor X	Homo sapiens	28-37
21385107-6	2011	AREAS COVERED: This review provides an overview of the two oral anti-FXa drugs at the most advanced stage of development (rivaroxaban and apixaban) and briefly describes and comments on the results of the most important studies.	Rivaroxaban	122-133	coagulation factor X	Homo sapiens	69-72
21327511-2	2011	Apixaban and rivaroxaban are specific inhibitors of Factor Xa while dabigatran inhibits Factor IIa.	Rivaroxaban	13-24	coagulation factor X	Homo sapiens	52-61
21434944-5	2011	This paper describes the development and future potential of rivaroxaban (Xarelto; Bayer Schering Pharma AG, Berlin, Germany)-the first oral, direct Factor Xa inhibitor to be approved for clinical use in the prevention of venous thromboembolism in adult patients undergoing elective hip or knee replacement surgery.	Rivaroxaban	74-81	coagulation factor X	Homo sapiens	149-158
21332248-4	2011	METHODS: Four randomized, active-controlled studies were conducted worldwide in subjects undergoing elective hip or knee replacement surgery to compare the efficacy and safety of the anticoagulant rivaroxaban, an oral, direct Factor Xa inhibitor, with the low-molecular-weight heparin, enoxaparin.	Rivaroxaban	197-208	coagulation factor X	Homo sapiens	226-235
21044021-5	2011	Currently, two agents, dabigatran etexilate and rivaroxaban, which inhibit thrombin and FXa, respectively have been approved in the European Union and Canada for venous thromboprophylaxis in patients undergoing elective hip- or knee-replacement surgery.	Rivaroxaban	48-59	coagulation factor II, thrombin	Homo sapiens	75-83
21286676-7	2011	Favorable preliminary results have been demonstrated for the factor Xa inhibitor rivaroxaban.	Rivaroxaban	81-92	coagulation factor X	Homo sapiens	61-70
20947383-2	2011	The oral, direct Factor Xa inhibitor, rivaroxaban, has not been studied in patients with HF.	Rivaroxaban	38-49	coagulation factor X	Homo sapiens	17-26
21044021-5	2011	Currently, two agents, dabigatran etexilate and rivaroxaban, which inhibit thrombin and FXa, respectively have been approved in the European Union and Canada for venous thromboprophylaxis in patients undergoing elective hip- or knee-replacement surgery.	Rivaroxaban	48-59	coagulation factor X	Homo sapiens	88-91
20844464-1	2010	Several new oral anticoagulants such as rivaroxaban (which targets Factor Xa) and dabigatran etexilate (which targets thrombin) are in advanced stages of clinical development and are already available for clinical use in some countries.	Rivaroxaban	40-51	coagulation factor X	Homo sapiens	67-76
20946166-1	2011	INTRODUCTION: Rivaroxaban is an oral direct factor Xa inhibitor developed for prophylaxis and treatment of thromboembolic disorders.	Rivaroxaban	14-25	coagulation factor X	Homo sapiens	44-53
20946166-4	2011	MATERIALS AND METHODS: Rivaroxaban was added to plasma from healthy subjects in the concentration range 0-1000 mug L(-1) and analyzed using different reagents for activated partial thromboplastin time (APTT), prothrombin time (PT), antithrombin, fibrinogen and activated protein C (APC) resistance assays.	Rivaroxaban	23-34	serpin family C member 1	Homo sapiens	232-244
20946166-4	2011	MATERIALS AND METHODS: Rivaroxaban was added to plasma from healthy subjects in the concentration range 0-1000 mug L(-1) and analyzed using different reagents for activated partial thromboplastin time (APTT), prothrombin time (PT), antithrombin, fibrinogen and activated protein C (APC) resistance assays.	Rivaroxaban	23-34	fibrinogen beta chain	Homo sapiens	246-256
21772662-7	2011	Real time-PCR from thoracic aortas revealed that rivaroxaban (5 mg/kg/day) treatment reduced mRNA expression of inflammatory mediators, such of IL-6, TNF-alpha, MCP-1, and Egr-1 (P &lt; .05).	Rivaroxaban	49-60	interleukin 6	Mus musculus	144-148
21772662-7	2011	Real time-PCR from thoracic aortas revealed that rivaroxaban (5 mg/kg/day) treatment reduced mRNA expression of inflammatory mediators, such of IL-6, TNF-alpha, MCP-1, and Egr-1 (P &lt; .05).	Rivaroxaban	49-60	tumor necrosis factor	Mus musculus	150-159
21772662-7	2011	Real time-PCR from thoracic aortas revealed that rivaroxaban (5 mg/kg/day) treatment reduced mRNA expression of inflammatory mediators, such of IL-6, TNF-alpha, MCP-1, and Egr-1 (P &lt; .05).	Rivaroxaban	49-60	mast cell protease 1	Mus musculus	161-166
21772662-7	2011	Real time-PCR from thoracic aortas revealed that rivaroxaban (5 mg/kg/day) treatment reduced mRNA expression of inflammatory mediators, such of IL-6, TNF-alpha, MCP-1, and Egr-1 (P &lt; .05).	Rivaroxaban	49-60	early growth response 1	Mus musculus	172-177
21164526-0	2011	The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor.	Rivaroxaban	33-44	coagulation factor X	Homo sapiens	62-71
21128814-1	2010	BACKGROUND: Rivaroxaban, an oral factor Xa inhibitor, may provide a simple, fixed-dose regimen for treating acute deep-vein thrombosis (DVT) and for continued treatment, without the need for laboratory monitoring.	Rivaroxaban	12-23	coagulation factor X	Homo sapiens	33-42
20950405-0	2010	The impact of elective knee/hip replacement surgery and thromboprophylaxis with rivaroxaban or dalteparin on thrombin generation.	Rivaroxaban	80-91	coagulation factor II, thrombin	Homo sapiens	109-117
20950405-7	2010	Good correlation was seen between rivaroxaban levels and TG-lag-time (rs = 0 46, P = 0 01); TG-time-to-Peak (rs = 0 53, P = 0 005); TG-peak-thrombin (rs = -0 59, P = 0 001); and TG-velocity-index-rate (rs = -0 61, P = 0 0009).	Rivaroxaban	34-45	coagulation factor II, thrombin	Homo sapiens	140-148
20809275-3	2010	Proof of effectiveness for the perioperative prophylaxis of venous thrombosis after hip and knee replacement has already been achieved for the direct thrombin inhibitor dabigatran etexilate as well as for the factor Xa inhibitors rivaroxaban und apixaban compared to low molecular weight heparins.	Rivaroxaban	230-241	coagulation factor X	Homo sapiens	209-218
20844464-6	2010	Focusing on rivaroxaban, there is emerging evidence that an anti-Factor Xa assay that uses rivaroxaban-containing plasma calibrators may provide the optimal method for determining plasma rivaroxaban concentrations.	Rivaroxaban	12-23	coagulation factor X	Homo sapiens	65-74
20844464-6	2010	Focusing on rivaroxaban, there is emerging evidence that an anti-Factor Xa assay that uses rivaroxaban-containing plasma calibrators may provide the optimal method for determining plasma rivaroxaban concentrations.	Rivaroxaban	91-102	coagulation factor X	Homo sapiens	65-74
20844464-6	2010	Focusing on rivaroxaban, there is emerging evidence that an anti-Factor Xa assay that uses rivaroxaban-containing plasma calibrators may provide the optimal method for determining plasma rivaroxaban concentrations.	Rivaroxaban	91-102	coagulation factor X	Homo sapiens	65-74
21039764-0	2010	Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor.	Rivaroxaban	84-95	coagulation factor X	Homo sapiens	113-122
20615303-3	2010	This study first compares the duration of treatment and satisfaction between patients prescribed low molecular weight heparin (LMWH) and rivaroxaban, a new oral Factor Xa inhibitor, following elective hip arthroplasty; and second, surveys the duration of LMWH use in other units.	Rivaroxaban	137-148	coagulation factor X	Homo sapiens	161-170
23051944-4	2010	This review takes a look at rivaroxaban, a direct factor Xa inhibitor and one of the most foremost competitors of warfarin.	Rivaroxaban	28-39	coagulation factor X	Homo sapiens	50-59
20812009-1	2010	PURPOSE: Rivaroxaban is a newly developed oral medicine that direct inhibits factor Xa for the prevention and treatment of thromboembolic disorders.	Rivaroxaban	9-20	coagulation factor X	Homo sapiens	77-86
20806114-0	2010	An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma.	Rivaroxaban	91-102	coagulation factor X	Homo sapiens	69-78
20802329-3	2010	New oral factor Xa inhibitors like apixaban and rivaroxaban are still on the horizon, awaiting definite evaluation in ACS, DVT and atrial fibrillation.	Rivaroxaban	48-59	coagulation factor X	Homo sapiens	9-18
21069505-6	2010	The factor Xa inhibitor rivaroxaban and the thrombin inhibitor dabigatran etexilate have become available for prevention of venous thromboembolism after elective hip and knee replacement surgery and registration of the factor Xa inhibitor apixaban is expected to occur soon.	Rivaroxaban	24-35	coagulation factor X	Homo sapiens	4-13
20584229-5	2010	Rivaroxaban (and possibly apixaban) is contraindicated in combination with drugs that strongly inhibit both cytochrome P450 3A4 and P-glycoprotein, such as azole antimycotics, and caution is required when used in combination with strong inhibitors of only one of these pathways.	Rivaroxaban	0-11	ATP binding cassette subfamily B member 1	Homo sapiens	132-146
20124518-0	2010	Role of orally available antagonists of factor Xa in the treatment and prevention of thromboembolic disease: focus on rivaroxaban.	Rivaroxaban	118-129	coagulation factor X	Homo sapiens	40-49
20589316-8	2010	Apixaban and other factor inhibitors, except the FXIa inhibitor, inhibited TF-induced platelet aggregation with IC50 (nM) values as follows: 4 +/- 1 (apixaban), 8 +/- 2 (rivaroxaban), 13 +/- 1 (BMS-593214), 46 +/- 1 (dabigatran) and 79 +/- 1 (argatroban).	Rivaroxaban	170-181	coagulation factor III, tissue factor	Homo sapiens	75-77
20539909-4	2010	The development and clinical investigation of two novel groups of oral anticoagulants targeting central factors of the coagulation system either factor Xa or thrombin (factor IIa) has now reached the daily clinical practice with the approval of the oral direct thrombin inhibitor dabigatran etexilate and the oral direct factor Xa inhibitor rivaroxaban.	Rivaroxaban	341-352	coagulation factor II, thrombin	Homo sapiens	158-166
20700042-4	2010	The most advanced oral anticoagulants in clinical development are the direct factor Xa inhibitors rivaroxaban and apixaban, and the direct thrombin inhibitor dabigatran etexilate.	Rivaroxaban	98-109	coagulation factor X	Homo sapiens	77-86
20564841-4	2010	Rivaroxan (Xarelto) inhibits reversibly the active site of fXa, the 10 mg-dose once daily is recommended started 6 to 12 hours after wound closure.	Rivaroxaban	11-18	coagulation factor X	Homo sapiens	59-62
19565250-4	2010	New oral anticoagulants (such as the direct thrombin inhibitor dabigatran etexilate and the Factor Xa inhibitor rivaroxaban) could address the current unmet need.	Rivaroxaban	112-123	coagulation factor X	Homo sapiens	92-101
20211293-3	2010	Rivaroxaban is an oral direct factor Xa inhibitor in advanced development as an alternative to warfarin for the prevention and treatment of thromboembolic disorders.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	30-39
21083465-3	2010	The first part of this article reviews oral Factor Xa inhibitors, such as rivaroxaban, apixaban, eribaxaban, edoxaban and YM150--exploring the outcomes of major clinical trials for prophylaxis and treatment of venous thromboembolism--and also briefly outlining their pharmacological properties.	Rivaroxaban	74-85	coagulation factor X	Homo sapiens	44-53
20353992-3	2010	Dabigatran etexilate (Pradaxa), a direct thrombin inhibitor (DTI), and rivaroxaban (Xarelto), the first in a new class of drugs, the oral direct factor Xa (FXa) inhibitors, are both fixed-dose orally administered agents.	Rivaroxaban	71-82	coagulation factor X	Homo sapiens	145-154
20353992-3	2010	Dabigatran etexilate (Pradaxa), a direct thrombin inhibitor (DTI), and rivaroxaban (Xarelto), the first in a new class of drugs, the oral direct factor Xa (FXa) inhibitors, are both fixed-dose orally administered agents.	Rivaroxaban	71-82	coagulation factor X	Homo sapiens	156-159
20135059-0	2010	Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor.	Rivaroxaban	43-54	coagulation factor X	Homo sapiens	72-81
20135059-1	2010	Although there is no need for routine coagulation monitoring with rivaroxaban--an oral, direct factor Xa inhibitor--a haemostasis assay might be valuable to measure its pharmacodynamic effects.	Rivaroxaban	66-77	coagulation factor X	Homo sapiens	95-104
20135059-12	2010	The chromogenic tests found a dose-dependent relationship between anti-factor Xa activity and rivaroxaban concentration.	Rivaroxaban	94-105	coagulation factor X	Homo sapiens	71-80
20139357-0	2010	Rivaroxaban: a new oral factor Xa inhibitor.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	24-33
20139357-1	2010	Rivaroxaban is a direct inhibitor of factor Xa, a coagulation factor at a critical juncture in the blood coagulation pathway leading to thrombin generation and clot formation.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	37-46
20139357-1	2010	Rivaroxaban is a direct inhibitor of factor Xa, a coagulation factor at a critical juncture in the blood coagulation pathway leading to thrombin generation and clot formation.	Rivaroxaban	0-11	coagulation factor II, thrombin	Homo sapiens	136-144
20139357-3	2010	Rivaroxaban inhibits factor Xa in a concentration-dependent manner (inhibitory constant [K(i)], 0.4 nmol/L) and binds rapidly (kinetic association rate constant [k(on)], 1.7x10(7) mol/L(-1) s(-1)) and reversibly (kinetic dissociation rate constant [k(off)], 5x10(-3) s(-1)).	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	21-30
20139357-4	2010	By inhibiting prothrombinase complex-bound (IC(50), 2.1 nmol/L) and clot-associated factor Xa (IC(50), 75 nmol/L), rivaroxaban reduces the thrombin burst during the propagation phase.	Rivaroxaban	115-126	coagulation factor X	Homo sapiens	14-28
20139357-4	2010	By inhibiting prothrombinase complex-bound (IC(50), 2.1 nmol/L) and clot-associated factor Xa (IC(50), 75 nmol/L), rivaroxaban reduces the thrombin burst during the propagation phase.	Rivaroxaban	115-126	coagulation factor X	Homo sapiens	84-93
20139357-4	2010	By inhibiting prothrombinase complex-bound (IC(50), 2.1 nmol/L) and clot-associated factor Xa (IC(50), 75 nmol/L), rivaroxaban reduces the thrombin burst during the propagation phase.	Rivaroxaban	115-126	coagulation factor II, thrombin	Homo sapiens	17-25
20139357-6	2010	In healthy individuals, rivaroxaban was found to have predictable pharmacokinetics and pharmacodynamics across a 5- to 80-mg total daily dose range, inhibiting factor Xa activity and prolonging plasma clotting time.	Rivaroxaban	24-35	coagulation factor X	Homo sapiens	160-169
20135071-4	2010	Of these, the thrombin inhibitor dabigatran and factor Xa inhibitor rivaroxaban have recently been licensed for thromboprophylaxis after orthopaedic surgery mainly in Europe.	Rivaroxaban	68-79	coagulation factor X	Homo sapiens	48-57
20135071-8	2010	However, alterations of rivaroxaban and apixaban pharmacokinetics upon interactions with inhibitors and inducers of CYP3A4 or P-glycoprotein may complicate the use of these compounds in daily practice, whereas dabigatran elimination largely depends on renal function.	Rivaroxaban	24-35	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	116-122
20135071-8	2010	However, alterations of rivaroxaban and apixaban pharmacokinetics upon interactions with inhibitors and inducers of CYP3A4 or P-glycoprotein may complicate the use of these compounds in daily practice, whereas dabigatran elimination largely depends on renal function.	Rivaroxaban	24-35	ATP binding cassette subfamily B member 1	Homo sapiens	126-140
19485937-5	2010	Rivaroxaban, a direct FXa inhibitor, appears to have at least equal efficacy and safety to established anticoagulants in the prevention of VTE.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	22-25
20040270-4	2009	Drugs in advanced development target factor Xa (rivaroxaban, apixaban) or thrombin (dabigatran etexilate).	Rivaroxaban	48-59	coagulation factor X	Homo sapiens	37-46
20211293-0	2010	Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	37-46
20617418-1	2010	Rivaroxaban is a small-molecule, direct factor Xa inhibitor that is under investigation for the prevention and treatment of venous and arterial thrombosis.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	40-49
20858184-2	2010	Newer agents targeting single coagulation factors such as the direct thrombin inhibitor dabigatran and the factor Xa inhibitors rivaroxaban and apixaban have demonstrated efficacy and safety for thromboembolism prophylaxis in the orthopedic population and have the additional benefit of oral administration and predictable pharmacokinetics.	Rivaroxaban	128-139	coagulation factor X	Homo sapiens	107-116
20858185-3	2010	These drugs consist of dabigatran, a direct thrombin inhibitor and rivaroxaban, a factor Xa inhibitor, both of which have been recently approved for clinical use.	Rivaroxaban	67-78	coagulation factor X	Homo sapiens	82-91
20062915-0	2010	Safety, pharmacokinetics and pharmacodynamics of single doses of rivaroxaban - an oral, direct factor Xa inhibitor - in elderly Chinese subjects.	Rivaroxaban	65-76	coagulation factor X	Homo sapiens	95-104
20062915-1	2010	Rivaroxaban is a novel, oral, direct factor Xa (FXa) inhibitor for the prevention and treatment of thromboembolic disorders.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	37-46
20062915-1	2010	Rivaroxaban is a novel, oral, direct factor Xa (FXa) inhibitor for the prevention and treatment of thromboembolic disorders.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	48-51
20062915-7	2010	Maximal inhibition of FXa occurred 2-3hours after dosing and returned to baseline after 24-48hours, reflecting rivaroxaban plasma concentrations.	Rivaroxaban	111-122	coagulation factor X	Homo sapiens	22-25
19888525-6	2009	Two agents, the direct thrombin inhibitor dabigatran and the direct Factor Xa inhibitor rivaroxaban, have recently been approved in the EU and several other countries for the prevention of VTE after total hip or knee replacement surgery.	Rivaroxaban	88-99	coagulation factor X	Homo sapiens	68-77
19925048-0	2009	Rivaroxaban, the first oral, direct factor Xa inhibitor.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	36-45
19911670-0	2009	[Rivaroxaban (Xarelto): new anticoagulant inhibitor of factor Xa].	Rivaroxaban	1-12	coagulation factor X	Homo sapiens	55-64
19911670-0	2009	[Rivaroxaban (Xarelto): new anticoagulant inhibitor of factor Xa].	Rivaroxaban	14-21	coagulation factor X	Homo sapiens	55-64
19550318-4	2009	RECENT FINDINGS: Several landmark studies are now available on the direct thrombin inhibitor, dabigatran etexilate, and the two factor Xa inhibitors, rivaroxaban and apixaban.	Rivaroxaban	150-161	coagulation factor X	Homo sapiens	128-137
19539361-1	2009	BACKGROUND: Rivaroxaban is an oral direct factor Xa inhibitor that has been effective in prevention of venous thromboembolism in patients undergoing elective orthopaedic surgery.	Rivaroxaban	12-23	coagulation factor X	Homo sapiens	42-51
19899386-6	2009	Apixaban and rivaroxaban are small molecules that directly block FXa following oral administration.	Rivaroxaban	13-24	coagulation factor X	Homo sapiens	65-68
19644596-4	2009	Rivaroxaban (Xareltoa) is the first direct FXa inhibitor which has recently been approved for the prevention of VTE in adult patients after elective hip or knee replacement in several countries, including the European Union and Canada.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	43-46
19351313-0	2009	The direct factor Xa inhibitor rivaroxaban.	Rivaroxaban	31-42	coagulation factor X	Homo sapiens	11-20
19660005-0	2009	Safety, pharmacokinetics and pharmacodynamics of single/multiple doses of the oral, direct Factor Xa inhibitor rivaroxaban in healthy Chinese subjects.	Rivaroxaban	111-122	coagulation factor X	Homo sapiens	91-100
19660005-1	2009	AIMS: To investigate the safety, pharmacokinetics and pharmacodynamics of rivaroxaban, an oral, direct Factor Xa (FXa) inhibitor, in healthy, male Chinese subjects.	Rivaroxaban	74-85	coagulation factor X	Homo sapiens	103-112
19660005-1	2009	AIMS: To investigate the safety, pharmacokinetics and pharmacodynamics of rivaroxaban, an oral, direct Factor Xa (FXa) inhibitor, in healthy, male Chinese subjects.	Rivaroxaban	74-85	coagulation factor X	Homo sapiens	114-117
19660005-9	2009	Maximal inhibition of FXa activity was achieved within 1-3 h of dosing in the single-dose study [at 20 mg FXa inhibition as a median percentage change from baseline, 45.92; 95% confidence interval (CI) 44.64, 50.70] and 2-3 h after administration at steady state in the multiple-dose study (at 20 mg median FXa inhibition as a median percentage change from baseline, 60.25; 95% CI 56.16, 63.05), in line with maximum rivaroxaban plasma concentrations.	Rivaroxaban	417-428	coagulation factor X	Homo sapiens	22-25
19187276-0	2009	Rivaroxaban -- an oral, direct Factor Xa inhibitor: lessons from a broad clinical study programme.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	31-40
19187276-3	2009	Rivaroxaban, an oral, once-daily, direct Factor Xa inhibitor, has recently completed the RECORD phase III programme for the prevention of VTE in patients undergoing total hip or knee replacement (THR or TKR), an indication for which it is approved in Europe and Canada.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	41-50
19187276-3	2009	Rivaroxaban, an oral, once-daily, direct Factor Xa inhibitor, has recently completed the RECORD phase III programme for the prevention of VTE in patients undergoing total hip or knee replacement (THR or TKR), an indication for which it is approved in Europe and Canada.	Rivaroxaban	0-11	transketolase like 1	Homo sapiens	203-206
19187276-6	2009	The four RECORD studies consistently showed that rivaroxaban was significantly more effective than enoxaparin in the prevention of VTE after THR and TKR, with a similar safety profile.	Rivaroxaban	49-60	transketolase like 1	Homo sapiens	149-152
19407299-1	2009	A once-daily dose of rivaroxaban 10 mg, an oral, direct Factor Xa inhibitor, was compared with enoxaparin 40 mg subcutaneously once daily for prevention of venous thromboembolism in three studies of patients undergoing elective hip and knee replacement (RECORD programme).	Rivaroxaban	21-32	coagulation factor X	Homo sapiens	56-65
19505271-5	2009	Rivaroxaban is the first of a new class of anticoagulants: the selective, direct Factor Xa inhibitors.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	81-90
19196845-0	2009	Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans.	Rivaroxaban	28-39	coagulation factor X	Homo sapiens	57-66
19196845-1	2009	Rivaroxaban is a novel, oral, direct factor Xa inhibitor for the prevention and treatment of thromboembolic disorders.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	37-46
19196846-0	2009	In vitro metabolism of rivaroxaban, an oral, direct factor Xa inhibitor, in liver microsomes and hepatocytes of rats, dogs, and humans.	Rivaroxaban	23-34	coagulation factor X	Homo sapiens	52-61
19196846-1	2009	The in vitro metabolism of rivaroxaban, a novel, oral, direct factor Xa inhibitor for the prevention and treatment of thromboembolic disorders, was investigated in several species, including humans.	Rivaroxaban	27-38	coagulation factor X	Homo sapiens	62-71
19712596-8	2009	Rivaroxaban will probably be the first available oral factor Xa (FXa) direct inhibitor anticoagulant drug.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	54-63
19712596-8	2009	Rivaroxaban will probably be the first available oral factor Xa (FXa) direct inhibitor anticoagulant drug.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	65-68
19351313-4	2009	Rivaroxaban, which inhibits activated factor X (Xa), is currently in clinical trials and is the most advanced factor Xa inhibitor.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	110-119
19351271-0	2009	Rivaroxaban, a new, oral, direct factor Xa inhibitor for thromboprophylaxis after major joint arthroplasty.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	33-42
19351271-1	2009	The new oral, antithrombotic drug rivaroxaban is a direct factor Xa inhibitor, which can restrict thrombin generation both in vitro and in vivo.	Rivaroxaban	34-45	coagulation factor X	Homo sapiens	58-67
19351271-1	2009	The new oral, antithrombotic drug rivaroxaban is a direct factor Xa inhibitor, which can restrict thrombin generation both in vitro and in vivo.	Rivaroxaban	34-45	coagulation factor II, thrombin	Homo sapiens	98-106
19271646-2	2009	Among the new drugs that are still in phase III clinical development in most indications, the oral factor Xa inhibitor rivaroxaban and the oral direct thrombin inhibitor dabigatran etexilate are expected to be soon introduced on the Swiss market for thromboprophylaxis following major orthopedic surgery.	Rivaroxaban	119-130	coagulation factor X	Homo sapiens	99-108
19204837-6	2009	Small molecules have also been developed that directly block FXa (rivaroxaban, apixaban) or thrombin (dabigatran etexilate) following oral administration.	Rivaroxaban	66-77	coagulation factor X	Homo sapiens	61-64
18671707-0	2008	Rivaroxaban--an oral, direct Factor Xa inhibitor--has potential for the management of patients with heparin-induced thrombocytopenia.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	29-38
19185782-1	2008	Rivaroxaban (Xarelto) is a new oral, direct and selective inhibitor of the factor Xa of the coagulation cascade.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	75-84
19185782-2	2008	The main pharmacokinetic characteristics of rivaroxaban are a bioavailability of approximately 80-100%, a maximum concentration obtained in 2 to 4 hours, a terminal half-life of elimination of 7 to 11 hours, a renal elimination for 1/3 for the active hepatic metabolism from the cytochrome P450 (3A4) for the other 2/3.	Rivaroxaban	44-55	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	279-299
19185782-6	2008	Pharmacodynamically, Rivaroxaban is a direct and selective factor Xa inhibitor without any effect on the factor IIa and without any interaction on platelets.	Rivaroxaban	21-32	coagulation factor X	Homo sapiens	59-68
19185785-4	2008	Moreover, among the new oral anticoagulants, rivaroxaban has a better efficacy than enoxaparin to prevent thromboembolic events after major orthopaedic surgery (THR and TKR).	Rivaroxaban	45-56	transketolase like 1	Homo sapiens	169-172
19170587-0	2009	Rivaroxaban: a novel, oral, direct factor Xa inhibitor.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	35-44
19170587-3	2009	Rivaroxaban is a novel, oral factor Xa inhibitor in clinical development for the treatment and prevention of thromboembolic diseases.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	29-38
19170587-4	2009	Rivaroxaban is a small molecule directed at active sites, and the agent mechanistically differs from traditional anticoagulants, such as heparins and fondaparinux, in that its activity is independent of antithrombin and its ability to inhibit prothrombinase bound factor Xa.	Rivaroxaban	0-11	serpin family C member 1	Homo sapiens	203-215
19170587-4	2009	Rivaroxaban is a small molecule directed at active sites, and the agent mechanistically differs from traditional anticoagulants, such as heparins and fondaparinux, in that its activity is independent of antithrombin and its ability to inhibit prothrombinase bound factor Xa.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	243-257
19170587-4	2009	Rivaroxaban is a small molecule directed at active sites, and the agent mechanistically differs from traditional anticoagulants, such as heparins and fondaparinux, in that its activity is independent of antithrombin and its ability to inhibit prothrombinase bound factor Xa.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	264-273
19342840-7	2009	Also being investigated are apixaban and rivaroxaban, orally active agents that inhibit factor Xa directly.	Rivaroxaban	41-52	coagulation factor X	Homo sapiens	88-97
19071881-3	2009	The two agents in the most advanced stages of development are dabigatran etexilate and rivaroxaban, which inhibit thrombin and FXa, respectively.	Rivaroxaban	87-98	coagulation factor II, thrombin	Homo sapiens	114-122
19071881-3	2009	The two agents in the most advanced stages of development are dabigatran etexilate and rivaroxaban, which inhibit thrombin and FXa, respectively.	Rivaroxaban	87-98	coagulation factor X	Homo sapiens	127-130
19719335-1	2009	Rivaroxaban (Xarelto), an oral oxazolidinone-based anticoagulant, is a potent, selective direct inhibitor of factor Xa that is used in the prevention of venous thromboembolism (VTE) in adult patients after total hip replacement (THR) or total knee replacement (TKR) surgery.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	109-118
19719335-1	2009	Rivaroxaban (Xarelto), an oral oxazolidinone-based anticoagulant, is a potent, selective direct inhibitor of factor Xa that is used in the prevention of venous thromboembolism (VTE) in adult patients after total hip replacement (THR) or total knee replacement (TKR) surgery.	Rivaroxaban	13-20	coagulation factor X	Homo sapiens	109-118
18671707-1	2008	Rivaroxaban is an oral, direct activated Factor Xa (FXa) inhibitor in advanced clinical development for the prevention and treatment of thromboembolic disorders.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	41-50
18671707-1	2008	Rivaroxaban is an oral, direct activated Factor Xa (FXa) inhibitor in advanced clinical development for the prevention and treatment of thromboembolic disorders.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	52-55
18715524-4	2008	Bioavailability, in terms of the area under the plasma concentration-time curve (AUC) and C(max), increased slightly (less than dose proportionally) after administration of rivaroxaban 40 mg compared with 30 mg, but was not increased further with rivaroxaban 50 mg. Rivaroxaban pharmacodynamic effects (inhibition of FXa activity and prolongation of prothrombin time, activated partial thromboplastin time and HepTest) all showed a similar pattern, with maximum inhibition of FXa activity increasing from 68% after rivaroxaban 30 mg to 75% after 40 mg and no further increase with the 50 mg dose.	Rivaroxaban	173-184	coagulation factor X	Homo sapiens	317-320
18715524-4	2008	Bioavailability, in terms of the area under the plasma concentration-time curve (AUC) and C(max), increased slightly (less than dose proportionally) after administration of rivaroxaban 40 mg compared with 30 mg, but was not increased further with rivaroxaban 50 mg. Rivaroxaban pharmacodynamic effects (inhibition of FXa activity and prolongation of prothrombin time, activated partial thromboplastin time and HepTest) all showed a similar pattern, with maximum inhibition of FXa activity increasing from 68% after rivaroxaban 30 mg to 75% after 40 mg and no further increase with the 50 mg dose.	Rivaroxaban	173-184	coagulation factor X	Homo sapiens	476-479
18836647-8	2008	New therapeutic strategies, like the factor Xa inhibitor rivaroxaban or the factor II inhibitor dabigatran, are actually evaluated in phase III studies.	Rivaroxaban	57-68	coagulation factor X	Homo sapiens	37-46
18579811-1	2008	BACKGROUND: This phase 3 trial compared the efficacy and safety of rivaroxaban, an oral direct inhibitor of factor Xa, with those of enoxaparin for extended thromboprophylaxis in patients undergoing total hip arthroplasty.	Rivaroxaban	67-78	coagulation factor X	Homo sapiens	108-117
18981864-0	2008	Orally administered factor xa inhibitor, rivaroxaban: a novel thromboembolic prophylaxis agent.	Rivaroxaban	41-52	coagulation factor X	Homo sapiens	20-29
18621928-0	2008	A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study.	Rivaroxaban	90-101	coagulation factor X	Homo sapiens	70-79
18693206-0	2008	Rivaroxaban: an oral direct inhibitor of factor Xa.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	41-50
18693206-2	2008	SUMMARY: Rivaroxaban, the first oral, direct factor Xa (FXa) inhibitor to reach Phase III trials, inhibits thrombin generation by both the intrinsic and the tissue factor pathways.	Rivaroxaban	9-20	coagulation factor X	Homo sapiens	45-54
18693206-2	2008	SUMMARY: Rivaroxaban, the first oral, direct factor Xa (FXa) inhibitor to reach Phase III trials, inhibits thrombin generation by both the intrinsic and the tissue factor pathways.	Rivaroxaban	9-20	coagulation factor X	Homo sapiens	56-59
18693206-2	2008	SUMMARY: Rivaroxaban, the first oral, direct factor Xa (FXa) inhibitor to reach Phase III trials, inhibits thrombin generation by both the intrinsic and the tissue factor pathways.	Rivaroxaban	9-20	coagulation factor II, thrombin	Homo sapiens	107-115
18814828-5	2008	The direct thrombin inhibitor dabigatran is furthest along in clinical development, followed by the factor Xa inhibitors rivaroxaban and apixaban.	Rivaroxaban	121-132	coagulation factor X	Homo sapiens	100-109
18675600-0	2008	Determination of rivaroxaban--a novel, oral, direct Factor Xa inhibitor--in human plasma by high-performance liquid chromatography-tandem mass spectrometry.	Rivaroxaban	17-28	coagulation factor X	Homo sapiens	52-61
18675600-1	2008	A high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) method allowing the sensitive and specific quantification of rivaroxaban (BAY 59-7939), a Factor Xa inhibitor in advanced development for the prevention and treatment of thromboembolic disorders, in human plasma is described.	Rivaroxaban	140-151	coagulation factor X	Homo sapiens	169-178
18675600-1	2008	A high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) method allowing the sensitive and specific quantification of rivaroxaban (BAY 59-7939), a Factor Xa inhibitor in advanced development for the prevention and treatment of thromboembolic disorders, in human plasma is described.	Rivaroxaban	153-164	coagulation factor X	Homo sapiens	169-178
18766262-1	2008	Rivaroxaban (Xarelto) is an oral, direct factor Xa inhibitor in advanced clinical development for the prevention and treatment of thromboembolic disorders.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	41-50
18766262-1	2008	Rivaroxaban (Xarelto) is an oral, direct factor Xa inhibitor in advanced clinical development for the prevention and treatment of thromboembolic disorders.	Rivaroxaban	13-20	coagulation factor X	Homo sapiens	41-50
18579812-1	2008	BACKGROUND: We investigated the efficacy of rivaroxaban, an orally active direct factor Xa inhibitor, in preventing venous thrombosis after total knee arthroplasty.	Rivaroxaban	44-55	coagulation factor X	Homo sapiens	81-90
18491993-0	2008	Rivaroxaban, an oral direct factor Xa inhibitor.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	28-37
18491993-1	2008	Rivaroxaban is a small molecule, direct Factor Xa inhibitor and may be a potentially attractive alternative to vitamin K antagonists.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	40-49
17629849-0	2007	Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct factor Xa inhibitor.	Rivaroxaban	44-55	coagulation factor X	Homo sapiens	79-88
18257025-9	2008	The limitations of warfarin prompted the development of new antithrombotic drugs, which include anticoagulants, such as direct oral thrombin inhibitors (dabigatran) and factor Xa inhibitors (rivaroxaban, apixaban).	Rivaroxaban	191-202	coagulation factor X	Homo sapiens	132-178
18278158-5	2008	Rivaroxaban is the first direct factor Xa inhibitor that was admitted for approval in the indication VTE-prevention.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	32-41
18393142-2	2008	This overview focuses on the indirect antithrombin dependent pentasaccharide derivatives of idraparinux and on the most advanced oral direct inhibitors to factor Xa (rivaroxaban and apixaban) and IIa (dabigatran).	Rivaroxaban	166-177	coagulation factor X	Homo sapiens	155-164
18095747-1	2008	BACKGROUND: Rivaroxaban (BAY 59-7939) is a novel, oral, direct Factor Xa inhibitor in advanced clinical development for the prevention and treatment of thromboembolic disorders.	Rivaroxaban	12-23	coagulation factor X	Homo sapiens	63-72
18095747-1	2008	BACKGROUND: Rivaroxaban (BAY 59-7939) is a novel, oral, direct Factor Xa inhibitor in advanced clinical development for the prevention and treatment of thromboembolic disorders.	Rivaroxaban	25-36	coagulation factor X	Homo sapiens	63-72
18096568-6	2008	Numerous oral, direct FXa inhibitors are in various stages of clinical development, including rivaroxaban, LY517717, YM150, DU-176b, apixaban, and betrixaban, and are anticipated to overcome the limitations of VKAs.	Rivaroxaban	94-105	coagulation factor X	Homo sapiens	22-25
18307374-0	2008	Population pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor--in patients undergoing major orthopaedic surgery.	Rivaroxaban	52-63	coagulation factor X	Homo sapiens	81-90
18307374-2	2008	Rivaroxaban is an oral direct Factor Xa (FXa) inhibitor in clinical development for the prevention and treatment of thromboembolic disorders.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	30-39
18307374-2	2008	Rivaroxaban is an oral direct Factor Xa (FXa) inhibitor in clinical development for the prevention and treatment of thromboembolic disorders.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	41-44
18307374-19	2008	In both studies, FXa activity correlated with rivaroxaban plasma concentrations following a maximum effect model, whereas prothrombin time prolongation correlated following a linear model with intercept.	Rivaroxaban	46-57	coagulation factor X	Homo sapiens	17-20
19066002-1	2008	Rivaroxaban (Xarelto) is a member of a new class of oral, direct (antithrombin-independent) factor Xa inhibitors, which restrict thrombin generation both in vitro and in vivo.	Rivaroxaban	0-11	coagulation factor II, thrombin	Homo sapiens	70-78
17873238-0	2007	Effects of the oral, direct factor xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity.	Rivaroxaban	48-59	coagulation factor X	Homo sapiens	28-37
17873238-0	2007	Effects of the oral, direct factor xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity.	Rivaroxaban	48-59	coagulation factor II, thrombin	Homo sapiens	80-88
17873238-0	2007	Effects of the oral, direct factor xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity.	Rivaroxaban	48-59	coagulation factor X	Homo sapiens	104-118
17873238-1	2007	Rivaroxaban (BAY 59-7939) is an oral, direct factor Xa inhibitor in advanced development.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	45-54
17873238-1	2007	Rivaroxaban (BAY 59-7939) is an oral, direct factor Xa inhibitor in advanced development.	Rivaroxaban	13-24	coagulation factor X	Homo sapiens	45-54
17873238-5	2007	Maximal effect of rivaroxaban was observed 2 hours after drug administration: prothrombinase-induced clotting time was prolonged 1.8 and 2.3 times baseline after rivaroxaban 5 and 30 mg, respectively.	Rivaroxaban	18-29	coagulation factor X	Homo sapiens	78-92
17873238-5	2007	Maximal effect of rivaroxaban was observed 2 hours after drug administration: prothrombinase-induced clotting time was prolonged 1.8 and 2.3 times baseline after rivaroxaban 5 and 30 mg, respectively.	Rivaroxaban	162-173	coagulation factor X	Homo sapiens	78-92
17873238-8	2007	There was a close correlation between plasma concentration of rivaroxaban and prolongation of prothrombinase-induced clotting time and reduction in endogenous thrombin potential.	Rivaroxaban	62-73	coagulation factor X	Homo sapiens	94-108
17873238-8	2007	There was a close correlation between plasma concentration of rivaroxaban and prolongation of prothrombinase-induced clotting time and reduction in endogenous thrombin potential.	Rivaroxaban	62-73	coagulation factor II, thrombin	Homo sapiens	97-105
17873238-9	2007	Rivaroxaban strongly inhibits platelet-induced thrombin generation, after activation of either platelets or the coagulation pathway, even in the presence of minimal factor Xa inhibition in plasma.	Rivaroxaban	0-11	coagulation factor II, thrombin	Homo sapiens	47-55
17938768-2	2007	Rivaroxaban (Xarelto) is a novel, oral, direct Factor Xa (FXa) inhibitor in late-stage development for the prevention and treatment of thromboembolic disorders.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	47-56
17938768-2	2007	Rivaroxaban (Xarelto) is a novel, oral, direct Factor Xa (FXa) inhibitor in late-stage development for the prevention and treatment of thromboembolic disorders.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	58-61
17938768-2	2007	Rivaroxaban (Xarelto) is a novel, oral, direct Factor Xa (FXa) inhibitor in late-stage development for the prevention and treatment of thromboembolic disorders.	Rivaroxaban	13-20	coagulation factor X	Homo sapiens	47-56
17938768-2	2007	Rivaroxaban (Xarelto) is a novel, oral, direct Factor Xa (FXa) inhibitor in late-stage development for the prevention and treatment of thromboembolic disorders.	Rivaroxaban	13-20	coagulation factor X	Homo sapiens	58-61
17938768-3	2007	Rivaroxaban inhibits clot-associated and free FXa activity, and prothrombinase activity, and reduces thrombin generation.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	46-49
17938768-3	2007	Rivaroxaban inhibits clot-associated and free FXa activity, and prothrombinase activity, and reduces thrombin generation.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	64-78
17576867-2	2007	Rivaroxaban (BAY 59-7939) is an oral direct factor Xa inhibitor currently under clinical development.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	44-53
17576867-2	2007	Rivaroxaban (BAY 59-7939) is an oral direct factor Xa inhibitor currently under clinical development.	Rivaroxaban	13-24	coagulation factor X	Homo sapiens	44-53
17629849-2	2007	One promising agent is rivaroxaban (a highly selective, oral, direct FXa inhibitor), which is in advanced clinical development for the prevention and treatment of thromboembolic disorders.	Rivaroxaban	23-34	coagulation factor X	Homo sapiens	69-72
17549294-1	2007	Rivaroxaban (BAY 59-7939) is an oral, direct factor Xa inhibitor in clinical development for the prevention and treatment of venous thromboembolism (VTE).	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	45-54
17576867-12	2007	CONCLUSIONS: Results of this proof-of-concept and dose-finding study support phase III evaluation of the orally active direct factor Xa inhibitor rivaroxaban, because efficacy and safety were apparent in the treatment of proximal deep-vein thrombosis across a 3-fold range of fixed daily dosing.	Rivaroxaban	146-157	coagulation factor X	Homo sapiens	126-135
17549294-1	2007	Rivaroxaban (BAY 59-7939) is an oral, direct factor Xa inhibitor in clinical development for the prevention and treatment of venous thromboembolism (VTE).	Rivaroxaban	13-24	coagulation factor X	Homo sapiens	45-54
17408122-0	2007	Drug evaluation: rivaroxaban, an oral, direct inhibitor of activated factor X. Bayer AG and Ortho-McNeil Pharmaceutical Inc are developing rivaroxaban, an oral Factor Xa inhibitor, for the potential prevention and treatment of thrombosis.	Rivaroxaban	17-28	coagulation factor X	Homo sapiens	160-169
17100983-6	2007	Rivaroxaban inhibited Factor Xa activity by 35% and prolonged prothrombin time [by 1.4 times baseline (tb)], activated partial thromboplastin time (1.3 tb) and the HepTest (1.9 tb).	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	22-31
17388799-0	2007	In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban.	Rivaroxaban	124-135	coagulation factor II, thrombin	Homo sapiens	23-31
17388799-0	2007	In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban.	Rivaroxaban	124-135	coagulation factor X	Homo sapiens	104-113
17595891-0	2007	Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor xa inhibitor--in healthy subjects.	Rivaroxaban	65-76	coagulation factor X	Homo sapiens	94-103
17595891-1	2007	OBJECTIVE: Rivaroxaban (BAY 59-7939) is an oral, direct Factor Xa (FXa) inhibitor being developed for the prevention and treatment of thromboembolic disorders.	Rivaroxaban	11-22	coagulation factor X	Homo sapiens	56-65
17595891-1	2007	OBJECTIVE: Rivaroxaban (BAY 59-7939) is an oral, direct Factor Xa (FXa) inhibitor being developed for the prevention and treatment of thromboembolic disorders.	Rivaroxaban	11-22	coagulation factor X	Homo sapiens	67-70
17595891-1	2007	OBJECTIVE: Rivaroxaban (BAY 59-7939) is an oral, direct Factor Xa (FXa) inhibitor being developed for the prevention and treatment of thromboembolic disorders.	Rivaroxaban	24-35	coagulation factor X	Homo sapiens	56-65
17595891-1	2007	OBJECTIVE: Rivaroxaban (BAY 59-7939) is an oral, direct Factor Xa (FXa) inhibitor being developed for the prevention and treatment of thromboembolic disorders.	Rivaroxaban	24-35	coagulation factor X	Homo sapiens	67-70
17595891-9	2007	FXa activity correlated with rivaroxaban plasma concentrations following an inhibitory Emax model; prothrombin time (PT) and rivaroxaban plasma concentrations correlated with a linear model, with a slope of 4.6 s/(100 microg/1).	Rivaroxaban	29-40	coagulation factor X	Homo sapiens	0-3
17244773-2	2007	Rivaroxaban (BAY 59-7939) is a novel, oral, direct factor Xa inhibitor in clinical development.	Rivaroxaban	0-11	coagulation factor X	Homo sapiens	51-60
17244773-2	2007	Rivaroxaban (BAY 59-7939) is a novel, oral, direct factor Xa inhibitor in clinical development.	Rivaroxaban	13-24	coagulation factor X	Homo sapiens	51-60
17701479-8	2007	Oral factor Xa inhibitors (rivaroxaban, apixaban, YM150) inhibit factor Xa directly, without antithrombin III mediation, and may prove to be more potent and safe.	Rivaroxaban	27-38	coagulation factor X	Homo sapiens	5-14
17701479-8	2007	Oral factor Xa inhibitors (rivaroxaban, apixaban, YM150) inhibit factor Xa directly, without antithrombin III mediation, and may prove to be more potent and safe.	Rivaroxaban	27-38	coagulation factor X	Homo sapiens	65-74